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Abstract 
 
Background:  The prevalence of Type 2 diabetes mellitus (T2DM) is increasing 
globally and Papua New Guinea (PNG) is no exception.  T2DM and the 
hyperglycaemia associated with it can virtually affect all systems of the human body.  
Preventive measures are therefore important in curtailing this epidemic. For those 
already diagnosed with the disease, optimal glycaemic control to slow the 
progression of complications improves quality of life and reduces premature death.  
One of the challenges of achieving optimal control is modifying lifestyle behaviours.  
Betel nut, a stimulant, and a social habit common in PNG, has been linked to 
hyperglycaemia and T2DM.  Determining the glycaemic effects of this habit in T2DM 
patients is important because they already have defects in glucose homeostasis.  If 
betel nut chewing contributes to poor glycaemic control in T2DM, patients must be 
educated on this complication. 
Aim:  This research project aimed to identify any relationship between betel nut 
chewing and glycaemic control as measured by oral glucose tolerance (OGT), 
capillary blood glucose (CBG) and/or glycated haemoglobin (HbA1c) in T2DM. 
Methods:  To identify any long term association of betel nut chewing with glycaemic 
control in T2DM (Phase 1), a questionnaire was developed based on the World 
Health Organization STEPS survey and was used to conduct face-to-face interviews 
with patients diagnosed with the disease.  Participants were recruited from the Port 
Moresby General Hospital (PMGH) Diabetes Clinic.  Information collected included 
demographics, lifestyle behaviours, and physical and biochemical measurements.  
Questions on diabetes management were included in the questionnaire and 
information on diabetes management was confirmed from patients’ clinical cards 
when available.  All responses were entered on the questionnaire forms used.  A 
total of 392 participants were recruited.  Because those with T2DM already have 
impaired blood glucose control, the study also included a cohort without T2DM (non-
T2DM cohort) to identify any long term association of betel nut chewing with 
glycaemic control (Phase 3).  Data for the non-T2DM cohort (N=972) were extracted 
from the PNG STEPS survey which was conducted 2-3 years prior to the present 
study.  Data for this were obtained from HOPE worldwide PNG in an Excel format.   
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Data for the two cross-sectional studies were entered into an Excel® data sheet and 
transferred into SPSS® versions 20/21 statistical software for statistical analysis.       
To determine the acute glycaemic effects of betel nut chewing in T2DM, betel nut 
chewers from Phase 1 who gave consent to participate, were enrolled into a clinical 
study (Phase 2). On Day 1 (betel nut chewing day), CBG was measured before and 
5-10 minutes after each chewing episode and hourly in between chewing episodes.  
On Day 2 (no betel nut day), measurements were made hourly.  Diet was 
standardised for both study days.  Measurements were entered onto a data 
collection sheet developed for the study.  Statistical analysis of the data used SAS® 
version 9.0. 
Results:  A total of 392 T2DM participants were recruited from a total pool of 2,572 
diabetes patients registered at the PMGH Diabetes Clinic for Phase 1 but 385 were 
included in the study.  The prevalence of betel nut chewing among this cohort was 
55.1% (N = 212).  Data for a total of 922 participants from the STEPS survey were 
included in Phase 3.  The prevalence of betel nut chewing among that cohort (non-
T2DM participants) was 80.8% (N=745).  Fasting CBG (FCBG) was not affected by 
betel nut chewing in both cohorts.  Betel nut chewing had a significant positive 
relationship with BMI, HbA1c/OGT and physical activity.  That is, betel nut chewers 
were leaner, were more physically active and had better glycaemic control than non-
chewers.  This was observed in both T2DM and non-T2DM participants.  Betel nut 
chewing was also strongly associated with alcohol consumption and smoking 
among those with and without T2DM.   
For the study aimed at determining the acute glycaemic effects of betel nut chewing 
(Phase 2), 148 (69.8%) of the 385 T2DM participants, were eligible.  Of these, 70 
(47.3%) gave consent to participate, 57 (38.5%) refused, and a further 21(14.2%) 
were excluded because they were not contactable by phone, or were hospitalised or 
deceased.  Thirty eight participants were included in this phase of the study.  
Results from this study showed that betel nut chewing did not have an acute 
glycaemic effect on those with T2DM.  Variable non-significant glucose changes 
(increase, decrease, no change) were observed.   
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Conclusions:  It was observed that betel nut chewing had a long term beneficial 
effect on HbA1c but not FCBG in T2DM.  This is supported by similar observations 
in the non-T2DM cohort which showed that betel nut had a beneficial effect on 
glucose tolerance but not FCBG.  However, this beneficial effect was more likely 
from lower doses of the betel nut compared to higher doses.  The acute glycaemic 
effect of betel nut chewing in T2DM from the clinical study was non-significant.  
Although this study provides evidence for a beneficial effect of betel nut on 
glycaemic control, the mechanism of action cannot be confirmed from this study.  
Further studies are required to confirm this relationship. 
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Chapter I: Introduction 
 
1.1 Introduction 
There is no country in the world that has been spared from the incidence of Type 2 
Diabetes Mellitus (T2DM), and Papua New Guinea (PNG) is no exception.   
Furthermore, the prevalence of T2DM is increasing in developing countries such as 
PNG.  PNG has a population of about 7 million people and the prevalence of T2DM 
in PNG has recently been reported to be 14.4%.1   There are many known factors 
which have been associated with T2DM.  Some of these factors are social habits, 
such as excessive alcohol consumption  2, 3 and tobacco smoking4-6.  Betel nut is a 
social habit which has been linked with T2DM and risk factors for the disease.7-12 
Two epidemiological studies linking betel nut chewing to hyperglycaemia were 
conducted in PNG; one in a cohort without diabetes 13 and another in a cohort with 
the disease.14 The two studies 13, 14 have reported that betel nut chewing is 
associated with hyperglycaemia.  An earlier study in PNG showed that about 60% of 
PNG patients with T2DM had poor glycaemic control.15  Whet: 
her betel nut is contributing to poor glycaemic control in those with T2DM requires 
further investigation because those with the disease already have underlying 
problems with optimal glycaemic control.  With a high prevalence of betel nut 
chewing and an increasing prevalence of T2DM in PNG, this study investigated the 
effects of betel nut chewing on the blood glucose levels of PNG patients with T2DM.   
1.2 Background 
Diabetes mellitus is a group of metabolic diseases resulting from defects in insulin 
secretion, insulin action or both; all of which lead to hyperglycaemia.16  It is capable 
of affecting virtually all the body systems.  There are two main types of diabetes 
mellitus: type 1 (T1DM) and type 2 (T2DM).  Understanding the pathogenesis of 
hyperglycaemia is very important when distinguishing between these two main 
categories.  The diagnosis of either T1DM or T2DM depends on the clinical 
presentation, and differentiating between these two main types and other types of 
diabetes mellitus requires understanding of the pathogenesis.  Understanding the 
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pathogenesis is also important because it determines how a particular type of 
diabetes can be treated effectively.16  T1DM accounts for ≤10% of all diabetes 
mellitus cases worldwide.16  
1.2.1 Type 1 diabetes mellitus 
This type of diabetes was previously known as insulin-dependent diabetes, or 
juvenile-onset diabetes.  T1DM results from β-cell destruction, which usually leads 
to absolute insulin deficiency.16   
The majority of patients with T1DM have the immune-mediated form while a minority 
have the idiopathic form with no known aetiology.  Immune-mediated T1DM results 
from destruction of the β-cells of the pancreas by the immune system and, 
therefore, markers of this destruction are usually detected in these patients.  These 
markers include islet cell autoantibodies, autoantibodies to insulin, autoantibodies to 
glutamic acid decarboxylase and autoantibodies to the tyrosine phosphatases.17  
 T1DM also has multiple genetic predispositions and may be related to 
environmental factors as well.  The clinical presentation depends on the rate of β-
cell destruction; rapid destruction is usually seen in infants and children while a 
slower rate of destruction is seen mainly in adults.  Ketoacidosis may present as the 
first manifestation of the disease.  In those where β-cell destruction is slow, they 
may not present with ketoacidosis for many years, perhaps not until there is 
absolute insulin deficiency that will require insulin replacement.16  
 Compared to immune-related T1DM, patients with idiopathic T1DM usually have 
varying degrees of insulin deficiency and, therefore, suffer from episodic 
ketoacidosis.  Idiopathic T1DM is strongly inherited and is mostly seen in those of 
Asian and African descent.18  Patients who have T1DM are usually lean, but this is 
not a diagnostic indicator.  Symptoms include excessive excretion of urine 
(polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes and 
fatigue.  Those with T1DM require lifelong exogenous insulin replacement therapy in 
order to survive.  
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1.2.2 Type 2 diabetes mellitus 
This type of diabetes was previously known as non-insulin-dependent diabetes or 
adult/maturity-onset diabetes.  Compared to T1DM, those with T2DM have only 
relative (rather than total) insulin deficiency and the majority may not need insulin 
replacement at all throughout their lifetime.16    
The two underlying problems in T2DM are impaired insulin secretion (β-cell failure) 
and function (insulin resistance). There are several mechanisms which may explain 
the pathogenesis of T2DM and these include glucotoxicity, lipotoxicity, oxidative 
stress, endoplasmic reticulum stress and amyloid deposition.19  All these 
mechanisms have a role in both insulin resistance and islet β-cell death, except 
amyloid deposition, which is thought to have a role in β-cell failure.  Furthermore, all 
these mechanisms are said to contribute to tissue inflammation and inflammation 
has been reported to be a contributory factor to development of T2DM.19 
In an insulin-resistant individual, insulin secretion may be normal or elevated but, 
because of higher blood glucose levels, those with the disease may need even 
higher insulin levels to compensate for insulin resistance.  Insulin secretion becomes 
defective as well, over time, as the -cells fail.  Insulin resistance is associated with 
obesity but not all obese insulin-resistant people actually develop T2DM.   
T2DM may go undiagnosed for many years without the person knowing s/he has the 
disease.  This is because the hyperglycaemia associated with the condition 
develops gradually and, in the initial stages, the classic symptoms of diabetes may 
go unnoticed.  Patients with the disease may present with non-specific signs and 
symptoms such as polyuria, fatigue and repeated infections like vaginal thrush in 
women.20  By the time T2DM is diagnosed, complications may already have 
occurred.  Complications such as cardiovascular disease, amputations, neuropathy, 
renal failure and cerebrovascular disease are major causes of premature morbidity 
and mortality.21-24 These complications are caused by poorly controlled 
hyperglycaemia.  Infections also have been identified as an important contributory 
cause of the high morbidity and mortality in patients with diabetes.25, 26  
Complications associated with T2DM lead to a poor quality of life and increased 
health care costs.  Health care costs are incurred from hospitalisations and 
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associated expenses, and the use of medications.27 The high cost of managing 
T2DM and its complications can be a significant economic burden to countries with 
a high prevalence of the disease. 
Although the specific aetiology for T2DM is unknown, there are factors which are 
known to contribute to the development of the disease.  One of the most important 
risk factors for T2DM is obesity.  Not only is obesity associated with insulin 
resistance but it is also associated with inflammation.28, 29 Other known risk factors 
are dyslipidaemia, lifestyle behaviours (for example, diet or physical activity) and 
genetics.  There is also increasing evidence of the role of the gut microbiota 
(independent of environmental factors) in T2DM.30  Drugs or chemicals also can 
induce or precipitate T2DM.31, 32 
T2DM can be prevented and, once diagnosed, proper management can retard the 
development of complications or premature mortality and morbidity.  Lifestyle 
modifications, coupled with diabetes education, are important interventions in the 
fight to reduce the prevalence of T2DM and impede the development of 
complications associated with the disease.  Prevention of T2DM should focus on 
lifestyle factors which may contribute to the development of the disease.  To delay 
the development of complications of T2DM and prevent premature deaths, a 
combination of lifestyle modifications, glucose monitoring and proper medication 
management is important. 
1.3 Significance  
This study is relevant in PNG because betel nut chewing is highly prevalent and also 
because of the high prevalence of T2DM in the country. Two cross-sectional 
studies13, 14 conducted in PNG reported an association of betel nut chewing with 
poor glycaemic control. Other cross-sectional studies 7-12 in other betel nut chewing 
countries have also linked betel nut chewing with risk factors for T2DM such as 
obesity.  There has not been any research done to investigate the acute glycaemic 
effect of betel nut chewing.  Investigating the acute glycaemic effect of betel nut may 
confirm the glycaemic effect of betel nut chewing and provide some understanding 
of any long term association of betel nut chewing with T2DM. 
26 
 
 
If betel nut chewing is contributing to poor glycaemic control, T2DM patients must be 
educated in regard to this issue.   Betel nut chewing is a social habit that may have 
to be modified to prevent T2DM, especially in those at risk of developing the 
disease. 
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Chapter II: Literature review 
2.1 Introduction 
Type 2 diabetes mellitus (T2DM) has the tendency to affect the working-age 
population as well as seniors.  The disease leads to premature mortality and 
increased morbidity, and an increased economic burden.1-5  Increased morbidity 
continues to contribute to poor quality of life for those diagnosed with the disease.  
Reduced quality of life, itself, can lead to increased costs and premature deaths.  
Apart from being an economic burden as a result of its impact on productivity, the 
costs associated with the disease are a burden not only to the individuals who are 
affected by the disease but also to their families who provide support and care.  
Furthermore, the economic impact of T2DM is burdensome for countries with a high 
prevalence of the disease.   
For those diagnosed with T2DM, emphasis on diabetes care and management 
focuses on optimal blood glucose control to prevent or retard micro- and/or macro-
vascular complications.  Complications or consequences of uncontrolled 
hyperglycaemia, such as cardiovascular disease, amputations, neuropathy, renal 
failure and cerebrovascular disease, are major causes of premature morbidity and 
mortality.1-4, 6-8 These complications further contribute to the economic burden 
associated with T2DM.  Health care costs are incurred from hospitalisations and 
associated expenses, including medications and other consumables such as 
syringes for insulin administration when necessary.5 
T2DM used to be a disease which affected those who were more than 30 years of 
age.  However, there is now evidence that the disease is affecting the much younger 
population.9, 10 This should be a concern to countries with a high prevalence of the 
disease because T2DM and the complications associated with it have the tendency 
to strike at the many productive members of society. 
An understanding of the pathogenesis, pathophysiology and, therefore, factors 
contributing to the development of diabetes is important in dealing with the T2DM 
epidemic. Understanding all these factors helps in identifying preventive measures 
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and, also, establishing appropriate glucose control for those already diagnosed with 
the disease.   
Normal glucose regulation is complex, requiring a balance between release and 
action of insulin and the counter-regulatory responses.  Insulin is released in 
response to blood glucose increases above normal physiological levels, while 
counter-regulatory responses are stimulated by falls in glucose levels below normal 
physiological levels.  Normal glucose homeostasis can be affected by other 
metabolic effects.  These metabolic effects can result from the environment and 
lifestyle factors interacting with inherent and acquired characteristics of an 
individual.  Pharmacotherapeutic and habitual drugs such as ethanol (alcohol) can 
also affect normal glucose homeostasis.11 
Research has shown that several chemical constituents of betel nut, a commonly 
used stimulant in Papua New Guinea (PNG), may affect glucose homeostasis.  Most 
of the studies conducted have used individual chemical constituents, such as 
arecoline, rather than the whole betel nut chew (betel nut chewed with other 
components).  Investigating the effect of betel nut alone on glucose homeostasis 
may not provide the same result as using the whole betel nut chew because betel 
nut is generally chewed with other components; the two most common additives 
being lime (calcium hydroxide or calcium oxide) and Piper betle leaf (PBL) or Piper 
betle inflorescence (PBI).  These additives add further to the number of chemicals 
which may affect glucose homeostasis or affect the absorption of its chemical 
components in a betel nut chewer.  
2.1.1 Examples of drugs which affect glucose homeostasis 
Drugs affecting glucose homeostasis may result in either hypoglycaemia or 
hyperglycaemia.11-13  Furthermore, some drugs may also have a synergistic effect 
upon each other to cause either hypoglycaemia or hyperglycaemia11 and some may 
induce or increase the risk of obesity, which is an important contributing factor in the 
development or worsening of T2DM14.  Drugs may also impair glucose homeostasis 
where there is concurrent diminished organ function, such as in liver disease.15 
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2.1.1.1 Drugs associated with hyperglycaemia or T2DM and their 
mechanisms of action 
Drugs which have been reported to have a potential for inducing hyperglycaemia 
include cardiovascular drugs [(β-blockers11-13, 16, thiazide diuretics12, 13, statins12, 13, 17-
21], corticosteroids11-13, 22, 23, atypical antipsychotic drugs12, 13, 24-26, calcineurin 
inhibitors27-29 and pregnane X receptor (PXR) agonists.30-32  Although the 
mechanisms by which these drugs cause hyperglycaemia are mostly unknown, 
potential mechanisms have been proposed.   
Corticosteroids are well known for causing hyperglycaemia.  The use of 
corticosteroids, therefore, is not only a risk for development of T2DM but also for the 
worsening of glycaemic control in those already suffering T2DM.  They are most 
commonly used in clinical practice as anti-inflammatories, immunosuppressants and 
chemotherapeutic agents, as well as in replacement therapy.   There are several 
mechanisms by which corticosteroids affect glucose homeostasis.  They blunt the 
action of insulin and promote hepatic gluconeogenesis.33   Studies34, 35 using mice, 
have demonstrated that the effect of corticosteroids on hepatic gluconeogenesis is 
through activation of liver x receptor-β (LXRβ) involving phosphoenolpyruvate 
carboxykinase (PEPCK) gene transcription.  Activation of LXRβ involving PEPCK 
increases hepatic gluconeogenesis, causing hyperglycaemia.34, 35    Recent studies 
using mice and cell-based assays have demonstrated that osteoblasts play a central 
role within systemic fuel metabolism;36-38 a role affected by corticosteroids39.  As 
demonstrated by these studies, a factor(s) originating from osteoblasts is(are) 
modified by glucocorticoid signalling in these cells, causing adverse glucose 
homeostasis.  Osteoblasts secrete osteocalcin, a hormone involved in regulating 
glucose homeostasis.40  Osteocalcin is an insulin secretagogue and influences 
blood insulin levels, glucose tolerance and insulin sensitivity. It also directly 
stimulates expression of the insulin genes.40 Furthermore, osteocalcin influences fat 
mass, proliferation of β-cells and energy expenditure.40  Glucocorticoids cause a 
marked decrease in serum osteocalcin levels.39 Ferron et al 38 demonstrated that 
increased osteocalcin activity through insulin signalling in osteoblasts is necessary 
for whole body glucose homeostasis.   Osteocalcin causes β-cells in the pancreas to 
release more insulin while, at the same time, directing adipose cells to release 
adiponectin that increases sensitivity to insulin.    Lee et al36 showed that lack of 
32 
 
 
osteocalcin leads to decreased β-cell proliferation, glucose intolerance and insulin 
resistance, all of which are important predisposing factors for T2DM. 
β-blockers are used for the treatment of hypertension.  Studies linking β-blockers 
and hyperglycaemia or T2DM have been conflicting.  One possible reason for these 
conflicting reports may be their differences in terms of their mechanisms of action 
and physiological effects and, therefore, β-blockers should not be considered as a 
homogenous class of drugs when investigating their glycaemic effects.16   Non-
vasodilating β-blockers (for example, atenolol and metoprolol) have been reported 
to have negative effects on glucose and on lipid metabolism.41  Studies investigating 
the glycaemic effect of this group of β-blockers also have been conflicting, but it has 
been suggested that conflicting results may arise from the type of glucose 
parameter measured.16  Fonseca16 suggests that glucose levels at a particular point 
in time (e.g. fasting glucose) may not reflect long term changes in glucose 
metabolism, as is reflected by glycated haemoglobin (HbA1c).  Evidence provided 
for this argument is the finding, in a randomised double-blind crossover study, that 
metoprolol did not affect fasting plasma glucose but increased HbA1c.16, 42   
Proposed mechanisms of non-vasodilating β-blockers on glucose metabolism 
include unopposed α1-adrenergic receptor activity resulting from the blocking of β1-
adrenergic or β1- and β2-adrenergic receptors.  This may result in vasoconstriction 
causing reduction in blood flow to muscles and insulin-stimulated glucose uptake in 
the periphery (insulin resistance).43   Insulin resistance is associated with increased 
activation of the renin-angiotensin-aldosterone system (RAAS), which results in 
stimulation of angiotensin receptors, thereby impairing insulin signalling at the 
vascular and skeletal muscle tissues.41, 44  Other potential mechanisms include 
interference with insulin secretion from pancreatic β-cells45 and reduction of the first 
phase of insulin release.41, 45  Non-vasodilating β-blockers also have been 
associated with worsening hyperglycaemia in those with abdominal obesity.14   
Thiazide diuretics not only have been reported to cause hyperglycaemia but also the 
development of T2DM.14, 46-49  There is evidence that new onset diabetes may be 
more prevalent in obese patients taking hydrochlorothiazide than in those who are 
not obese.14, 50  The exact mechanism of action of thiazides on glucose homeostasis 
that results in hyperglycaemia is unknown.  They appear to exert their effects on 
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glucose homeostasis through many complex and interacting mechanisms.51  
Several postulated mechanisms resulting in hyperglycaemia include worsening of 
insulin resistance, inhibition of glucose uptake, reduction of insulin release, induction 
of hypokalaemia and down-regulation of peroxisome proliferator-activated receptor 
gamma.51-55 The latter not only activates the RAAS but also decreases insulin 
release.  By activating the RAAS, angiotensin II (ANG II) and aldosterone are 
elevated, with consequent hyperglycaemia. The hyperglycaemia results as a 
consequence of induced insulin resistance via increased oxidative stress and 
altered insulin signalling that lead to decreased glucose transport.56    ANG II also 
increases the risk of hyperglycaemia by contributing to oxidative stress, 
inflammation and apoptosis in pancreatic β-cells.56    It also has been reported that 
genetics may play a role in the development of diabetes in those who are taking 
thiazides.57, 58   Bozkurt et al57 reported a reduction in the risk of diabetes in patients 
with polymorphisms in the guanine nucleotide binding protein β-polypeptide 3 gene 
(GNβ3) who were taking thiazides.  That study 57 showed that those with 
polymorphisms in the angiotensin converting enzyme (ACE), who also were taking 
thiazides, showed an increased risk.   
Statins (HMG-CoA reductase inhibitors) inhibit cholesterol biosynthesis and are 
therefore used to treat hyperlipidaemia.  They are commonly used among those with 
T2DM because obesity is a usual presentation in those with the disease.  Reports of 
hyperglycaemia or new-onset diabetes in patients receiving statins have been a 
concern, as statins have been reported to benefit T2DM patients with 
hyperlipidaemia in preventing or reducing premature adverse cardiovascular 
outcomes such as myocardial infarction, stroke or cardiovascular death.59-61   The 
hyperglycaemic effects of statins may not be a class action but may apply more in 
certain statins than others.18, 20, 62-64   Furthermore, this effect may be dose-
dependent17-19, 64-66, more pronounced in older patients17 and influenced by the 
pharmacology of individual statins.62, 64, 65   The exact mechanism remains unknown 
but several conflicting mechanisms have been postulated.  These include 
perturbations of the metabolic pathway such as the ATP-dependent potassium 
channel,21 depolarisation and calcium influx,21, 65 and glucokinase.67  Statins also 
may worsen glycaemic control and increase insulin resistance by affecting the 
cholesterol synthetic pathways, especially by affecting metabolites such as 
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isoprenoids and ubiquinone.66, 68-70  Effects of statins on glucose homeostasis also 
may be genetically influenced.71  
Cyclosporin and tarcrolimus are examples of calcineurin inhibitors which have been 
implicated in elevated glucose levels.  These drugs are usually employed in 
transplant therapy to avoid allograft rejection.  Heit et al72 used knockout mice to 
demonstrate calcineurin function in glucose homeostasis.  They deleted the 
calcineurin phosphatase regulatory unit, calcineurin 1, and observed that the mice 
developed age-dependent diabetes resulting from decreased β-cell proliferation and 
mass, reduced pancreatic insulin content and hypoinsulinaemia.  These findings 
indicate that inhibition of calcineurin contributes to the development of diabetes.  
Again, several mechanisms have been postulated.  Administration of cyclosporin 
and tacrolimus to rats for up to two weeks resulted in hyperglycaemia73, 74, reduction 
in serum and pancreatic insulin levels73-76, glucose intolerance75, 76 and a decreased 
insulin transcription which was time-dependent.76  In a recent study by Goodyer et 
al77, it was observed that inactivation of calcineurin in mouse islets impaired 
biogenesis of dense core granules, and reduced both insulin secretion and cell 
proliferation and mass.  The study used islets of knockout mice similar to those used 
by Heit et al.72  Interestingly, recent animal studies78 have demonstrated that long-
term activation of calcineurin by transgenic overexpression of active calcineurin 
induces impaired glucose tolerance by altering β-cell mass.  The findings of these 
studies suggest that chronic activation of calcineurin affects β-cell proliferation and 
survival.  Another mechanism by which calcineurin inhibitors cause hyperglycaemia 
may involve inhibition of calcineurin-dependent glucose sensing in pancreatic β-
cells.79 
Atypical antipsychotic drugs (AAPDs) such as risperidone, olanzapine and clozapine 
are commonly used in the treatment of schizophrenia and bipolar disorder.  
Schizophrenia itself has long been associated with diabetes mellitus80 and has also 
been reported to be associated with a higher  prevalence of metabolic syndrome, 
compared to the general population.81-83   Use of AAPDs has been reported to affect 
glucose homeostasis resulting in hyperglycaemia, which increases the risk of T2DM 
or can worsen hyperglycaemia in those already affected by the disease.84-87  Apart 
from AAPDs being associated with hyperglycaemia resulting from long term use, 
35 
 
 
acute hyperglycaemia also has been reported after short term use.88   It is thought 
that hyperglycaemia is most likely due to the weight gain promoted by these agents.  
Some of the likely mechanisms by which weight gain is promoted are through 
antagonism at serotonin and central histamine H1 receptors, development of insulin 
resistance by affecting cellular glucose transport, impaired insulin secretion and 
alterations in leptin levels.85-90   However, human studies88 investigating the acute 
hyperglycaemic effects of AAPDs, as well as animal studies,91-93 have demonstrated 
that AAPDs have direct effects on blood glucose levels that are independent of 
obesity and, therefore, T2DM can develop in the absence of obesity.  Although the 
exact mechanism by which AAPDs affect glucose homeostasis is unknown, many 
complex mechanisms have been proposed.  In an animal study89 using mice, it was 
reported that a mechanism by which this group of drugs causes hyperglycaemia 
may be activation of the sympathetic nervous system (SNS).  Although Ikegami et 
al,94 in another study using mice, demonstrated that olanzapine causes 
hyperglycaemia by increasing hepatic glucose production via the SNS and does so 
by activating hypothalamic adenosine 5’-monophosphate-activated protein kinase 
(AMPK).  In the study, systemic administration of olanzapine increased blood 
glucose in both fasted and unfasted mice, but more so in unfasted mice.  Central 
administration of the drug, however, only increased blood glucose levels in the 
unfasted mice.  Further tests were performed to investigate the effect of olanzapine 
on the mRNA levels of gluconeogenic or glycolytic enzymes in mouse liver, the 
results of which showed an increase in the mRNA level of Glucose-6-Phosphatase 
(G6Pase) but no effect on other enzymes.  The authors suggested that olanzapine 
activated AMPK in the hypothalamus, which stimulated the SNS, thereby increasing 
hepatic G6Pase via the β-adrenergic receptors and, consequently, resulting in 
hyperglycaemia.  Activation of the hypothalamic AMPK increased endogenous 
glucose production.95 Using an animal model, Hahn et al93 also centrally 
administered olanzapine and demonstrated that the drug reduced insulin secretion 
in response to glucose challenge.  An earlier study96 used the same model but 
administered olanzapine and clozapine peripherally (subcutaneous injection) and 
found that these drugs increased hepatic glucose production, decreased peripheral 
glucose utilisation and impaired β-cell function (reflected by the decrease in insulin 
secretion).  The two aforementioned studies93, 96 demonstrate that centrally 
administering AAPDs such as olanzapine, perhaps, has no effect on insulin 
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sensitivity.  Other mechanisms by which hyperglycaemia is induced via the SNS 
include impairment of cholinergic-stimulated insulin secretion by blocking muscarinic 
M3 receptors,97 and activation of hypothalamic AMPK by antagonising histamine H1 
receptors, dopamine D2 receptors, serotonergic 5HT2A receptors and α1-
adrenoceptors91, 98.  Mechanisms such as increase in hepatic phosphorylase activity, 
increased expression of the level of G6Pase, mitochondrial damage and 
inflammation also have been proposed.92, 99 In terms of inflammation and its 
association with T2DM, research has shown that microbiota resident in the human 
gut play an important role in the development of diabetes.  Gut microbiota modulate 
intestinal permeability, which increases metabolic endotoxin secretion leading to 
chronic low-level inflammation and consequent T2DM.100  Recently reported animal 
studies101 suggest that olanzapine causes metabolic adverse effects by changing 
the gut flora. When an antibiotic cocktail was administered to olanzapine-treated 
rats, a shift in gut flora attenuated the adverse metabolic effects of the drug.  
PXR activators have been reported to cause hypoglycaemia but the majority of 
evidence supports a stronger link with hyperglycaemia or T2DM.  PXR has been 
found to be species-specific.31  Two known potent human PXR activators reported to 
induce hyperglycaemia are rifampicin and rifaximin (a rifampicin analogue). 30-32 
PXR is mainly expressed in the liver and in the small intestine.32  Rifaximin has been 
reported to be a gut-specific human PXR activator. 102   There are several pathways 
by which PXR activation is suggested to affect metabolic homeostasis.  Most of the 
data suggests that hyperglycaemia results from interference with transcription 
factors or co-factors involved in transcriptional regulation of gluconeogenic enzymes 
such as G6Pase and PEPCK.  These interferences result in repression of 
gluconeogenesis, glucose transport and glycogen storage. PXR regulates not only 
the expression of enzymes and transporters involved in drug metabolism but also 
the genes involved in the metabolism and excretion of endobiotics.103, 104  
Furthermore, PXR affects energy metabolism through direct gene regulation, or 
through crosstalk with other transcriptional regulators, and orchestrates immune 
responses to protect against stresses caused by exposures to xenobiotics.103, 105,   
Recent animal studies31, 106 have shown down-regulation of the hepatic glucose 
transporter 2 (Glut 2), pyruvate dehydrogenase kinase isoenzyme 2 (Pdk2) and 
glucokinase by PXR activation.  Hyperglycaemia can also result from disruption of 
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lipid formation and catabolism provoked by PXR activation.104  Activation provokes 
reduction of β-oxidation related gene expression, increased fatty acid uptake in the 
liver resulting in hepatic steatosis, and increased hepatic expression of transcription 
factors and enzymes which are involved in lipogenesis.107, 108  
2.1.1.2 Drugs associated with hypoglycaemia and their mechanisms 
of action 
Apart from known hypoglycaemic effects of agents clinically used to lower blood 
glucose, alcohol109, aspirin (salicylates)109 and some cardiovascular drugs [β-
blockers109, 110, Renin-angiotensin system (RAS) blockers (ACE inhibitors and 
angiotensin receptor blockers)]111, 112 and constitutive androstane receptor (CAR) 
agonists [(example; phenobarbital)113, 114] may induce hypoglycaemia.  Some of 
these drugs may act synergistically with hypoglycaemic agents used for diabetes 
treatment to cause or worsen hypoglycaemia.  Hypoglycaemia is, therefore, more 
common in those with diabetes mellitus compared to those without the disease.   
Vasodilating β-blockers, also known as non-selective β-blockers have been reported 
to be associated with hypoglycaemia.  Non-selective β-blockers are more likely to 
cause hypoglycaemia, compared to selective agents.  Similarly, selective β-blockers 
(non-vasodilating β-blockers) are less likely to be associated with hypoglycaemia 
compared to those which are non-selective.115, 116 Two mechanisms have been 
proposed for this hypoglycaemic effect in non-selective β-blockers. The first of these 
is the blunting of the signs and symptoms of hypoglycaemia.115 This may worsen a 
hypoglycaemic episode or delay recovery from a hypoglycaemic attack.116  The 
second mechanism involves these β-blockers directly potentiating the effects of 
insulin, which results in a heightened insulin effect.109  The consequences of a 
heightened insulin effect are increased glucose utilisation in the periphery and 
inhibition of lipolysis. Further, use of β-blockers may cause a reduction in 
glycogenolysis and gluconeogenesis resulting from a diminished physiologic 
response to hypoglycaemia.115, 117  
ACE inhibitors and angiotensin receptor blockers block the RAS.  These drugs are 
thought to cause hypoglycaemia through haemodynamic or direct effects resulting 
from the inhibition of the RAS.  Haemodynamic effects increase insulin release from 
the pancreas and improve delivery of glucose to peripheral tissues.111-113, 118  ANG II 
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has a direct inhibitory effect on insulin signalling and glucose transport. Therefore, 
inhibition of the RAS prevents this inhibitory effect, resulting in improved insulin 
sensitivity, improved delivery of glucose to insulin-sensitive tissues and reduced 
glucose levels.119-126     Other possible mechanisms by which the blocking of RAS 
causes hypoglycaemia are improvement of insulin sensitivity through greater 
differentiation of adipocytes from pre-adipocytes as a result of increased adiponectin 
levels, retention of potassium or protection of pancreatic islets from glucotoxicity and 
oxidative stress.127 
Aspirin, a salicylate drug, is a common non-steroidal analgesic.  The exact 
mechanism by which it causes hypoglycaemia is not known but there are several 
which have been postulated.    These include reduction of hepatic gluconeogenesis, 
increased insulin secretion, reduced insulin clearance and enhanced plasma insulin 
response.128, 129  Gao et al130 also demonstrated that aspirin prevented insulin-
induced glucose uptake in 3T3-L1 adipocytes pre-treated with TNF-α and they 
concluded that aspirin probably protects insulin receptor substrate proteins from 
serine phosphorylation catalysed by multiple kinases.  In protecting these proteins, 
aspirin may enhance insulin sensitivity, causing hypoglycaemia.130  Paracetamol, 
another analgesic, has been said to cause symptomatic hypoglycaemia as a result 
of hepatic necrosis following an overdose and, at therapeutic levels, causes 
hypoglycaemia, especially in children.131, 132  
The association of hypoglycaemia with alcohol intake is well-established, especially 
in those with T2DM and more so in patients who are on insulin or sulphonylureas.133, 
134  Alcohol causes hypoglycaemia by inhibiting gluconeogenesis.109, 135   It is also 
thought that alcohol may increase endogenous insulin secretion, thus causing 
hypoglycaemia.116 In a fasting state, T2DM patients who consume alcohol, and who 
are receiving hypoglycaemic agents, can experience severe hypoglycaemia.  This is 
because, during the fasting state, the body relies on other sources of glucose but, if 
alcohol is inhibiting gluconeogenesis and hypoglycaemic agents such as insulin are 
reducing glucose, severe hypoglycaemia is experienced and the person can end up 
in a hypoglycaemic coma.  Hartling et al134 in their study involving 10 normal-weight 
non-diabetic participants demonstrated that the return of blood glucose toward 
fasting level was delayed by ethanol.  In their study, they used glipizide, a 
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sulphonylurea.  The study evaluated -cell secretory activity by measuring 
concentrations of insulin and C-peptide; concentrations of which were unchanged by 
ethanol.  Hartling et al134 therefore argued that ethanol can prolong, but does not 
augment, hypoglycaemia.  Alcohol-associated hypoglycaemia also has been 
reported in those without T2DM.136 
The CARs are closely related to the PXRs and they both suppress gluconeogenesis 
but CARs appear to have a beneficial effect on blood glucose, compared to PXRs. 
Phenobarbital is a CAR agonist which has been reported to decrease blood glucose 
levels and improve insulin sensitivity in T2DM.113, 114 Animal and cell culture studies 
have demonstrated that, similar to PXRs, phenobarbital represses gluconeogenesis 
by suppressing the expression of PEPCK and G6Pase.137, 138  However, unlike 
PXRs, CAR activation appears to offer a beneficial effect on glucose homeostasis.  
This perhaps suggests that other factors, or other metabolic pathways, interact with 
CARs to achieve this beneficial effect.   Activation of CARs also may improve 
glucose control by improving lipid profiles as they have been demonstrated to inhibit 
lipogenesis.139   Improving lipid profiles improves insulin sensitivity.  In mice, the 
nuclear receptor has been reported to significantly suppress or reverse adiposity 
induced by a high fat diet.139 
Betel nut is said to be one of the most commonly used drugs in the world, after 
tobacco, alcohol and caffeine. It has been estimated that approximately 600 million 
people consume betel nut worldwide.140  The nut is said to be indigenous to India, 
Sri Lanka, the Maldives, Bangladesh, Myanmar, Taiwan and many islands in the 
South Pacific, including PNG.140  It contains chemicals which may contribute to the 
development of hyper- or hypo-glycaemia.  Some mechanisms by which betel nut 
affects glucose homeostasis already have been postulated but evidence supporting 
the glycaemic effects of betel nut and its chewing components, so far, are 
conflicting.  It is, therefore, important that research continues to investigate not only 
the glucose homeostatic effects of the chemical components of betel nut itself, but 
also the effect of betel nut and its additives during and after mastication.  
Furthermore, it is important to investigate the glycaemic effect of betel nut chewing 
in T2DM patients as they already have impaired glucose homeostasis.  Any findings 
from such research will assist efforts to improve glycaemic control in these patients 
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and thereby reduce morbidity, premature mortality and the economic burden of the 
disease, especially in those countries where the habit of betel nut chewing is 
endemic.  
2.2 Global perspectives of T2DM 
Over the last decade and a half, there have been several estimates of the worldwide 
prevalence of diabetes.  These estimates, based on available data from different 
countries, all project an increase in the prevalence of diabetes worldwide.  Different 
methodologies are used to calculate estimates and new data are incorporated into 
the analysis as they become available.  However, estimates may generally under- or 
over-estimate the prevalence of diabetes and, therefore, country-level reporting 
using standardised formats may improve estimates, especially when based on the 
reporting of new incidences of diabetes.  There may also be a need to develop 
systematic ways of assessing which studies to incorporate when calculating 
estimates for the prevalence of diabetes.141  However, the estimates reported by 
different organisations are very close to each other, suggesting that there is indeed 
an increase in the prevalence of diabetes. 
The most recent estimates from the International Diabetes Federation (IDF) suggest 
that the number of people with diabetes, worldwide, was 366 million in 2011 and 382 
million in 2013, more than 90% of whom had T2DM.142, 143   Increases in the 
prevalence of T2DM have been seen in many population groups and mostly in 
populations with a genetic susceptibility to the development of T2DM.  It is estimated 
that 8.3% of those aged 20-79 years live with diabetes and this is projected to 
increase to 9.9% in 2030.142, 143  The estimated worldwide prevalence of diabetes is 
expected to increase to 592 million by 2035. 142, 143 
Most of the increase in T2DM is reported to be occurring in developing countries 
and within disadvantaged minority groups in developed countries.  Regions 
estimated to have the highest prevalence of diabetes among adults aged 20-79 
years in both 2011 and 2030 are the Middle East and North Africa, North America 
and the Caribbean, South East Asia and the Western Pacific.142, 143  The top 10 
countries for diabetes prevalence in 2011 and 2030 were, and will be, in the Middle 
East and North Africa and the Western Pacific regions.142, 143  
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2.3 T2DM in the Pacific Island Countries 
The region with the highest estimated number of people with diabetes (138 million) 
is the Western Pacific region,142, 143  which includes the Pacific Island countries 
(PICs).  The PICs are divided into three regions: Melanesia comprising of PNG, the 
Solomon Islands, Vanuatu, Fiji and New Caledonia; Polynesia comprising of Tonga, 
the Cook Islands, Niue, American and Western Samoa, Tahiti, Wallis and Futuna, 
and Tokelau; and Micronesia comprising of Kiribati, Nauru, the Federated States of 
Micronesia, the Marshall Islands, the Northern Mariana Islands and Guam.  Of the 
top 10 countries/territories for comparative prevalence of diabetes among 20-79 
year olds in 2013 142, seven of these were PICs, which is alarming. 
In early 2000, the World Health Organization (WHO) initiated collaborative country 
surveys within PICs, aiming to identify risk factors for non-communicable diseases 
such as diabetes in the region.  These surveys were conducted with a step-wise 
approach commencing with behavioural risk factors, followed by physical 
measurements and then biochemical measurements, hence the name ‘STEPS’ 
survey.   Several reports of these surveys have been released.  Results of these 
surveys have shown that, among the PICs, Polynesian144-147 countries have the 
highest prevalence of T2DM based on fasting capillary blood glucose (FCBG), with 
American Samoa147 having one of the highest rates (47.3%) in the world.  The 
prevalence rates range from 13.5% to 47.3% in Polynesia 144-147, 14.4% to 21.2% in 
Melanesia 148-151 and 19.6% to 28.1% in Micronesia 152-154.  Some of these country 
reports calculated prevalence rates for age groups 15-64 years while others did so 
for age groups 25-64 years.  The prevalence rates may therefore be higher for those 
countries that calculated prevalence rates based on the age group 25-64 years 
compared to those that based calculations on the ages 15-64 years, considering 
that T2DM now affects young adults in their twenties.  Most of these countries used 
values of FCBG ≥6.1mmol/L to indicate fasting hyperglycaemia while a few used 
FCBG ≥7.0 mmol/L which may lead to under- or over-estimation of fasting 
hyperglycaemia when comparing rates between these countries.   
Earlier studies in Melanesian populations showed a low prevalence of T2DM which 
led to the suggestion that this group of Pacific Islanders had genes which protected 
them from impaired glucose tolerance.155 However, as indicated by the recent 
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STEPS surveys in Melanesian countries, the prevalence of diabetes is certainly 
increasing 148-151, mostly in those populations that have been westernised and are 
living in urban or periurban areas.156-162 These findings question the protective gene 
theory. Thus far no gene has been isolated. It is thought that, as communities 
become  more westernised, their finely tuned metabolic systems break down.163 
 
2.4 T2DM in Papua New Guinea 
PNG has a population of about 7 million people.  It is estimated142 that over 200,000 
people in PNG have T2DM, and only about 45% of these know that they have it.  In 
2013, the national prevalence of diabetes, estimated using extrapolated data from 
similar countries, was 5.4%.142 However, a preliminary report from the STEPS 
survey conducted in PNG from 2007 to 2008 has reported a diabetes prevalence 
rate of 14.4%.151  The preliminary national prevalence rate for diabetes is the first to 
be reported from a national survey in PNG and confirms the high prevalence of 
diabetes in the country. 
Several small surveys carried out within certain populations in PNG from 1962 to 
1983 also have demonstrated this increase in the number of people with T2DM.156-
158, 161, 164-167 These surveys were not performed using a standardised methodology 
and only involved small samples of a few populations, yet they do indicate an 
increase in the number of people with T2DM within the populations studied.  The 
increase in the prevalence of T2DM in PNG has been attributed to several factors.  
These factors include westernisation and urbanisation.168-171  Westernisation and 
urbanisation have led to changes in diet, physical activity and social habits.168-172  
Before westernisation and urbanisation, people worked in their gardens to grow their 
own food and were physically active.  Urbanisation has led to land development 
and, therefore, loss of garden land.  As a result of westernisation and urbanisation, 
people are now consuming refined foods and living more sedentary lifestyles.  
Those in urbanised areas are at higher risk because of their more sedentary 
lifestyles, increased mechanisation of manual tasks and changes in diet.  Although 
the diet of rural villagers also is changing, these villagers are mostly subsistence 
farmers and, therefore, are more physically active.  Studies have shown that the 
prevalence of T2DM is higher in urban populations compared to rural populations. 
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157, 158, 160, 161  Western civilisation was only introduced to the highlands of PNG in the 
1930s and studies carried out in some populations in this region of the country have 
shown a low prevalence of T2DM.159, 160  A study comparing a highlands population 
with a coastal population showed no T2DM in the highland population of 257 studied 
and a 4% prevalence of diabetes in the coastal population of 273.159  The same 
study159 showed a 1.9% prevalence of impaired glucose tolerance in the highlands 
population. This indicates the increasing risk of T2DM for this ethnic group as 
westernisation and urbanisation progress. 
Studies in PNG have shown that a significantly high percentage of T2DM patients 
exhibit poor glycaemic control,7, 173, 174 although no recent studies have been 
conducted or published to validate this finding.   A study by Savige et al. also 
showed that diabetes in PNG has a high case fatality rate with a median survival of 
4 to 5 years.175 Important contributory causes of the high mortality and morbidity in 
patients with diabetes in PNG, as reported in the late 1980s, were diabetic coma 
and infections.7, 175 
Despite the high morbidity and mortality associated with T2DM in PNG, resources 
allocated to manage the disease are very much limited. Not all the hospitals in the 
country have specialist diabetes clinics.  The capacity to detect new cases of the 
disease, and to monitor complications, also is limited.176 In a country with economic 
constraints and limited resources, it is even more critical to reduce the prevalence of 
T2DM.  
2.5 Betel nut chewing 
Betel nut, scientifically known as Areca nut, is obtained from the Areca catechu palm 
tree.  The palm tree is widely distributed throughout East Africa, South Asia and the 
Pacific Islands.177 It is in these countries where chewing of betel nut is common 
among certain populations.  Betel nut chewing is also popular in migrant 
communities from countries where the habit is common, as observed among the 
PNG community living in Perth.  Different components chewed with betel nut vary in 
different parts of the world where the habit is practised. 
Before chewing, betel nut may be prepared in different ways; it may be used fresh, 
or dried and cured, before chewing.  The nut can be boiled, baked or roasted.178 In 
44 
 
 
Asian countries, a fresh or dried seed of betel nut is chewed with a fresh PBL, a dab 
of slaked lime (calcium hydroxide), and various flavourings such as cardamom and 
tobacco.  The mixture of ingredients wrapped in PBL is termed the betel quid.  The 
betel quid is prepared by smearing a betel leaf with slaked lime.  Pieces of betel nut, 
as well as other flavouring agents, are added to the PBL smeared with slaked lime.  
The ingredients are then enfolded by the PBL and chewed.140, 178 In mainly Chinese 
chewers in Taiwan, a piece of the PBI and red lime paste are sandwiched between 
two unripe halves of betel nut.179  
Adding known carcinogens such as tobacco to the betel nut quid is a practice 
reported in Asian countries.  In a study180 investigating betel quid dependence, it 
was reported that chewers in Taiwan, Malaysia, Sri Lanka, Indonesia and Nepal 
added tobacco to the quid, with the prevalence of tobacco-added quid varying 
among these countries.  The study indicated that the prevalence of tobacco-added 
quid was the highest in Nepal, with 100% of chewers adding tobacco, while 100% of 
Chinese chewers in mainland China did not add tobacco.  The next highest 
prevalence of tobacco-added quid was seen among Indonesian chewers and this 
was followed by Malaysia and Sri Lanka, with Taiwan having the lowest prevalence.  
Interestingly, the study reported that 100% of the mainland Chinese users chewed 
the husk of betel nut rather than the seed. 
In Melanesian PICs, such as PNG, the fresh nut (ripe or unripe) is chewed with PBI 
or rolled PBL dipped in powdered lime, with the use of PBI being more common 
than PBL.  All different components of the betel nut chew in PNG (Figure 2.1) are 
added individually into the mouth (making up the betel nut chew), starting with the 
betel nut itself.   PBI is dipped in lime before adding it to the mashed nut in the 
mouth and this is done until the chew turns red.  The excessive saliva and/or betel 
nut juice is either swallowed or spat out.  Whether juice is swallowed or spat out 
mostly depends on the bitterness of the betel nut.  Most chewers swallow the betel 
nut chew once it is red or the amount of saliva produced during mastication is 
reduced.  In PNG, betel nut is consumed at different stages of maturity according to 
individual chewers’ preferences.  The outer shell of the palm nut is removed before 
the seed is chewed.  Lime is usually prepared by heating sea shells or corals until a 
powdered form is obtained. 
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Betel nut chewing is more common along the coastal areas of PNG but it has been 
introduced to those in the highlands of PNG where the source palm tree does not 
grow.  The habit is socially acceptable and, therefore, common in social gatherings 
such as peace ceremonies, weddings and other cultural ceremonies.  It also is used 
by traditional healers as part of healing rituals, or may be used to cast out evil 
spirits. 
                              
Betel nut and PBI  PBI  Lime PBI dipped in lime 
Figure 2.1 Components of the PNG betel nut chew (Source:  Martina 
Burain, 2014) 
2.6 Chemical composition of betel nut and additives 
The elemental composition of betel nut has been investigated and common 
elements found include sodium, aluminium, chloride, calcium, potassium, bromide, 
manganese and copper.  Other elements also have been detected. 181-183    
Betel nut contains alkaloids, proteins (peroxidase), carbohydrates, lipids, fibre and 
polyphenols (flavonoids, tannins, syringic acid).184-189 Flavonoids include catechin 
and epicatechin.188  The main alkaloids are arecoline, arecaidine, guvacine and 
guvacoline.184, 185, 187 Of all these alkaloids, arecoline is reported to be the most 
abundant.185  However, the main alkaloid found in a mixture of betel nut quid and 
blood of chewers is arecaidine.186, 190  Arecaidine is a by-product of betel nut when 
chewed with lime.  Variations in total alkaloid content of betel nut also have been 
observed and are thought to be due to seasonal factors and/or geographical 
location.184  
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The chemical constituents increase as more components are added to the betel nut 
quid.  It is also thought that betel nut contains many other chemicals which are yet to 
be discovered. These yet-to-be-identified chemicals may be responsible for 
pathological effects with unknown mechanisms.  
The PBL also has been found to contain elements such as manganese, zinc, 
potassium, chloride, arsenic and rubidium.182  Other minerals found are calcium, 
iron, iodine and phosphorus.   The leaf has been reported to contain proteins, 
carbohydrates, minerals, fat, fibre, essential oil, tannin and an alkaloid, arakene.  
Additionally, vitamins B1, B2, B3, A and C have been reported.191 PBI also contains 
phenolic compounds such as safrole and hydroxychavicol.192  
Chewing betel nut, therefore, exposes the chewer not only to chemicals contained in 
the betel nut but also to chemicals contained in the other components chewed with 
the nut.   
2.7 Consequences of betel nut chewing 
Diverse consequences of betel nut have been reported by studies using betel nut 
and/or PBI/PBL extracts, or the pure chemical constituents of betel nut.192-210  The 
types of studies investigating such consequences include cell, animal, human and 
epidemiological studies.  Results of many studies have been conflicting and there is 
continuing research on betel nut chewing and its components.  Claims or 
experiences reported by betel nut chewers have led to more investigations to 
determine evidence, if any, to support such claims. 
2.7.1 Traditional benefits  
Traditionally, betel nut has been used in some societies for treatment of indigestion, 
constipation and halitosis.  Betel nut chewers have reported increased well-being 
and stamina, heightened alertness, prevention of hunger, increased capacity to 
work, sweating and a warm sensation, soothing effects on digestion (carminative), 
protection of the mouth and gums, and some euphoria.193, 194 
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2.7.1.1 Mechanisms of actions for traditional benefits of betel nut 
chewing 
The major alkaloid in betel nut, arecoline, mainly acts on the central and the 
autonomic nervous systems.  Arecoline possesses parasympathomimetic properties 
that lead to stimulation of both muscarinic and nicotinic receptors.194 
A number of studies have been conducted by Chu to investigate claims of the 
effects of betel nut chewing by chewers.  These investigations have included 
cardiovascular responses,195 effects on performance reaction time196, 
electroencephalographic (EEG) activity197, skin temperature198 and sympathetic skin 
responses199.  
In one of Chu’s studies, cardiovascular responses were compared between habitual, 
occasional and fresh (novice) chewers.195 It showed a decrease in heart rate, which 
was related to the duration of betel nut exposure.  As the duration of exposure was 
increased, the mean heart rate decreased.  That is, the highest increase in heart 
rate was seen in fresh chewers, followed by occasional chewers; the least increase 
was seen in habitual chewers. This also is consistent with findings by Lin et al.200   
Blood pressure, however, was significantly increased only for those who were fresh 
chewers.200  
To investigate claims of heightened alertness, Chu investigated the effect of betel 
nut chewing on performance reaction time.196  The study investigated both simple 
and choice reaction times in habitual users, with chewing gum and practice groups 
being the control groups.  The study demonstrated no differences in simple reaction 
time among the three groups but a significant shortening of choice reaction time in 
the betel nut chewing group.  The finding that there was no difference in the simple 
reaction time is different to that found by an earlier study.  The study by Stricherz et 
al201 found that reaction time latencies were significantly lengthened in those who 
chewed all three components of the quid compared to those who did not chew betel 
nut and those who only chewed betel nut and PBL.  Further, Stricherz et al201 
observed that simple reaction time was lengthened only during the first 20 reaction 
time trials, a finding they attributed to practice or “inhibition of familiarity”. However, 
the timing of the onset of the reaction time tests during betel nut chewing may have 
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contributed to the finding.  The study allowed only 60 seconds to elapse after 
chewing before introduction of the reaction time stimulus, which may have been too 
early for any effect of betel nut chewing to make any difference.  The longer onset of 
the effects of betel nut chewing is supported by the finding of Chu that the onset of 
cardiovascular effects of betel nut chewing begins within 2 minutes with a maximal 
effect within 4-6 minutes.195  EEG activity measurements using spectral analysis and 
topographic mapping, both before and during betel nut chewing, showed that betel 
nut chewing was associated with a state of arousal and a state of relaxation (to a 
lesser extent).197  
The immediate effects of betel quid chewing include palpitations, sweating and facial 
flushing, with a feeling of skin warmth.198, 200 In the Chu study198, the measurement 
of body temperature was conducted to investigate claims that betel nut chewing 
produces sweating, facial flushing and a warm sensation in the body.  This was 
conducted by recording skin temperature before and during betel nut chewing 
among habitual chewers.  The study showed that the skin temperature of betel nut 
chewers was increased by 0.5 to 2.0°C, an effect which was abolished by atropine 
and partially inhibited by propranolol.  Lin et al, in their study,200 reported that betel 
nut chewing enhanced blood flow in the external carotid artery (main supplying 
artery to the face and scalp).  These studies support reports that betel nut chewing 
produces sweating, facial flushing and a sensation of warmth in the body.  
Gilani et al202 investigated the claim that betel nut is used as a digestive aid, a 
laxative and a carminative in an animal study using mice. The study showed that 
betel nut extract had gastrointestinal stimulant activities and produced wet faeces 
(laxative).  The effects of the extract in the study were similar to that of 
physostigmine, a standard acetylcholinesterase (AChE) inhibitor.  The authors 
therefore concluded that these effects may be due to some unknown constituent(s) 
of betel nut because arecoline and other known constituents of betel nut did not 
exhibit AChE inhibitory activity in the study.   
There are also reports that betel nut causes heightened alertness and increased 
capacity to work.  Psychological well-being and dependence caused by betel nut 
chewing are said to result from stimulation of the central and autonomic nervous 
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systems.194   The stimulation of the central nervous system may also be a result of 
AChE inhibition by betel nut.202 
The finding that betel nut relieves constipation is supported by a study conducted by 
Li et al203 which demonstrated that arecoline stimulates distal colonic contraction in 
rats. Constipation is consequently relieved by stimulating muscle contraction.203 
2.7.2 Possible health benefits 
There are claims of potential health benefits of betel nut and other components 
chewed with it. 
Hannan et al204 investigated the antioxidant activities of different betel nut extracts 
(obtained using different solvents) by determining their reducing powers and 
hydrogen peroxide scavenging abilities using spectrophotometry.  The antioxidant 
activities of these extracts were compared with ascorbic acid as a standard.  That 
study also quantified tannins and determined phenolic contents of the different betel 
nut extracts.  The betel nuts used in the study were found to contain high tannin and 
total phenolic content and the latter was related to their antioxidant properties.  
Three types of betel nut extracts (methanol, methanol-water, water) showed high 
reducing power and significantly higher hydrogen peroxide scavenging power than 
ascorbic acid.   The results from this study were consistent with the findings of 
Zhang et al.188 that betel nut has a high phenolic content and antioxidant properties.  
Possessing antioxidant properties suggests that betel nut may be useful in oxidative 
stress-related diseases.  However, the study investigated betel nut only, and 
whether or not these antioxidant properties remain when betel nut is chewed with 
other additives needs to be investigated.  
Studies have also examined the antioxidant properties of PBL/PBI.  Lei et al.192 
conducted in vitro studies to investigate the antioxidative effects of aqueous extracts 
of PBI.  The study used xanthine and xanthine oxidase to produce superoxide 
radicals which were inhibited by the extract in a dose-dependent manner.  The 
extract also scavenged hydroxyl radicals produced by hydrogen peroxide and 
ferrous chloride.  These findings are consistent with findings by Choudhary and 
Kale205, and Rathee et al206.  Choudhary and Kale205 also included an in vivo study, 
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supplemental to the in vitro study.  The in vivo study used albino Swiss mice that 
were administered the PBL extract orally for two weeks.  The hepatic oxidant status 
of each mouse was assessed.  Results of the study showed that PBL has 
antioxidant activity and has potential to elevate the antioxidant status. In that study, 
the presence of the leaf extract during irradiation of rat liver microsomes inhibited 
the oxidative damage.   The most recent study by Hasan et al further supports these 
findings that PBL has antioxidant activity.207  The study by Hasan confirmed that 
PBL activated the nuclear factor-erythroid 2 p45 factor 2 and induced the antioxidant 
response element. 
Other potential benefits of betel nut and its additives that have been reported are 
anti-migraine effects208, hepatoprotective effects209, 210, antimicrobial properties211, 
212, vasorelaxation213 and inhibition of platelet aggregation192, 214.  The 
hepatoprotective effects have been shown to be due to PBL in a study210 using male 
albino Wistar rats.  This finding is supported by Young et al209 who induced liver 
damage in rats using carbon tetrachloride. Levels of liver enzymes, elevated in the 
presence of injury, were inhibited by the PBL extract.  Furthermore, histological 
examinations showed that the PBL extract had a protective effect on the liver from 
damage induced by carbon tetrachloride. 
More studies are required to ascertain any such health benefits of betel nut in 
humans.  
2.7.3 Pathological consequences  
Betel nut chewing has been associated with various health problems.  The most 
common problem associated with betel nut chewing is oral cancer.  Betel nut is 
listed as a carcinogen by the International Agency for Research on Cancer 
(IARC).178  There are numerous epidemiological studies linking betel nut chewing 
with different oral and oropharyngeal cancers.215-219  There are also many studies, 
including many animal studies which have investigated the possible mechanisms for 
development of oral cancer associated with betel nut chewing. 
Additionally, betel nut chewing has been shown to affect the gastrointestinal system.  
Gastrointestinal adverse effects include peptic ulceration220, 221, abnormal liver 
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function tests in rodents222 and stimulation of pancreatic lipase secretion in rats.223  
The latter is said to be caused by PBL.214   However, PBL/PBI has been reported to 
have hepatoprotective properties.209, 210 
Betel nut has been linked to inflammation. 224  This is of concern because there is 
increasing evidence of the association of inflammation with T2DM.225, 226  The finding 
that betel nut causes inflammation is different to the findings that the betel nut chew 
additive PBI/PBL has anti-inflammatory properties.212, 227, 228  There are many 
pathways involved in the inflammatory process, and pathways by which betel nut 
causes inflammation are being investigated.  A study224 comparing betel nut 
chewers in Karachi, Pakistan, reported that betel nut chewers had significantly 
higher odds of an elevated C-reactive protein (CRP) compared to controls who were 
non-betel nut chewers.  This study suggests that systemic inflammation may be a 
pathway by which betel nut increases the risk of systemic diseases such as T2DM.  
With some evidence that PBI/PBL has anti-inflammatory properties, it would be 
useful to investigate whether PBI/PBL in the betel nut chew offers protection from 
inflammation associated with T2DM. 
2.8 Metabolic consequences of betel nut chewing 
Metabolic consequences include effects on blood pressure, HDL cholesterol, 
triacylglycerols (triglycerides), glucose and BMI or waist circumference.  A number 
of epidemiological studies have reported the association of betel nut chewing with 
the metabolic syndrome, as a whole, or with individual components of the syndrome.  
Results of studies investigating the metabolic effects of betel nut chewing have been 
conflicting.  Furthermore, most of the studies have been conducted in Taiwan.229-234  
Such studies in other countries where betel nut chewing is endemic are lacking. 
2.8.1 Studies linking betel nut chewing to the metabolic syndrome 
Yen et al229 investigated the association of betel nut chewing and the metabolic 
syndrome in men in a large population-based study in Taiwan.  That study excluded 
women because the prevalence of betel nut chewing was less than 1.0% among 
women.  The prevalence of betel nut chewing in the study population was 15%.  
Higher risks for the metabolic syndrome were found with age and a family history of 
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diabetes or hypertension.  The study reported a high age-adjusted prevalence rate 
of metabolic syndrome in betel nut chewers compared to non-chewers.  Duration of 
betel nut exposure also was associated with metabolic syndrome.  Those who had 
chewed for more than 20 years or chewed more than 20 chews per day were more 
likely to have the metabolic syndrome compared to those who did not.    
Interestingly, quitting the habit had an effect on risk of metabolic syndrome with the 
risks among chewers decreasing over time after they had quit.   
In another smaller Taiwanese study230 including both males and females aged 20-64 
years old, the daily rate of betel nut use significantly and independently  increased 
the odds of  incidence of the metabolic syndrome. 
The finding by Yen et al229 is consistent with that of Shafique et al235 in Pakistan.  
The cross-sectional study by Shafique et al was similar but had a smaller study 
sample (N=1070) than the former (N=19,839).   The prevalence of betel nut chewing 
in that study sample was 32.5% and included both males and females aged 16-75 
years old.    Females were slightly more likely to chew betel nut than males in that 
cohort and had a slightly higher prevalence of metabolic syndrome than the males.  
The study also included those who chewed betel nut with tobacco and reported that 
the subgroup had a stronger association with metabolic syndrome than those who 
chewed without tobacco.   In contrast to the study by Yen et al229, that study did not 
include other well known risk factors such as diet, family history of metabolic 
disorders and physical activity.  The study 235 adjusted for age, gender and social 
class only. 
2.8.2 Studies linking betel nut chewing to blood pressure 
Reports of the influence of betel nut on blood pressure have been inconsistent.   
Heck et al236 reported an association of betel nut chewing with blood pressure 
among Bangladeshi adults aged 18-75 years.  Their study reported that betel nut 
chewers who chewed the nut without tobacco had higher systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and arterial pressure compared to those who 
had never used betel nut.  A stronger association between high blood pressure and 
betel nut chewing was observed in females, compared to males.  After controlling for 
other factors, the association with SBP remained.  Higher SBP was not associated 
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with the level of betel nut exposure (frequency and duration).  The finding that higher 
blood pressure was associated with betel nut chewing is consistent with findings by 
Guh et al.230  A recent finding by Lin et al231 that betel nut chewing is associated with 
higher SBP further supports both Heck et al236 and Guh et al230.  The former 
study231, however, included those aged 50 years and older.  It is known that, as age 
increases, the risk of SBP also increases.237, 238 
Lin et al200 studied the cerebral haemodynamic effects of betel nut chewing in 30 
healthy participants who were divided into three groups of 10; 1) chronic chewers, 2) 
occasional chewers and 3) new chewers (never chewed or tried only a few times 
before).    After baseline measurements of blood pressure, the participants firstly 
chewed fruit flavoured gum for 10 minutes, rested for 10 minutes and then were 
asked to chew betel nut, slaked lime and PBL.  The study showed that SBP tended 
to increase, especially in new chewers, but this was not statistically significant.  
Interestingly, betel nut chewing reduced DBP.200 
Studies also have shown that betel nut chewing has rapid effects on the 
cardiovascular system, for example heart rate.195, 200  Chu195 demonstrated that the 
onset of increased heart rate was within 2 minutes after chewing, the peak effect 
was reached within 4-6 minutes and the effect lasted for an average of 16.8 
minutes.195   The study by Lin et al200 showed that the increase in heart rate was 
more significant in new and occasional chewers when compared to chronic 
chewers, probably suggesting that tolerance develops in habitual chewers.  
2.8.3 Studies linking betel nut chewing to obesity and lipids 
2.8.3.1 Epidemiological studies 
Chang et al232 reported an association between betel nut chewing and obesity 
among non-aboriginal Taiwanese male adults aged 20-59 years of age.  Females 
were excluded from the study because of the low prevalence of betel nut chewing 
among this group.  The study reported that betel nut chewing was associated with 
obesity and that betel nut chewers were more likely to be obese compared to non-
chewers.  The study also reported that betel nut chewers were more likely to have 
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more helpings of rice per day compared to their counterparts who were non-chewers 
or who had quit the habit.  
This finding, that betel nut chewing is associated with obesity, is consistent with 
other studies 229, 230, 233-235, 239, although not all studies have found this association.236   
The study by Heck et al236 found that weight and BMI were highest among those 
who had never chewed betel nut.  All Taiwanese studies which investigated the 
associations of betel nut chewing consistently showed that betel chewers were more 
likely to be obese. This is contradictory to the Bangladeshi236 and Pakistani224, 235 
studies that did not show such an association.  An exception to this was one of the 
Pakistani235 studies, which showed that betel nut chewers who chewed the nut with 
tobacco were more likely to have a higher waist circumference compared to both 
those who chewed the nut without tobacco and non-chewers.   The Pakistani study 
(235) accounted for age, gender and social class (based on employment type) but 
did not account for confounding factors for obesity such as physical activity, alcohol 
and dietary intake. The Bangladeshi study only accounted for socioeconomic factors 
such as education, occupation and television ownership. 
There are also studies which have shown an association between betel nut chewing 
and lipid levels.229, 230, 233, 234  All of these were Taiwanese studies and they showed 
that betel nut chewers were more likely to have hypertriglyceridaemia (high levels of 
triglycerides). However, the Pakistani study,235 which also included lipid levels as a 
variable, reported no difference in cholesterol levels between betel nut chewers and 
non-chewers.  The study by Guh et al230 showed that betel nut chewers were more 
likely to have hypertriglyceridaemia but there was no association with HDL-
cholesterol.  One of the strengths of the Taiwanese studies is that they had large 
sample sizes ranging from 1049 to 56, 116.  However, the Bangladeshi study had a 
larger sample size (n=19,934) than some of the Taiwanese studies.  
2.8.3.2 Animal studies 
Animal studies reporting the effects of betel nut on cholesterol or obesity also have 
been inconsistent.  A number of animal studies 240-243 have found a favourable effect 
of betel nut or arecoline on lipids.  Zhou et al240 found that a low dose of areca oil 
plus arecoline significantly reduced total cholesterol and increased the level of HDL. 
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They concluded that areca oil plus arecoline may play a synergistic role in 
enhancing hypolipidaemia in rats.  Chiang et al241 used two-week old hamsters, 
which were fed with betel nut for 18 months, and observed decreasing body weight 
in these animals.  Ling et al243 reported increased mRNA PXR and CAR levels, a 
reduced lipid measurement and improved insulin sensitivity in diabetes-induced rats.  
Iqbal et al, in a rat model,242 reported no association of betel nut with 
hypertriglyceridaemia but a dose-related effect on total cholesterol, with a low dose 
causing a significant increase and a high dose having no effect.  That study also 
reported no body weight gain from betel nut.  In contrast, an earlier study by 
Boucher et al,244 using young adult CD1 mice fed with betel nut that was mixed with 
standard feed, for 2-6 days, reported the mice developing central obesity. Betel nut 
extract also has been demonstrated to inhibit activity on cholesterol absorption in 
high cholesterol diets, resulting in reduced plasma lipid concentrations.245, 246 
2.8.4 Studies linking betel nut chewing to glycaemic control 
2.8.4.1 Epidemiological studies 
Tung et al247, in a large population-based cross-sectional survey including 
Taiwanese men (N=14,816 ), reported an association of betel but chewing with 
hyperglycaemia.  Using fasting plasma glucose levels of ≥6.1 mmol/L to indicate 
hyperglycaemia, the study reported that the unadjusted prevalence rate for 
hyperglycaemia was 9.3% in chewers and 10.7% in non-chewers but, when 
participants were categorised according to age groups, chewers aged 50-69 were 
significantly more likely to have hyperglycaemia compared to non-chewers in the 
same age group.   After adjusting for age and other confounders, results indicated 
that betel nut chewers were more likely to have hyperglycaemia or T2DM.  The 
significant association of betel nut chewing with hyperglycaemia or T2DM was in the 
manner of a dose-response (duration of chewing and quantity of nuts chewed), with 
those chewing betel nut for more than 20 years and those chewing more than 20 
pieces of betel nut per day being more likely to be affected when compared to non-
chewers.  
Tseng248 compared ever-chewers (current and those who had quit) with non-
chewers in a study investigating betel nut chewing and the incidence of newly 
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diagnosed T2DM in Taiwanese men.  This study included those with known T2DM.  
The authors combined those who had quit chewing with current chewers because 
the number of those who had quit the habit was too small.   Results of the study 
reported a link between betel nut chewing and the development of T2DM.  
Furthermore, there was an age-specific incidence of newly diagnosed T2DM that 
increased with age, reaching a peak in the age group of 60-69 years in ever-
chewers but increasing beyond that age in those who were never-chewers.   Betel 
nut chewers in this study were younger, with those aged 60-69 years having the 
lowest prevalence.  It is well established that, as age increases, the risk of T2DM 
also increases.  If betel nut has a link with hyperglycaemia or T2DM, the results of 
this study indicate that betel nut may not have an immediate but, rather, a long term 
effect on glycaemic control, if there is any effect at all.   The study did not include 
important confounding factors such as physical activity and diet.  
Yen et al, in their study229 investigating any association between betel nut chewing 
and the metabolic syndrome reported that the association between betel nut 
chewing and hyperglycaemia was smaller than that for hypertriglyceridaemia .  That 
study 229 also included dietary data, which Tung et al247 and Tseng248 did not include.    
Another Taiwanese study by Guh et al230 did not find any association between betel 
nut and hyperglycaemia.  Shafique et al235 found that Pakistanis who chewed betel 
nut with tobacco were more likely to have hyperglycaemia when compared to non-
chewers and those who chewed the nut without tobacco. 
Two smaller cross-sectional epidemiological studies in PNG also reported an 
association of betel nut chewing with fasting hyperglycaemia.249, 250  One study was 
conducted among non-T2DM participants and the other among those with T2DM.   
Both studies were conducted in the National Capital District in Port Moresby.  The 
non-T2DM study had a sample number (N=769) less than that used by Tung et al247 
and other Taiwanese population-based studies.  Using FCBG ≥7.0 mmol/L to 
indicate hyperglycaemia, the study249 reported that betel nut chewing was 
significantly associated with T2DM but did not adjust for confounding factors such as 
diet, physical activity and alcohol consumption.  That study had a small number of 
betel nut chewers (102/769) because 78% of the participants were from the religious 
group, Seventh Day Adventist, which discourages betel nut chewing among its 
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followers.  As with other studies, the prevalence of hyperglycaemia increased with 
increasing age.  
2.8.4.2 In vivo / in vitro studies 
Boucher et al244 demonstrated, in their study, that feeding betel nut to young adult 
mice can cause glucose intolerance.  Other studies, however, have shown either no 
effect242 or a beneficial effect243, 251 of betel nut or arecoline on glucose levels.  Ling 
et al243 recently demonstrated a reduction in fasting blood glucose in T2DM rats 
treated with different doses of arecoline.  Beneficial effects of betel nut extract on 
glucose control also have been demonstrated in Alloxan-induced diabetic rats.252  
Chempakan, in a small study, showed that subcutaneously administered injections 
of arecoline induced hypoglycaemia.251  However, routes of administration other 
than orally or through the buccal mucosa may not appropriately reflect the effect of 
betel nut chewing.  
Glycaemic effects of betel nut chewing also have been investigated using PBL.  In a 
study by Arambewela et al, different doses of hot water and cold ethanol extracts of 
PBL were orally administered to rats to investigate their antidiabetic activities.253  
Effects on fasting blood glucose levels were determined after fasting the rats for 16 
hours.  Effects of PBL extracts on the oral glucose tolerance of normoglycaemic rats 
and the blood glucose levels of streptozotocin (STZ)-induced diabetic rats also were 
determined.  The hypoglycaemic potential of the two types of PBL extract were 
compared to that of tolbutamide, a known hypoglycaemic drug, which was used as 
the reference.  Interestingly, all doses of hot water extract significantly reduced 
fasting blood glucose levels for up to four hours, except for the lowest dose, which 
impaired the blood glucose only for the first two hours.  In contrast, the cold ethanol 
extract impaired blood glucose levels for up to four hours.  The study reported a 
marked dose-dependent impairment of blood glucose levels using both extracts.  In 
regard to the effects of the extracts on glucose tolerance, a significant improvement 
was observed for up to three hours; an observation which was comparable to the 
effect of tolbutamide.  In diabetes-induced rats, the 200 mg/kg dose (the only dose 
used) of hot water extract significantly reduced hyperglycaemia induced by STZ. 
58 
 
 
2.9 Mechanisms of betel nut and additives on glycaemic control  
Several mechanisms have been linked to the pathological consequences of betel 
nut chewing.  Of importance to this current research is (are) the mechanism(s) by 
which betel nut chewing may cause or increase the risk of developing T2DM.  
Many of the mechanisms postulated from human studies are mostly based on 
experiences of betel nut chewers and biochemical measurements of blood glucose 
and lipids.  There also have been a number of animal studies conducted to 
investigate the glycaemic effects of betel nut alkaloids. 
2.9.1 GABA inhibition 
Arecal alkaloids, by inhibiting GABA, probably block the inhibitory effects of GABA 
on glucagon and somatrophin secretion, thereby increasing their release. 193, 254  A 
rise in glucagon leads to insulin release with subsequent hypoglycaemia. As 
hyperglucagonaemia becomes chronic a person could develop diabetes. 193 
It has been suggested that arecaidine and guvacine contribute to the psychic effects 
observed in betel nut chewers and that the mechanism of action of these effects is 
through inhibition of GABA uptake.255 Inhibition of GABA uptake increases the 
extracellular concentrations of the neurotransmitter.    Although GABA is largely a 
central nervous system (CNS) neurotransmitter, it has been reported to exist in 
places other than the CNS.  Outside of the CNS, GABA is found in the pancreatic 
islets.256  The concentration of GABA in the pancreatic islets is reported to be the 
highest outside the CNS.257, 258 
However, Lodge et al259, in their study using the CNS of cats, reported that it is 
unlikely that the behavioural effect of betel nut is due to the reduction of GABA 
inactivation.  The study further suggests that some components of the betel nut 
chew may be influencing GABA either directly or indirectly.  One of the mechanisms 
suggested by this study is that some components in the betel nut chew may be 
modifying the blood-brain barrier or arecaidine metabolism.  Constituents of betel 
nut may, therefore, affect glucose homeostasis by direct or indirect action on GABA 
in the pancreas.  
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An in vitro study260 using isolated mouse islets in the presence of 0.5 mmol/L 
glucose showed that GABA inhibited the release of glucagon to a similar extent as in 
the presence of 10 mmol/L of glucose.  Another in vitro study261 using rat insulinoma 
INS-1 cells suggested that GABA activates the GABAAR (GABA A receptor) by 
depolarising the β-cells in the pancreas to enhance insulin secretion.  The study261 
further suggests that insulin down-regulates GABA-GABAAR signalling in a feedback 
mechanism to fine-tune β-cell secretion. 
2.9.2 Catecholamine stimulation 
The catecholamines, adrenaline and noradrenaline, are involved in glucose 
homeostasis.  These catecholamines inhibit insulin release from β-cells and 
stimulate glucagon release from α-cells in the pancreas, thereby increasing plasma 
glucose. 
Animal studies investigating the effect of betel nut on catecholamines have reported 
release or elevation of catecholamine levels.262, 263  Using bovine adrenal chromaffin 
cells, Wang et al262 investigated the effect of betel nut chewing juice mixtures and 
found that these mixtures and their additives stimulated basal catecholamines.  This 
finding is an indication that betel nut and its additives have an influence on adrenal 
function and may, therefore, have a role to play in glycaemic control.  Furthermore, 
the chewing juices inhibited carbachol-induced catecholamine secretion, perhaps 
indicating competitive receptor binding or some other mechanism. Possible 
mechanisms for the inhibition were further investigated by Wang et al and they 
found that catecholamine release evoked by K+ was inhibited by chewing juices, 
possibly indicating that catecholamine release was not by depolarisation.262  The 
authors suggest that the inhibition of catecholamine release by K+ and carbachol 
may have been mediated by calcium influx through voltage-sensitive channels or the 
steps of secretion after calcium entry.  The results of that study indicate that 
particular chemicals in betel nut and its additives also activate the SNS whereas the 
major alkaloid in betel nut, arecoline, has been reported to affect the 
parasympathetic nervous system.    Betel nut and PBI contain different chemicals 
and, when betel nut is chewed with lime, by-products such as arecaidine and 
guvacaidine are formed.  
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2.9.3 Modulation of metabolic signals. 
Two randomised, placebo-controlled, double-blind studies by Strickland et al264 
showed that arecoline appears to modulate metabolic signals regulating human 
appetite for food in both the fed and fasted states.  The studies were divided into 
two, with Study 1 consisting of fasted individuals and Study 2 consisting of fed 
individuals.  In study 1, participants were randomly assigned to receive a 
predetermined and unique sequence of treatments over the four hour runs so as to 
minimise possible effects of dose order. Bioadhesive gel formulations delivered 0, 5, 
10 or 20 mg arecoline to the buccal mucosa.   After an overnight fast, those in the 
fasted group were given different doses of arecoline, including the placebo after 
measurement of the basal metabolic rate (BMR). In study 2, after an overnight fast, 
participants were fed after measurement of BMR and 10-15 minutes after the 
standard meal, these participants only had the placebo or 10 mg arecoline. 
Participants were randomly allocated to receive two alternate gel sequences with a 
minimum 5-day wash out period allowed between measurements.  The protocol was 
identical for both studies after administration of the gel.  Measurements included 
calorimetry and blood samples at 15, 155 and 365 minutes after dosing for assays 
of plasma arecoline, urea and insulin, and to determine glucose at 365 minutes.  
Plasma arecoline, insulin and glucose levels, energy expenditure, delta energy 
expenditure and substrate utilisation rates (urinalysis) were measured or calculated 
at predetermined time points.  Twenty minutes before starting the final hour’s 
measurement, participants in both groups were instructed to chew and swallow any 
remaining gel.  Hunger (appetite) was a subjective measurement (feelings of 
hunger, thoughts of food, urges to eat, fullness of stomach).  In the fasted state, 
plasma arecoline was dose-dependent, with a final surge in levels at 365 minutes 
(end of study) probably resulting from chewing and swallowing the remainder of the 
gel.  No participant showed evidence of fasting hyperinsulinaemia.  The dose of 
arecoline affected hunger, which was lowest after 10 mg and highest after 20 mg.  
Arecoline increased carbohydrate utilisation transiently in a dose-dependent manner 
but glucose status was not affected.  In the fed state, marginally increased rates of 
carbohydrate disposal, reduced blood glucose and reduced fat utilisation were 
observed following arecoline.  In both groups, arecoline affected hunger, but in a 
non-linear dose-dependent manner.  Betel nut both lowered hunger ratings at given 
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levels of delta energy expenditure and altered the nature of this relationship.   
Arecoline also appeared to disrupt the correlation between delta carbohydrate 
utilisation and hunger in the post prandial state.  Furthermore, arecoline appeared to 
influence hunger independently of delta carbohydrate utilisation in both studies.  The 
finding in this study, that hunger following placebo was higher than after betel nut, is 
different to the epidemiological study by Chang et al232, where betel nut chewers 
were more likely to have more servings of noodles compared to the non-chewers.  
Both studies share the limitation that hunger is entirely subjective. 
2.9.4 Other possible mechanisms for glycaemic effects 
Arambewela et al determined the possible mode of hypoglycaemic activity of PBL 
using a 200 mg/kg dose of hot water extract.253    Their investigations included 
effects on the liver and skeletal muscle glycogen and glucose absorption from the 
intestine.  Findings from these investigations indicated that the extract did not 
significantly inhibit glucose absorption from the lumen of the intestine but stimulated 
and increased accumulation of glycogen in the liver and the skeletal muscle.  
Increased weight of the spleen was observed, which the authors suggest may have 
been due to lymphoproliferative activity.  
Ling et al243 reported an increase in both PXRs and CARs and a significant 
decrease in levels of fasting blood glucose, lipids, insulin and mRNA G6Pase, 
PEPCK, IL-6 and TNF-α. Reduction of PEPCK and G6Pase are associated with 
reduced fasting blood glucose levels resulting from repression of hepatic 
gluconeogenesis.  An increase in p-AKT and GLUT 4 protein expression also were 
observed.  Further, hepatic insulin resistance was improved.  Increased expression 
of GLUT 4 by arecoline is supported by the findings of a study by Prabhakar and 
Doble.265  PXR activation has been reported to adversely affect blood glucose while 
CARs have a beneficial effect.32, 105, 107  Inhibition of AKT disrupts glucose transport 
and inhibits enzymes involved in glycolysis, while activation results in the 
accumulation of Fox01 which stimulates expression of PEPCK and G6Pase, and 
suppresses glucokinase in liver cells.107 
In the study by Ling et al243, they used fructose-induced diabetic rats.  Diabetes 
induced by a fructose diet results in loss of normal insulin function or in insulin 
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resistance that is due to the diminished ability of insulin to suppress hepatic output, 
rather than by decreasing the glucose uptake of muscle. 266, 267  So, the resultant 
reduced fasting glucose levels via arecoline may have resulted from suppression of 
hepatic output of glucose.  PXRs and CARs are known to repress gluconeogenesis.  
There are different complex metabolic pathways that could have been affected by 
feeding the diabetic rats with arecoline.  It is likely that CAR activity may have 
dominated, resulting in reduced plasma glucose and improved insulin sensitivity 
because phenobarbital, an activator of this nuclear receptor, is known to decrease 
plasma glucose levels and improve insulin sensitivity in diabetic patients.113  There is 
also a possibility that PXR may have been involved via an unknown mechanism.  
There are other chemicals in betel nut, such as procyanidins, which have been 
reported to suppress fasting glucose by reducing hepatic gluconeogenesis. 268  
2.10 Mechanisms of betel nut constituents and additives on major 
risk factors for T2DM 
2.10.1 Obesity and Adiposity 
Obesity is one of the most important modifiable risk factors for the development of 
T2DM.  The exact mechanism(s) by which obesity leads to T2DM is(are) not well 
established.  Increased amounts of non-esterified fatty acids, glycerol, hormones 
and pro-inflammatory cytokines are released from adipose tissue in an obese 
individual.269, 270  These factors have been shown to be involved in the development 
of insulin resistance.  The exact mechanism linking betel nut chewing and obesity is 
unknown. It is, however, speculated that betel nut increases appetite for food, which 
increases the risk of obesity.232  
In an in vitro study by Hsu et al271 it was shown that arecoline affects adipogenesis, 
lipolysis and glucose uptake of adipocytes.  The study, using 3T3-L1 preadipocytes 
from mouse embryos exposed to different concentrations of arecoline, reported that 
betel nut modulates adipose cell metabolism. This could explain the association of 
betel nut chewing with obesity as shown in a number of epidemiological studies.  
Results of that study271 concluded that betel nut may modulate adipose cell 
metabolism by inhibiting the adipogenic differentiation of preadipocytes, inducing 
lipolysis in adipocytes through an adenylyl cyclase-dependent pathway and 
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attenuating insulin-induced glucose uptake by adipocytes.  Although the study used 
cells from mouse embryos, which may not be comparable to fat cells from different 
tissues or organs, this study demonstrates a possible mechanism by which betel nut 
may be diabetogenic or worsen glycaemic control in people with T2DM.  It would 
also be important, as suggested by the authors, to determine how the arecoline 
concentrations used in this study were comparable to internal concentrations of 
arecoline in those who chew betel nut, especially when all components of the betel 
nut chew are masticated together.  A small study190 comprising of 15 participants 
attempted to determine a correlation between betel nut chewing and arecoline 
concentrations.  The study190 reported that there are different chemical constituents, 
additional to arecoline, in betel nut and these may have different effects on glucose 
homeostasis.  
Another similar study272 using both betel nut extract and arecoline, rather than 
laboratory grade arecoline only, found that both the extract and arecoline block 
insulin signalling and lipid storage in 3T3-L1 adipocytes.   That study reported the 
same finding: that arecoline reduced lipid droplet accumulation in adipocytes.  This 
study and the previous study,271 however, disagreed on the cause of the reduced 
lipid droplet formation.  The former study suggested that the reduction in droplets 
was due to a reduced number of differentiated adipocytes, while the latter suggested 
otherwise because their research used differentiated adipocytes.  Unlike the 
previous study271, this study272 used both betel nut extract (betel nut and PBL) and 
pure arecoline.  The betel nut extract, despite having an estimated amount of 
arecoline less than that of the laboratory grade arecoline used, had a better effect in 
reducing cellular lipids.  This suggests that there may be other constituents of betel 
nut extract that inhibit the accumulation of lipids in adipocytes, not only from betel 
nut but also Piper betle. 
There is emerging evidence that arecoline increases mRNA levels of CARs and 
PXRs and, therefore, it may be an agonist for both nuclear receptors.243 Activation of 
PXRs may partly explain the in vitro findings by the two studies271, 272 previously 
described.  Activation of PXRs stimulates lipogenesis and inhibits lipid oxidation, 
gluconeogenesis, glycogen storage and glucose transport.32, 103, 107  There are also 
findings that rats orally fed with betel nut extract have lowered absorption of 
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cholesterol245 or triglycerides246 and, therefore, reduced plasma lipid concentrations.  
The study by Ling et al243, which showed activation of CARs and PXRs by arecoline, 
reported a reduction in lipids and improved hepatic insulin resistance in fructose-
induced diabetic rats.  All these studies reflect inconsistencies and some of these 
may be due to the types of study (in vitro versus in vivo) and interspecies 
differences in metabolic pathways.  It is important to consider that the gut 
microbiome plays an important role in energy metabolism that may partly lead to the 
differences seen in the in vitro and in vivo studies. 
Apart from the type of diet affecting weight gain as a consequence of energy 
content, alterations in gut microbiota may also affect weight gain.273  There are 
substantial changes in composition and metabolic function of gut microbiota under 
obesity, indicating an influence of gut microbes on energy metabolism.273  This may 
be due to interactions between diet, gut microbiota and host metabolism.273-275  
Hormones such as glucagon-like peptide-1 (GLP-1) and ghrelin are involved in 
glucose and energy homeostasis and these may be affected by alterations in gut 
microbiota.276  
2.10.2 Blood pressure  
Regulation of blood pressure is complex and involves different mechanisms, such 
as neural mechanisms (sympathetic nervous system), renal endocrine-hormonal 
mechanisms, local endothelium-derived factors and other hormones. 
Betel nut and its constituents may also have a central sympathetic effect that results 
in increased heart rate.200  It has been reported by Lin et al that betel nut chewing 
reduces DBP, which shows that betel and/or its additives may have a peripheral 
cholinergic effect.200 
Betel nut may also affect blood pressure through an effect on catecholamine 
release.  In the Gilani study, using rabbit jejunum, the crude betel nut extract 
showed a dose-dependent spasmodic effect in the spontaneously contracting 
jejunum; an effect similar to that produced by physostigmine.202  This means that 
betel nut, like physostigmine, probably increases plasma adrenaline.   In a human 
study by Kennedy et al277, it was shown that high doses of physostigmine 
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significantly increased heart rate and systolic and diastolic blood pressure but a low 
dose, despite increasing adrenaline levels, did not alter plasma adrenaline or 
increase heart rate or systolic or diastolic blood pressure.  
Gilani et al,278 in an earlier study, investigated the presence of cholinomimetic and 
calcium antagonist constituents in PBL.  The researchers used PBL extracts on 
isolated guinea pig ileum and rabbit jejunum for their investigations.  To determine 
possible calcium channel antagonist activity, the rabbit jejunum was selected.  After 
depolarising the preparation with K+ to cause spontaneous contractions, the crude 
plant extract was added cumulatively.  Results showed a dose-dependent relaxant 
effect caused by the PBL crude extract, indicating spasmolytic activity.  The ethyl 
extract of PBL, however, was more potent (10 times) than the crude extract.    The 
authors suggest that the PBL crude extract’s inhibition of K+-induced contractions 
may be a result of blocking the calcium channels.  It was further observed that the 
ethyl extract inhibited Ca2+ contractions, followed by the displacement of high Ca2+ 
concentrations, which the authors conclude supports the presence of calcium 
channel inhibitory agent(s) in the ethyl fraction.278  The finding that PBL may contain 
calcium channel antagonist(s) adds to the evidence of effects of multiple chemical 
constituents of the betel nut chew.   Furthermore, this finding may assist in 
understanding the variable effects of betel nut chewing on blood pressure and, more 
specifically, its hypotensive effect. 
2.10.3 Systemic inflammation 
It is known that chronic inflammation is a risk factor for T2DM.279.  Betel nut has 
been linked to inflammation, thereby increasing the risk of T2DM in betel nut 
chewers.  Epidemiological studies have shown increased levels of inflammatory 
markers in betel nut chewers when compared to non-chewers.  Chung et al280 
reported increased plasma TNF-α in men who were betel nut chewers.  Shafique et 
al224 found increased levels of CRP in betel nut chewers.  Therefore, inflammation 
associated with betel nut chewing predisposes the chewer to T2DM. 
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2.11 Summary of findings from the literature 
Most of the studies investigating the metabolic consequences of betel nut chewing 
are epidemiological.  These studies contribute important findings of the associations 
between betel nut and metabolic derangements.  However, a few studies have 
reported contradictory findings. As with epidemiological findings, a causal 
relationship between betel nut use and metabolic derangements cannot be 
established.  Attempts to establish mechanisms of action have been pursued using 
in vitro or in vivo animal studies.   These studies may assist in clarifying the links 
between betel nut and metabolic derangements.  However, as seen from the 
studies, betel nut and its additives (PBL/PBI) contain many chemicals which may 
exert their effects in many ways.  The metabolic homeostasis is a complex process.  
Animal studies may not appropriately reflect what happens in a human body.  
Furthermore, there are other factors, such as ethnicity, genetics, socioeconomic 
status or development, environment and lifestyle, which may affect metabolic 
homeostasis. 
Similarly, there may be differences in the chemical contents of betel nut, with some 
studies showing differences in the arecoline content of betel nut from different 
countries including PNG, and also differences according to betel nut maturity.  Also, 
it is possible that the methods of chewing may influence the chemical constituents in 
the chew.  
Of importance to this research is the association between betel nut chewing and 
hyperglycaemia or T2DM.  Studies linking betel nut chewing with hyperglycaemia or 
T2DM used fasting glucose levels only.  Fasting glucose levels are a reflection of 
hepatic glucose output during fasting states, rather than post prandial glucose 
levels, and may not reflect any direct immediate effect of betel nut chewing on 
glucose levels.  It is therefore important to establish the glycaemic effect of betel nut 
during mastication to establish any immediate effect of betel nut chewing on 
glycaemic control. 
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Chapter III: Hypothesis and Aim 
 
 
3.1 Null Hypothesis 
 
H0: Betel nut chewing has no significant glycaemic effect in type 2 diabetes 
mellitus (T2DM) 
 
 
3.2 Alternative hypothesis 
 
H1: Betel nut chewing significantly increases blood glucose levels in T2DM. 
 
 
3.3 Main aim of the study 
 
The main aim of the study is to identify if any relationship occurs between betel nut 
chewing and glycaemic control [as measured by oral glucose tolerance, capillary 
blood glucose and/or glycated haemoglobin in T2DM patients 
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Chapter IV: Glycaemic effects of betel nut chewing 
and its associated factors in patients with T2DM 
4.1 Objectives 
The main objectives of this part of the research, involving a cohort of type 2 diabetes 
mellitus (T2DM) patients, were to: 
1 Identify their characteristics, with a focus on their demographics, lifestyle 
behaviours, diabetes management, and physical and biochemical 
measurements 
2 Estimate prevalence of betel nut use 
3 Identify demographic, lifestyle and physical factors associated with betel nut 
chewing 
4 Determine the effects of factors associated with betel nut chewing on 
glucose control [as measured by glycated haemoglobin (HbA1C)] 
5 Determine whether betel nut chewing is associated with poor glycaemic 
control and whether the association, if any, is independent of other 
confounding factors included in this research. 
4.2 Methodology 
 
4.2.1 Study setting  
 
The study was conducted at the Port Moresby General Hospital (PMGH) Diabetes 
Clinic in Papua New Guinea (PNG).  This is the largest hospital in PNG, and, as it is 
a referral hospital, it also has the largest Diabetes Clinic in terms of patient numbers. 
 
4.2.2 Study design 
This research was a cross-sectional study. 
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4.2.3 Study participants 
All ethnic Papua New Guineans who were diagnosed with T2DM and were 
registered at the PMGH Diabetes Clinic were considered for inclusion.  Patients 
included in the study were those who had been diagnosed with T2DM at least three 
months prior to recruitment.  This ensured that recently diagnosed patients were 
excluded from study, as one of the main items of interest concerned glucose control 
over the three months leading up to enrolment in the study.  These patients were 
identified from the Diabetes Clinic appointment book. Patients diagnosed with 
HIV/AIDS, pregnant women and those using a wheelchair were excluded from the 
study.  These patients were excluded because their physical measurements were 
either difficult to obtain (wheelchair bound), or confounded (HIV/AIDS or pregnant).  
Patients who lacked understanding of the study and what was required of them also 
were excluded.  This group included those who could not understand either of the 
two languages (Pidgin and English) used during the interview.   
 
4.2.4 Participant recruitment 
A verbal announcement was made about the study by the diabetes nurse each 
morning of the Diabetes Clinic.  On the first day of the study, participant information 
sheets [(PIS) Appendix 6] were handed to all the possible eligible participants.  From 
the second day until the end of the study, a list of participants already recruited was 
given to the clinic clerk.  The clinic clerk only handed the PIS to those who had not 
been already recruited during previous clinics.  The recruitment process is shown in 
Figure 4.1. 
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Figure 4.1  Recruitment process 
The number of registered patients at the clinic was 2,572.  All were potential 
participants. 
The total number of patients who attended the clinic during the study was 
1,496. 
Arrival of patients at waiting area 
Nursing observations (BP, weight, CBGL) and entry of results onto clinic 
cards at the nursing station 
Clinic books/cards presented to the clerk and patients called into the medical 
consultation waiting area   
Announcement about the 
study and handing out of PIS 
Consent sought from eligible 
patients 
Participant understood 
the study and gave 
consent (N=392), 7 
excluded 
Request for verbal 
clarification of 
study protocol 
Participant 
refused 
Total number of participants included 
was 385. 
 
 
Routine 
clinic 
procedures 
 
 
Participant 
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Data 
collection 
 
Patient 
awareness 
about the 
study 
First eligibility 
check by clerk 
Exclusion:  
Pregnant, 
wheelchair, 
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non-PNG, 
already 
recruited 
Second 
eligibility check 
by investigator 
Exclusion:  
HIV-positive, 
pregnant, non-
PNG, already 
recruited 
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4.2.5 Data collection 
4.2.5.1 Pilot questionnaire 
The study questionnaire (Appendix 8) was constructed using the World Health 
Organization (WHO) STEPwise approach to surveillance of non-communicable 
diseases (STEPS). 1   The STEPS questionnaire was chosen based on prior 
knowledge because it was used to collect data in PNG two years prior to the current 
study.  Data collected from participants with T2DM (current study) was to be 
compared with data from the non-T2DM participants of the STEPS study to meet the 
objectives of the study as a whole.     Questions on betel nut use within the STEPS 
questionnaire were expanded and questions on medication and some biochemical 
measurements were added into the instrument.  Some questions on social 
behaviour were modified to achieve the aims of the study. For example, the STEPS 
survey asked participants how many times they used betel nut daily while the 
current study asked participants how many betel nuts they chewed per day. This 
question was modified based on prior knowledge that some betel nut chewers chew 
more than one nut each time they chew betel nut.  Data collected included 
demographic information, behavioural measurements (betel nut chewing, vegetable 
and fruit consumption, physical activity, smoking and alcohol consumption), physical 
measurements (height, weight, waist and hip circumferences and blood pressure), 
biochemical measurements (fasting/random blood glucose, HbA1c, lipid profile, 
urea, creatinine, and urine protein and glucose) and diabetes management.  Certain 
items in STEPS, such as Oral Glucose Tolerance tests and questions on oral health 
were not included in the questionnaire.  The questionnaire was pretested at the 
PMGH Diabetes Clinic. 
 
4.2.5.2 Final questionnaire 
The pretesting of the questionnaire did not result in any changes in the 
questionnaire.   
 
4.2.5.3 Interviews 
Data were collected using face-to-face interviews.  All responses were entered onto 
the questionnaire used.  Show cards used in the STEPS (Appendix 9) survey also 
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were used to clearly explain terms such as servings of fruits and vegetables, and 
quantities of alcohol.   During the pretesting of the questionnaire, it was found that 
participants were not able to understand the term “serving” and when this was 
equated to a cup, they could not visualise a cup.  In PNG, the usage of the word 
“cup” is not specific to cup as a measure and it commonly includes a mug as well.  
To visualize a cup as a measure, a measuring cup was used to guide the 
participants in estimating the quantity of vegetable and fruit they consumed.  The 
number of cups was entered onto the questionnaire and was later converted to 
number of servings before data entry using the STEPS show card. 
 
4.2.5.4 Clinic Cards 
 
Participants’ clinic cards were used to validate some of the responses and 
information required, such as names of medications, their doses, date of birth, 
suburb of residence, pathology tests, and year of diagnosis and/or registration at the 
Diabetes Clinic. 
 
4.2.5.5 Measurement of HbA1c 
HbA1c was measured using the Point-of-Care Siemens/Bayer DCA 2000 Vantage™ 
analyser (Siemens Medical Solutions USA Inc, Palvern, PA, USA).  This machine 
was only able to measure HbA1c to 14.0%, so any reading more than 14.0% was 
given as >14.0% with no specific reading.  During data entry, this was entered as 
15.0% to indicate a reading in excess of 14.0%. 
 
4.2.6 Sample size and sampling 
The objectives of the study were to estimate the prevalence of betel nut chewing 
and to develop regression models to identify factors associated with betel nut 
chewing and glycaemic control.  A sample size of N=385 should lead to an estimate 
of prevalence with a 95% confidence interval of no more than +/-5%.  The 
confidence interval would be widest if the prevalence estimate was near 50%, and it 
would be narrower when it is either lower or higher than this.  For the regression 
model, a sample of this size would be adequate to identify any independent 
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variables exhibiting a small to moderate effect size.2 Hence, the study aimed to 
recruit N=385 participants. The method of sampling was convenience sampling. 
4.2.7 Ethics 
Patients were provided with a PIS (Appendix 6) to read before they were asked if 
they wanted to participate.  The PIS was written in English or orally translated into 
Pidgin English to those who requested it.  Patients also were asked whether they 
wanted the interview in English or Pidgin English before the interview commenced.  
Only those eligible patients who consented were recruited for the study.  Consent 
forms were signed by both the interviewer and the participant before the interview 
began. 
 
Approval for the study was granted by the Curtin University Human Research Ethics 
Committee [(HR 38/2011) Appendices 1,3)], The University of PNG School of 
Medicine and Health Sciences Research and Ethics Committee (Appendix 4) and 
the Medical Research Advisory Committee of the National Department of Health of 
PNG (Appendix 5).  Permission to undertake the study at the Diabetes Clinic at the 
PMGH was granted by the Chief Executive Officer of the hospital. 
 
4.2.8 Statistical analysis 
Data were entered into an Excel dataset and transferred into SPSS versions 20/21 
statistical software for analysis.  Simple descriptive statistics (frequencies and 
percentages or means and standard deviations, or medians and ranges, as 
appropriate) were used to summarise demographic and lifestyle factors, physical 
measurements, diabetes management and biochemical measurement variables. 
4.2.8.1  Univariate analyses 
The statistical significance of differences in betel nut chewing habits according to 
demographic factors including age, gender, suburb of residence, region of origin, 
level of education, employment status and lifestyle factors were assessed using the 
Chi-square statistics.  Similarly, univariate differences in glycaemic control between 
demographic variables, as well as lifestyle factors, physical activity, diabetes 
management and physical measurements such as body mass index (BMI) and 
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blood pressure, also were assessed using these tests.  Univariate logistic regression 
models were used to investigate the direction of the associations for different 
categories of each variable. 
 
4.2.8.2  Multivariate analyses 
Multiple Logistic Regression models were developed to identify which (if any) of the: 
i) demographic and lifestyle variables were independently associated with the 
prevalence of betel nut chewing; and    
ii) demographic, lifestyle, biochemical, physical measurement and diabetes 
management variables were independently associated with poor glycaemic 
control (HbA1c>7.0%). 
The results of regression analysis were presented as Odds Ratios, along with their 
95% confidence intervals and p-values.  Following convention, a p-value of <0.05 
was taken to indicate a statistically significant association in all tests. 
4.3 Results 
4.3.1 Study setting  
Apart from provincial divisions, PNG also is divided into four regions.  These regions 
are Southern, New Guinea Islands (NGI), Momase and Highlands as shown in 
Figure 4.2.  Port Moresby, the national capital of PNG is situated in the Southern 
region.  Port Moresby is not only the national capital of PNG but is also the capital of 
the Central Province.  The Central Province has its headquarters in Port Moresby 
but the administration is responsible for affairs of the Central Province only.  The 
administrative unit of the city of Port Moresby is the National Capital District (NCD) 
and the administrative authority of the city is the NCD Commission.   Although not a 
province as such, NCD is classified as the equivalent of a province. 
Each province in PNG has a provincial hospital, except for the two newly 
established provinces of Jiwaka and Hela.  The largest hospital in the country is the 
PMGH.  This hospital not only serves those who live in the city but also those who 
live in the rural areas of the Central Province.  Furthermore, this is the country’s 
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referral hospital, where all medical or surgical cases which cannot be dealt with in 
other provincial hospitals are managed.  
Not all provincial hospitals have specialist diabetes clinics.  When that is the case, 
patients with diabetes are usually cared for in general internal medicine clinics.  
There are five diabetes clinics in PNG, of which four are in Port Moresby.  Of all 
these clinics, PMGH Diabetes Clinic is the largest.  The clinic not only cares for 
patients who live in Port Moresby but also those from other provinces in the country 
who have registered at the clinic.   
During the time of the study, the PMGH diabetes clinic was run once a week for 
three hours on Tuesday mornings.  The consultation rooms are shared with other 
internal medicine specialties and paediatrics and, therefore, clinics for these 
specialties are usually rostered to run on a weekly basis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Regions of Papua New Guinea (Source:  Andrew Tulo, 2014) 
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4.3.2 Study participant recruitment 
Data were collected from 5th July to 25th October 2011 and then from 13th March 
2012 to 12th June 2012.  Data collection ceased in October 2011 because, in 
November of that year, the clinic was only attending to patients who were unstable 
in terms of cardiovascular morbidities (e.g. high blood pressure and blood glucose 
levels).  In December 2011 and January 2012, data could not be collected because 
of the annual closure of the clinic during these two months. 
Data were collected once weekly over 32 weeks (on Tuesdays) excluding the 
annual closure of the clinic in December and January.  This length of time was 
sufficient to recruit any patient who had previously refused to participate, if they 
changed their minds.  Of these 32 days, there were five days when the clinic was 
closed for a variety of reasons (shortage of staff, examinations for undergraduate 
and postgraduate medical students, or civil and political unrest). 
A total of 2,572 diabetes patients were registered at the Diabetes clinic during the 
time of this study.  During the study, a total of 1,496 patients attended the clinic.  A 
total of 392 participants were recruited but seven were later excluded.  Of those 
seven excluded, six were not Papua New Guineans and one was pregnant.  A final 
total of 385 participants were recruited into the study, with an average of 15 patients 
recruited into the study each clinic day. 
4.3.3 Demographic characteristics 
Of the 385 participants, 241 (62.6%) were females and 294 (76.4%) participants 
were from the Southern region of PNG where Port Moresby is situated (Table 4.1).  
The mean age for participants was 54.4±10.5 years (range 14 to 85 years). Three 
hundred and sixty five (94.8%) participants knew their date of birth while 20 (5.2%) 
did not.   This affected any data which required age for calculation of other variables, 
for example, calculation of the age when a participant started smoking or chewing 
betel nut.  The highest numbers of participants were in the age group 50-59 years.   
As shown in Table 4.1, the majority of participants resided in the many individual 
suburbs of Port Moresby; while 20% were from rural villages, 20% from urban 
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villages or settlements surrounding Port Moresby and about 4% were from other 
provinces. The suburbs or residential places were reclassified into areas of 
residence, namely: urban, peri-urban, rural and other province (Figure 4.3).  Urban 
dwellers were those who were living in urbanised suburbs within the city, peri-urban 
were those living in partly urbanised villages or settlements between the city’s 
suburbs and the rural villages within the outskirts of the city, rural dwellers were 
those living in rural villages in the Central Province and dwellers in “other province” 
were those who lived outside of the NCD and Central Province.   The peri-urban 
areas were administratively under the NCD.  More than 50% of the participants lived 
in urban residences.  Forty one percent of the participants had lived in Port Moresby 
for more than 10 years, and 20.5% were born in Port Moresby and had spent their 
entire lifetime there.  Ninety seven (25.2%) of the participants were not residing in 
Port Moresby; these participants were residing either in the rural or other province 
areas.  
Participants were asked about the highest level of education they had achieved 
where a certificate of completion was awarded.  Of the 385 participants, 88 (22.9%) 
either had no formal education or did not complete basic primary education (Grades 
6). Eighty six (22.3%) participants attained a secondary school certificate by 
completing Grades 10 or 12.  Vocational training in PNG was previously after 
completion of Grade 6 but is currently after completion of Grade 8.  Vocational 
training, however, may also be undertaken after completion of Grades 10 and 12.  
For those participants who indicated that they completed vocational training, it was 
not known whether they did the training after completion of basic primary education 
or secondary education.   
One hundred and ninety five (50.6%) participants were either in unpaid employment 
(volunteers, homemakers, Christian missionaries, students) or were unemployed. 
Twenty one percent of the participants were in regularly paid employment, both in 
the government and non-government sectors, while 39 (10.1%) were self-employed. 
Seventy (18.2%) participants were retired.  Table 4.1 shows the demographic 
characteristics of the participants. 
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Figure 4.3 Areas of residence of participants (Source:  Andrew Tulo,  
  2014) 
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Table 4.1 Demographic characteristics of study participants (N=385) 
Characteristic n* Percentage 
Gender 
Male 
Female 
 
144 
241 
 
37.4 
62.6 
Age category (years) 
<40 
40–49 
50–59 
60–69 
≥70 
 
24 
89 
145 
86 
21 
 
6.2 
23.1 
37.7 
22.3 
5.5 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
294 
26 
29 
36 
 
76.4 
6.8 
7.5 
9.4 
Level of education 
No formal education 
Less than Grade 6 
Grade 6 
Grade 8 
Grade 10 
Grade 12 
Vocational training 
Tertiary education 
 
39 
49 
71 
40 
74 
12 
29 
70 
 
10.1 
12.7 
18.4 
10.4 
19.2 
3.1 
7.5 
18.2 
Area of residence 
Urban 
Peri-urban 
Rural village 
Other province 
 
212 
77 
80 
15 
 
55.1 
20.0 
20.8 
3.9 
Employment status 
Homemaker 
Retired 
Unpaid 
Self-employed 
Unemployed, able to work 
Unemployed, unable to work 
Government worker 
Non-Government worker 
Student 
 
125 
70 
8 
39 
34 
25 
47 
34 
3 
 
32.5 
18.2 
2.1 
10.1 
8.8 
6.5 
12.2 
8.8 
0.8 
Number of years of in Port Moresby 
0# 
1-2 
3-5 
6-10  
 >10 
Lifetime 
 
97 
11 
5 
12 
159 
79 
 
25.2 
2.9 
1.3 
3.1 
41.3 
20.5 
* Number may not always add up to total because of missing values for some items; 
#Participant does not reside in Port Moresby 
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4.3.4 Lifestyle characteristics 
Lifestyle characteristics included in the study were alcohol consumption, smoking, 
betel nut chewing, physical activity, and fruit and vegetable consumption.   
4.3.4.1 Alcohol consumption 
The Chi-square statistic was used to test for any associations between alcohol 
consumption and the demographic factors (categorical variables).  Those variables 
which were found to show some association (p<0.05) were entered into a univariate 
logistic regression model to investigate the direction of the associations for different 
categories of each variable.   
Only a small number of 38 (9.9%) participants reported consuming alcohol in the 
preceding three months before the study (Table 4.2).  Of those who consumed 
alcohol in the preceding three months, 63.9% reported consuming 10 drinks or less 
on a single occasion, while 36.1% consumed more. For this subgroup, the mean 
number of days that male participants had consumed five or more standard drinks in 
a single day within the preceding three months was 5.27±4.48 days (n=15).  In 
comparison, the mean number of days that female participants had consumed four 
or more standard drinks in a single day was 1.29±0.76 days (n=7).  The most 
common sources of alcohol were friends and relatives.  More than 60% of the 
participants who consumed alcohol, had ≤10 alcoholic drinks as their largest number 
of drinks on a single occasion.  Although drinking at a party was not listed on the 
questionnaire as an option, it was one of the sources of alcohol reported by two 
participants who consumed alcohol but could not identify an appropriate alcohol 
source within the list of the questionnaire.  These parties were work-related and, 
therefore, alcohol was supplied by the employers of these two participants.   
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Table 4.2 Alcohol consumption amongst participants 
Variables Frequency [n/N(%)] 
Alcohol consumed in the previous three months 
No  
Yes  
 
347/385 (91.9) 
38/385 (9.9) 
Frequency of having at least one drink in the 
previous 3 months 
1-7 days/week 
1-3 days/month 
Less than once a month 
 
 
7/38 (18.4) 
14/38 (37.8) 
16/38 (43.2) 
Alcohol consumed in the previous 30 days 
No 
Yes  
 
7/38 (18.4) 
31/38 (81.6) 
Average number of alcoholic drinks at any one time 
in a day 
≤5 
6-10 
>10 
 
 
20/38 (52.6) 
11/38 (28.9) 
7/38 (18.4) 
Alcohol consumed in the previous seven days 
No  
Yes 
 
25/38 (65.8) 
13/38 (34.2) 
Largest number of drinks on a single occasion in the 
previous three months 
1-10 
11-20 
>20 
 
 
23/38 (63.9) 
10/38 (27.8) 
3/38 (8.3) 
Source of alcohol* 
Bought by self 
Friends 
Relatives 
Parties 
 
18/38 (47.4) 
25/38 (65.8) 
25/38 (65.8) 
2/38 (5.3) 
*Numbers add to more than the total number of those who consumed alcohol because 
participants gave more than one source of alcohol supply. 
 
Age, gender and employment status had a statistically significant association with 
alcohol consumption in the preceding three months.  As age increased, the number 
of participants who consumed alcohol decreased (Table 4.3).  Those aged <50 
years were more likely to consume alcohol compared to those aged 50 years or 
older.  Male participants appeared to consume more alcohol than their female 
counterparts.  Of all the 38 participants who consumed alcohol, 24 (63.2%) of these 
were males.  Those who did not complete basic education and those who completed 
primary education only were less likely to consume alcohol compared to their 
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counterparts in other categories of education. Employment status also had an 
important influence on alcohol consumption, with those in paid employment and 
those who were self-employed more likely to consume alcohol than the other 
participants. 
Table 4.3 Associations of demographic factors with alcohol 
consumption  
Variable Alcohol consumed in the 
previous three months 
p-value* 
No Yes 
Gender 
Female 
Male 
 
227 (94.2) 
120 (83.3) 
 
14 (5.8) 
24 (16.8) 
0.001 
Age category (years) 
<50 
50-59 
≥60 
 
90 (79.6) 
134 (92.4) 
103 (96.3) 
 
23 (20.4) 
11 (7.6) 
4 (3.7) 
<0.001 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
87 (98.9) 
103 (92.8) 
74 (86.0) 
24 (82.8) 
58 (82.9) 
 
1 (1.1) 
8 (7.2) 
12 (14.0) 
5 (17.2) 
12 (17.1) 
0.003 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
66 (81.5) 
185 (94.9) 
66 (94.3) 
30 (76.9) 
 
15 (18.5) 
10 (5.1) 
4 (5.7) 
9 (23.1) 
<0.001 
Area of residence 
Urban 
Peri-urban 
Rural village 
Other Province 
 
193 (91.0) 
69 (89.6) 
70 (87.5) 
14 (93.3) 
 
19 (9.0) 
8 (10.4) 
10 (12.5) 
1 (6.7) 
0.798 
Region of origin 
Southern region 
New Guinea Islands 
Momase 
Highlands 
 
266 (90.5) 
30 (83.3) 
25 (96.2) 
26 (89.7) 
 
28 (9.5) 
6 (16.7) 
1 (3.8) 
3 (10.3) 
0.395 
Years of residence in Port Moresby 
0# 
1-10 
>10 
Lifetime 
 
85 (87.6) 
25 (89.3) 
150 (94.3) 
68 (86.1) 
 
12 (12.4) 
3 (10.7) 
9 (5.7) 
11 (13.9) 
0.143 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; #Participant does not reside in Port Moresby 
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Using a reply of “Yes” to the question of whether alcohol was consumed as the 
dependent variable, multivariate logistic regression analysis indicated that age, 
gender and years of residence in Port Moresby were independently associated with 
alcohol consumption.   Participants aged <50 years were 10 times more likely to be 
consuming alcohol compared to their counterparts aged 60 years and older.  
Female participants had lower odds of consuming alcohol compared to their male 
counterparts.  Those who were not born in Port Moresby were less likely to 
consume alcohol and this was significant for those who had moved to and lived in 
Port Moresby for more than 10 years.  Those who completed vocational training had 
a positive risk of consuming alcohol. However, this did not reach statistical 
significance.  All other demographic variables did not appear to be associated with 
alcohol consumption.  The results of the multivariate logistic regression analysis are 
shown in Table 4.4.   
Although employment status had an influence on alcohol consumption, as shown in 
Table 4.3, backward elimination (logistic regression) dropped this variable and this 
may have been due to its correlation with age. Retired participants are included in 
the age group 60 years and older. 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
Table 4.4 Multivariate logistic regression analysis of demographic risk 
factors for alcohol consumption (N=38) 
Variable n(%)* Adjusted OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60 
 
23 (20.4) 
11(7.6) 
4 (3.7) 
 
10.76 
2.37 
1 (reference) 
 
3.06-37.92 
0.64-8.80 
<0.001 
<0.001 
0.198 
Gender 
Female 
Male 
 
14 (5.8) 
24 (16.8) 
 
0.26 
1 (reference) 
 
0.12-0.61 
0.002 
Years of residence in Port 
Moresby 
0# 
1-10 
>10 
Lifetime 
 
 
12 (12.4) 
3 (10.7) 
9 (5.7) 
11 (13.9) 
 
 
0.90 
0.24 
0.19 
1 (reference) 
 
 
0.32-2.51 
0.04-1.48 
0.06-0.67 
0.037 
 
0.837 
0.124 
0.009 
*The column showing ‘n/N (%)’ shows the number of people (and percentage) of alcohol 
consumers within each variable. The dependent variable was “Yes” to alcohol consumed in 
the previous three months; #Participant does not reside in Port Moresby 
 
4.3.4.2 Tobacco smoking 
Tobacco smokers were further categorised according to their tobacco smoking 
status (current, never and quit), and as to whether they were ever (both current and 
those who had quit) or never smokers.  The number of years of smoking also was 
calculated and participants were categorised according to these numbers of years. 
Age at onset and cessation of smoking, and the number of years of smoking, were 
not normally distributed and therefore are reported as median and range where 
appropriate. 
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Like the consumption of alcohol, the number of participants who smoked tobacco 
was small, with only 24 (6.2%) of the participants reporting that they were current 
smokers (Table 4.5).  Of these 24 smokers, 19 (79.2%) were daily smokers.  Two 
hundred and seventy two (70.6%) participants had never smoked tobacco, while 
113 (29.4%) were “ever” (current and quit) smokers.  Of these, 89 (78.8%) 
participants had quit the habit.   
For those classified as smokers, the median age at which participants had started 
smoking was 18 but this ranged over 44 years (range: 12-56 years).  The median 
number of years of daily smoking for current smokers was 28.5 but this ranged over 
38 years (range: 3-41 years).   
For participants who had quit smoking, the median age at which these participants 
had quit the habit was 43 but this ranged over 54years (range: 15-69 years).  The 
median number of years that this group of participants had been smoking before 
they quit was 13, with a range of 43.5 years (range: 0.5-44 years) 
Thirteen (54.2%) participants who were smokers had been smoking for more than 
20 years. Of the 24 participants who were smokers, 6 (25.0%) could not remember 
when they had started smoking and, therefore, the number of years these 
participants had smoked could not be calculated and were reported as missing data. 
Manufactured cigarettes were the most common type of tobacco product used by 
smokers.  Of the 24 smokers, 14 (58.3%) smoked manufactured cigarettes while 
eight (33.3%) smoked hand-rolled cigars. Two participants did not indicate the type 
of tobacco product they smoked, while none of those who smoked used pipes of 
tobacco.  Of the fourteen who smoked manufactured cigars, 85.8% smoked 20 
cigars or less per day, while all those who smoked hand-rolled cigars smoked less 
than 10 per day (Table 4.5).   
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Table 4.5 Frequency of tobacco smoking and the characteristics of 
participants 
Variables Frequency* [n/N (%)] 
Current smoker 
No  
Yes  
 
361/385 (93.8) 
24/385 (6.2) 
Age (years) at onset of smoking for current smokers 
[median (range)]  
18 (12-56) 
Age (years) when quit smoking [median (range)] 43 (15-69) 
Number of years of smoking for current smokers 
[median (range)] 
28.5 (3-41) 
No. of years of smoking for those who quit [median 
(range)] 
13 (0.5-44) 
Smoker status 
Never  
Quit 
Current  
 
272/385 (70.6) 
89/385 (23.1) 
24/385 (6.2) 
Number of years of smoking 
≤ 10 
11–20 
21-30 
>30 
 
1/24 (4.2) 
4/24 (16.7) 
7/24 (29.2) 
6/24 (25.0) 
Number of manufactured cigars smoked/day 
1-10 
11-20 
>20 
14/24 (58.3) 
6/14 (42.9) 
6/14 (42.9) 
2/14 (14.3) 
Number of hand-rolled cigars smoked/day 
1-10 
11-20 
>20 
8/24 (33.3) 
8/8 (100) 
0/8 (0) 
0/8 (0) 
*May not add up to the total because of missing values 
As age increased, the number of those smoking decreased.  The younger aged 
participants were more likely to smoke, especially those who were younger than 50 
years of age (Table 4.6).   
Sample numbers were very small for the smoking categories because of the small 
number of participants who were classified as smokers and, therefore, no further 
analysis could be performed to draw any additional valid conclusions. 
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Table 4.6 Demographic factors associated with tobacco smoking 
(N=385)  
Variable Current tobacco smoker [n (%)] p-value* 
No Yes 
Age category (years) 
<50 
50-59 
≥60 
 
99 (87.6) 
138 (95.2) 
104 (97.2) 
 
14 (12.4) 
7 (4.8) 
3 (2.8) 
0.009 
Area of residence 
Urban 
Peri-urban 
Rural village 
Other Province 
 
204 (96.2) 
71 (92.2) 
72 (90.0) 
13 (86.7) 
 
8 (3.8) 
6 (7.8) 
8 (10.0) 
2 (13.3) 
0.068§ 
Years of residence in Port Moresby 
0# 
1-10 
>10 
Lifetime 
 
87 (89.7) 
28 (100.0) 
153 (96.2) 
73 (92.4) 
 
10 (10.3) 
0 (0.0) 
6 (3.8) 
6 (7.6) 
0.090§ 
*The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; §Fisher’s Exact Test; #Participant does not reside in Port Moresby 
 
4.3.4.3 Fruit and vegetable consumption 
Participants were requested to think of a typical week (in the preceding three 
months) when they had consumed vegetables or fruit, and recall the number of days 
and the number of cups of fruits or vegetables consumed during that week.  The 
number of cups was converted to number of servings, based on the conversions in 
Appendix 9. 
As shown in Table 4.7, vegetable and fruit consumption was poor. Ninety two 
percent of the participants reported consuming ≤3 servings of vegetables per day in 
a typical week.  Despite eating less serves of vegetable in a day, 42.3% of the 
participants reported eating vegetables 6-7 days in a typical week.  When compared 
with vegetable consumption, 70% of the participants consumed fruit on two days or 
less in a typical week, and 70% had ≤2 serves of fruit on a day when they had fruit. 
Univariate logistic regression analysis indicated that the number of fruit servings was 
associated with gender and this relationship was statistically significant.  Male 
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participants were almost twice as likely to consume <2 serves of fruit (Crude 
OR=1.872, 95% CI=1.20-2.93, p=0.006) compared to their female counterparts.  
There was no statistically significant relationship between fruit consumption and 
employment status, level of education, area of residence or age.  Similarly, no 
demographic variable had a statistically significant impact on vegetable 
consumption. 
Table 4.7 Frequencies of fruit and vegetable consumption 
characteristics (N=385) 
Variables Frequency*n (%) 
Vegetable servings/day 
<3 
≥3 
 
355 (92.2) 
28 (7.3) 
Number of vegetable-eating days/week 
0-2 
3-5 
6-7 
 
96 (24.9) 
124 (32.2) 
163 (42.3) 
Fruit servings/day  
<2 
 ≥2 
 
271 (70.4) 
112 (29.1) 
Number of fruit-eating days/week 
0-2 
3-5 
6-7 
 
272 (70.6) 
70 (18.2) 
41 (10.6) 
*May not add up to total because of missing values 
4.3.4.4 Physical activity 
Participants were asked about physical activity in a typical week within the 
preceding three months before the study.  Physical activity included work-related 
physical activity, walking and cycling to get to and from places, and participation in 
sports, fitness and recreational activities.  They were asked if they were involved in 
these activities for at least 10 minutes continuously on a single occasion.  The 
response was ‘no’ if the physical activity took less than 10 minutes.  None of the 
participants cycled to get to and from places.  Work-related physical activity included 
paid or unpaid work such as study/training, household chores, planting, tending and 
harvesting food crops, fishing or hunting for food, marketing and seeking 
employment.  
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Work-related physical activity was classified according to moderate- and vigorous-
intensity activities (MIA and VIA, respectively).  Likewise, sports, fitness and 
recreational activities also were classified according to moderate- and vigorous-
intensity activities (MISFRA and VISFRA, respectively).  A show card (Appendix 12) 
was used to identify which physical activities were classified as moderate- or 
vigorous-intensity activities.  The number of minutes each participant reported 
undertaking a particular activity was multiplied by the number of days in a week 
such activities were undertaken to calculate the total minutes of physical activity per 
week.   
Participants were further categorised according to the amount of physical activity 
they performed in a week.  These categories were: sufficient, insufficient and no 
physical activity.  Participants were classified as doing sufficient physical activity (in 
minutes per week), if any of the types of physical activity they participated in met the 
WHO recommendations for the number of minutes per week for a particular intensity 
of physical activity. 3  
 As shown in Table 4.8, results indicated that walking to get to and from places was 
the most common physical activity, with 76.9% (n=296) reporting that they had 
walked for at least 10 minutes continuously to get to and from places.   
In comparison to walking as a type of physical activity, the numbers of participants 
participating in both work-related VIA and VISFRA were small.  Only 53 (13.8%) and 
34 (8.8%) of the study participants were involved in work-related VIA and VISFRA, 
respectively.  In general, as the intensity of physical activity increased, the number 
of participants undertaking these activities decreased. 
Two hundred and eighteen (56.6%) participants reported undertaking sufficient 
physical activity while the remainder either performed insufficient or no physical 
activity (Table 4.8).  
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Table 4.8 Frequencies of self-reported physical activity  
Variables Frequency* [(n/N)%] 
Work-related VIA for at least 10 minutes 
No 
Yes 
 
332/385 (86.2) 
53/385 (13.8) 
Minutes of work-related VIA /week 
<75 
≥75 
 
17/53 (32.1) 
35/53 (66.0) 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
351/385 (91.2) 
34/385 (8.8) 
Minutes of VISFRA/week 
 <75 
≥75 
 
14/34 (41.2) 
20/34 (58.8) 
Work-related MIA for at least 10 minutes 
No  
Yes 
 
225/385 (58.4) 
160/385 (41.6) 
Minutes of work-related MIA/week 
<150 
 ≥150 
 
56/160 (35.0) 
102/160 (63.8) 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
317/385 (82.3) 
68/385 (17.7) 
Minutes of MISFRA/week 
<150 
≥150 
 
51/68 (75.0) 
17/68 (25.0) 
Walks to get to and from places for at least 10 minutes 
No 
Yes 
 
89/385 (23.1) 
296/385 (76.9) 
Minutes walking /week 
<150 
≥150 
 
133/296 (44.9) 
152/296 (51.4) 
Amount of physical activity 
Insufficient 
Sufficient 
None 
 
109/385 (28.3) 
218/385 (56.6) 
58/385 (15.1) 
*May not add up to total because of missing values; VIA = vigorous-intensity activity; MIA = 
moderate-intensity activity; VISFRA = vigorous-intensity sports, fitness and recreational 
activity; MISFRA = moderate-intensity sports, fitness and recreational activity. 
 
Using Chi-square statistics, the amount of physical activity, which summarises all 
types of physical activity, was further examined to determine if there was an 
association and, if so, the strength of any association with demographic factors.  
Furthermore, the Chi-square statistics also were used to determine if there was an 
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association between age and employment status, and different types of physical 
activities. 
Chi-square analysis indicated that age and employment appeared to be associated 
with the amount of physical activity (Table 4.9).  Those who were less than 50 years 
old were more likely to do sufficient physical activity.  In reference to employment 
status, those who were self-employed were more likely to do sufficient physical 
activity, while those who were retired were more likely to lack sufficient physical 
activity. Participants who were rural village dwellers were more likely to do sufficient 
physical activity compared to their counterparts who lived in other residential areas, 
but this did not reach statistical significance.   
Age influenced whether or not respondents participated in sports, fitness and 
recreational activities but it did not affect work-related physical activities.  Those 
aged 50 years and older were less likely to participate in both MISFRA (χ2, p=0.002) 
and VISFRA (χ2, p<0.001).  There was no significant association between age and 
different intensities of work-related physical activity. 
The Chi-square statistics indicated that both work-related physical activity and 
participation in sports, fitness and recreational activities were influenced by 
employment status. 
Participants who were self-employed were more likely to undertake work-related 
MIA and VIA at their workplaces compared to the other categories of employment 
status (χ2, p=0.015, p<0.001 for each scale of intensity of physical activity, 
respectively).   Those who were self-employed were also more likely to participate in 
MISFRA and VISFRA compared to the other categories of employment status (χ2, 
p=0.008, p=0.019 for each scale of intensity of physical activity, respectively).  
Overall, retirees were the least active, while those who were self-employed were the 
most physically active in terms of both work-related physical activities, and sports, 
fitness and recreational activities. 
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Table 4.9 Demographic factors associated with amount of physical 
activity   
Variable Sufficient 
physical 
activity 
Insufficient 
physical 
activity 
Lack of 
physical 
activity 
p-value* 
Age category (years) 
<50 
50-59 
≥60 
 
78 (69.0) 
80 (55.2) 
65 (60.7) 
 
19 (16.8) 
48 (33.1) 
21 (19.6) 
 
16 (14.2) 
17 (11.7) 
21 (19.6) 
0.012 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
49 (60.5) 
115 (59.0) 
40 (57.1) 
30 (76.9) 
 
22 (27.2) 
53 (27.2) 
11 (15.7) 
7 (17.9) 
 
10 (12.3) 
27 (13.8) 
19 (27.1) 
2 (5.1) 
0.016 
Years of residence in Port 
Moresby 
0# 
1-10 
>10 
Lifetime 
 
 
69 (71.1) 
16 (57.1) 
96 (60.4) 
41 (51.9) 
 
 
16 (16.5) 
5 (17.9) 
39 (24.5) 
27 (34.2) 
 
 
12 (12.4) 
6 (16.7) 
3 (11.5) 
6 (20.7) 
0.079 
*The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; #Participant does not reside in Port Moresby 
 
As shown in Table 4.8, walking as a type of physical activity was the most common, 
with more than 70% of the participants reporting that they walked to get to and from 
places.  
Demographic factors shown in Table 4.1 were examined using univariate logistic 
regression to confirm any significant association between walking to get to and from 
places and the recommended number of minutes (≥150) of walking per week.  
Univariate logistic regression also was used to examine the direction of 
associations, in addition to the p-values. 
As shown in Table 4.10, univariate logistic regression analysis indicated that the 
only demographic factor which had an impact on a participant walking to get to and 
from places was gender.  Female participants were more likely to walk to get to and 
from places.  Age, employment status, area of residence and region of origin of the 
participants had Odds Ratios of more than 1 (more likely to walk to get to and from 
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places), but these did not reach statistical significance.  Multivariate logistic 
regression analysis indicated that gender was the only significant independent 
influence on the likelihood of walking to get to and from places.  The adjusted odds 
for female participants walking to get to and from places was almost two (OR 1.709, 
95% CI 1.031-2.831, p=0.038). 
Table 4.10 Univariate logistic regression analysis of demographic 
factors affecting whether or not a participant walked to get to and from 
places  
Variable Crude OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60 
 
1.36 
1.87 
1 (reference) 
 
0.75-2.47 
1.04-3.36 
0.116 
0.315 
0.038 
Gender 
Female 
Male 
 
1.70 
1 (reference) 
 
1.05-2.75 
0.030 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
1.44 
1.30 
0.88 
0.61 
1 (reference) 
 
0.67-3.12 
0.63-2.66 
0.43-1.82 
0.24-1.56 
0.329 
0.350 
0.477 
0.727 
0.302 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1.67 
1.78 
1.04 
1 (reference) 
 
0.70-3.97 
0.83-3.82 
0.44-2.43 
0.224 
0.244 
0.141 
0.933 
Area of residence 
Urban 
Peri-urban 
Rural village 
Outside Province 
 
1.15 
1.39 
1.35 
1 (reference) 
 
0.35-3.76 
0.39-4.94 
0.38-4.77 
0.897 
0.820 
0.614 
0.644 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
1.29 
1.14 
1.60 
1 (reference) 
 
0.55-3.05 
0.38-3.47 
0.45-5.70 
0.889 
0.560 
0.814 
0.468 
Years of residence in Port Moresby 
 0# 
1-10 
>10 
Lifetime 
 
1.30 
0.67 
1.01 
1 (reference) 
 
0.63-2.67 
0.26-1.72 
0.54-1.90 
0.574 
0.475 
0.404 
0.979 
The dependent variable was “Yes”, respondent walks to get to and from places. 
#Participant does not reside in Port Moresby 
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Although female participants were more likely to walk to get to and from places, they 
were less likely to walk for ≥150 minutes per week (Table 4.11).  Area of residence 
did not influence whether or not a participant walked to get to and from places 
(Table 4.10) but, when examining the number of minutes that participants walked in 
a week, area of residence had an influence (Table 4.11).  Those living in rural areas 
and outside of Port Moresby were more likely to walk for ≥150 minutes per week 
compared to their urban and peri-urban counterparts. 
Univariate logistic regression indicated that rural village dwellers were more likely to 
walk for ≥150 minutes or more per week to get to and from places compared to their 
study counterparts.  Participants who had not lived in Port Moresby were three times 
more likely to walk for ≥150 minutes in a week, while those who had moved to live in 
Port Moresby were twice as likely to walk for ≥150 minutes compared to their 
counterparts who were born in Port Moresby (Table 4.11) 
Table 4.11 Univariate analysis of demographic factors affecting the 
number of minutes a participant walked to get to and from places   
Variable Crude OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60 
 
1 (reference) 
0.51 
0.72 
 
 
0.29-0.90 
0.38-1.38 
0.067 
 
0.021 
0.324 
Gender 
Female 
Male 
 
0.55 
1 (reference) 
 
0.34-0.91 
0.021 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
0.46 
0.43 
0.69 
1 (reference) 
 
0.17-1.21 
0.18-1.06 
0.25-1.92 
0.195 
0.117 
0.066 
0.479 
Area of residence 
Urban 
Peri-urban 
Rural village 
Outside Province 
 
1 (reference) 
0.63 
1.87 
1.37 
 
 
0.34-1.15 
1.01-3.48 
0.37-5.05 
0.036 
 
0.131 
0.048 
0.636 
Years of  residence in Port Moresby 
0# 
1-10 
>10 
Lifetime 
 
3.68 
2.68 
2.36 
1 (reference) 
 
1.79-7.54 
0.93-7.73 
1.23-4.51 
0.005 
<0.001 
0.068 
0.010 
The dependent variable was ≥ 150 minutes per week spent walking; #Participant does not 
reside in Port Moresby 
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4.3.5 Medical characteristics 
Medical characteristics included the number of years since being diagnosed with 
diabetes, diabetes management, and biochemical and physical measurements.  The 
number of years since a participant had been diagnosed with diabetes, capillary 
blood glucose (CBG) and HbA1c were not normally distributed and are reported as 
median and range, where appropriate.  Waist circumference, BMI, fasting CBG and 
HbA1c were classified according to the PNG Diabetes Clinical Guidelines 2012.  
There were discrepancies in hip circumference measurements and, therefore, no 
further analysis was undertaken using this variable. 
The median number of years since having been diagnosed with diabetes was 4.0, 
with a minimum and maximum of 0.5 and 30.0 years, respectively. 
As shown in Table 4.12, the median and range values for HbA1c and fasting CBG, 
and for BMI, at time of enrolment were above the ideal values of ≤7.0% (HbA1c), ≤7 
mmol/L (CBG) and <25 kg/m2, respectively.  Mean systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) were also above normal.  The mean waist 
circumference was at the normal value for male participants (normal is ≤102 cm) but 
was higher than normal for female participants (normal is ≤88cm). 
Diabetes management included lifestyle modifications, as well as pharmacological 
and other types of treatment employed by the participant, whether or not participants 
missed their prescribed doses of medications, and reasons for missing doses if they 
did, and pharmacological management of co-morbidities. 
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Table 4.12 Medical characteristics of participants at the time of 
enrolment (N=385) 
Variable n/N (%)* Mean SD 
Weight (kg) 371 (96.4) 70.6 14.2 
Waist circumference (cm) 
Female 
Male 
384 (99.7) 
240/385 (62.3) 
144/385 (37.4) 
101.3 
102.2 
99.8 
11.7 
12.0 
11.2 
Hip circumference (cm) 382 (99.2) 101.8 11.2 
BMI (kg/m2) 368 (95.6) 27.0 4.9 
SBP (mmHg) 380 (98.7) 150.1 25.0 
DBP (mmHg) 380 (98.7) 83.0 13.9 
CBG (mmol/L) 
Fasting 
Random 
Unknown 
380 (98.7) 
147/380 (38.7) 
150/380 (39.5) 
83/380 (21.8) 
10.4† 
9.3† 
12.3† 
9.9† 
2.0 – 34.0§ 
2.0 – 23.9§ 
4.7 – 34.0§ 
3.1- 23.7§ 
HbA1c (%) 362 (94.0) 8.7† 4.8 - >14.0§ 
Number of years diagnosed with 
diabetes 
 
384 (99.7) 
 
4.0† 
 
0.5 - 30.0§ 
*Percentages do not add up to 100% because of missing values; †Median; §Range; BMI = 
body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; CBG = 
capillary blood glucose; HbA1c = glycated haemoglobin 
 
4.3.5.1 Initial diabetes management when diagnosed 
Participants were questioned about their initial management when they were first 
diagnosed with diabetes. Of the 385 participants, 336 (87.3%) were treated with 
hypoglycaemic medications while 48 (12.5%) were diet-controlled.  Of those treated 
with hypoglycaemic medications, 45 (13.4%) were treated with insulin (as a single 
agent or with oral therapy) and 317 (94.3%) were treated with oral hypoglycaemic 
medications.  Twenty five participants (7.4% of those on hypoglycaemic 
medications) were treated with both insulin and oral hypoglycaemic medications.  
None of the participants was on a prescribed diet, as such, but 99 (25.7%) were 
advised about their diet.  Of these, 59 (59.6%) changed their diet in line with advice 
provided by their medical officers. 
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Apart from hypoglycaemic medications and diet management, participants 
employed other ways to manage their diabetes. Twenty three (6.0%) used herbal 
products, while 15 (3.9%) used traditional medicine. 
4.3.5.2 Diabetes management in the three months preceding study 
recruitment 
Three hundred and fifty six (92.5%) participants were prescribed hypoglycaemic 
medications in the preceding three months (Table 4.13).  However, five of these 356 
participants had ceased their medications for more than three months.  These five 
participants continued to attend scheduled reviews but did not inform their medical 
officers that they had ceased taking their hypoglycaemic medications.  These 
participants were, therefore, excluded from any statistical analysis on 
hypoglycaemic medication use.  In the preceding three months, only 29 of the 
participants had diet-controlled diabetes. 
4.3.5.3 Hypoglycaemic medications in the preceding three months 
Glibenclamide, metformin and insulin were the only hypoglycaemic medications 
available through the public health care system during the time of this study.  
Glibenclamide was available in 5mg, and metformin in 500 mg, tablets.  There was 
an inconsistent supply of insulin and insulin syringes during the period of the study.  
More than 50% of the participants were receiving only one hypoglycaemic 
medication.  The least used hypoglycaemic medication was insulin, with only 19 
(5.4%) using it, and the most commonly used medication was glibenclamide 
(76.9%).  More than 80% of participants were on the mid- and highest dose ranges 
for both glibenclamide and metformin, as shown in Table 4.13. 
Results indicated a change of diabetes management for 48 of the participants, from 
diet control to the use of pharmacological agents in the preceding three months, and 
a reduction in the number of participants treated with insulin since diagnosis with 
T2DM.   
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Table 4.13 Hypoglycaemic medication use and participants’ self-
reported adherence  
Variable Frequency* 
n/N (%) 
Any hypoglycaemic medications prescribed in the previous three 
months 
No  
Yes  
 
 
29/385 (7.5) 
356/385 (92.5) 
Missed any hypoglycaemic doses in the previous three months 
No  
Yes  
 
 
143/351 (40.7) 
208/351 (59.3) 
Number of hypoglycaemic agents 
1 
2 or 3 
 
187/351 (53.3) 
159/351 (45.3) 
Hypoglycaemic used† 
Glibenclamide 
Metformin 
Insulin 
 
270/351 (76.9) 
223/351 (63.5) 
19/351 (5.4) 
Glibenclamide used† 
No  
Yes  
 
108/351 (30.8) 
270/351 (76.9) 
Glibenclamide dose/day 
≤5mg 
7.5–15 mg 
>15 mg 
 
44/270 (16.3) 
152/270 (56.3) 
74/270 (27.4) 
Glibenclamide dose missed 
No 
Yes  
 
112/270 (41.5) 
158/270 (58.5) 
Metformin used 
No  
Yes  
 
156/351 (40.5) 
223/351 (57.9) 
Metformin doses/day 
≤500mg 
750–1,000 mg 
>1,000 mg 
 
39/223 (17.5) 
112/223 (50.2) 
71/223 (31.8) 
Metformin dose missed 
No  
Yes  
 
99/223 (44.4) 
123/223 (55.2) 
* May not add up to total because of missing values; †Exceeds total because some 
participants took more than one medication 
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4.3.5.4 Hypoglycaemic medication use and duration of diabetes 
The use of hypoglycaemic medication was significantly associated with duration of 
diabetes, as shown in Table 4.14.  The daily dose of insulin was not included in the 
analysis because more than 80% of the 19 participants on insulin could not recall 
their doses of insulin.  The daily doses of glibenclamide and metformin were higher 
for those who had been undergoing treatment for diabetes for >5 years, compared 
to their counterparts.  Those taking two or three hypoglycaemic medications were 
more likely to be those who had been suffering with diabetes for more than five 
years.  Participants diagnosed with diabetes for >5 years were also more likely to 
use insulin than their counterparts. 
Table 4.14 Association of hypoglycaemic medication use with duration 
of diabetes  
Variable Duration of diabetes (years) p-value* 
≤ 5 > 5 
Glibenclamide use 
No 
≤5 mg/day 
7.5-15mg/day 
>15mg/day 
 
72 (66.7) 
25 (56.8) 
86 (57.0) 
27 (36.5) 
 
36 (33.3) 
19 (43.3) 
65 (43.0) 
47 (63.5) 
0.001 
Metformin use 
No 
≤500 mg/day 
750-1,000mg/day 
>1,000mg/day 
 
92 (59.4) 
26 (66.7) 
64 (57.7) 
28 (39.4) 
 
63 (40.6) 
13 (33.3) 
47 (42.3) 
43 (60.6) 
0.0015 
Insulin use 
No  
Yes 
 
208 (57.0) 
4 (21.1) 
 
157 (43.0) 
15 (78.9) 
0.002 
No. of hypoglycaemic medications/day 
0# 
1 
2 or 3 
 
22 (75.9) 
117 (62.6) 
71 (44.9) 
 
7 (24.1) 
70 (37.4) 
87 (55.1) 
<0.001 
#* The p-values were obtained from the Chi-square statistic, and assess the strength of 
association 
 
4.3.5.5 Adherence with hypoglycaemic medications 
Of the 351 participants who were prescribed hypoglycaemic medications, 208 
(59.3%) missed some of their doses while 143 (40.7%) reported that they did not 
miss any of their doses.  Age had a statistically significant impact on adherence, 
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with those aged 60 years or more being more adherent than their younger 
counterparts (when adherence was defined both as missing any dose and missing 
10% of doses) as shown in Table 4.15.  The data shown in Table 4.15 are based 
upon non-adherence parameters.  
Table 4.15 Results of Multivariate logistic regression with ‘non-
adherence’ as the dependent variable 
Variable Non-adherence 
n/N (%)* 
Odds Ratio 95% Confidence 
interval 
p-value 
100% adherence 
Age 
   >60 
   ≤60 
 
 
51/105 (48.6) 
157/246 (63.8) 
 
 
1 (reference) 
1.87 
 
 
 
1.18- 2.97 
 
 
 
0.0081 
95% adherence 
Age 
   >60 
   ≤60 
 
 
27/104 (26.0) 
77/241 (32.0) 
 
 
1 (reference) 
1.34 
 
 
 
0.80-2.24 
 
 
 
0.2669 
90% adherence 
Age 
   >60 
   ≤60 
 
 
13/104 (12.5) 
54/241 (22.4) 
 
 
1 (reference) 
2.02 
 
 
 
1.05-3.89 
 
 
 
0.0353 
80% adherence 
Age 
   >60 
   ≤60 
 
 
9/104 (8.7) 
38/241 (15.8) 
 
 
1 (reference) 
1.98 
 
 
 
0.92-4.25 
 
 
 
0.0815 
“Non-adherence’ was the dependent variable; *The column showing ‘n/N (%)’ shows the 
number of people (and percentage) within each adherence level who were non-adherent 
 
4.3.5.6 Association of hypoglycaemic daily doses with adherence 
More than half of the participants (58.5%) prescribed glibenclamide missed some of 
their doses (Table 4.13).  As shown in Table 4.16, of the 74 participants prescribed 
doses greater than 15mg daily, 53 (71.6%) missed some of their doses.  The picture 
was much the same for metformin. Forty one participants, or 57.7% of the 71 
participants prescribed the highest daily dose of 1,000mg or more, missed some of 
their doses.  Those who were on the highest dose of metformin and glibenclamide 
appeared to be more non-adherent than those on lower doses, however, as shown 
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in Table 4.16, the association between missing any dose and daily doses of 
metformin and glibenclamide was not significant.   
When comparing levels of adherence with the different categories of daily doses of 
glibenclamide and metformin, there was a significant association between doses of 
glibenclamide, but not with metformin, and 80% adherence.   At this level of 
adherence, the proportion of those who were adherent increased as the dose of 
glibenclamide increased.   Participants prescribed >15mg of glibenclamide were 
more likely to be more adherent, compared to those on lower doses (Table 4.16).   
Those who missed their metformin and glibenclamide doses appeared to be more 
likely to be younger than 60 years.  However, the differences in adherence rates 
between those younger than 60 and those 60 years or older was not statistically 
significant for metformin (χ2, p=0.055) or glibenclamide (χ2, p=0.081). 
 
Table 4.16 Association of metformin and glibenclamide daily doses 
with medication adherence ≥80%   
Variable Level of adherence tested 
100% adherence 80% adherence 
Adherent 
n/N(%) 
Non-
adherent 
n/N(%) 
p-value Adherent 
n/N(%) 
Non-
adherent 
n/N(%) 
p-
value* 
Glibenclamide 
(mg/day) 
[n=270] 
≤5 
7.5–15 
>15 
 
 
 
19 (43.2) 
66 (43.4) 
21 (28.4) 
 
 
 
25 (56.8) 
86 (56.6) 
53 (71.6) 
0.080  
 
 
32 (74.4) 
129 (86.6) 
67 (91.8) 
 
 
 
11 (25.6) 
20 (13.4) 
6 (8.2) 
0.032 
Metformin 
(mg/day) 
[n=222]§ 
≤500  
750-1,000 
>1,000 
 
 
 
13 (33.3) 
42 (37.5) 
30 (42.3) 
 
 
 
26 (66.7) 
70 (62.5) 
41 (57.7) 
0.635  
 
 
31 (81.6) 
97 (88.2) 
62 (88.6) 
 
 
 
7 (18.4) 
13 (11.8) 
8 (11.4) 
0.526 
§Excludes one missing value; *The p-values were obtained from the Chi-square statistic, and 
assess the strength of association. 
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4.3.5.7 Self-reported factors contributing to non-adherence with 
hypoglycaemic medications 
Two hundred and eight participants missed taking their medications (Table 4.13).  
Of these, 207 (99.5%) gave reasons for omitting doses of their hypoglycaemic 
medications.  The most common factors cited by participants for omitting their 
hypoglycaemic medication doses were “patient-related” followed by “health care 
system” related factors (Table 4.17).  The most common patient factor was 
forgetting to take doses.  Seventy four (35.7%) participants forgot to take their 
doses.  The next most common patient-related reason was not refilling prescriptions 
(32.4%). The most common factor related to the health care system was access to 
the diabetes clinic for repeat prescriptions. Problems with accessibility to the clinic 
were contributed to by the increasing number of patients registered, scheduling of 
appointments, number of clinic days and hours per week, cancellation/rescheduling 
of clinic times, shortage of staff and closure of clinic for 2 months every December 
and January. (Personal communication)  Further, rural village dwellers found it 
difficult to travel to and from Port Moresby.   
 
Table 4.17  Identified number of factors contributing to non-adherence 
(N=207).   
Factors influencing adherence Percentage* n (%) 
Patient-related factors   
Forgot 
Had script but did not refill 
Refused to take hypoglycaemic medications 
Others  
(Travel, transport costs to and from remote 
villages to the city, alternative therapy, lack of 
psychosocial support) 
 
74 (35.7%) 
67 (32.4%) 
22 (10.6%) 
15 (7.2%) 
Medication-related factors  
Medication costs 
Perceived adverse effects 
 
15 (7.2%) 
12 (5.8%) 
Health care system-related factors 
Access to and from remote villages 
Inconsistent medical supplies in public hospitals 
Access to diabetes clinics for repeat scripts 
 
5 (2.4%) 
7 (3.4%) 
33 (15.9%) 
Prescriber factors 
Insufficient information about disease and  
medications 
 
4 (1.9%) 
Other reasons  
Theft of bag containing medications   
 
2 (1.0%) 
*Total percentage >100% because some participants gave more than one reason 
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4.3.5.8 Medications for co-morbidities in the three months preceding 
study recruitment 
Data for diagnosed co-morbidities were not recorded but participants were 
questioned about other medications they were prescribed apart from their 
hypoglycaemic medications.  Patient clinic cards also were used to verify the names 
of these co-medications and their doses. 
Two hundred and twenty three participants (57.9%) were prescribed medications for 
co-morbidities (co-medications).  Of these, 219 (98.2%) were participants who were 
prescribed hypoglycaemic medications and only four (1.8%) were participants 
whose diabetes was diet-controlled.  Of the four who were not on hypoglycaemic 
medications, two ceased taking both their hypoglycaemic and antihypertensive 
medications without their doctor’s advice for almost a year and therefore could not 
remember what medications they were on. The most common group of co-
medications prescribed were those for hypertension. One hundred and ninety eight 
(88.8%) participants were prescribed enalapril, making enalapril the most prescribed 
co-medication.    Table 4.18 shows the co-medication frequencies prescribed for co-
morbidities. 
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Table 4.18 Co-medications use among participants (N=385) 
Variable Frequency* [n/N (%)] 
Medications for co-morbidities 
No  
Yes 
 
164/385 (42.6) 
221/385 (57.4) 
Number of co-medications 
1 
2 
3 or 4 
 
119/223 (53.4) 
62/223 (27.8) 
42/223 (18.8) 
Co-medications prescribed† 
Antihypertensives     
Enalapril 
Atenolol 
Nifedipine 
Methyldopa 
Antiplatelet 
Aspirin 
NSAID analgesics 
Diuretics  
Frusemide 
Lipid lowering agents 
Simvastatin 
Others 
 
 
198/223 (88.8) 
41/223 (18.4) 
58/223 (26.0) 
17/223 (7.6) 
 
17/223 (7.6) 
9/223 (4.0) 
 
5/223 (2.2) 
 
16/223 (7.2) 
11/223 (4.9) 
*May not add up to total because of missing values; †Exceeds total because some 
participants took more than one medication; NSAID = non-steroidal anti-inflammatory drug 
 
4.3.5.9 Non-pharmacological management 
Participants were questioned about whether they were using any non-
pharmacological type of management for their diabetes.  
Many participants of this study also were using other forms of management for their 
diabetes, but 232 (60.3%) participants did not choose to use any non-
pharmacological types of management for their diabetes. Of the 351 participants 
who were prescribed hypoglycaemic medications, 71 (20.2%) reported that they 
were doing exercise and 37 (10.5%) reported that they had modified their diet as 
part of their diabetes management.  There was no participant on a specific 
prescribed diet.  There were no Dietetics or Nutrition services during the time of the 
study. 
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A small number of participants were using herbal products and traditional medicines 
for their diabetes.  Of the total participants, 37 (9.6%) were taking herbal products 
and 17 (4.4%) were using traditional medicines.  Seven (1.8%) participants used 
other products like ionised/holy water, charcoal, honey and vinegar mixture, linseed 
and olive oil, and mushroom tea. 
Using other forms of management for diabetes was influenced by whether or not a 
participant was taking a hypoglycaemic medication for diabetes. Those who were 
not taking any hypoglycaemic medications were five times more likely to use any 
other forms of management, such as herbal products, compared to those who were 
using hypoglycaemic medications (Crude OR = 5.946, 95% CI = 2.662-13.282, 
p<0.001).  There were no statistically significant differences in the use of exercise as 
diabetes management between those who were on hypoglycaemic medications and 
those who used diet control. 
4.3.6 Physical measurements 
Physical measurements of participants included height, weight, SBP and DBP, and 
waist and hip circumferences.  Height and weight measurements were used to 
calculate the body mass index (BMI) of participants.  The categorical data on the 
number of years since diagnosis of diabetes was included with physical 
measurements (Table 4.19). 
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Table 4.19 Frequencies of physical characteristics of participants 
(N=385) 
Variable Frequency 
n (%) 
SBP (mmHg) 
≤130 
>130 
 
93 (24.2) 
287 (74.5) 
DBP (mmHg) 
≤80 
>80 
 
174 (45.2) 
206 (53.5) 
BMI category 
Underweight 
Normal weight 
Overweight 
Obese 
 
12 (3.1) 
117 (30.4) 
143 (37.1) 
96 (24.9) 
Waist circumference 
Normal 
Above normal  
 
114 (29.7) 
270 (70.1) 
No. of years since diagnosis of diabetes 
≤5 years 
>5 years 
 
212 (55.1) 
172 (44.7) 
SBP = systolic blood pressure; DBP = diastolic blood pressure;  BMI = body mass index;   
Normal waist circumference is ≤88cm (females) and ≤102cm (males) 
 
4.3.6.1 Blood pressure 
Blood pressure was categorised according to the PNG Diabetes Management 
Guidelines, where an SBP of >130 mmHg and a DBP of >80mmHg were classified 
as being high.  About 50% of the participants had a high DBP while almost three 
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quarters (74.5%) of the participants had a higher than normal SBP (Table 4.19).   As 
shown in Table 4.12, the mean SBP was 150±25 mmHg (Range: 95 mmHg to 235 
mmHg) while the mean DBP was 83±14 mmHg (Range: 43 mmHg to 143 mmHg).   
The likelihood of younger participants having an abnormally high SBP was lower, 
compared with those aged 60 years or older (Table 4.20).  As age increased, the 
odds of an abnormally high SBP increased.  Participants aged 60 years or older 
were five times more likely to have an abnormally high SBP compared to their 
younger counterparts.  Employment status also had a statistically significant impact 
on SBP, with the odds of those in the unpaid/unemployed category and retirees 
having an abnormally high SBP being greater than for those who were in paid 
employment. BMI also had an impact on SBP.   Participants with BMI ≥ 25 kg/m2 
had almost twice the likelihood of having an abnormally high SBP compared to their 
counterparts.  Those who were underweight were more than 10 times less likely to 
have an abnormally high SBP.   
Results indicated that smoker status was the most important factor (Table 4.21).  
Participants classified as non-smokers (including those who had quit) were three 
times more likely to have an abnormally high SBP compared to smokers.  Another 
variable which appeared to influence SBP was the number of minutes of MISFRA in 
a week.  Those who participated in MISFRA for ≥150 minutes in a week were less 
likely to have an SBP of >130 mmHg.  Betel nut chewers who chewed betel nut 
only, or with PBI but not lime, were twice as likely to have an SBP of >130 mmHg 
but this did not reach statistical significance.  Those who were not alcohol 
consumers were also more likely to have a higher than normal SBP, but this did not 
reach statistical significance either. 
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Table 4.20 Univariate logistic regression of demographic and medical 
factors associated with high SBP (>130 mmHg)   
Variable Crude OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60 
 
1 (reference) 
2.08 
5.40 
 
 
1.22-3.57 
2.65-10.98 
<0.001 
 
0.007 
<0.001 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1 (reference) 
2.07 
3.11 
1.48 
 
 
1.17-3.67 
1.41-6.85 
0.64-3.40 
0.019 
 
0.012 
0.005 
0.360 
Area of residence 
Urban 
Peri-urban 
Rural 
 
1 (reference) 
2.00 
1.11 
 
 
1.01-3.98 
0.63-1.96 
0.138 
 
0.047 
0.718 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
1.76 
 
 
1.05-2.95 
0.033 
BMI  
Underweight 
Normal weight 
Overweight 
Obese 
 
0.09 
0.45 
0.51 
1 (reference) 
 
0.02-0.32 
0.23-0.91 
0.26-1.00 
0.003 
<0.001 
0.026 
0.051 
Co-medications taken with 
hypoglycaemic medications 
No  
Yes 
 
 
0.21 
1 (reference) 
 
 
0.13-0.35 
<0.001 
Waist circumference 
Normal 
Above normal 
 
1 (reference) 
1.48 
 
 
0.91-2.43 
0.118 
The dependent variable was SBP > 130 mmHg; BMI = body mass index 
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Table 4.21 Univariate logistic regression of lifestyle factors associated 
with high SBP (>130 mmHg)   
Variable Crude OR 95% CI p-value 
Alcohol consumption in the previous three 
months 
No 
Yes 
 
 
1.94 
1 (reference) 
 
 
0.96-3.93 
0.065 
Smoker status 
Current 
Never 
Quit 
 
1 (reference) 
3.34 
3.58 
 
 
1.43-7.80 
1.39-9.24 
0.016 
 
0.005 
0.008 
Number of years of betel nut chewing 
≤25 
>25 
 
1 (reference) 
1.96 
 
 
0.81-4.76 
0.135 
Betel nut chew composition 
Bete nut, lime and PBI 
Betel nut only or with PBI but no lime 
 
1 (reference) 
2.12 
 
 
0.77-5.80 
0.145 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
1.67 
1 (reference) 
 
0.94-2.96 
0.081 
Minutes of MISFRA/week 
<150 
≥150 
 
1 (reference) 
0.31 
 
 
0.10-0.98 
0.046 
Minutes of work-related VIA/week 
<75  
≥75 
 
1 (reference) 
0.291 
 
 
0.06-1.50 
0.140 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
1.88 
1 (reference) 
 
0.89-3.98 
0.101 
Amount of physical activity/week 
Sufficient 
Insufficient 
None 
 
0.48 
0.63 
1 (reference) 
 
0.23-1.04 
0.27-1.49 
0.153 
0.064 
0.293 
The dependent variable was SBP > 130 mmHg.  MISFRA = moderate-intensity sports, 
fitness and recreational activities; VISFRA = Vigorous-intensity sports, fitness and 
recreational activities; VIA = vigorous-intensity activity; PBI = Piper betle inflorescence 
 
As shown in Tables 4.20 and 4.22, age was an important factor influencing SBP.  
Participants aged 50 years and older were more likely to have an abnormally high 
SBP.  Those aged 60 years and older had four times the likelihood of having an 
SBP that was >130 mmHg.  Use of co-medications was the most important factor 
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independently influencing SBP.  Those who were on co-medications were three 
times more likely to have an SBP that was >130 mmHg.  Smoking was also an 
independent factor influencing SBP, with those who had never smoked and those 
who had quit being three and two times more likely to have an abnormally high SBP, 
respectively.  Although participants with BMI > 25 kg/m2 had higher odds of high 
SBP (Table 4.20), this did not reach statistical significance when demographic, 
medical and lifestyle factors were adjusted for each other (Table 4.22) and, 
therefore, BMI was not found to be an independent risk factor. 
Table 4.22 Multivariate logistic regression of variables independently 
associated with high SBP (>130 mmHg) 
Variable n/N(%)* Adjusted OR 95% CI p-value 
Age (years) 
<50 
50-59 
≥60 
 
66/111 (59.5) 
107/142 (75.4) 
95/107 (88.8) 
 
1 (reference) 
1.58 
3.24 
 
 
0.84-2.97 
1.48-7.09 
0.013 
 
0.160 
0.003 
Co-medications taken 
with hypoglycaemic 
medications 
No  
Yes 
 
 
 
89/151 (58.9) 
193/221 (87.3) 
 
 
 
1 (reference) 
3.39 
 
 
 
 
2.13-6.76 
<0.001 
Smoker status 
Current 
Never 
Quit 
 
12/24 (50.0) 
207/269 (77.0) 
68/87 (78.2) 
 
1 (reference) 
3.70 
2.55 
 
 
1.32-10.38 
0.81-8.01 
0.036 
 
0.013 
0.109 
The dependent variable was SBP > 130 mmHg; *The column showing ‘n/N (%)’ shows the 
number of people (and percentage) within each variable with SBP > 130 mmHg; 
SBP=systolic blood pressure 
 
Univariate logistic regression analysis indicated that employment status, gender, 
age and BMI had a statistically significant impact on DBP (Table 4.23).  Participants 
who were retired, and those in the unpaid/unemployed category, tended to have 
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lower likelihood of an abnormally high DBP when compared with those who were in 
paid employment, but this only reached statistical significance when comparing 
retirees with those in paid employment. The odds of those who were self-employed 
having a DBP that was >80 mmHg appeared to be higher than those in paid 
employment but this did not reach statistical significance. Female participants, all 
those aged 50 years or older and those with BMI < 25kg/m2 had a lower odds of 
having an abnormally high DBP.    The only lifestyle factors associated with a high 
DBP were vegetable servings per day (χ2, p=0.033) and work-related VIA (χ2, 
p=0.002).   
 
Table 4.23 Univariate logistic regression of factors having an impact 
on DBP 
Variable Crude OR 95% CI p-value 
Gender 
Female 
Male 
 
1 (reference) 
1.54 
 
 
1.01-2.35 
0.044 
Age category (years) 
<50 
50-59 
≥60 
 
1 (reference) 
0.59 
0.44 
 
 
0.35-0.98 
0.26-0.76 
0.011 
 
0.042 
0.003 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1 (reference) 
0.70 
0.48 
1.64 
 
 
0.41-1.20 
0.25-0.93 
0.72-3.77 
0.019 
 
0.193 
0.030 
0.241 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
1.86 
 
 
1.170-2.97 
0.009 
The dependent variable was DBP > 80 mmHg.  BMI = Body mass index; DBP = diastolic 
blood pressure 
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Gender, age and BMI were the most important factors which influenced DBP. (Table 
4.24) The odds of female participants having a DBP > 80 mmHg was lower, 
compared to their male counterparts.  Older participants (≥50 years old) also had a 
lower odds of having a DBP > 80 mmHg, when compared with their younger 
counterparts, but this only reached significance when comparing those who were 60 
years and older with those who were <50 years old.  Participants with BMI ≥ 
25kg/m2 were twice as likely to have a DBP that was >80 mmHg, compared with 
their counterparts. 
Table 4.24 Multivariate analysis of factors independently associated 
with abnormally high DBP (>80 mmHg) 
Variable n/N(%)* Adjusted OR 95% CI p-value 
Gender 
Female 
Male 
 
119/237 (56.2) 
87/143 (60.8) 
 
0.54 
1 (reference) 
 
0.33-0.87 
0.011 
Age category (years) 
<50 
50-59 
≥60 
 
72/111 (64.9) 
74/142 (52.1) 
48/107 (44.9) 
 
1 (reference) 
0.60 
0.36 
 
 
0.35-1.04 
0.20-0.65 
0.003 
 
0.070 
0.001 
BMI (kg/m2) 
<25 
≥25 
 
44/104 (42.3) 
138/239 (57.7) 
 
1 (reference) 
2.14 
 
 
1.29-3.53 
0.003 
*The column showing ‘n/N (%)’ shows the number of people (and percentage) within each 
variable with DBP > 80 mmHg.  Note:  The dependent variable was DBP > 80 mmHg. DBP = 
diastolic blood pressure; BMI = body mass index. 
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4.3.6.2 Body mass index  
More than 50% of the participants were either overweight (37.1%) or obese (24.9%) 
and only 30.4% had normal weight (Table 4.19). Univariate logistic regression was 
used to determine any association between demographic variables and BMI, and 
the direction of any association.  Those who were underweight were excluded from 
the analysis because the sample number was too small.  Results indicated that the 
region from where the participants originated appeared to be associated with a BMI 
of ≥25 kg/m2 (p = 0.041).  A statistically significant association was observed 
between participants from the Highlands region and their BMI.  Those from the 
Highlands region were three times more likely to have a BMI ≥ 25 kg/m2 when 
compared with participants from the Southern region.  There was no statistically 
significant difference in having an abnormally high BMI among those from the NGI, 
Momase and the Southern regions. (Table 4.25)   
 Using backward logistic regression (multivariate) analysis to determine which 
demographic factors (if any) were independently associated with BMI, there was an 
indication that the region of origin of participants appeared to independently 
influence BMI, but this did not reach statistical significance (p=0.061).  The 
association was only significant when comparing those from the Highlands region 
with those from the Southern region, where those from the latter region had the 
lowest odds of having a BMI ≥ 25kg/m2.  Participants from the Highlands region 
were five times more likely to have a BMI ≥ 25kg/m2 when compared with those from 
the Southern region (Adjusted OR = 5.148, 95% CI = 1.18 - 22.53, p=0.030).   
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Table 4.25 Univariate logistic regression of demographic factors 
significantly associated with BMI   
Variable Crude OR 95% CI p-value 
Gender 
Female 
Male 
 
1.28 
1 (reference) 
 
0.80-2.05 
0.309 
Level of Education 
Did not complete basic 
education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
 
0.71 
0.49 
0.42 
1.11 
1 (reference) 
 
 
0.32-1.56 
0.24-1.03 
0.20-0.90 
0.35-3.52 
0.094 
 
0.391 
0.060 
0.025 
0.854 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
1 (reference) 
2.27 
2.22 
3.14 
 
 
0.90-5.71 
0.73-6.81 
1.57-9.33 
0.041 
 
0.082 
0.161 
0.039 
The dependent variable was BMI ≥ 25 kg/m2; BMI = body mass index 
 
Lifestyle factors other than physical activities were investigated for an association 
with BMI, and the direction of any association, using univariate logistic regression 
analysis.  These lifestyle factors included betel nut chewing, smoking, alcohol 
consumption within the preceding three months, and fruit and vegetable 
consumption.  Results indicated that betel nut exposure had an association with 
BMI. Results indicated that, of all the aforementioned factors, betel nut exposure 
was the only variable which influenced BMI (Table 4.26).  Participants who had quit 
and those who chewed <5 nuts per day had lower odds of having a BMI that was 
≥25 kg/m2.  The number of years of chewing did not have an association with BMI 
being ≥25 kg/m2.  Neither vegetable and fruit consumption nor smoking had an 
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association with BMI.  Those who did not consume alcohol were less likely to have a 
BMI ≥ 25 kg/m2 but this did not reach statistical significance. 
Table 4.26 Univariate logistic regression of lifestyle factors 
significantly associated with BMI.  
Variable Crude OR 95% CI p-value 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
0.56 
0.32 
0.39 
1 (reference) 
 
0.25-1.25 
0.14-0.71 
0.18-0.84 
0.028 
0.154 
0.005 
0.016 
Alcohol consumed in the previous three months 
No 
Yes 
 
0.44 
1 (reference) 
 
0.18-1.10 
0.080 
The dependent variable was BMI ≥ 25 kg/m2; BMI = body mass index 
 
Multivariate logistic regression analysis was performed on both lifestyle and 
demographic factors, where each variable was dropped one at a time until those 
independently associated with BMI remained (backward elimination).  As there was 
very little difference in the odds ratios associated with BMI among participants from 
the NGI and Momase regions, these two categories were combined to increase 
sample numbers. 
In the regression model, betel nut exposure was used as a variable.  Results 
indicated that region of origin appeared to be the most important factor influencing 
BMI (Table 4.27).  Participants from the Highlands region were more likely to have a 
BMI ≥ 25 kg/m2 compared to their counterparts from other regions.  The odds of 
participants from the Highlands region having a BMI ≥ 25 kg/m2 was seven times 
that of those from the Southern region.  The odds of those from the NGI/Momase 
regions having a BMI ≥ 25 kg/m2 was twice that of those from the Southern region, 
but this did not reach statistical significance.  Age and betel nut exposure also had 
an independent significant influence on BMI.  The odds of participants younger than 
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50 years and with less or no exposure to betel nut having a BMI ≥ 25 kg/m2 
appeared to be significantly lower than those who chewed >5 betel nuts per day 
(Table 4.27). 
Table 4.27  Multivariate logistic regression analysis of demographic 
and lifestyle factors associated with BMI 
Variable n/N (%)*# Adjusted OR 95% CI p-value 
Gender 
Female 
Male 
 
154/215 (71.6) 
85/128 (66.4) 
 
1.60 
1 (reference) 
 
0.94-2.74 
0.086 
Age category (years) 
<50 
≥50 
 
67/101 (66.3) 
160/222 (72.1) 
 
0.55 
1 (reference) 
 
0.31-0.98 
0.044 
Alcohol consumption in 
the previous three 
months 
No 
Yes 
 
 
 
210/308 (68.2) 
29/35 (82.9) 
 
 
 
0.44 
1 (reference) 
 
 
 
0.16-1.22 
0.114 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
62/86 (72.1) 
41/69 (59.4) 
67/104 (64.4) 
51/62 (82.3) 
 
0.44 
0.30 
0.38 
1 (reference) 
 
0.18-1.05 
0.12-0.72 
0.17-0.85 
0.047 
0.063 
0.007 
0.018 
Region of origin 
Southern 
NGI/Momase 
Highlands 
 
172/262 (65.6) 
43/53 (81.1) 
24/28 (85.7) 
 
1 (reference) 
2.20 
7.03 
 
 
0.99-4.88 
1.51-32.71 
0.011 
 
0.052 
0.013 
The dependent variable was BMI ≥ 25 kg/m2  ; *The column showing ‘n/N (%)’ shows the 
number of people (and percentage) within each variable with BMI ≥ 25 kg/m2; #The total may 
not add up because of missing data; BMI = body mass index; NGI = New Guinea Islands 
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4.3.6.3 Waist circumference 
Waist circumference was categorised into normal and above normal.  The normal 
waist circumference used for females and males was ≤88cm and ≤102cm, 
respectively, based on the PNG Diabetes Clinical Guidelines 2012.  
Two hundred and seventy (70.1%) participants had a higher than normal waist 
circumference (Table 4.18).  
Univariate logistic regression analysis was carried out to determine which (if any) 
factors were associated with an abnormally high waist circumference and, also, to 
examine the direction of any associations.  
It was not possible to use univariate logistic regression analysis using participants’ 
area of residence because one of the cells for this variable had a sample number 
which was less than five.  To increase the sample number, those participants from 
other provinces were regrouped into either “urban” or “rural village” depending on 
their residential addresses in the provinces where they were living.  Those who lived 
in urban towns (n=6) were included in the urban category and those in rural villages 
(n=9) were included with the original rural village category.   
Univariate logistic regression analysis indicated that the most important 
demographic variable which influenced waist circumference was gender.  Female 
participants were nine times more likely to have an abnormally high waist 
circumference compared to their male counterparts, as shown in Table 4.28.   
Employment also had a statistically significant influence on waist circumference but 
this was only significant in those who were unpaid/unemployed.  The odds of 
unpaid/unemployed participants having an abnormally high waist circumference 
were two-fold higher when compared with those in paid employment. The odds of 
retirees and participants who were self-employed having an abnormally high waist 
circumference also appeared to be higher, but these did not reach statistical 
significance.  Although area of residence was not a significant influence on waist 
circumference, the odds of participants who lived in peri-urban areas having an 
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abnormally high waist circumference was almost two-fold higher and this appeared 
to be statistically significant (p=0.044), as shown on Table 4.28. 
As shown in Table 4.29, none of the lifestyle variables (other than physical activity) 
had an influence on waist circumference. When participants were categorised 
according to betel nut exposure, the odds of an abnormally high waist circumference 
being associated with betel nut exposure did not reach statistical significance.  
However, the odds of those who never chewed betel nut having an abnormally high 
waist circumference was significantly lower than those who chewed >5 betel nuts 
per day. Those who had consumed alcohol in the preceding three months, and 
those who had vegetables on 0-5 days per week also appeared to have lower odds 
of having an abnormally high waist circumference, but these associations did not 
reach statistical significance. Participants who were current smokers and those who 
had never smoked tended to have higher odds of having an abnormally high waist 
circumference but this, again, was not statistically significant.   
Table 4.28 Univariate analysis of demographic factors associated with 
waist circumference  
Variable Crude OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60 
 
0.65 
1.12 
1 (reference) 
 
0.37-1.16 
0.63-1.97 
0.124 
Gender 
Female 
Male 
 
9.17 
1 (reference) 
 
5.56-15.15 
p<0.001 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
1.90 
1.31 
0.75 
1.09 
1 (reference) 
 
0.93-3.91 
0.68-2.50 
0.39-1.45 
0.43-2.76 
0.089 
0.079 
0.423 
0.390 
0.860 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1 (reference 
2.56 
1.36 
1.45 
 
 
1.47-4.46 
0.70-2.63 
0.65-3.22 
0.007 
 
0.001 
0.368 
0.365 
Area of residence 
Urban 
Peri-urban 
Rural village 
 
1 (reference) 
1.89 
1.29 
 
 
1.02-3.51 
0.75-2.21 
0.119 
 
0.044 
0.358 
The dependent variable was waist circumference above normal. Normal waist circumference 
is ≤88cm (females) and ≤102cm (males); NGI = New Guinea Islands.  
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Table 4.29 Univariate analysis of lifestyle factors associated with waist 
circumference  
Variable Crude OR 95% CI p-value 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
0.43 
0.59 
0.51 
1 (reference) 
 
0.21-0.88 
0.27-1.26 
0.25-1.02 
0.131 
0.021 
0.171 
0.057 
Smoker history 
Current 
Never 
Quit 
 
1.86 
1.65 
1 (reference) 
 
0.67-5.13 
0.99-2.73 
0.133 
0.234 
0.053 
Alcohol consumed in the preceding three 
months 
No 
Yes 
 
 
1 (reference) 
0.62 
 
 
 
0.31-1.23 
0.167 
Number of vegetable days/week 
0-5 
6-7 
 
0.64 
1 (reference) 
 
0.41-1.00 
 
0.051 
Waist circumference above normal was the dependent variable; PBI = Piper betle 
inflorescence; Normal waist circumference is ≤102 cm (male) and ≤88cm (female) 
 
Work-related moderate-intensity activities and walking to get to and from places 
appeared to have an influence on waist circumference (Table 4.30).  Those who did 
work-related MIA were more likely, and those who did not walk were less likely, to 
have an abnormally high waist circumference.  Those who did VIA for <75 minutes 
per week were twice as likely to have an abnormally high waist circumference 
compared to those who did ≥75 minutes per week, but this did not reach statistical 
significance.  The impact of the amount of physical activity on waist circumference 
was only seen when comparing those who were insufficiently physically active with 
those who were not engaged in any physical activity.  Surprisingly, the latter was 
less likely to have an abnormally high waist circumference compared to the former.   
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Multivariate logistic regression analysis was performed on both lifestyle and 
demographic factors, where each variable was dropped one at a time until those 
independently associated with BMI remained (backward elimination).  Level of 
education was regrouped to increase sample numbers, so that the vocational and 
tertiary education categories were combined to form one category. Participants 
within these two categories are more likely to be employed than those with lower 
attainment levels.   
As shown in Table 4.31, the logistic regression model indicated that the most 
important independent factor which influenced waist circumference was gender.  
Female participants were 13-fold more likely to have a waist circumference above 
normal, compared to their male counterparts.  Although the association of age with 
waist circumference did not reach statistical significance, the odds of those aged 
<50 years having an abnormally high waist circumference appeared to be lower 
when compared with their counterparts who were 60 years and older.  Level of 
education was associated with waist circumference.  The odds of an abnormally 
high waist circumference were lower for participants who had completed basic 
primary and secondary education only.  This association was statistically significant.  
The association of betel nut exposure and waist circumference was of borderline 
significance but those who chewed ≤5 nuts per day and those who never chewed 
betel nut had lower odds of an abnormally high waist circumference, and this was 
statistically significant (p=0.017 and p=0.012, respectively).  None of the physical 
activity characteristics were independently associated with waist circumference. 
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Table 4.30 Univariate analysis of physical activity associated with 
waist circumference.  
Variable Crude OR 95% CI p-value 
Amount of physical activity 
Sufficient 
Lacking 
Insufficient 
 
0.74 
0.46 
1 (reference) 
 
0.43-1.29 
0.22-0.94 
0.098 
0.289 
0.032 
Work-related VIA for at least 10 minutes 
No  
Yes 
 
1 (reference) 
0.60 
 
 
0.33-1.09 
0.091 
Minutes of work-related VIA/week 
<75 
 ≥75 
 
2.02 
1 (reference) 
 
0.59-6.97 
0.265 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
1 (reference) 
0.87 
 
 
0.41-1.85 
0.722 
Minutes of VISFRA/week 
<75 
≥75 
 
2.44 
1 (reference) 
 
0.51-11.62 
0.261 
Work-related MIA for at least 10 minutes 
No   
Yes 
 
1 (reference) 
1.65 
 
 
1.04-2.60 
0.032 
Minutes of MIA at work/week 
<150 
≥150 
 
0.80 
1 (reference) 
 
0.38-1.69 
0.552 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
1 (reference) 
0.73 
 
 
0.42-1.27 
0.266 
Minutes of MISFRA/week  
<150 
≥150 
 
0.48 
1 (reference) 
 
0.14-1.67 
0.247 
Walks to get to and from places for at least 
10 minutes 
No 
Yes 
 
 
0.59 
1 (reference) 
 
 
0.36-0.97 
0.037 
Minutes of walking/week 
<150 
≥150 
 
1.68 
1 (reference) 
 
0.98-2.88 
0.060 
The dependent variable was waist circumference “above normal”.  Normal waist 
circumference is 88cm (females) and 102cm (males); VIA = vigorous-intensity activity; MIA = 
moderate-intensity activity; VISFRA = vigorous-intensity sports, fitness and recreational 
activity; MISFRA = moderate-intensity sports, fitness and recreational activity 
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Table 4.31  Multivariate logistic regression analysis of demographic 
and lifestyle factors associated with waist circumference.   
Variable n/N (%)*# Adjusted OR 95% CI p-value 
Gender 
Female 
Male 
 
209/241 (86.7) 
61/144 (42.4) 
 
1 (reference) 
0.07 
 
 
0.03-0.15 
<0.001 
Age category (years) 
<50  
≥50 
 
72/113 (63.7) 
186/251 (74.1) 
 
0.49 
1 (reference) 
 
0.24-1.03 
0.058 
Level of Education 
Did not complete basic 
education 
Primary basic education 
Secondary education 
Tertiary/Vocational 
 
70/88 (79.5) 
 
80/110 (72.7) 
52/86 (60.5) 
67/99 (67.7) 
 
1.08 
 
0.35 
0.33 
1 (reference) 
 
0.37-3.16 
 
0.13-0.91 
0.13-0.86 
 
0.027 
0.889 
 
0.032 
0.024 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
60/95 (63.2) 
54/54 (70.1) 
79/118 (66.9) 
56/70 (80.0) 
 
0.26 
0.36 
0.25 
1 (reference) 
 
0.09-0.78 
0.11-1.17 
0.09-0.73 
0.066 
0.017 
0.089 
0.012 
The analysis used betel nut exposure as a variable. The dependent variable was waist 
circumference above normal.  Normal waist circumference is 88cm (females) and 102cm 
(males); *The column showing ‘n/N (%)’ shows the number of people (and percentage) 
within each variable with waist circumference above normal; #The total may not add up 
because of missing data. 
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4.3.7 Biochemical measurements 
Biochemical measurements of participants included capillary blood glucose levels, 
total cholesterol, triglycerides, HbA1c, urine protein and glucose, and urea and 
creatinine levels. 
Of all the biochemical measurements, CBG and HbA1c were measured on the day 
of the visit.  Hospital outpatient toilet facilities were closed during the periods of data 
collection, so urine and protein measurements were not possible on the day of data 
collection.  Thirty one patients (8.1%) agreed to collect urine the next morning and 
dropped off samples at the Diabetes Clinic for measurement of urine glucose and 
protein.   
The most recent lipid profiles of nearly all participants were not available for data 
collection.  Only a few records were found.  Of all lipid profiles, no LDL 
measurements were found, whilst only one, 12 and 15 records of HDL, triglycerides 
and total cholesterol were included, respectively.  Urea and creatinine 
measurements were only available for 20 and 19 participants, respectively (Table 
4.32). 
It is assumed that patients fasted before capillary blood testing on the day of their 
diabetes review, as per the protocol; however it was found that not all patients 
fasted before CBG testing.  During the course of the study, a decision was made to 
also interview participants about whether their CBG was a random or fasting level 
after it was observed that many participants had very high CBG readings.  Of all the 
participants, 147 (38.2%) had a fasting level and 150 (39%) had a random level 
(Table 4.30).  The remaining 83 (21.6%) participants’ CBG were categorised as 
unknown because this was the group of participants whose CBG was assumed to 
be fasting but may have also included those who did not fast. Records of CBG for 
five participants were missing and these were excluded in any analysis using CBG. 
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Table 4.32 Biochemical data of participants 
Variable Frequency; n/N (%)* 
CBG  
Fasting 
Random 
Unknown  
 
147/385 (38.1) 
150/385 (39.0) 
83/385 (21.5) 
Glycated haemoglobin [HbA1c (%)] 
≤7.0 
7.0-10.0 
>10.0 
 
73/385 (19.0) 
173/385 (44.9) 
116/385 (30.1) 
Lipids 
Total cholesterol (data available) 
≤5.0mmol/L 
>5.0 
Triglycerides (data available) 
<2.0 
≥2.0 
LDL 
HDL 
 
15/385 (3.9) 
3/15 (20.0) 
12/15 (80.0) 
12/385 (3.1) 
3/12 (25.0) 
9/12 (75.0) 
0/385 (0) 
1/385 (0.3) 
Urea (mmol/L) 
≤7.1 
>7.1  
 
12/20 (60.0) 
8/20 (40.0) 
Creatinine (µmol/L) 
62-133 
>133 
 
14/19 (73.7) 
5/19 (26.3) 
Urine Glucose  
Negative 
Trace 
2+ 
3+ 
4+ 
 
21/32 (65.6) 
3/32 (9.4) 
4/32 (12.5) 
1/32 (3.1) 
2/32 (6.3) 
Urine Protein 
Negative 
Trace 
1+ 
2+ 
3+ 
4+ 
 
2/32 (6.3) 
9/32 (28.1) 
10/32 (31.3) 
3/32 (9.4) 
3/32 (9.4) 
5/32 (15.6) 
LDL = low density lipoprotein; HDL = high density lipoprotein; CBG = capillary blood glucose; 
*May not add up to total because of missing values 
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4.3.8 Betel nut chewing 
Betel nut chewers, like tobacco smokers, were further categorised according to their 
betel nut chewing status (current, never and quit), as well as whether they were ever 
(both current and those who had quit) or never chewers.  The number of years of 
chewing betel nut also was calculated and participants were categorised according 
to these numbers of years.  The age of onset of chewing for both current chewers 
and those who had ceased chewing, and the number of years since cessation of 
betel nut chewing, were not normally distributed and are presented as median and 
range. 
4.3.8.1 Prevalence of betel nut chewing  
Of the 385 participants studied, 55% (212) reported that they were currently chewing 
betel nut.  Ninety six (24.9%) participants had never chewed betel nut, while 77 
(20.0%) had quit chewing betel nut.  Overall, of all the participants studied, 289 
(75.1%) had chewed betel nut at some time in their lives (Table 4.33). 
As shown in Table 4.33, for those classified as current betel nut chewers, the 
median age for onset of chewing betel nut was 15 years (range: 4-59 years).  The 
mean number of years of chewing betel nut was 37.2±13.0 years.  The median 
quantity of betel nut chewed per day was 4.0 (range: 0.25-25.0).  
For participants who had quit the habit, the median age for onset of chewing was 
15.5 years (range: 3.0-52.0 years).  The median number of years of cessation of 
betel nut chewing was 9.0 (range:  0.08-46.0). 
The majority of participants in this study chewed betel nut with lime (calcium oxide) 
and Piper betle inflorescence (PBI).  Of the 212 participants who reported chewing 
betel nut, 177(83.5%) chewed the nut with lime and with PBI. There were 22 
(10.4%) who chewed the nut only and 12 (5.7%) who chewed the nut with PBI but 
without lime. Betel nut chewing variables are shown in Table 4.33. 
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Table 4.33 Frequencies of betel nut chewing characteristics   
Variables Frequency* 
n/N(%) 
Betel nut chewer 
No 
Yes    
 
173/385 (44.9) 
212/385 (55.1) 
No. of betel nuts/day 
 ≤5 
6-9 
≥10 
 
118/212 (55.7) 
31/212 (14.6) 
39/212 (18.4) 
Betel nut chewing history 
Never  
Quit 
Current 
 
96/385 (24.9) 
77/385 (20.0) 
212/385 (55.1) 
Number of years of chewing betel nut 
≤25 
26-49 
≥50 
 
25/212 (11.8) 
119/212 (56.1) 
25/212 (11.8) 
Betel nut chewing components 
Betel nut only  or + PBI with no lime 
Betel nut + PBI + lime 
 
34/212 (16.0) 
177/212 (83.5) 
Mean number of years of chewing ±SD 37.2±13.0 
Age at onset of chewing for current betel nut chewers [median 
(range)] 
15.0 (4.0-59.0) 
Age at onset of chewing for those who quit betel nut chewing 
[median (range)] 
15.5 (3.0-52.0) 
No. of years since betel nut cessation for those who quit [median 
(range)] 
9.0 (0.08-46.0) 
No. of betel nuts chewed/day [median (range)] 4.0 (0.25-25.0) 
*May not add up to the total because of missing values; PBI = Piper betle inflorescence; SD 
= standard deviation 
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Age, the level of education and employment status were regrouped for logistic 
regression analysis because some of the categories had small sample numbers.  
Age was regrouped into three categories only.  Level of education was categorised 
according to the former education structures in PNG, as the participants were too 
old with respect to the current education restructure.  Employment status was 
regrouped to reflect financial income.  Homemakers and students were reclassified 
as unpaid, and unpaid and unemployed were combined into one category.  
Government and non-government employees were combined under paid 
employment and categories of retirees and self-employed were retained.  These 
categories were used when examining the relationships between the prevalence of 
betel nut chewing and these demographic factors. 
The statistical process was chi-square testing, univariate logistic regression and 
then multivariate logistic regression. 
 
4.3.8.2 Factors associated with betel nut chewing:  Chi-Square 
testing 
Chi-square statistical analysis was carried out to test for any associations between 
betel nut chewing and the demographic characteristics of participants such as 
gender, age, area of residence, level of education, region of origin, employment 
status and years of residence in Port Moresby. 
According to the Chi-square statistic, the demographic factors influencing 
prevalence of betel nut chewing were the participant’s area of residence, region of 
origin, years of residence in Port Moresby and level of education (Table 4.36).  Age 
tended to be a factor but did not reach statistical significance.  There were no 
differences in the prevalence of betel nut chewing between genders and different 
types of employment.  Rural village and peri-urban dwellers were more likely to 
chew betel nut than those who resided in the urban suburbs, as well as those who 
were not residing in Port Moresby (p<0.001).  Those who originated from the 
Southern region of PNG had a higher prevalence of betel nut chewing than those 
from the NGI, Momase and Highlands regions, as shown in Table 4.34. 
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Chi square analysis indicated that alcohol consumption, smoking, work-related MIA 
and amount of physical activity in a week were significantly associated with betel nut 
chewing, while the association of number of vegetable servings consumed, work-
related VIA and walking to get to and from places with betel nut chewing was of 
borderline significance (Table 4.35).  Smokers, alcohol consumers and those 
consuming <3 serves of vegetables in a day were more likely to be betel nut 
chewers.  Betel nut chewers were more likely to perform work-related VIA and MIA, 
to walk to get to and from places and to undertake sufficient amount of physical 
activity in a week, compared to their counterparts. 
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Table 4.34 Association of demographic variables with betel nut 
chewing   
Variable Betel nut chewer p-value
* 
Yes (N [%]) No (N [ %]) 
Gender 
Female 
Male 
 
140 (58.1) 
72 (50.0) 
 
101 (41.9) 
72 (50.0) 
0.123 
Age category (years) 
≤39 
40-49 
50-59 
60-69 
≥70 
 
15 (62.5) 
56 (62.9) 
83 (56.8) 
44 (51.2) 
6 (28.6) 
 
9 (37.5) 
33 (37.5) 
63 (43.2) 
42 (48.8) 
15 (71.4) 
0.052 
Area of residence 
Urban 
Peri-urban 
Rural 
Other province 
 
90 (42.5) 
54 (70.1) 
60 (75.0) 
7 (46.7) 
 
122 (57.5) 
23 (29.9) 
20 (25.0) 
8 (53.3) 
<0.001 
Level of education 
No formal education 
Less than Grade 6 
Grade 6 
Grade 8 
Grade 10 
Grade 12 
Vocational training 
Tertiary  
 
11 (28.2) 
25 (51.0) 
38 (53.5) 
28 (70.0) 
45 (60.8) 
6 (50.0) 
18 (62.1) 
41 (58.6) 
 
28 (71.8) 
24 (49.0) 
33 (46.5) 
12 (30.0) 
29 (39.2) 
6 (50.0) 
11 (37.9) 
29 (41.4) 
0.015 
Employment status 
Unemployed - unable to 
 work 
Unemployed - able to work 
Unpaid 
Homemaker 
Self-employed 
Government 
Non-government 
Retired 
Student 
 
14 (56.0) 
 
18 (52.9) 
5 (62.5) 
74 (59.2) 
23 (59.0) 
26 (55.3) 
19 (55.9) 
32 (45.7) 
2 (66.7) 
 
11 (44.0) 
 
16 (47.1) 
3 (37.5) 
51 (40.8) 
16 (41.0) 
21 (44.7) 
15 (44.1) 
38 (54.3) 
1 (33.3) 
0.822§ 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea islands 
 
183 (62.2) 
7 (26.6) 
6 (20.7) 
16 (44.4) 
 
111 (37.8) 
19 (73.1) 
23 (79.3) 
20 (55.6) 
<0.001 
Years of residence in Port Moresby 
0# 
1-10 
 >10 
 Lifetime 
 
68 (70.1) 
9 (32.1) 
68 (42.8) 
55 (69.6) 
 
29 (29.9) 
19 (67.9) 
91 (57.2) 
24 (30.4) 
<0.001 
*The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; §Fisher’s exact test 
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Table 4.35 Lifestyle factors associated with betel nut chewing 
Variable Betel nut chewer p-value
# 
Yes (N [%]) No (N [ %]) 
Alcohol consumed in the previous 
three months 
No  
Yes 
 
 
179 (51.6) 
33 (86.8) 
 
 
168 (48.4) 
5 (13.2) 
<0.001 
Current smoker 
No 
Yes 
 
191 (52.9) 
21 (87.5) 
 
170 (47.1) 
3 (12.5) 
0.001 
Vegetable servings/day 
<3 
≥3 
 
199 (56.1) 
11 (39.3) 
 
156 (43.9) 
17 (60.7) 
0.086 
Number of vegetable-eating  days in 
a typical week 
0-2 
3-5 
6-7 
 
 
52 (54.2) 
68 (54.8) 
90 (55.2) 
 
 
44 (45.8) 
56 (45.2) 
73 (44.8) 
0.987 
Fruit servings/day 
<2 
≥2 
 
145 (53.5) 
65 (58.0) 
 
126 (46.5) 
47 (42.0) 
0.418 
Number of fruit-eating days in a 
typical week 
0-2 
3-5 
6-7 
 
 
144 (52.9) 
40 (57.1) 
26 (63.4) 
 
 
128 (47.1) 
30 (42.9) 
15 (36.6) 
0.414 
Work-related VIA for at least 10 
minutes 
No 
Yes 
 
 
177 (53.3) 
35 (66.0) 
 
 
155 (46.7) 
18 (34.0) 
0.084 
Work-related MIA for at least 10 
minutes 
No 
Yes 
 
 
108 (48.0) 
104 (65.0) 
 
 
117 (52.0) 
56 (35.0) 
0.001 
Performs MISFRA for at least 10 
minutes 
No  
Yes 
 
 
171 (53.9) 
41 (60.3) 
 
 
146 (46.1) 
27 (39.7) 
0.339 
Walks to get to and from places for 
at least 10 minutes 
No 
Yes 
 
 
42 (47.2 
170 (57.4) 
 
 
47 (52.8) 
126 (42.6) 
0.089 
Amount of physical activity/week 
Sufficient 
None/insufficient 
 
141 (60.3) 
71 (47.0) 
 
93 (39.7) 
80 (53.0) 
0.011 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; VIA = vigorous-intensity activity; MIA = moderate-intensity activity; MISFRA = 
moderate-intensity sports, fitness and recreational activity; VISFRA = vigorous-intensity 
sports, fitness and recreational activity 
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4.3.8.3 Factors associated with betel nut chewing:  univariate logistic 
regression analysis 
The odds of betel nut chewing within each category defined by age group, area of 
residence, level of education and region of origin were compared using univariate 
logistic regression.  Those variables which were found to show some association 
were entered into a (univariate) logistic regression model to investigate the direction 
of associations for different categories of demographic factors.  Comparisons were 
performed for variables that had a statistically significant relationship using chi-
square testing. 
The odds of those living in rural villages and peri-urban areas chewing betel nut 
were four-fold and three-fold higher, compared to their urban counterparts, 
respectively.  Participants from the Southern region were most likely to chew betel 
nut compared to those from the Highlands region.  Participants from the Southern 
region and those from the NGI were six-fold and three-fold more likely, respectively, 
to chew betel nut when compared to their counterparts from the Highlands region.  
Although participants from the Momase region appeared to be more likely to chew 
betel nut when compared with those from the Highlands region, this did not reach 
statistical significance.   There was no difference in prevalence of betel nut chewing 
between those who were not living in Port Moresby and those who had spent their 
lifetime there.  Level of education and age were less important factors, although 
those less than 50 years of age were, significantly, almost twice as likely to 
consume betel nut when compared with those ≥60 years of age.  With respect to 
level of education, participants who did not complete basic education were 
significantly less likely to chew betel nut compared to those who had completed 
tertiary education (Table 4.36). 
As shown in Table 4.37, alcohol consumers and smokers were six times more likely 
to chew betel nut compared to those who did not; an association which was 
statistically significant.  Betel nut chewers were almost two times more likely to 
consume <3 servings of vegetables compared to those who were not chewers, but 
this was of borderline significance. 
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Table 4.36 Univariate logistic regression analysis of demographic 
factors associated with betel nut chewing   
Variable Crude OR 95% CI p-value 
Age category (years) 
<50 
50-59 
≥60  
 
1.93 
1.53 
1 (reference) 
 
1.13-3.30 
0.92-2.52 
0.052 
0.017 
0.099 
Area of residence 
Urban 
Peri-urban 
Rural village 
Other Province 
 
1 (reference) 
3.18 
4.07 
1.19 
 
 
1.82-5.57 
2.29-7.23 
0.42-3.39 
P<0.001 
 
P<0.001 
P<0.001 
0.750 
Region of origin 
Southern 
New Guinea islands 
Momase 
Highlands 
 
6.32 
3.07 
1.41 
1 (reference) 
 
2.50-16.00 
1.01-9.34 
0.41-4.92 
P<0.001 
P<0.001 
0.049 
0.588 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
0.49 
1.04 
1.03 
1.16 
1 (reference) 
 
0.26-0.93 
0.57-1.91 
0.54-1.96 
0.48-2.81 
0.053 
0.028 
0.906 
0.926 
0.747 
Years of residence in Port Moresby 
0# 
1-10 
>10 
Lifetime 
 
1.02 
0.21 
0.33 
1 (reference) 
 
0.54-1.95 
0.08-0.52 
0.18-0.58 
P<0.001 
0.945 
0.001 
P<0.001 
The dependent variable was ‘Yes’ to being a betel nut chewer; #Participant does not reside 
in Port Moresby 
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Table 4.37 Univariate logistic regression analysis of lifestyle factors 
associated with betel nut chewing   
Variable Crude OR 95% CI p-value 
Alcohol consumed in the previous 
three months 
No  
Yes 
 
 
1 (reference) 
6.19 
 
 
 
2.36 – 16.24 
<0.001 
Current smoker 
No 
Yes 
 
1 (reference) 
6.23 
 
 
1.83 – 21.26 
0.003 
Vegetable servings/day 
<3 
≥3 
 
1.97 
1 (reference) 
 
0.90 – 4.33 0.091 
Work-related VIA for at least 10 
minutes 
No 
Yes 
 
 
1 (reference) 
1.70 
 
 
 
0.93 – 3.13 
0.086 
Work-related MIA for at least 10 
minutes 
No 
Yes 
 
 
1 (reference) 
2.01 
 
 
 
1.33 – 3.05 
0.001 
Walk to get to and from places for at 
least 10 minutes 
No 
Yes 
 
 
1 (reference) 
1.51 
 
 
 
0.94 – 2.43 
0.090 
Amount of Physical activity/week 
Sufficient 
None/insufficient 
 
1.71 
1 (reference) 
 
1.13 – 2.58 0.011 
The dependent variable was ‘Yes’ to being a betel nut chewer; VIA = vigorous-intensity 
activity; MIA = moderate-intensity activity 
 
4.3.8.4 Factors associated with betel nut chewing:  multivariate 
logistic regression analysis 
A logistic regression modelling procedure was applied to all the data for 
demographic characteristics. In each of these models, all the variables were initially 
included as covariates, and then dropped one at a time until all variables remaining 
in the model were associated with the prevalence of betel nut chewing (backward 
regression).  The dependent variable was the “yes” response when the participants 
were asked whether or not they were betel nut chewers. 
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Results of logistic regression modelling (multivariate) indicated that the three major 
factors which were independently associated with the prevalence of betel nut 
chewing were age, area of residence and region of origin (Table 4.38).  
The odds of participants younger than 60 years of age chewing betel nut was twice 
that of those who were 60 years or older.  Those aged <50 years had almost three 
times the odds of chewing betel nut compared to their counterparts who were 60 
years or older.  The analysis also showed that participants from the Southern region 
were five times more likely to chew betel nut than those from the Highlands region.  
Betel nut chewing was significantly more prevalent in the rural village dwellers 
(p<0.001).  Rural village dwellers and peri-urban dwellers were four and two times 
more likely to chew betel nut, respectively, than their counterparts in urban areas.  
Level of education also tended to have an independent significant influence on betel 
nut chewing, but this was a less important factor than age, area of residence and 
region of origin. The odds of participants who did not complete basic education 
chewing betel nut were significantly lower compared to those who had completed 
tertiary education and this association was statistically significant (Adjusted OR = 
0.303, 95% CI=0.133-0.689, p=0.004).   
In the univariate logistic regression, years of residence in Port Moresby was one of 
the most important factors which influenced betel nut chewing.  This variable 
however, was not independently associated with betel nut chewing, possibly 
because of its correlation with area of residence and region of origin.  Those who 
had resided for zero years in Port Moresby were those who were rural village and 
outer province dwellers, whilst those who had spent their lifetime in Port Moresby 
were from the Southern region.   
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Table 4.38 Multivariate logistic regression of factors independently 
associated with betel nut chewing. 
Variable “Yes” betel nut 
chewer 
n/N (%)* 
Adjusted  
Odds Ratio 
95% CI p-value 
Age category (years) 
 <50 
50-59 
≥60 
 
71/113(62.8) 
83/145 (57.2) 
50/107 (46.7) 
 
2.14 
2.00 
1 (reference) 
 
1.13-4.06 
1.12-3.54 
0.028 
0.019 
0.018 
Area of residence 
Peri-urban 
Rural village 
Other Province 
Urban 
 
54/77 (70.1) 
60/80 (75.0) 
7/15 (46.7) 
90/212 (42.5) 
 
3.24 
3.16 
1.65 
1 (reference) 
 
1.72-6.11 
1.63-6.13 
0.50-5.50 
<0.001 
<0.001 
0.001 
0.415 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
183/294 (62.2) 
16/36 (44.4) 
7/26 (26.9) 
6/29 (20.7) 
 
6.32 
3.52 
1.60 
1 (reference) 
 
2.07-19.26 
0.94-13.17 
0.38 -6.72 
0.001 
0.001 
0.062 
0.525 
Alcohol consumed in the 
previous three months 
No  
Yes  
 
 
179/347 (51.6) 
33/38 (86.8) 
 
 
1 (reference) 
6.36 
 
 
 
2.11-19.14 
0.001 
Current smoker 
No 
Yes 
 
191/361 (52.9) 
21/24 (87.5) 
 
1 (reference) 
3.30 
 
 
0.85-12.76 
0.084 
Work-related MIA for at least 
10 minutes 
No 
Yes 
 
 
108/225 (48.0) 
104/160 (65.0) 
 
 
1 (reference) 
1.92 
 
 
 
1.18– 3.12 
0.009 
The dependent variable was “Yes” to being a betel nut chewer; *The column showing ‘n/N 
(%)’ shows the number (and percentage) of betel nut chewers within each variable; MIA = 
moderate-intensity activity 
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4.3.9 Factors influencing glycaemic control 
Optimal glycaemic control was defined according to the PNG Diabetes Clinical 
Guidelines 2012; that is, HbA1c ≤ 7.0%.  Consequently, poor glycaemic control was 
defined as HbA1c > 7.0.  The Chi-square statistic was used to test for any 
association between optimal glycaemic control and the demographic, medical and 
lifestyle factors (categorical variables).  Those variables which were found to show 
some association were entered into a (univariate) logistic regression model to 
investigate the direction of the associations for different categories of each variable.  
Variables which appeared to show even a weak association with glycaemic control 
on univariate analysis with p<0.5 were included in a multivariate logistic regression 
model to identify which (if any) of these variables were independently associated 
with glycaemic control.  A backwards elimination strategy was used to find the most 
parsimonious model, whereby all independent variables were initially included in the 
model, and then the least significant was dropped, one at a time, until all variables 
remaining in the model were statistically significantly associated with optimal 
glycaemic control (p<0.05).  Regrouping of categories of some variables was 
performed as required (if the numbers were too small in some categories).  
Variables which contained categories with very small sample numbers (< 5) and 
which could not be re-grouped, were excluded from logistic regression modelling. A 
final multivariate logistic regression analysis was performed (as described above) 
including variables from all of the three main groups of factors.  The results of the 
final analysis showed all variables which appeared to be independently associated 
with glycaemic control [from all the demographic, medical (including physical 
measurements) and lifestyle factors taken together]. 
4.3.9.1 Univariate and multivariate analysis of demographic factors 
associated with poor glycaemic control 
Demographic variables included in the analyses included gender, age, level of 
education, employment status, area of residency, region of origin and years of 
residency in Port Moresby.   
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The median HbA1c for all participants was 9.15% (Table 4.39).  Results showed that 
the median HbA1c within each category of the demographic variables at the time of 
enrolment was higher than the recommended optimal target of ≤7.0% (Table 4.39). 
Table 4.39 Median and range values of HbA1c at time of enrolment in 
the study  
Variable n/N* (%) Median 
HbA1c 
(%) 
HbA1c 
Range 
(%) 
All participants 362/385 (94.0) 8.7 4.8 - >14.0 
Gender  
Female 
Male 
 
228/241 (94.6) 
134/144 (93.1) 
 
8.7 
8.5 
 
5.0 - >14.0 
4.8 - >14.0 
Age category (years) 
<50 
50-59 
≥60 
 
107/113 (94.7) 
135/145 (93.1) 
102/107 (95.3) 
 
9.1 
8.4 
8.3 
 
5.2 - >14.0 
5.0 - >14.0 
4.8 - 14.0 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
81/88 (92.0) 
105/111 (94.6) 
83/86 (96.5) 
27/29 (93.1) 
65/70 (92.9) 
 
8.5 
8.5 
9.1 
8.4 
8.7 
 
4.9 - >14.0 
5.2 - >14.0 
5.5 - >14.0 
5.9 - 14.0 
4.8 - >14.0 
Employment status 
Paid employment 
Unpaid/unemployed 
Retired 
Self-employed 
 
76/81 (93.8) 
184/195 (94.4) 
66/70 (94.3) 
36/39 (92.3) 
 
9.4 
8.5 
7.9 
9.3 
 
5.9 - >14.0 
4.9 - >14.0 
4.8 - >14.0 
5.5 - 14.0 
Area of residence 
Urban 
Peri-urban 
Rural 
Other Province 
 
199/212 (93.9) 
73/77 (94.8) 
74/80 (92.5) 
15/15 (100.0) 
 
8.5 
8.5 
8.9 
7.3 
 
4.8 - >14.0 
5.4 - >14.0 
5.5 - 14.0 
5.2 - >14.0 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
275/294 (93.5) 
35/36 (97.2) 
24/26 (92.3) 
28/29 (96.6) 
 
8.8 
9.0 
7.9 
8.4 
 
4.9 - >14.0 
4.8 - >14.0 
6.0 - 12.6 
5.5 - 13.2 
Years of residence in Port Moresby 
0# 
1-10 
>10  
Lifetime 
 
92/97 (94.9) 
26/28 (92.9) 
150/159 (94.3) 
72/79 (91.1) 
 
8.9 
8.4 
8.5 
8.3 
 
5.2 - >14.0 
4.8 - >14.0 
4.9 - >14.0 
5.4 - >14.0 
*The column n/N (%) represents the number of participants and % within each category 
whose HbA1c was measured at the time of enrolment; HbA1c = glycated haemoglobin; 
#Participant does not reside in Port Moresby 
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Results from Chi-square testing indicated that gender, age and employment status 
had a statistically significant association with glycaemic control (Table 4.40).  
Female participants appeared to have poor glycaemic control compared to their 
male counterparts.   Younger participants (<50 years) and those who were self-
employed also appeared to have poorer glycaemic control.    Area of residence, 
region of origin, level of education and years of residence in Port Moresby did not 
have any statistically significant association with glycaemic control. 
Table 4.40 Demographic factors associated with poor glycaemic 
control (HbA1c > 7.0%).   
Variable HbA1c categories 
≤7.0 (N [%]) >7.0(N [ %]) p-value* 
Gender 
Female 
Male 
 
38 (16.7) 
35 (26.1) 
 
190 (83.3) 
99 (73.9) 
0.03 
Age category (years) 
<50 
50-59 
≥60 
 
13 (12.1) 
31 (23.0) 
27 (26.5) 
 
94 (87.9) 
104 (77.0) 
75 (73.5) 
0.026 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
20 (24.7) 
17 (16.2) 
13 (15.7) 
7 (25.9) 
16 (24.6) 
 
61 (75.3) 
88 (83.8) 
70 (84.3) 
20 (74.1) 
49 (75.4) 
0.348 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
11 (14.5) 
35  (19.0) 
22 (33.3) 
5 (13.9) 
 
65 (85.5) 
149 (81.0) 
44 (66.7) 
31 (86.1) 
0.037 
Area of residence 
Urban 
Peri-urban 
Rural village 
Other Province 
 
41 (20.6) 
14 (19.2) 
12 (16.2) 
6 (40.0) 
 
158 (79.4) 
59 (80.8) 
62 (83.8) 
9 (60.0) 
0.218 
Region of Origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
56 (20.4) 
5 (14.3) 
3 (12.5) 
9 (32.1) 
 
219 (79.6) 
30 (85.7) 
21 (87.5) 
19 (67.9) 
0.248 
Years of residence in Port Moresby 
0# 
1-10 
>10 
Lifetime 
 
18 (19.6) 
6 (23.1) 
32 (21.3) 
13 (18.1) 
 
74 (80.4) 
20 (76.9) 
118 (78.7) 
59 (81.9) 
0.924 
*The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; #Participant does not reside in Port Moresby 
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Univariate logistic regression confirmed the significant association between optimal 
glycaemic control and age, gender and employment status (Table 4.41), while also 
providing the direction of associations.  Younger participants (<50 years) were  2.6 
times as likely to have poor glycaemic control compared to those aged 60 years and 
older.  The odds ratio of female participants having poor glycaemic control was 
almost twice that of their male counterparts.  Retirees were most likely to have 
better glycaemic control compared to those who were self-employed, and the 
difference in glycaemic control between these groups was statistically significant.  
However, there was no statistically significant difference in risk when comparing 
other categories (paid and unpaid/unemployed) with the self-employed. 
 
Table 4.41 Univariate logistic regression analysis of demographic 
factors associated with poor glycaemic control (HbA1c>7.0%) 
Variable Crude OR 95% CI p-value 
Gender 
 Female 
 Male 
 
1.77 
1 (reference) 
 
1.05-2.97 
 
0.032 
Age category (years) 
 <50 
 50-59 
 ≥60 
 
2.60 
1.21 
1 (reference) 
 
1.26-5.39 
0.67-2.19 
0.03 
0.010 
0.534 
Employment status 
 Paid 
 Unpaid/unemployed 
 Retired 
 Self-employed 
 
0.95 
0.69 
0.32 
1 (reference) 
 
0.31-2.98 
0.25-1.89 
0.11-0.95 
0.026 
0.934 
0.467 
0.039 
The dependent variable was HbA1c>7.0%.  HbA1c = glycated haemoglobin 
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A multiple logistic regression analysis involving only the demographic variables 
indicated that employment status and gender were independently associated with 
glycaemic control (Table 4.42) and, therefore, other factors did not appear to make a 
significant contribution to the model after these two were taken into account.    
Female participants had twice the risk of having poor glycaemic control, and retirees 
had a lower risk of having poor glycaemic control (more likely to have optimal 
control) than those who were self-employed.  Although the odds of poor glycaemic 
control for those aged 49 years or younger appeared to be almost twice that for the 
older group, this did not reach statistical significance.  This was almost certainly 
because of the correlation between age group and employment status (Table 4.42). 
Table 4.42 Multivariate logistic regression analysis of demographic 
factors independently associated with poor glycaemic control (HbA1c > 
7.0%) 
Variable n/N(%)* Adjusted OR 95% CI p-value 
Gender 
Female 
Male 
 
190 (83.3) 
99 (73.9) 
 
2.04 
1 (reference) 
 
1.05-2.97 
0.022 
Age category (years) 
<50 
50-59 
≥60 
 
94 (87.9) 
104 (77.0) 
75 (73.5) 
 
1.80 
1.00 
1 (reference) 
 
0.80-4.02 
0.53-1.87 
0.256 
0.154 
0.991 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
65 (85.5) 
149 (81.0) 
44 (66.7) 
31 (86.1) 
 
0.78 
0.39 
0.26 
1 (reference) 
 
0.23-2.68 
0.12-1.26 
0.08-0.83 
0.023 
0.695 
0.117 
0.023 
The dependent variable was HbA1c > 7.0%; HbA1c = glycated haemoglobin; *The column 
showing ‘n/N (%)’ shows the number of people (and percentage) within each variable with 
poor glycaemic control (HbA1c > 7.0). 
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4.3.9.2 Univariate and multivariate analysis of lifestyle factors 
associated with poor glycaemic control 
Lifestyle factors included betel nut chewing, vegetable and fruit consumption, 
smoking, alcohol consumption and physical activity.  
Of these lifestyle factors, the only one which appeared to show an association with 
glycaemic control was smoking status (Table 4.43).  A statistically significant 
association appeared between those who had ever smoked (both current smokers 
and those who had quit) and never smoked.  A greater proportion of those who had 
never smoked appeared to have poor glycaemic control compared to their 
counterparts who had ever smoked.  The number of vegetable-eating days in a 
typical week appeared to be associated with glycaemic control but this was of 
borderline significance.   
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Table 4.43 Association of alcohol, vegetable and fruit consumption, 
and tobacco smoking with poor glycaemic control (HbA1c > 7.0%)   
Variable HbA1c categories p-value# 
≤7.0 (N [%]) >7.0 (N [ %]) 
Alcohol consumption in the previous three 
months 
No  
Yes 
 
 
65 (19.9) 
8 (22.2) 
 
 
261 (80.1) 
28 (77.8) 
0.746 
Vegetable servings/day 
<3 serves 
≥3 serves 
 
65 (19.6) 
6 (21.4) 
 
267 (80.4) 
22 (78.6) 
0.813 
Number of vegetable-eating days in a 
typical week 
0-2 
3-5 
6-7 
 
 
16 (17.6) 
16 (14.2) 
39 (25.0) 
 
 
75 (82.4) 
97 (85.8) 
117 (75.0) 
0.074 
Fruit servings/day 
<2 serves 
≥2 serves 
 
47 (18.7) 
24 (22.2) 
 
205 (81.3) 
84 (77.8) 
0.435 
Number of fruit-eating days in a typical  
week 
0-2 
3-5 
6-7 
 
 
55 (21.7) 
11 (16.2) 
5 (12.8) 
 
 
198 (78.3) 
57 (83.8) 
34 (87.2) 
0.307 
Current smoker 
No 
Yes 
 
67 (19.8) 
6 (26.1) 
 
272 (80.2) 
17 (73.9) 
0.465 
Smoker status 
Current smoker 
Never a smoker 
Quit  
 
6 (26.1) 
44 (17.4) 
23 (26.7) 
 
17 (73.9) 
209 (82.6) 
63 (73.3) 
0.134 
Smoker history 
Ever 
Never 
 
29 (26.6) 
44 (17.4) 
 
80 (73.4) 
209 (82.6) 
0.045 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association 
 
Betel nut chewing was assessed in different ways. Whether or not a participant was 
a betel nut chewer did not affect glycaemic control.  As shown in Table 4.44, Chi-
square testing indicated that betel nut chewing was significantly associated with 
glycaemic control only when participants were categorised according to their betel 
nut chewing history.  A greater proportion of those who never chewed betel nut had 
poor glycaemic control compared to those who had ever done so (current chewers 
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and those who had quit).  However, for those classified as betel nut chewers,  the 
quantity of betel nuts chewed per day and number of years of chewing betel nut did 
not appear to be associated with glycaemic control.  The accompaniments with 
which betel nut was chewed also did not influence glycaemic control. 
 
Table 4.44 Association of betel nut chewing with poor glycaemic 
control (HbA1c > 7.0%).   
Variable HbA1c categories 
≤7.0 (N [%]) >7.0 (N [ %]) p-value# 
Betel nut chewer 
No  
Yes  
 
33 (20.2) 
40 (20.1) 
 
130 (79.8) 
159 (79.9) 
0.973 
Betel nut chewing history 
Current chewer 
Never a chewer 
Quit  
 
40 (20.1) 
10 (11.5) 
23 (30.3) 
 
159 (79.9) 
77 (88.5) 
53 (69.7) 
0.012 
Betel nut chewing status 
Never 
Ever 
 
10 (11.5) 
63 ( 22.9) 
 
77 (88.5) 
212 (77.1) 
0.021 
Quantity of betel nuts chewed/day 
≤ 5 
6-9 
≥10 
 
25 (22.5) 
3 (10.0) 
8 (22.9) 
 
86 (77.5) 
27 (90.0) 
27 (77.1) 
0.297 
Number of years of betel nut chewing 
≤25 
26-49 
≥50 
 
2 (9.1) 
21 (19.1) 
5 (20.0) 
 
20 (90.9) 
89 (80.9) 
20 (80.0) 
0.550* 
Composition of betel nut chew 
Betel nut + PBI + Lime 
Betel nut only, or with PBI (no 
lime) 
 
34 (20.0) 
6 (21.4) 
 
136 (80.0) 
22 (78.6) 
0.862 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association. *Fisher’s Exact Test; HbA1c = glycated haemoglobin; PBI = Piper betle 
inflorescence 
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The number of participants who were involved in sports, fitness and recreational 
activities was small, as has been demonstrated earlier in Table 4.8.  When these 
active participants were categorised according to whether or not they achieved 
optimal or poor glycaemic control, the number of those achieving optimal glycaemic 
control was small.  Four of the measures of physical activity had small sample 
numbers (<5) in the group which achieved optimal glycaemic control.  Of the 16 
participants who performed MISFRA for ≥150 minutes per week, only one (6.3%) 
participant achieved optimal glycaemic control, while the remaining 15 (93.8%) had 
poor glycaemic control.  Participants who did not participate in MISFRA appeared to 
have better control than their counterparts who did, but this did not reach statistical 
significance (Table 4.45).  Participants undertaking VISFRA for both <75 and ≥75 
minutes per week also had small sample numbers achieving optimal glycaemic 
control. 
As shown in Table 4.45, results indicated that work involving VIA appeared to have 
an association with glycaemic control.   Surprisingly, those who were not involved in 
work-related VIA tended to have better glycaemic control than those who were.  
Only four (8.2%) out of the 49 participants involved in work-related VIA achieved 
optimal glycaemic control.  The other physical activity factor which appeared to have 
an association with glycaemic control was the number of minutes per week that a 
participant spent walking to get to and from places.  Participants who walked for 
≥150 minutes per week also tended to have better glycaemic control than those who 
walked for <150 minutes per week.  Although a greater proportion of participants 
who were involved in work-related MIA for ≥150 minutes per week appeared to have 
optimal glycaemic control than those not doing this level of activity, the difference 
did not reach statistical significance.  Whether a participant achieved good 
glycaemic control appeared not to be associated with the overall measure of amount 
of physical activity, other than walking. 
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Table 4.45 Association of physical activity with poor glycaemic 
control (HbA1c > 7.0%).  
Variable HbA1c categories 
≤7.0 (N [%]) >7.0 (N [ %]) p-value# 
Work-related MIA for at least 10 minutes 
No  
Yes   
 
47 (22.2) 
26 (17.3) 
 
165 (77.8) 
124 (82.7) 
0.259 
Minutes of MIA at work/week 
<150 
≥150 
 
5 (9.4) 
21 (22.1) 
 
48 (90.6) 
74 (77.9) 
0.052 
Performs  MISFRA for at least 10 minutes 
No  
Yes  
 
67 (22.5) 
6 (9.4) 
 
231 (77.5) 
58 (90.6) 
0.055 
Minutes of MISFRA/week 
<150 
≥150 
 
5 (10.4) 
1 (6.3) 
 
43 (89.6) 
15 (93.8) 
0.620 
Work-related VIA for at least 10 minutes   
No  
Yes   
 
69 (22.0) 
4 (8.2) 
 
244 (78.0) 
45 (91.8) 
0.047 
Minutes of VIA at work/week 
<75 
≥75 
 
2 (12.5) 
2 (6.3) 
 
14 (87.5) 
30 (93.8) 
0.592* 
Performs VISFRA for at least 10 minutes 
No  
Yes  
 
68 (20.6) 
5 (15.6) 
 
262 (79.4) 
27 (84.4) 
0.503 
Minutes of VISFRA/week 
<75 
≥75 
 
1 (8.3) 
4 (20.0) 
 
11 (91.7) 
16 (80.0) 
0.626* 
Walks to get to and from places for at least 
10 minutes  
No  
Yes  
 
 
16 (19.8) 
57 (20.3) 
 
 
65 (80.2) 
224 (79.7) 
0.916 
Minutes of walking/week 
<150 
≥150 
 
20 (15.6) 
36 (25.4) 
 
108 (84.4) 
106 (74.6) 
0.049 
Amount of physical activity/week 
Sufficient 
Insufficient 
None 
 
44 (21.8) 
18 (16.8) 
11 (20.8) 
 
158 (78.2) 
89 (83.2) 
42 (79.2) 
0.582 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association. *Fisher’s Exact Test; MIA = Moderate-intensity activities; MISFRA = moderate-
intensity sports, fitness and recreational activities; VIA = vigorous-intensity activities; VISFRA 
= vigorous-intensity sports, fitness and recreational activities 
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Univariate logistic regression analysis of lifestyle factors (other than physical activity) 
indicated that betel nut exposure was the most important factor influencing 
glycaemic control (Table 4.46).  Participants who had never chewed betel nut had 
poorer glycaemic control compared to their counterparts who had chewed betel nut.  
For those who had never chewed betel nut, the odds of poor glycaemic control was 
almost twice that of those who had done so.  However, those who had quit the habit 
had a lower chance of poor glycaemic control than those who were current chewers.  
The other betel nut chewing characteristics which showed a weak trend were the 
number of nuts chewed per day and the number of years of chewing, but neither of 
these reached statistical significance.  As shown in Table 4.46, those who chewed 
betel nut for 25 years or less had twice the odds of poor glycaemic control and those 
who chewed five or fewer nuts per day were less likely to have poor glycaemic 
control.   
Smoking appeared to be associated with glycaemic control but was a less important 
factor compared to betel nut chewing.  Participants who had ever smoked appeared 
to have a lower risk of having poor glycaemic control compared to those who had 
never smoked.   
Although the number of days of consuming vegetables did not reach statistical 
significance, participants who consumed vegetables for five or fewer days in a 
typical week tended to have a higher chance of poor glycaemic control, and this risk 
was significant when comparing those who consumed vegetables for 6-7 days with 
those who consumed vegetables for 3-5 days. Those who consumed vegetables for 
3-5 days were twice as likely to have poor glycaemic control.  Participants who 
consumed two or more servings of fruit appeared to have a lower chance of poor 
glycaemic control.   However, this was not statistically significant (Table 4.46). 
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Table 4.46 Univariate logistic regression analysis of lifestyle factors 
associated with poor glycaemic control (HbA1c > 7.0%) 
Variable Crude OR 95% CI p-value 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
1 (reference) 
0.30 
0.45 
0.64 
 
 
0.13 - 0.68 
0.20 - 0.99 
0.25 - 1.61 
0.027 
 
0.004 
0.047 
0.340 
Years of chewing betel nut 
≤25 
 >25 
 
2.39 
1 (reference) 
 
0.52 - 10.85 
0.261 
Smoker status 
Current smoker 
Never a smoker 
Quit 
 
1 (reference) 
1.68 
0.97 
 
 
0.63 - 4.49 
0.34 - 2.75 
0.137 
 
0.304 
0.949 
Smoker history 
Ever 
Never 
 
0.58 
1 (reference) 
 
0.34 - 0.99 
0.046 
Number of vegetable-eating days in a 
typical week 
0-2 
3-5 
6-7 
 
 
1.56 
2.02 
1 (reference) 
 
 
0.82 - 2.99 
1.06 - 3.84 
0.077 
 
0.178 
0.031 
Fruit servings/day 
<2 serves 
≥2 serves 
 
1 (reference) 
0.80 
 
 
0.46 - 1.40 
0.436 
Number of fruit-eating days in a typical 
week 
0-2 
3-5 
6-7 
 
 
1 (reference) 
1.44 
1.89 
 
 
 
0.71 - 2.93 
0.71 - 5.06 
0.313 
 
0.316 
0.206 
The dependent variable was HbA1c > 7.0%;   HbA1c = glycated haemoglobin 
 
As shown in Table 4.47, the only physical activity variable which had any significant 
influence on glycaemic control was work-related VIA. Results indicated that the odds 
ratio of those performing work-related VIA having poor glycaemic control was three-
fold higher than those who did not.  Although the odds of having poor glycaemic 
control was almost three-fold in participants who performed work-related MIA for 
<150 minutes per week compared with those performing ≥150 minutes per week, 
this did not reach statistical significance.  Participants who had walked to and from 
places for <150 minutes per week were almost twice as likely to have poor 
glycaemic control compared to those who walked for ≥150 minutes per week but this 
difference also did not reach statistical significance.   
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Table 4.47 Univariate logistic regression analysis of physical activities 
associated with poor glycaemic control (HbA1c > 7.0%) 
Variable Crude OR 95% CI p-value 
Work-related MIA for at least 10 minutes 
No  
Yes  
 
1 (reference) 
1.36 
 
 
0.80 - 2.31 
0.260 
Minutes of MIA at work/week 
 <150 
≥150 
 
2.72 
1 (reference) 
 
0.96 - 7.71 
0.059 
Work-related VIA for at least 10 minutes   
No  
Yes  
 
1 (reference) 
3.18 
 
 
1.11 – 9.16 
0.036 
Minutes of walking/week 
<150 
≥150 
 
1.83 
1 (reference) 
 
0.99 - 3.37 
0.051 
Performs  MISFRA for at least 10 minutes 
No  
Yes 
 
1 (reference) 
2.80 
 
 
1.16 - 6.78 
0.022 
The dependent variable was HbA1c > 7.0%;   HbA1c = glycated haemoglobin; MIA = 
moderate-intensity activity; VIA = vigorous-intensity activity; MISFRA = moderate-intensity 
sports, fitness and recreational activity 
 
Lifestyle factors with a significant, or near significant, association with glycaemic 
control, as highlighted by the univariate analyses, were entered into the multivariate 
logistic regression model to determine which factors were independently associated 
with poor glycaemic control. 
Results indicated that performing MISFRA, minutes of work-related MIA and the 
number of days/week on which participants had vegetables were each 
independently associated with glycaemic control, however, the only significant 
lifestyle variable which appeared to influence glycaemic control was the number of 
minutes that work-related MIA was undertaken in a typical week (Table 4.48).  
Those who were walking for <150 minutes per week were four times more likely to 
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have poor glycaemic control than those who walked for ≥150 minutes per week.  
Participants who did not consume vegetables, and those who had vegetables for up 
to 5 days appeared to be more likely to have poor glycaemic control compared to 
those who had vegetable for 6-7 days in a week.  However, this did not reach 
statistical significance.  Those who performed MISFRA were five times more likely to 
have poor glycaemic control when compared with those who did not.  However, like 
the association between number of days of vegetable consumption and poor 
glycaemic control, this did not reach statistical significance.  Betel nut chewing was 
not an independent factor for poor glycaemic control. 
Table 4.48 Multivariate logistic regression analysis of lifestyle factors 
associated with poor glycaemic control (HbA1c > 7.0%)   
Variable n/N (%)* Adjusted OR 95% CI p-value 
Performs MISFRA for at 
least 10 minutes  
No 
Yes 
 
 
231/298 (77.5) 
58/64 (90.6) 
 
 
1 (reference) 
5.06 
 
 
 
0.61-41.64 
0.132 
Minutes of MIA at 
work/week 
<150 
≥150 
 
 
48/53 (90.6) 
74/95 (77.9) 
 
 
4.18 
1 (reference) 
 
1.10-15.88 
0.036 
Number of vegetable-
eating days in a typical 
week 
0-5 days 
6-7 days 
 
 
 
172/204 (84.3) 
117/156 (75.0) 
 
 
 
2.77 
1 (reference) 
 
 
 
0.98-7.86 
0.056 
The dependent variable was HbA1c > 7.0%;   HbA1c = glycated haemoglobin; *The column 
showing ‘n/N (%)’ shows the number of people (and percentage) within each variable with 
poor glycaemic control (HbA1c > 7.0); MIA = moderate-intensity activity; MISFRA = 
moderate-intensity sports, fitness and recreational activity 
 
4.3.9.3  Univariate analysis of medical and physical factors 
associated with glycaemic control 
Variables such as hypoglycaemic medications, co-medications for co-morbidities, 
other types of management, number of years living with diabetes and physical 
characteristics were tested for an association with glycaemic control.   
As shown in Table 4.49, using a hypoglycaemic medication over the preceding three 
months had an influence on glycaemic control.  Participants who were prescribed 
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hypoglycaemic medications for their diabetes were more likely to have poor 
glycaemic control when compared to their counterparts who were not prescribed 
these medications.   
Usage of, and the daily dosage of, glibenclamide also had an influence on 
glycaemic control (Table 4.49) Those who were prescribed glibenclamide were more 
likely to have poor glycaemic control compared to those who were not (either diet-
controlled or other hypoglycaemic agents).  Participants prescribed the lowest dose 
of glibenclamide appeared to have more optimal glycaemic control, compared to 
those prescribed higher doses. The -prescription of metformin and the number of 
hypoglycaemic medications prescribed by participants did not affect glycaemic 
control, as shown in Table 4.49. 
Glycaemic control was examined at four different thresholds of adherence, namely: 
100% (complete adherence with hypoglycaemic treatment), 95%, 90% and 80%.  
Glycaemic control also was examined at a glycaemic control of HbA1c greater than 
10.0% (abnormally high = poor control) and greater than 8.0%.  The cut-off for 
HbA1c of ≤10.0% was previously accepted as good glycaemic control but a cut-off 
of ≤8.0% is now accepted as good glycaemic control, in clinical practice.4 
Apart from Chi-square testing, the distribution of levels of HbA1c achieved, 
according to different levels of adherence to treatment, was examined. HbA1c levels 
were categorised at three different levels of glycaemic control.  These HbA1c levels 
were ≤7.0% (optimal), 7-10% (high) and >10.0% (abnormally high). Percentages of 
participants who were categorised under these different levels were calculated. 
(Figure 4.4) 
Figure 4.4 shows that, as the level of adherence decreased the percentage of 
participants who achieved optimal glycaemic control also decreased, in general. 
There was a significant impact of adherence on glycaemic control when the level of 
adherence fell from 100% to 90% but there was no significant impact when 
adherence fell from 90% to 80%, as shown in Figure 4.4 
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Table 4.49 Association of hypoglycaemic and co-medication variables 
with optimal glycaemic control (HbA1c > 7.0%)   
Variable HbA1c (%) categories 
≤7.0 (N [%]) >7.0 (N [ %]) p-value# 
Hypoglycaemics used in the previous 
three months 
No 
Yes 
 
 
10 (38.5) 
63 (18.9) 
 
 
16 (61.5) 
271 (81.1) 
0.017 
Hypoglycaemic doses missed 
No 
Yes 
 
28 (20.6) 
35 (17.7) 
 
108 (79.4) 
163 (82.3) 
0.504 
Metformin doses/day 
None 
≤500 mg 
750–1,000 mg 
>1,000 mg 
 
28 (18.9) 
9 (25.5) 
25 (24.5) 
10 (14.1) 
 
120 (81.1) 
27 (75.0) 
77 (75.5) 
61 (85.9) 
0.322 
Metformin doses missed 
No 
Yes 
 
22 (23.2) 
22 (19.3) 
 
73 (76.8) 
92 (80.7) 
0.496 
Glibenclamide dose/day 
None 
≤5 mg 
7.5–15 mg 
>15 mg 
 
30 (29.4) 
11 (28.9) 
25 (17.2) 
6 (8.2) 
 
72 (70.6) 
27 (71.1) 
120 (82.8) 
67 (91.8) 
0.002 
Glibenclamide doses missed 
No 
Yes 
 
19 (17.8) 
23 (15.2) 
 
88 (82.2) 
128 (84.8) 
0.588 
Number of hypoglycaemics used 
1 
2 or 3 
 
37 (20.6) 
25 (16.8) 
 
143 (79.4) 
124 (83.2) 
0.383 
Co-medications used 
No 
Yes 
 
23 (16.0) 
47 (22.4) 
 
121 (84.0) 
163 (77.6) 
0.137 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association. 
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Figure 4.4 Percentages of patients attaining different HbA1c targets 
 
The impact of adherence to the use of hypoglycaemic medications on glycaemic 
control was tested at two different levels of glycaemic control using chi-square 
statistics at the level of optimal control (HbA1c ≤ 7.0%) and abnormally high levels 
(HbA1c > 10.0%).   
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Results indicated that, when the impact of adherence on glycaemic control was 
examined using the optimal glycaemic control cut-off of HbA1c ≤ 7.0%, glycaemic 
control was found not to be associated with level of adherence used.  However, 
when glycaemic control was examined using an HbA1c of ≤10.0%, results indicated 
that missing any dose had an impact on glycaemic control.  Those who were 100% 
adherent were more likely to have an HbA1c of ≤10.0% (p=0.003), as shown in 
Table 4.50. 
Using the currently acceptable glycaemic control of HbA1c ≤ 8.0, there appeared to 
be no difference in glycaemic control across different levels of adherence. 
Table 4.50 Associations of different levels of hypoglycaemic 
medication adherence with two levels of glycaemic control   
Level of Adherence 
tested  
HbA1c (%) categories 
≤7.0 
(N%]) 
>7.0 
N[%]) 
p-
value 
≤10.0 
(N%]) 
>10.0 
(N[%]) 
p-
value# 
100% 
Adherent 
Non-adherent 
 
28 (20.6) 
35 (17.7) 
 
108 (79.4) 
163 (82.3) 
0.504  
105 (77.2) 
122 (61.6) 
 
31 (22.8) 
76 (38.4) 
0.003 
95% 
Adherent 
Non-adherent 
 
43 (18.9) 
16 (16.0) 
 
185 (81.1) 
84 (84.0) 
0.535  
159 (69.7) 
63 (63.0) 
 
69 (30.3) 
37 (37.0) 
0.230 
90% 
Adherent 
Non-adherent 
 
50 (18.9) 
9 (14.1) 
 
214 (81.1) 
55 (85.9) 
0.362  
183 (69.3) 
39 (60.9) 
 
81 (30.7) 
25 (39.1) 
0.198 
80%  
Adherent 
Non-adherent 
 
53 (18.7) 
6 (13.3) 
 
230 (81.3) 
39 (86.7) 
0.381  
196 (69.3 
26 (57.8) 
 
87 (30.7) 
19 (42.2) 
0.126 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association.  
 
Results indicated that those who had had diabetes for five years or less were more 
likely to have optimal glycaemic control than their counterparts who had had 
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diabetes for more than five years (p=0.009).  Other physical measurements were 
not associated with glycaemic control, as shown in Table 4.51. 
 
Table 4.51  Associations of physical measurements and number of 
years living with diabetes, with optimal glycaemic control (HbA1c > 
7.0%)   
Variable HbA1c (%) categories 
≤7.0 (N [%]) >7.0 (N [ %]) p-value# 
BMI category 
Underweight 
Normal weight 
Overweight 
Obese 
 
1 (12.5) 
23 (20.9) 
25 (18.4) 
19 (21.6) 
 
7 (87.5) 
87 (79.1) 
111 (81.6) 
69 (78.4) 
0.873 
SBP (mmHg) 
≤130 
>130 
 
17 (19.5) 
55 (20.4) 
 
70 (80.5) 
215 (79.6) 
0.867 
DBP (mmHg) 
≤80 
>80 
 
39 (24.1) 
33 (16.9) 
 
123 (75.9) 
162 (83.1) 
0.094 
Waist circumference 
Normal 
Above normal  
 
26 (24.3) 
47 (70.1) 
 
81 (75.7) 
208 (81.6) 
0.204 
No. of years living with diabetes 
≤5 years 
>5 years 
 
50 (25.3) 
23 (14.1) 
 
148 (74.7) 
140 (85.9) 
0.009 
#The p-values were obtained from the Chi-square statistic, and assess the strength of 
association; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; Normal waist circumference is 88 cm (females) and 102 cm (males) 
 
For univariate logistic regression analysis, BMI was regrouped into a 2-category 
group (<25 kg/m2 and ≥25 kg/m2).   
Results of univariate logistic regression analysis indicated that the medical variables 
which had an influence on glycaemic control were usage of hypoglycaemic 
medications over the preceding three months, glibenclamide use and number of 
years living with diabetes (Table 4.52). 
178 
 
 
Participants who were using both one and two or three hypoglycaemic medications 
were two and three times more likely, respectively, to have poor glycaemic control 
compared to their counterparts who were not taking any hypoglycaemic 
medications.  Those taking a glibenclamide dose of >15 mg daily were four times 
more likely to have poor glycaemic control, while those on 7.5-15 mg/day were twice 
as likely.   
Those who had lived with diabetes for >5 years had twice the odds of having poor 
glycaemic control.  Physical measurements such as BMI, waist circumference and 
blood pressure did not influence HbA1c.  DBP appeared to be associated with 
HbA1c but this did not reach statistical significance.   Although taking co-
medications lowered the odds of poor glycaemic control, this also did not reach 
statistical significance, as can be seen in Table 4.52. 
Table 4.52 Univariate logistic regression analysis of medical variables 
associated with poor glycaemic control (HbA1c > 7.0%)  
Variable Crude OR 95% CI p-value 
 
Hypoglycaemics used in the previous 
three months 
0 
1 
2 or 3 
 
 
1 (reference) 
2.42 
3.10 
 
 
 
1.01-5.76 
1.26-7.62 
0.048 
 
 
0.047 
0.014 
Co-medications used 
No 
Yes 
 
1 (reference) 
0.66 
 
 
0.38-1.14 
0.139 
Glibenclamide dose/day 
None 
≤5 mg 
7.5–15 mg 
>15 mg 
 
1 (reference) 
1.02 
2.00 
4.65 
 
 
0.45-2.32 
1.09-3.67 
1.82-11.88 
0.004 
 
0.957 
0.025 
0.001 
Number of years living with diabetes 
≤5 years 
>5 years 
 
0.49 
1 (reference) 
 
0.28-0.84 
0.010 
BMI (kg/m2) 
<25 
≥25 
 
0.80 
1 (reference) 
 
0.45-1.41 
0.437 
Waist circumference 
Normal 
Above normal 
 
0.70 
1 (reference) 
 
0.41-1.21 
0.206 
DBP (mmHg) 
≤80 
>80 
 
0.64 
1 (reference) 
 
0.38-1.08 
0.095 
The dependent variable was HbA1c > 7.0%.  HbA1c = glycated haemoglobin; BMI = body 
mass index; DBP = diastolic blood pressure; Normal waist circumference is 88 cm (females) 
and 102 cm (males) 
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Results of univariate logistic regression analysis examining 100% adherence and 
abnormally high HbA1c indicated that missing any dose had an influence on 
glycaemic control with respect to abnormally high HbA1c (HbA1c > 10.0%).  
Participants who did not miss any doses were less likely to have an abnormally high 
HbA1c (Crude OR = 0.474, 95% CI = 0.29-0.78, p=0.003).   
4.3.9.4 Multivariate logistic regression analysis of medical and 
physical factors and glycaemic control   
Multivariate logistic regression analysis was performed for different levels of 
adherence with hypoglycaemic medications to investigate which level of adherence 
influenced an abnormally high HbA1c (>10%).  Each participant was classified into 
their level of adherence, and the dependent variable was HbA1c > 10%. 
Odds Ratios for the adherence levels were expressed relative to the completely 
adherent subjects.  This analysis showed explicitly that the odds of abnormally high 
HbA1c was greater than one for all levels of non-adherence, but only significantly 
higher for the adherence levels 95-99%, and <80% (Table 4.53). 
Table 4.53 Multivariate logistic regression analysis: The influence of 
medication adherence on abnormally high HbA1c (>10.0%).   
Adherence level HbA1c > 10% 
n/N (%)* 
Odds Ratio 95% Confidence 
Interval 
p-value 
100% 31/136 (22.8) 1 (reference)   
95-99% 38/92 (41.3) 2.4 1.3 - 4.2 0.003 
90-94% 12/36 (33.3) 1.7 0.8 - 3.8 0.197 
80-89% 6/19 (31.6) 1.6 0.5 - 4.5 0.403 
<80% 19/45 (42.2) 2.5 1.2 - 5.1 0.012 
The dependent variable was HbA1c > 10.0%.  HbA1c = glycated haemoglobin; *The column 
showing ‘n/N (%)’ shows the number of people (and percentage) within the given adherence 
level who had high HbA1c. 
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According to multivariate logistic regression analysis, medical and physical factors 
which were independently associated with glycaemic control were glibenclamide 
use, co-medication use, DBP, number of years diagnosed with diabetes and BMI. 
However, DBP did not reach statistical significance, as shown in Table 4.54.  
Participants who were prescribed >15 mg of glibenclamide were five times more 
likely to have poor glycaemic control.  There was no statistically significant 
difference in association between being prescribed ≤5 to 15 mg of glibenclamide 
daily and not being prescribed any glibenclamide.  Participants not prescribed co-
medications and those diagnosed with diabetes for more than five years were twice 
as likely to have poor glycaemic control. 
 
Table 4.54 Multivariate logistic regression analysis of medical factors 
associated with poor glycaemic control (HbA1c > 7.0%) 
Variable n/N (%)* Adjusted OR 95% CI p-value 
 
Glibenclamide dose/day 
None 
≤5 mg 
7.5–15 mg 
>15 mg 
 
72/102 (70.6) 
27/38 (71.1) 
120/145 (82.8) 
67/73 (91.8) 
 
1 (reference) 
1.21 
1.77 
5.62 
 
 
0.30 - 4.28 
0.73 - 4.28 
1.60 - 19.69 
0.046 
 
0.812 
0.223 
0.013 
Co-medication use 
No  
Yes  
 
121/144 (84.0) 
163/210 (77.6) 
 
2.23 
1 (reference) 
 
1.08 - 4.62 
0.031 
No. of years diagnosed 
with diabetes 
≤5 
>5 
 
 
148/198 (74.7) 
140/163 (85.9) 
 
 
1 (reference) 
2.10 
 
 
 
1.06 - 4.17 
0.034 
DBP (mmHg) 
≤80 
>80 
 
123/162 (75.9) 
162/195 (83.1) 
 
1 (reference) 
1.88 
 
 
1.06 - 4.17 
0.058 
BMI (kg/m2) 
<25 
≥25 
 
75/98 (76.5) 
180/224 (80.4) 
 
1 (reference) 
2.42 
 
 
1.22 - 4.79 
0.011 
The dependent variable was HbA1c > 7.0%;   HbA1c = glycated haemoglobin; *The column 
showing ‘n/N (%)’ shows the number of people (and percentage) within each variable with 
poor glycaemic control (HbA1c > 7.0); DBP = diastolic blood pressure;   BMI = body mass 
index 
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4.3.10 Multivariate logistic regression analysis of all factors which 
had an influence on glycaemic control 
 
Hypoglycaemic medication variables were combined to form a new four-category 
variable.  These variables were: no hypoglycaemic medication, metformin only, 
glibenclamide only and combination.  Insulin only was not included because of the 
small sample number of participants using this hypoglycaemic agent.  The variable 
‘minutes of work-related MIA’ was regrouped into three categories to include those 
who did not participate in work-related MIA at all. 
 
As shown in Table 4.55, variables which independently influenced glycaemic control 
in this study were gender, betel nut exposure, MISFRA, work-related MIA, 
hypoglycaemic medication use and DBP.     
 
Those at risk of poor glycaemic control were females, those who never chewed 
betel nut or those who chewed >5 nuts daily, those who participated in MISFRA, 
those diagnosed with diabetes for more than five years, those taking single or 
combined hypoglycaemic agents and those with high DBP.    
 
Female participants had twice the risk of having poor glycaemic control compared to 
their male counterparts.   
 
Those who quit betel nut chewing were less likely to have poor glycaemic control.  
Those who chewed ≤5 betel nuts daily also tended to be less likely to have poor 
glycaemic control but this failed to achieve statistical significance.  There was no 
difference in association of poor glycaemic control between those who never 
chewed betel nut and those who chewed >5 nuts daily.  
 
Participants who performed any MISFRA were three times more likely to have poor 
glycaemic control.  Those with DBP > 80 mmHg and diagnosed with diabetes more 
than five years ago had twice the risk of poor glycaemic control compared to their 
counterparts.  Interestingly, taking metformin, glibenclamide or a combination of 
hypoglycaemic agents was associated with poor glycaemic control.  Those on 
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glibenclamide and those on a combination of hypoglycaemic agents both had six 
times the odds of having poor glucose control compared to those using metformin, 
with only thrice the odds.  However the association between metformin use as a 
single agent and poor glycaemic control was of borderline significance. 
 
Other variables that were independently associated with poor glycaemic control but 
were of borderline significance were number of vegetable-eating days in a typical 
week, number of minutes of work-related MIA and use of co-medications.  Both 
consuming vegetables for five days or less in a week and not taking co-medications 
appear to be associated with poor glycaemic control.  In regard to work-related MIA, 
those who were spending <150 minutes performing such physical activities in a 
week were four times more likely to have poor glycaemic control; an association 
which was statistically significant. 
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Table 4.55 Multivariate logistic regression analysis of factors 
independently associated with poor glycaemic control (HbA1c > 7.0%) 
Variable n/N (%)* Adjusted OR 95% CI p-
value 
 
Gender 
Female 
Male 
 
190/228 (83.3) 
99/134 (73.9) 
 
2.19 
1 (reference) 
 
1.11-4.32 
0.024 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
77/87 (88.5) 
53/76 (69.7) 
86/111 (77.5) 
54/65 (83.1) 
 
1 (reference) 
0.33 
0.39 
1.28 
 
 
0.12 - 0.89 
0.15 - 1.01 
0.41 - 4.01 
0.025 
 
0.028 
0.051 
0.669 
Performs MISFRA for at least 
10 minutes 
No  
Yes 
 
 
231/298 (77.5) 
58/64 (90.6) 
 
  
1 (reference)
 3.89 
 
 
 
1.29-11.69 
0.016 
Work-related MIA  for at least 
10 minutes 
None 
<150 minutes 
≥150 minutes 
 
 
165/212 (77.8) 
48/53 (90.6) 
74/95 (77.9) 
 
 
1 (reference) 
4.55 
1.18 
 
 
 
1.80-54.80 
0.54-2.60 
0.050 
 
 
0.014 
0.685 
Hypoglycaemic medication 
use 
None 
Metformin 
Glibenclamide 
Combination 
 
 
16/26 (61.5) 
39/58 (67.2) 
88/105 (83.8) 
128/153 (83.7) 
 
 
1 (reference) 
3.75 
6.59 
6.42 
 
 
 
0.93-15.13 
1.68-25.87 
1.75-23.59 
0.029 
 
 
0.063 
0.007 
0.005 
DBP (mmHg) 
≤80 
>80 
 
123/162 (75.9) 
162/195 (83.1) 
 
1 (reference) 
2.28 
 
 
1.01-5.11 
0.047 
Number of years diagnosed 
with diabetes 
 ≤5 
 >5 
 
 
148/198 (74.7) 
140/163 (85.9) 
 
 
1 (reference) 
2.71 
 
 
 
1.27-5.81 
0.010 
Number of vegetable-eating 
days in a typical week 
0-5 
6-7 
 
 
172/204 (84.3) 
117/156 (75.0) 
 
 
1.87 
1 (reference) 
 
 
0.95-3.67 
0.069 
Co-medication used 
No  
Yes 
 
121/144 (84.0) 
163/210 (77.6) 
 
2.03 
1 (reference) 
 
0.92-4.47 
0.079 
The dependent variable was HbA1c > 7.0%;   HbA1c = glycated haemoglobin; *The column 
showing ‘n/N (%)’ shows the number of people (and percentage) within each variable with 
poor glycaemic control (HbA1c > 7.0). MIA = moderate-intensity activity; MISFRA = 
moderate-intensity sports, fitness and recreational activity; DBP = diastolic blood pressure 
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4.4 Discussion 
4.4.1 Demographic characteristics 
A majority of the total 385 participants were from the Southern region (76.4%) and 
were urban dwellers (55.1%).  The predominance of participants from the Southern 
region and from urban dwellings may have been because of the location of the 
PMGH Diabetes Clinic.  The finding that the majority of participants were from the 
Southern region is similar to that of Benjamin et al, 5  whose study was conducted in 
the same setting.  The PMGH Diabetes Clinic also serves those from the Central 
province (Southern region).  It is possible that there are more people living with 
T2DM in urban areas, such as the city of Port Moresby, where there are more 
predisposing factors than in rural areas.  Previous studies in PNG have 
demonstrated higher prevalence rates of T2DM in urban areas compared to rural 
areas.6-9  Furthermore, studies have also shown differences in T2DM risk factors, 
such as lipids or obesity, between urban and rural dwellers.10, 11  Those living with 
diabetes in rural areas may have once lived in urban areas because, in PNG, most 
of those employed in the cities and towns retire to their childhood villages where 
they own land.  
A high proportion (32.5%) of participants was either homemakers or unemployed 
(15.3%), which may be a reflection of the levels of education achieved.  More than 
40% of the participants had only completed basic primary education or had not 
completed even that. In general, the higher the level of education, the more likely it 
is that a person will be employed and therefore the high proportion of homemakers 
or unemployed may have been due to low levels of education.  The high number of 
females in the study may have also contributed to the high proportion of 
homemakers.    The high percentage of females being homemakers may also be 
due to cultural norms and expectations in PNG where women are responsible for 
taking care of the family.  The observation that a high proportion of participants were 
either homemakers or unemployed may have been because their time was more 
flexible to allow participation in the study. 
The highest proportion (37.7%) of participants in the current study was aged 50-59 
years.  As the categories of age increased, the number of participants increased up 
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to the age group 50-59 years and then decreased after that age group.  The 
increase is due to the fact that T2DM is commonly a maturity-onset disease.  The 
decrease in the number of participants after the ages 50-59 years may be due to 
deaths.  The life expectancy at birth for Papua New Guineans has been reported to 
be 65.5 and 61.2 years for females and males, respectively.12  
4.4.2 Lifestyle factors 
4.4.2.1 Alcohol consumption 
The number of participants who reported consuming alcohol in this study was small 
and therefore valid conclusions could not be drawn.  However, alcohol consumption 
appeared to be influenced by age, gender and employment status.   Participants 
younger than 50 years, males and those who were employed (paid and self-
employed) appeared to be more likely to consume alcohol. On the other hand, those 
who had not completed basic education and those who had only completed primary 
education appeared to be less likely to consume alcohol.    In PNG, from personal 
knowledge, consumption of alcohol is not common among females, mostly due to 
cultural reasons.  There were more females in this study, which may have therefore 
contributed to the low levels of alcohol consumption.  It may also be that participants 
may have quit alcohol as part of their diabetes management. This study did not 
gather information on whether or not participants had quit alcohol consumption. 
 
4.4.2.2 Tobacco smoking 
Like alcohol consumption, the percentage of those who smoked tobacco was small 
(6.2%).  The finding that the prevalence of smoking was low in this study is similar to 
other studies that have found low prevalence of smoking by those with T2DM 
compared with those who do not have diabetes.13, 14  A Malaysian study 14  showed 
8% of those with T2DM were smokers.  Kengne et al 15, however, reported a similar 
prevalence of current smokers in both their cohorts with and without diabetes.  
Smoking appeared to be affected by age in the present study, but sample numbers 
for those who were classified as smokers were too small to draw any valid 
conclusions. 
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4.4.2.3 Vegetable and fruit consumption 
Participants were requested to think of a typical week in the preceding three months 
when they had consumed vegetables or fruit, and recall both the number of days 
and the number of cups of fruit or vegetables consumed on those days.  For each 
person, the number of cups was converted to number of servings using the show 
card (Appendix 9) for fruit and vegetable intake. 
Results of this study indicated that vegetable and fruit consumption was poor, with 
92% and 70.4% of the participants reporting that they consumed less than three and 
less than two servings of vegetables and fruits, respectively.  There are no national 
guidelines on the amount of fruit or vegetables to be consumed daily; rather 
recommendations from Australia have been adapted.  PNG traditionally has a diet 
rich in leafy vegetables, so this finding of the study possibly indicates indirectly that 
diet is changing in PNG.  Studies have shown changes in diet of Papua New 
Guineans which have been attributed to urbanisation and westernisation. 16, 17  
There has been a shift from garden food to processed food.  The cost of feeding a 
large family with processed food is usually cheaper than feeding them with garden 
food sold either in the local markets or grocery shops.  The cost of living in Port 
Moresby therefore may also be contributing to low levels of fruit and vegetable 
intake.   
Consuming a diet poor in fruit and vegetables further increases the risk of 
cardiovascular diseases in these participants with T2DM. 18-20  Fruit and vegetables 
are high in antioxidants which boost immunity and protect against other nutrient 
deficiencies.  Studies also have shown that a high intake of dietary fibre improves 
glycaemic control, decreases hyperinsulinaemia and plasma lipid concentrations in 
patients with T2DM. 21, 22  Therefore, poor consumption of fruit and vegetable may 
contribute to poor glycaemic control among the participants of the present study. 
 
4.4.2.4 Physical activity 
Fifty six percent of participants reported doing a sufficient amount of physical 
activity, which was mostly contributed to by the high proportion of participants 
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walking as their mode of travel.  The most common type of physical activity was 
walking for travel, with 296 (76.9%) participants reporting that they walked to get to 
and from places.  The only significant demographic factor which influenced this type 
of physical activity was gender.  Females were more likely to walk, but the amount 
of walking (minutes per week) they did was less than that of their male counterparts.  
Area of residence and years of residence in Port Moresby had a significant influence 
on the amount of walking, while the influence of age was of borderline significance.  
Compared to those who were born in Port Moresby and had spent their entire 
lifetimes there, rural village dwellers and those who had migrated to the city were 
significantly more likely to do more walking. 
Twenty percent of participants of this study were from rural villages where there are 
hardly any motor vehicles.  In many rural areas of PNG, the most common types of 
motor vehicle in the villages are public motor vehicles, which are usually open-
backed trucks.  These vehicles are used to transport passengers to and from the 
towns.  Therefore, those residing in the villages are more likely to walk to get to and 
from places.  For those who live in Port Moresby, walking for travel may have been 
further influenced by the limited transport system in the National Capital District.  
Usually, people have to walk long distances to the nearest bus stop.  (Personal 
knowledge) 
As the intensity of physical activity increased, the number of participants undertaking 
those activities decreased.  One hundred and sixty participants (41%) did work-
related MIA while only fifty three (13.8%) did work-related VIA.  Similarly, the 
prevalence of those doing MISFRA was higher than that of VISFRA.  These results 
were influenced by age.  Univariate (Chi-square) analysis indicated that age was 
associated with participation in sports, fitness and recreational activities but not 
work-related MIA and VIA.  As age increased, the number of participants taking part 
in sports, fitness and recreational activities significantly decreased.  As age 
increases, there is a natural trend to reduce physical activity.  Although this study 
did not document the type of work-related activity, this may be a reflection of 
employment status.  More than 70% of participants were either unpaid or 
unemployed and therefore had to find a means of survival if they lived in the city.  If 
they lived in their rural villages, they could depend on subsistence farming or fishing 
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for their livelihoods. The small number of those performing leisure-time physical 
activities may also indicate that people would rather put their time towards work-
related activities than leisure-time physical activities because of the need to provide 
food, shelter and other necessities.  Additionally, as the present study cohort was 
comprised of those with T2DM, complications or factors related to this disease may 
have contributed to decreased physical activity among these participants. Safe 
participation in physical activity such as exercise in those with T2DM can be 
complicated by the presence of disease-related complications such as 
cardiovascular disease, hypertension, neuropathy or microvascular changes. 23  
Other studies have reported a high number of T2DM patients are inactive. 24, 25  It is 
important that T2DM engage in physical activity at a level of intensity that is 
comfortable and safe for them.    
 
4.4.3 Medical factors 
4.4.3.1 Diabetes management 
The change of diabetes management of 48 (12.5%) participants from diet-controlled 
to pharmacological agents in the preceding three months indicates a need for better 
glycaemic control for these participants.  .  This is the usual progressive 
management for T2DM because, as time passes and diabetes advances, there is 
loss of β-cell function and, therefore, a greater need for pharmacological agents to 
deal with the resulting hyperglycaemia.  Although 25% were advised about their diet, 
none of the participants were on a prescribed diet.  This is a reflection of services 
available for those living with diabetes in PNG.  From personal knowledge, since a 
2001 report 26, there are still insufficient resources, such as nutritional and dietetic 
services, and specialist endocrinologists to support diabetes management in the 
country.  The reason for the availability of a limited range of hypoglycaemics 
(glibenclamide, metformin and insulin) through the public health care system during 
the time of the study is because the list of medicines purchased is based on the 
WHO Model List of Essential Medicines.  The use of essential medicines only is to 
ensure affordable medicines are widely available.   
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Participants were requested to report management of their T2DM when they were 
initially diagnosed with the disease.  The reduction in the number of patients on 
insulin over time may have been partly due to changing from inpatient services to 
outpatient services.  Some of these participants may have received insulin while in 
hospital at the time of initial diagnosis but may have been discharged on oral 
hypoglycaemic medications.  It is also possible that T2DM patients who require 
insulin may not be able to use insulin for reasons such as the storage requirements 
of this medication.  Usage of insulin in PNG is limited by its requirement for 
refrigeration.  As seen in this study, about 20% of the participants lived in rural areas 
and 20% lived in peri-urban areas.  In rural PNG, only a few homes have portable 
electricity generators but electricity is produced mostly for smaller appliances and 
lighting purposes only.  Some peri-urban areas may not have consistent electricity 
supplies and, in particular, may not have refrigerators. 
 
4.4.3.2 Medication adherence 
Adherence to medications is of paramount importance because there are strong 
correlations between medication adherence, patient outcomes and treatment costs. 
27-30  
The type of medication adherence investigated by the present study was omission 
of doses, which is the most common type of non-adherence. 31  This may be 
intentional or non-intentional.    A high proportion of participants (59.6%) reported 
omitting at least some of their doses.  This is consistent with the trends that have 
been reported elsewhere. 32-36   
The only significant factor which affected adherence to medication regimens was 
age.  Those aged 60 years or older were more likely to be adherent to their diabetes 
medications.  Younger people tend to have other priorities in their lives and lead 
busier lives than the elderly, because of employment and other social activities.  
This may partly explain why the younger age group was less adherent to their 
hypoglycaemic medications than the older age group in the present study.   
190 
 
 
Older people also may have been more adherent within this study population 
because the study setting has a medication supply policy that exempts those aged 
60 years or older from medication fees.  Furthermore, in a society like PNG’s where 
extended family usually live together in a single household, care of the elderly may 
have led to better adherence by those aged 60 years and older.  This finding, that 
older people are more adherent, is consistent with other studies showing that better 
hypoglycaemic medication adherence is associated with increased age. 34, 37, 38  A 
Scottish study, however, reported that younger people were more adherent in taking 
their hypoglycaemic medications, compared to their older counterparts.39    
There is evidence that strong psychosocial support improves medication 
adherence.40  Participants in this study were living in a society where extended 
families usually live in the one house.  Family ties are strong and, usually, younger 
family members care for their elder relatives within the family home.  With the 
advantage of strong psychosocial support in PNG, patients and their family carers 
may have better opportunity to develop good routines in medication behaviour, as it 
has been shown that developing such routines usually leads to higher levels of 
adherence.40  
The most common reasons cited by participants for omitting doses were patient- 
and health care system-related.   The most common patient-related reason for 
omitting doses cited by participants was that they simply forgot to take their 
medications.  The next most common patient-related factor was participants not 
refilling their medications, despite having prescriptions.  This group of participants 
did not elaborate further on their reasons for not doing so. 
All participants who had problems with access to the diabetes clinic reported that 
they were waiting for their next medical review to pick up their new prescriptions.  
This led to them not continuing their medications as required.  The contributing 
factors to this were:  increase in the number of patients attending the clinic, 
scheduling of appointments, the number of clinic days and hours per week, 
cancellation/rescheduling of clinic times, shortage of staff at the clinic and closure of 
the clinic from the beginning of December to the end of January every year.  
Scheduling of review dates for each individual patient depends on availability of an 
appointment time.  Even if a doctor wants to see a patient one month later, for 
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example, the next available appointment may not be until two weeks after that.  This 
may lead to a patient missing out on their medications for two weeks, because the 
doctor will usually prescribe only one month’s supply of medication based on the 
understanding that the patient will be seen again after a month.  Despite the 
increase in the number of people diagnosed with diabetes, this clinic was still only 
open for three hours per week.  To make matters worse, shortages in staff (both 
nursing and medical) often led to cancellation of appointments or scaling down of 
the clinic’s operations. (personal observation) 
 Cost of medications is a crucial issue in medication adherence, especially for those 
who have been diagnosed with chronic diseases like T2DM, because therapy is 
ongoing (life-long). A further cost burden is often incurred due to the complications 
associated with diabetes.  Most patients in PNG do not have private medical 
insurance but all patients benefit from subsidised medications through the public 
health system.  Despite minimal medicine costs, many patients still cannot afford 
medications.  There are also associated costs, such as consultation fees and the 
cost of transport to the clinic.  Almost 20% of the participants in this study lived in 
rural villages where the cost of transport is even more than the cost of medicines.  
Apart from transport costs, those who live in the rural areas have to find temporary 
accommodation in the city where the diabetes clinic is situated.  Studies elsewhere 
have shown that the cost of medications contributes to reduced adherence.36, 41, 42  
Similarly, the inconvenience of travel and the cost of travel also play a role. 
There are three main policies which affect access to hypoglycaemic medications in 
PNG.  Hypoglycaemic medications are only available in hospitals, which makes 
access more expensive for those living in rural villages.  Another policy involves 
pharmacy fee exemptions.  Patients with chronic diseases like cardiovascular 
diseases and asthma are exempted from paying for their disease-related 
medications but the same concession is not available, in general, for patients with 
diabetes.  The exception is that patients who are 60 years and older are exempted 
from the costs of all medical problems.  This policy may need revising to improve 
adherence to hypoglycaemic medications.  The third policy concerns the total 
quantities dispensed per patient.   Pharmacy departments usually only dispense one 
month’s supply, even if the prescriber makes a request for three month’s supply, for 
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example.  Patients are then required to travel to the hospital pharmacy more often 
for their monthly refills. 
4.4.4 Physical measurements 
4.4.4.1 Blood pressure 
The high prevalence of systolic (74.5%) and diastolic (53.5%) hypertension in this 
cohort was not surprising as it is well known that hypertension is associated with 
T2DM.   Susceptibility of hypertension in Papua New Guineans may also be 
contributed to by genetic polymorphisms.43 The observation from this study that the 
majority of diabetes patients have poorly-controlled hypertension is similar to other 
studies.44-46  Findings of a systematic review of observational studies by McLean et 
al 45 reported that only 12% of T2DM patients had their blood pressures adequately 
controlled (≤130/85 mmHg).  Some of the studies referenced in the review did not 
report the age groups included and some studies also included those with type 1 
diabetes mellitus. 
Univariate analysis indicated that factors which influenced SBP in the current study 
were age, employment status, tobacco smoking, duration of MISFRA, BMI and use 
of co-medications.  After adjusting for each other, the factors with an independent 
significant influence on SBP were age, smoking and co-medications taken with 
hypoglycaemic drugs. High SBP was observed in those aged 50 years and older, 
smokers and quitters, and those taking co-medications, even after adjusting for 
confounders.   
Due to the small number of smokers, no valid conclusion could be drawn regarding 
the influence of smoking on blood pressure in the study cohort.  Studies have shown 
that any independent chronic effect of smoking on blood pressure is small 47 and 
smoking is associated with hypertension in a dose-dependent manner 48  Cigarette 
smoking is said to exert a hypertensive effect mainly through stimulation of the 
sympathetic nervous system.49 
The finding of higher SBP with increasing age is consistent with those reported 
elsewhere.50-53.  Ageing is associated with progressive loss of the visco-elastic 
properties of conduit vessels, increased atherosclerotic arterial disease, and 
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hypertrophy and sclerosis of muscular arteries and arterioles; factors which 
contribute to amplification of systolic pressure and a fall in diastolic pressure.54, 55   
Age-related changes in blood pressure are also due to a progressive decline in 
organ function and other pathophysiological processes.  The ability of the kidneys to 
secrete salt loads efficiently, for example, declines with age, thereby resulting in 
increasing blood pressure.56  Total and renal vascular resistance also increase, and 
cardiac output, heart rate, stroke volume, intravascular volume, renal blood flow and 
plasma renin activity are reduced.54, 57  Further, the present study cohort includes 
those with T2DM; a disease which not only adversely affects kidney function 58 but 
also accelerates vascular injury. 59, 60  More than 80% of the participants had poorly 
controlled T2DM, increasing the risk of endothelial dysfunction and subsequent 
arterial stiffness. 
Use of co-medications was probably associated with a high SBP because the most 
common class of co-medications used by participants was an antihypertensive, and 
not because of any adverse effect of co-medications on blood pressure per se. 
None of the physical activities investigated were significantly associated with SBP in 
this study. However, undertaking MISFRA for less than 150 minutes per week 
appeared to be associated with a high SBP.  Performing MISFRA and VISFRA 
appeared to have a beneficial influence on SBP but this did not reach significance.  
These findings, that none of the physical activities were significantly associated with 
SBP are contrary to other studies which have reported a beneficial association 
between physical activity and SBP. 24, 61  A meta-analysis 61 of 42 randomised 
control studies reported an improvement in blood pressure in association with 
supervised exercise among those with T2DM.  That study did not find a significant 
association between SBP and either aerobic or resistance exercise alone, but a 
significant association was observed when aerobic and resistance exercises were 
combined.   
Factors influencing DBP were gender, age, employment status and BMI, with 
gender, age and BMI remaining significant after adjusting for other confounders.  As 
previously indicated females and those aged 50 years or older were significantly 
less likely to have a high DBP, compared to those who were younger.  Those who 
had a BMI ≥25 kg/m2 were more likely to have a high DBP.  Compared to SBP, a 
194 
 
 
number of studies have reported that DBP is either maintained or decreases with 
increased age. 50-52  The present study found that DBP decreased with increasing 
age, while SBP increased with increasing age.  The trend in blood pressure changes 
with age observed in the present study is different to what has been reported earlier 
in rural areas of PNG where people live a traditional life. 11, 62-64  A PNG survey 62 in 
the Highlands of PNG in the 1960s showed a decrease in both SBP and DBP with 
increasing age.  The authors attributed the falling blood pressure to a fall in body 
build after the third decade of age in that population.  In 1985, another survey 63 in 
the Highlands of PNG showed little evidence of an association between either age 
or adiposity and blood pressure.  Studies conducted in remote rural areas of PNG 
and other countries where the lifestyle is more traditional, have observed the same 
findings that there is little or no increase in BP with increasing age.64, 65  This 
perhaps indicates the role of urbanisation (or modernisation) and its consequent 
dietary changes on BP, as observed in the present study.   
Obesity is recognised as a major risk factor for high blood pressure.  The pathogenic 
associations of obesity include the stimulatory effects of insulin and leptin on the 
sympathetic nervous system and activation of the renin-angiotensin-aldosterone 
system (RAAS) in obesity.66  The prevalence of high SBP among this cohort was 
almost similar to the prevalence of poor glycaemic control, increased BMI and waist 
circumference. 
 
4.4.4.2 Measures of obesity and adiposity 
In the present study, BMI was used as an indicator for general obesity while waist 
circumference was an indicator for central obesity.  Lipid profiles were only available 
for a few participants.   
More than 60% of participants were either overweight or obese.  Region of origin of 
participants, betel nut exposure and age were significant independent factors 
associated with BMI.  Although gender was an independent factor, the association 
was not significant.    Those from the New Guinea Islands and the Momase regions 
were twice as likely to have a BMI ≥25kg/m2, but this was not significant.  However, 
being from the Highlands region was significantly associated with a BMI ≥25kg/m2.  
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The increasing trend of obesity among the urban Highlanders in PNG is different to 
what has been observed in rural Highlanders living a more traditional lifestyle.62-64 64, 
67, 68  This is an indication of lifestyle changes as a result of residing in urban areas. 
When age was regrouped into two categories and entered into the logistic 
regression models, it became a significant independent factor affecting BMI.  Those 
aged ≥50 years of age were significantly associated with a higher BMI after 
adjusting for other confounders.  Studies have shown that obesity increases 
progressively from 20 to 60 years and decreases after 60 years of age.69, 70   It 
would have been useful to examine the association with an age cut-off at 60 years.  
A decline in physical activity and hence total energy expenditure may partly be 
contributing to the gradual increase in body fat with advancing age in the present 
cohort.  This study observed a decline in physical activity with advancing age. 
This study showed that a high proportion (70.1%) of participants had an abnormally 
high waist circumference.  The most important factor influencing waist 
circumference was gender.  Females were nine times more likely to have a waist 
circumference above normal, compared to the males.  This finding is inconsistent 
with other findings that males are more likely to have central adiposity compared to 
females.71  One possible reason for this finding in PNG is parity.  Papua New 
Guineans usually have large families predisposing mothers to central adiposity.  
Studies have reported an adverse influence of having three or more children on 
waist circumference. 72, 73  However, in rural villages of PNG, even women who have 
many children usually do not put on weight or have central obesity.  The finding that 
women are more likely to have increased waist circumference or BMI is different to 
what has been observed in rural areas, especially on the mainland of Papua New 
Guinea, where females are more likely to have a BMI or waist circumference within 
the normal limits.  This is mostly due to increased habitual/occupational physical 
activity in rural areas.11, 74, 75  The inconsistencies in studies investigating factors 
associated with obesity reflect the multifactorial risks of this disorder and, in some 
cases, the predominance of certain risk factors. 
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4.4.5 Betel nut chewing 
4.4.5.1 Prevalence of betel nut chewing 
Fifty five percent of the participants in this study were betel nut chewers. A review of 
literature found only one study reporting the prevalence of betel nut chewing among 
those living with T2DM.  The PNG study 5 76 which was also conducted at the PMGH 
Diabetes clinic, reported a higher prevalence (74%) of betel nut chewing.  That 
study included a smaller sample (n = 210) than the present study.    
 
4.4.5.2 Demographic factors associated with betel nut chewing 
Betel nut chewing for this cohort was associated with the participant’s area of 
residence, the region of origin of the participant, years of residence in Port Moresby 
and level of education.  Age also appeared to have an influence on the prevalence 
of betel nut chewing but the association was not significant.   
Rural village dwellers had the highest proportion of betel nut chewers.  This finding 
is similar to that of a comparison between rural and urban males in Sri Lanka, where 
the prevalence of betel nut chewing in the rural district was ten times that of the 
urban district. 77  Betel nut trees are grown in rural areas and, therefore, the nuts are 
more readily available and may be cheaper for rural dwellers.  Urban dwellers 
mostly have to pay for betel nuts, so chewing betel nut may be a strain on the 
budget.  However, employment did not have an influence on betel nut chewing, so it 
is more likely that the high prevalence of betel nut chewing may have been as a 
result of availability rather than cost.   
Those from the Southern region were more likely to chew betel nut, most probably 
because betel nut is readily available and accessible for those from the Southern 
region, especially for those from the Central and Gulf provinces because these two 
provinces are linked to Port Moresby by road.  This prevalence may have been 
correlated to area of residence, since those from the rural villages were those from 
the Southern region. 
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In terms of years of residence in Port Moresby and its association with betel nut 
chewing, the habit was more prevalent in those residing outside of the city of Port 
Moresby and those who had been in Port Moresby for a lifetime.  Those who 
indicated that they had spent their lifetimes in Port Moresby were mostly those living 
in urban villages, who usually have family in rural villages, which increases their 
access to betel nut.  
The lowest prevalence of betel nut chewing was observed among those who did not 
complete basic primary education, compared to all other categories of education 
level.  There was no difference observed among all other higher levels of education.  
It is not known why those with this level of education were least likely to chew betel 
nut.  Although this may be a reflection of the affordability of betel nut, employment 
status did not influence the prevalence of betel nut chewing.  One of the reasons for 
this is that betel nut is commonly shared, as a gesture of goodwill, during meet and 
greet events and other social gatherings, and as a sign of friendship or kinship.     
 
4.4.5.3 Lifestyle factors associated with betel nut chewing 
Alcohol, smoking, work-related MIA and amount of physical activity per week were 
significantly associated with betel nut chewing.  Walking as a means of travel, work-
related VIA and number of vegetable servings also appeared to be associated with 
betel nut chewing but the association did not reach significance. After adjusting for 
other confounding factors, alcohol consumption, work-related MIA and smoking 
were independent factors influencing betel nut chewing.  The influence of smoking 
however was not significant.  This may be because of the small number of 
participants who were smokers. 
The finding that alcohol and smoking are associated with betel nut is consistent with 
findings in settings where betel nut chewing is endemic. 77-82  However, the finding 
that betel nut chewers are more physically active is in contrast with what has been 
reported in Taiwan.79 In PNG, alcohol, tobacco products and betel nut are commonly 
shared and consumed during social gatherings. 
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4.4.5.4 Physical factors associated with betel nut chewing 
Although those who had chewed betel nut for more than 25 years appeared more 
likely to have a high SBP in comparison to their counterparts, this was not 
statistically significant.  Betel nut chewing did not influence DBP.  Consequently, 
betel nut chewing did not influence blood pressure among this cohort of T2DM.  This 
finding is different to that reported elsewhere in population-based studies.78, 82  This 
indicates that there are more important risk factors, other than betel nut chewing, 
affecting blood pressure among those with T2DM.  
Betel nut chewing was significantly associated with BMI.  Quitting the habit and 
chewing ≤5 nuts per day had a beneficial effect on BMI.  Never having chewed betel 
nut appeared to have a beneficial effect but this did not reach significance when 
compared with those who chewed >5 nuts per day.  When adjustments were made 
for other confounding factors, the overall significance of betel nut chewing on BMI 
remained, but it was less significant. It appears that, apart from the beneficial effects 
of never having chewed or quitting the habit, a lower dose of betel nut chewing also 
has a beneficial influence on BMI in those with T2DM. 
Although betel nut chewing did not have an influence on waist circumference, based 
on the univariate analysis, adding waist circumference to the multivariate logistic 
regression models demonstrated an independent association with betel nut 
chewing, but this was of borderline significance.  Never having chewed betel nut, 
chewing ≤5 nuts per day, and quitting the habit had beneficial influences on waist 
circumference in comparison to chewing >5 nuts per day.  These results indicate a 
dose effect of betel nut on obesity in those with T2DM.    The finding that betel nut 
chewing is associated with BMI and waist circumference is consistent with findings 
among non-diabetic populations. 78-81, 83-85  but a beneficial influence appears to 
result from a low dose of betel nut; too much of it may predispose the chewer to a 
higher BMI. 
Animal studies reporting the effects of betel nut on cholesterol or obesity have been 
inconsistent.  Several studies have reported a favourable effect 86-88 of betel nut or 
arecoline on lipids while Boucher et al 89 have reported the reverse.  Zhou et al 87 
reported a significant reduction in total cholesterol and increased HDL by low dose 
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of areca oil plus arecoline in rats.  Iqbal et al 90, however reported a low dose of 
betel nut causing a significant increase on total cholesterol while a high dose had no 
effect in a rat model. Animal studies have demonstrated that betel nut inhibits 
activity on cholesterol absorption in high cholesterol diets resulting in reduced 
plasma lipid concentrations 88, 90 
4.4.6 Glycaemic control 
The present study showed that only a small number of participants (18.3%) 
achieved the optimal target for glycaemic control of ≤7.0%.  The proportion of 
participants achieving optimal glycaemic control in the present study is lower than 
that reported elsewhere 41, 91, 92 In comparison with some recent reports from the 
Pacific Island Countries (PICs), the prevalence of optimal glycaemic control in the 
present cohort is similar to what has been reported in the neighbouring Solomon 
Islands (17.0%) and Nauru (20.0%) but less than that reported in those from 
Vanuatu (28.0)%. 93.  An earlier study 94 in PNG showed 64% (N = 83) had poor 
glycaemic control (HbA1c >10.0%). That study, however, used a higher HbA1c cut-
off than the present study.  Differences in prevalence rates of poor glycaemic control 
may partly be explained by the different cut-offs for appropriate glycaemic control.  
Studies elsewhere using the optimal target of HbA1c ≤7.0% have reported higher 
prevalence rates of poor glycaemic control than that observed in the present study. 
95-98  
 
4.4.6.1 Influence of demographic factors  
Using Chi-square statistics, the demographic factors which appeared to have an 
association with glycaemic control were gender, age and employment.  Logistic 
regression analysis indicated that females and those younger than 50 years had 
poor glycaemic control while those who had retired exhibited better glycaemic 
control.  
It is possible that older aged patients with T2DM who have been diagnosed much 
later in their life, may have had no or minimal risk factors for much of their lives, at 
least until later in life.  Further, older aged T2DM patients may have had relatively 
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good glycaemic control after diagnosis and, therefore, lived longer than those who 
did not.  Hsieh et al 99  reported an association between glycaemic control and age 
at diagnosis, with those diagnosed later in life having better glycaemic control.  In 
the present study, better glycaemic control may be partly explained by better 
medication adherence among older participants (≥60 years). Female participants of 
the present study may have had poor glycaemic control because this group of 
participants appeared to be more likely to have a higher than normal BMI and waist 
circumference, both of which are risk factors for T2DM. The finding that female 
participants had poor glycaemic control, compared to their male counterparts, is 
consistent with other studies 100, 101, although not all studies have found an 
association of gender with glycaemic control. 102  One of these studies reporting 
poorer glycaemic control among women, compared to their male counterparts, was 
a Saudi Arabian cross-sectional study of 1,000 diabetes patients.  Apart from the 
finding that females had poorer control than males, the study also found that 
females were more obese than their male counterparts.  Further, the current study 
found that females significantly had an abnormally higher waist circumference, 
which is a risk factor for poor glycaemic control.  However, results of the present 
study indicated that waist circumference was not associated with poor optimal 
glycaemic control. 
 
4.4.6.2 Influence of lifestyle factors  
Lifestyle factors which had an association with glycaemic control were smoking 
status, work-related VIA and minutes of walking to get to and from places.  The 
associations of performing MISFRA and minutes of work-related MIA were of 
borderline significance.  
Participants who had never smoked tobacco were more likely to have poor 
glycaemic control, compared to those who did. 
Interestingly, results of this study indicated that those who did work-related VIA and 
MISFRA were more likely to have poor glycaemic control.  Those whose work 
involved VIA, or who were performing MISFRA, were three times more likely to have 
poor glycaemic control compared to those who did not participate in these activities.  
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This may have been due to compensatory over-eating after such physical activities.  
This compensatory over-eating may have had a cultural component as well because 
from personal knowledge, a person who works hard for income or brings food home 
for a family is rewarded with a large meal, for those who can afford such meals.  In 
this study, work was not merely employment-related but also included activities such 
as household chores, gardening and fishing, for example.  It is also possible that 
those who are physically active develop bigger appetites. Participants of this study 
who were physically active were probably consuming low energy meals before 
engaging in physical activity.  Hubert et al 103 reported that low energy breakfast 
increased hunger and increased energy intake.  Further, that study reported that low 
energy breakfast failed to generate the inhibitory satiety signals.  High dose exercise 
however does not induce hunger. 104  Martins et al argue that the effect of exercise 
on energy intake and appetite is a controversial area because the mechanisms that 
operate to regulate appetite are complex. 105 
The present study requested that participants think of a typical week when they 
performed physical activity and answer questions related to such activities.  
Participants may have remembered only a week when they were most physically 
active.   The responses included in this study were self-reported, possibly explaining 
why results observed were different to studies involving directly-observed physical 
activities and their associations with glycaemic control.  However, other studies 
involving self-reported activities have reported that physical activity had a beneficial 
influence on glycaemic control. 24  Effects of exercise interventions have also 
reported a beneficial effect on glycaemic control. 106, 107  A meta-analysis 108 of 
controlled trials reported that all forms of exercise training conferred small benefits 
on HbA1c. 
Genetics also may have played a role in the results observed.  A recent study 109 
has shown that genes may play a part in affecting the outcomes of physical activity 
on glycaemic control.  That study reported an association between the glucagon 
gene and both moderate and high-intensity physical activity, whereby those with the 
C-C genotype who did moderate or high-intensity physical activity had a reduced 
risk of T2DM.  The study further reported that those with the T-T haplotype who did 
high-intensity physical activity had increased risk of T2DM.  The glucagon gene 
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encodes glucagon, glucagon-like peptides 1 and 2, and oxyntomodulin proteins 
which are involved in glucose metabolism homeostasis.  More research on these 
genes may assist in devising programs for the prevention of T2DM and also 
appropriate management programs aiming at achieving optimal glycaemic control 
for those with T2DM. 
4.4.6.3 Influence of physical and medical factors 
Use of hypoglycaemic medications, glibenclamide dose per day and number of 
years living with T2DM were important factors influencing glycaemic control.  
SBP did not influence glycaemic control and the influence of DBP was of borderline 
significance.  After adjusting for other medical confounders, the significant influence 
of daily dose of glibenclamide and number of years living with T2DM remained.  The 
borderline significant influence of DBP also remained but the significance increased.  
Those with high DBP were more likely to have poor glycaemic control compared to 
their counterparts.  The association of high DBP with poor glycaemic control has 
been reported elsewhere.110 
Although BMI was not associated with glycaemic control in the univariate analysis, 
adding this variable to the multivariate logistic regression models resulted in BMI 
having an independent influence on glycaemic control.  Obesity is a contributing 
factor to insulin resistance which is one of the underlying problems leading to 
T2DM.111   
It is well known that, as T2DM progresses, β-cell function declines and may decline 
faster in poorly controlled T2DM.  The association of poor glycaemic control with 
longer disease progression observed in the present study has been reported 
elsewhere. 99, 112  Further, disease progression is associated with complications of 
the disease. 93 
It is known that hypoglycaemic medications lower blood glucose.  For this reason, it 
was unexpected in the present study that being prescribed hypoglycaemic 
medication was adversely associated with glycaemic control.  As the number of 
prescribed hypoglycaemic medications increased, the likelihood of poor glycaemic 
control also increased.  This is probably an indication of the progressive nature of 
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the disease.  As T2DM progresses, the likelihood of being prescribed 
hypoglycaemic medications or a combination of them increases.  Those on diet-
controlled management are usually those who have had a shorter duration of T2DM 
and appropriate glycaemic control that does not require drug therapy.  It is also 
possible that those prescribed hypoglycaemic medications are not complying with 
other aspects of management, such as lifestyle modification, because they are more 
reliant on medications to lower blood glucose while eating carelessly.  It is also 
possible that hypoglycaemic regimens prescribed for those in this study may have 
been insufficient to control hyperglycaemia. An overstretched and poorly resourced 
clinic further adds to the problem because these factors may be contributing to 
inadequate follow up of patients.  The observation of poor glycaemic control in those 
prescribed hypoglycaemic drug therapy has been reported elsewhere. 110  The 
UKPDS study 113 reported that the need to increase the number of hypoglycaemic 
medications is indicative of the progressive decline of β-cell function.  The study 
further reports that by three years of diagnosis, 50% of T2DM patients will need 
more than one pharmacological agent and by nine years, 75% will need multiple 
therapies. The present study showed that more than 50% of the participants who 
had lived with diabetes for more than five years were taking one or no 
hypoglycaemic medication.  This indicates that more than half of these patients were 
receiving insufficient therapy for their diabetes.   
 
4.4.6.4 Influence of betel nut chewing  
Betel nut chewing history/status exhibited an association with glycaemic control.  
The beneficial influence of betel nut chewing on glycaemic control also tended to be 
dose-related. 
Using never chewers as the reference, those who had quit and those who chewed 
≤5 nuts per day were significantly more likely to have better glycaemic control.  
Although chewing >5 nuts per day appeared to be associated with better glycaemic 
control in comparison to those who had never chewed, this association was not 
significant.  After controlling for other confounders, betel nut chewing continued to 
be associated with glycaemic control and, therefore, betel nut independently 
influenced glycaemic control. 
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A search of the literature did not find any studies on glycaemic control among betel 
nut chewers with T2DM in other countries where the habit is prevalent.  The only 
similar study was a PNG study by Benjamin et al. 5   That study reported that 73% of 
those with poor glycaemic control were betel nut chewers, a finding that is 
contradictory to that of the present study  The blood glucose levels used in the study 
were reported to be the most recent blood glucose measurements recorded in 
medical notes, with no specific indication of time between measurements and data 
collection.  Benjamin et al 5 did not further investigate whether or not betel nut 
chewing was independently associated with poor glycaemic control, which was 
defined in that study as blood glucose ≥10 mmol/L. 
 Other studies which have investigated the association between betel nut chewing 
and glycaemic control in the general populations of other countries have also 
reported an influence of betel nut chewing on poor glycaemic control. 79, 114  Tung et 
al 114 further reported a dose-dependent influence of betel nut on glycaemic control.  
Tseng reported an association between betel nut chewing and incident T2DM. 85   
However, those studies did not investigate the glycaemic effects of betel nut 
chewing in relation to T2DM but were focussed on the general population.  Further, 
most of these studies included males only and have been conducted in Taiwan.  
The beneficial association of betel nut chewing observed in the present study is 
similar to that observed in a small study by Chempakan 115 involving humans who 
were subcutaneously administered injections of arecoline. 
Findings from animal studies also have been inconsistent.  These studies have not 
only investigated the glycaemic effect of betel nut or its chemical constituents but 
also that of PBL.  Boucher et al 89 reported glucose intolerance in adult mice fed with 
betel nut.  Ling et al 86 reported a decreased level of fasting blood glucose in Wistar 
rats after treating these rats with different doses of arecoline.  Using PBL extract, 
Arambewela et al 116 reported hypoglycaemic effects in normoglycaemic and 
diabetes-induced rats.  That study reported a glucose-lowering effect comparable to 
tolbutamide, a hypoglycaemic drug.  Iqbal et al, 90  however, demonstrated no effect 
of betel nut on glucose and body weight in a normoglycaemic rat model.  In 
diabetes-induced rats, oral administration of a betel nut extract for 30 days 
demonstrated that the nut possesses antidiabetic properties which are comparable 
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to gliclazide, an oral hypoglycaemic drug. 117   Possible mechanisms of betel nut and 
additives on glycaemic control have already been discussed in the literature review. 
In the present study, a low dose of betel nut had a beneficial influence on general 
and central obesity, both of which are known risk factors for T2DM or poor 
glycaemic control. 
4.5  Conclusions 
The present study observed a high prevalence of betel nut chewing among those 
with T2DM.    The prevalence of poor glycaemic control was high (82.0%).  
Significant independent factors associated with glycaemic control were gender, betel 
nut exposure, MISFRA, work-related MIA, number of years diagnosed with T2DM, 
DBP and hypoglycaemic medication use.  Of these factors, physical activity had a 
significant association with betel nut chewing.   Betel nut chewing had a significant 
independent association with glycaemic control, with chewers and quitters being 
more likely to have better glycaemic control than those who had never chewed; a 
finding that contradicts what has been reported among the general population in 
Taiwan. 
In conclusion, low dose of betel nut chewing has a beneficial influence on glycaemic 
control among those with T2DM.  This study is a cross-sectional study and, 
therefore, has limitations in explaining any mechanism of action for the glucose 
lowering effects of betel nut in T2DM.   
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Chapter V: Glycaemic effects of betel nut chewing 
and its associated factors in a non-T2DM cohort 
5.1 Objectives 
 
The main objectives of this part of the research, involving a cohort of participants 
without T2DM, were to:   
1 Identify their characteristics with a focus on their demographics, lifestyle 
behaviours, and physical and biochemical measurements. 
2 Estimate the prevalence of betel nut use. 
3 Identify demographic, lifestyle, biochemical [as measured by bioelectric 
impedance analysis (% body fat)] and physical factors associated with betel nut 
chewing. 
4 Determine the effects of factors associated with betel nut chewing on glucose 
control [as measured by oral glucose tolerance (OGT) and fasting capillary blood 
glucose (FCBG)]. 
5 Determine whether betel nut chewing is associated with poor glucose control 
and whether the association, if any, is independent of other confounding factors 
included in this research. 
5.2 Methodology 
5.2.1 Study setting 
This study was undertaken in the National Capital District (NCD), where the Port 
Moresby General Hospital (PMGH) Diabetes Clinic is situated.  The study included 
two urbanised suburbs and one peri-urban area in the NCD. 
5.2.2 Data collection 
Data for this phase was taken from the World Health Organization (WHO) 
STEPwise approach to surveillance (STEPS) survey.1  The survey used a 
standardised method for collecting data in many developing countries.  In PNG, the 
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study was completed on the 22nd of March 2007 to the 30th of March 2008 by HOPE 
worldwide PNG (Papua New Guinea), in association with the PNG National 
Department of Health, with funding from the WHO. 
Data collection for this survey is described elsewhere 1 and was modified for PNG 
(Appendix 13). Briefly, data collected for this survey was in relation to behavioural 
and other health risk factors for non-communicable diseases such as diabetes and 
hypertension.  Data was collected in a step-wise approach, commencing with 
behavioural risk factors, followed by physical measurements and then biochemical 
measurements. 
5.2.3 Statistics 
Data was obtained from HOPE worldwide PNG in an Excel format and was imported 
into SPSS version 22.0 for data analysis.  Those people excluded from analysis 
were those whose information was discrepant, those who reported being diagnosed 
with diabetes or were undergoing treatment for diabetes and women who were 
pregnant. 
All statistical analyses outlined in chapter IV that were performed on participants 
with diabetes were repeated on the STEPS data for non-diabetic participants.   
5.2.4 Ethics 
 
Approval for the study was granted by the Curtin University Human Research Ethics 
Committee (approval number HR 38/2011), the University of PNG’s School of 
Medicine and Health Sciences Research and Ethics Committee, and the Medical 
Research Advisory Committee of the National Department of Health of PNG. 
 
Data was received from HOPE worldwide PNG in de-identified format and, 
therefore, consent was not required from participants in this survey. 
 
Permission to use the data for this study was granted by HOPE worldwide PNG. 
 
218 
 
 
5.3 Results 
5.3.1 Study setting 
This study was undertaken in NCD, the same district where PMGH is located. The 
study included participants from three selected suburbs in the NCD, one of which 
was a peri-urban suburb.   
5.3.2 Demographic characteristics 
Of the 922 participants, 511 (55.4%) were females and most of the participants were 
either from the Southern (39.9%) or the Highlands (37.7%) regions.  The mean age 
for participants was 36.6±13.0, with ages ranging from 15 to 67 years.  The highest 
number of participants were in the age group <30 – 39 years while the least number 
of participants was in the age group 60 – 69 years. 
Participants of this study resided in the urban and peri-urban areas of the NCD, with 
more than half (67.5%) of the participants in urban areas.  Three hundred and 
seventy seven (40.9%) participants had lived in the Port Moresby suburb from 
where they were recruited for more than 10 years.  The number of years of living in 
that suburb was used as an estimate for the number of years of living in Port 
Moresby. 
Of the 922 participants, 188 (20.4%) either had no formal education or had not 
completed basic primary education (Grades 6 or 8).  Three hundred and forty seven 
(37.6%) participants had completed basic primary education and 355 (38.5%) 
attained a secondary school certificate by completing Grades 10 and 12. 
Five hundred and thirty three participants were either in non-paid employment 
(homemakers, volunteers, students) or were unemployed (Table 5.1).  Two hundred 
and fifty (27.1%) participants were in regularly paid employment, either in the 
government or non-government sectors, while 114 (12.4%) were self-employed.  
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Table 5.1 Demographic characteristics of study participants (N = 922) 
Characteristic n* Percentage 
Gender 
Male 
Female 
 
411 
511 
 
44.5 
55.4 
Age category 
< 40 
40 – 49 
50 – 59 
60 – 69 
 
647 
132 
108 
35 
 
70.2 
14.3 
11.7 
3.8 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
368 
117 
348 
86 
 
39.9 
12.7 
37.7 
9.3 
Level of education 
No formal education 
Less than Grade 6 
Grade 6 
Grade 8 
Grade 10/vocational 
Grade 12 
Tertiary education 
 
89 
99 
177 
170 
248 
107 
26 
 
9.7 
10.7 
19.2 
18.4 
26.9 
11.6 
2.8 
Area of residence 
Urban 
Peri-urban 
 
622 
300 
 
67.5 
32.5 
Employment status 
Homemaker 
Retired 
Unpaid 
Self-employed 
Unemployed, able to work 
Unemployed, unable to work 
Government 
Non-government 
Student 
 
177 
11 
5 
114 
214 
24 
94 
156 
113 
 
19.2 
1.2 
0.5 
12.4 
23.2 
2.6 
10.2 
16.9 
12.3 
Years of residence in Port Moresby 
1 – 2 
3 – 5 
6 – 10 
> 10   
 
79 
116 
277 
377 
 
8.6 
12.6 
30.0 
40.9 
*The number may not add up to the total because of missing values for some 
categories. 
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5.3.3 Lifestyle characteristics 
The lifestyle characteristics, which were recorded, included alcohol consumption, 
tobacco smoking, betel nut chewing, fruit and vegetable consumption and physical 
activity. 
5.3.3.1 Alcohol consumption 
Almost half (41.4%) of the 922 participants had consumed alcohol in the preceding 
12 months.(Table 5.2)  Of those who consumed alcohol in the preceding 12 months, 
more than half (61.3%) had consumed alcohol in the preceding 30 days.  
One hundred and thirty nine (36.4%) participants consumed alcohol at least once 
per week.  Of those who consumed alcohol in the preceding 12 months, 51.3% 
reported consuming 10 drinks or less on a single occasion, while 38.7% had 
consumed more.   
For males in this subgroup, the mean number of days on which they had consumed 
five or more standard drinks in a single day over the preceding 12 months was 
6.2±6.0 days (n = 107 participants).  In comparison, the mean number of days for 
which female participants had consumed four or more standard drinks in a single 
day was 3.3±3.5 days (n = 54).   
The most common source of alcohol was friends/relatives (46.6%), followed by 
participants buying their own alcohol (45.5%).  More than 50% of the participants 
who had consumed alcohol recorded more than 10 alcoholic drinks as their largest 
number of drinks on a single occasion.   
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Table 5.2 Alcohol consumption amongst participants 
Variable n/N* Percentage 
Alcohol consumed in the previous 12 months 
No 
Yes 
 
540/922 
382/922 
 
58.6 
41.4 
Frequency of having at least one drink in the 
previous 12 months 
1 - 7 days/week 
1 - 3 days/month 
Less than once a month 
 
 
139/382 
67/382 
146/382 
 
 
36.4 
17.5 
38.2 
Alcohol consumed in the previous 30 days 
No 
Yes 
 
140/382 
234/382 
 
36.6 
61.3 
Alcohol consumed in the previous 7 days 
No 
Yes 
 
206/382 
176/382 
 
53.9 
46.1 
Average number of alcoholic drinks at any one 
time in a day 
≤ 5 
6 - 10 
>10 
 
 
67/382 
129/382 
148/382 
 
 
17.5 
33.8 
38.7 
Largest number of drinks on a single occasion  
in the last 12 months 
1 - 10 
11 - 20 
 >20 
 
 
115/382 
109/382 
109/382 
 
 
30.1 
28.5 
28.5 
Source of alcohol* 
Bought by self 
Friends/relatives 
Homebrew 
 
174/382 
178/382 
8/382 
 
45.5 
46.6 
2.1 
*May not add up to the total because of missing values 
The Chi-square statistic was used to test for any association between alcohol 
consumption and the demographic factors (categorical variables).  Those variables 
which were found to show some association (p < 0.05) were entered into a 
multivariate logistic regression model to investigate both the direction of the 
associations for different categories of each variable and factors independently 
associated with alcohol consumption in the preceding 12 months.   
Gender, age, education and employment had statistically significant associations 
with alcohol consumption in the preceding 12 months, while gender, employment 
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and area of residence had significant influences on alcohol consumption in the 
preceding 30 days (Table 5.3). 
For those who had consumed alcohol in the preceding 12 months, the likelihood of 
consuming alcohol varied with age.  Those aged <50 years were more likely to 
consume alcohol, compared to those aged 50 years or older.  Male participants 
were more likely to have consumed alcohol in the preceding 12 months or 30 days, 
compared to their female counterparts. 
Those who had completed tertiary education and those in regular paid employment 
were more likely to have consumed alcohol in the preceding 12 months.   
Using “yes, alcohol consumed in the previous 12 months” as the dependent 
variable, multivariate logistic regression analysis indicated that age, gender, level of 
education, employment status, smoking and betel nut exposure were independently 
associated with alcohol consumption, with age, gender, smoking and betel nut 
exposure being the most important factors (Table 5.4). For multivariate analysis, a 
4-employment status was collapsed into two categories because of the small 
sample number for those who were retired.  Those who had retired were included in 
the unpaid/unemployed category and self-employed participants were combined 
with those in paid employment to create the category “employed”. 
Those younger than 50 years were six times more likely to consume alcohol, 
compared to their counterparts aged 60 years and older.  Female participants had 
lower odds of consuming alcohol in comparison to their male counterparts.  
Although education had an independent influence on alcohol consumption, the 
association was only significant when comparing those who had completed basic 
primary education with those who had not.  Those who were employed and those 
who were betel nut chewers were more likely to consume alcohol, compared to their 
counterparts.  Heavy betel nut chewers (>5 nuts/day) were more likely to consume 
alcohol compared to those who never chewed, those who had quit and those who 
chewed ≤5 nuts/day.    
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Table 5.3 Associations of demographic factors with alcohol 
consumption 
Variable Alcohol consumed in 
the previous 12 months 
p-value Alcohol consumed in 
the previous 30 days 
p-
value# 
No Yes No Yes 
Gender 
Female 
Male 
 
385 (75.3) 
155 (37.7) 
 
126(24.7) 
256(62.3) 
<0.001  
64(52.9) 
76(30.0)  
 
57(47.1) 
177(70.0) 
<0.001 
 
 
Age 
<50 
50 - 59 
≥60 
 
432 (55.5) 
80 (74.1) 
28 (80.0) 
 
347(44.5) 
28(25.9) 
7(20.0) 
<0.001  
128(37.5) 
9(33.3) 
3(50.0) 
 
213(62.5) 
18(66.7) 
3(50.0) 
0.741 
Level of Education 
Did not 
complete basic 
education 
Primary basic 
education 
Secondary/   
Vocational  
Tertiary  
 
111 (59.0) 
 
 
232 (66.9) 
 
182 (51.3) 
 
11 (42.3) 
 
77(41.0) 
 
 
115(33.1) 
 
173(48.7) 
 
15(57.7) 
<0.001  
34(47.2) 
 
 
45(39.8) 
 
54(31.4) 
 
7(46.7) 
 
38(52.8) 
 
 
68(60.2) 
 
118(68.6) 
 
8(53.3) 
0.093 
Employment status 
Paid 
Unpaid/  
unemployed 
Retired 
Self-
employment 
 
114 (45.6) 
351 (65.9) 
 
6 (54.5) 
64 (56.1) 
 
136(54.4) 
182(34.1) 
 
5(45.5) 
50(43.9) 
<0.001  
32(23.0) 
81(45.8) 
 
2(40.0) 
21(42.9) 
 
102(76.1) 
96(54.2) 
 
3(60.0) 
28(57.1) 
0.001 
Area of residence 
Urban 
Peri-urban 
 
365(58.7) 
175(58.3) 
 
257(41.3) 
125(41.7) 
0.920  
87(33.9) 
53(45.3) 
 
170(66.1) 
64(34.7) 
0.034 
Region of origin 
Southern  
NGI 
Momase 
Highlands 
 
211 (57.3) 
48 (55.8) 
76 (65.0) 
204 (58.6) 
 
157(42.3) 
38(44.2) 
41(35.0) 
144(41.4) 
0.481  
53(34.4) 
15(36.6) 
57(41.0) 
14(36.8) 
 
101(65.6) 
26(63.4) 
82(59.0) 
24(63.2) 
0.711 
Years of residence 
in Port Moresby 
≤10 
>10 
 
 
289 (61.2) 
212 (56.2) 
 
 
183(38.8) 
165(43.8) 
0.141  
 
66(36.7) 
59(36.6) 
 
 
114(63.3) 
102(63.4) 
0.997 
Smoker status 
Current 
Quit 
Never 
 
92 (26.3) 
65 (69.1) 
379 (80.3) 
 
258 (73.7) 
29 (30.9) 
93 (19.7) 
<0.001  
89 (34.8) 
9 (34.6) 
41 (45.6) 
 
167(65.2) 
17 (65.4) 
49 (54.4) 
0.182 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
124 (88.6) 
25 (83.3) 
250 (62.0) 
129 (39.2) 
 
16 (11.4) 
5 (16.7) 
153 (38.0) 
200 (60.8) 
<0.001  
7 (43.8) 
1 (25.0) 
59 (39.6) 
71 (36.0) 
 
9 (56.3) 
3 (75.0) 
90 (60.4) 
126(64.0) 
0.805 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations. NGI = New Guinea Islands 
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Table 5.4 Multivariate logistic regression analysis of demographic 
risk factors for alcohol consumption within the previous12 months   
 
Variable 
 
n/N (%)* 
 
 
Adjusted OR 
 
95% CI 
 
p-value 
Age 
<50 
50 - 59 
≥60 
 
347/779 (44.5) 
28/108 (25.9) 
7/35 (20.0) 
 
7.68 
2.92 
1 (reference) 
 
2.44 - 24.14 
0.83 – 10.20 
 
 
<0.001 
<0.001 
0.094 
Gender 
Female 
Male 
 
126/511(24.7) 
256/411(62.3) 
 
0.26 
1 (reference) 
 
0.18 - 0.37 
<0.001 
Level of Education 
Did not complete basic 
education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
77/188 (41.0) 
 
115/347 (33.1) 
173/355 (48.7) 
15/26 (57.7) 
 
1 (reference) 
 
0.43 
1.02 
2.34 
 
 
 
0.26 - 0.71 
0.63 - 1.65 
0.77 - 7.27 
0.005 
 
 
0.001 
0.930 
0.132 
Employment status 
Employed 
Unpaid/unemployed 
 
186/364 (51.1) 
187/544 (34.4) 
 
1 (reference) 
0.64 
 
 
0.44 – 0.92 
0.017 
Smoker status 
Current 
Quit 
Never 
 
258/350 (73.7) 
29/94 (30.9) 
93/472 (19.7) 
 
1 (reference) 
0.25 
0.16 
 
 
0.14 – 0.45 
0.11 -0.23 
<0.001 
 
<0.001 
<0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
16/140 (11.4) 
5/30 (16.7) 
153/403 (38.0) 
200/329 (60.8) 
 
0.16 
0.21 
0.49 
1 (reference) 
 
0.09 – 0.32 
0.06 – 0.71 
0.33 – 0.71 
<0.001 
<0.001 
0.013 
0.001 
The dependent variable was the answer “Yes” to alcohol consumption in the previous 12 
months; *The column ‘n/N (%)’ shows the number (and percentage) of alcohol consumers 
within each variable who had consumed alcohol.   
 
5.3.3.2 Tobacco smoking 
Three hundred and fifty (38.0%) participants reported currently smoking tobacco.  Of 
these smokers, 312 (89.1%) were daily smokers.  Four hundred and seventy two 
(51.2%) participants had never smoked tobacco, while 444 (48.2%) had ‘ever’ been 
smokers (either currently or had quit).  Of these, 94 (21.2%) participants had quit the 
habit. 
 
225 
 
 
For those classified as smokers, the median age was 29 with a minimum of 15 and 
a maximum of 67 years.  For this subgroup, the median age for onset of smoking 
was 17, with a minimum of 10 and a maximum of 42 years.  The median number of 
years of daily smoking was 9, with a minimum of 0 (<1 year) and a maximum of 45 
years.  For participants who had quit smoking, the median age at which these 
participants had given up the habit was 25, with a minimum age of 13 and a 
maximum of 47 years.  Seventy (20.0%) participants who were smokers had been 
smoking for more than 20 years. 
Manufactured cigarettes were the most common type of tobacco products used.  Of 
the 350 smokers, 299 (85.4%) used manufactured cigarettes.  Of those who smoked 
manufactured cigarettes, 256 (85.6%) smoked 20 cigarettes or less per day, while 
116 (99.1%) of those who smoked hand-rolled cigarettes smoked less than 10 per 
day. 
Table 5.5 Frequency of tobacco smoking and the characteristics of 
participants 
Variables Frequency* n/N (%) 
Current smoker 
No 
Yes 
 
566/922 (61.4) 
350/922 (38.0) 
Smoking status 
Never  
Quit 
Current  
 
472/922 (51.2) 
94/922 (10.2) 
350/922 (38.0) 
Smoking history 
Never 
Ever 
 
472/922 (51.2) 
444/922 (48.2) 
Number of years of smoking 
≤ 10 
11 - 20 
21 - 30 
>30 
 
185/350 (52.9) 
72/350 (20.6) 
45/350 (12.9) 
25/350 (7.1) 
Number of manufactured cigarettes smoked/day 
1 - 10 
11 - 20 
>20 
 
235/299 (78.6) 
21/299 (7.0) 
43/299 (14.4) 
Number of hand-rolled cigarettes smoked/day 
1 - 10 
11 - 20 
 >20 
 
116/117 (99.1) 
1/117 (0.9) 
0/117 (0.0) 
Number of pipes of tobacco smoked/day 
<5 
≥5 
 
8/12 (66.7) 
4/12 (33.3) 
*May not add up to the total because of missing values 
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As shown in Table 5.6, tobacco smoking was influenced by gender, age and 
employment status, alcohol consumption in the previous 12 months and betel nut 
exposure.  Male participants were more likely to smoke, compared to their female 
counterparts.  As age increased, the number of participants who smoked decreased.  
Those who were retired were more likely to smoke tobacco, but it must be noted that 
the sample number for this category was small.  When comparing the categories of 
employment, those who were employed (both paid and self-employment) were more 
likely to smoke, compared to those in the unpaid/unemployed category.  Betel nut 
chewers, betel nut chewers who chewed all three components of the betel nut and 
those who had consumed alcohol in the previous 12 months were more likely to 
smoke.   
For multivariate analysis, whether or not a participant chewed betel nut was used in 
the model, rather than betel nut exposure, because the number of those who had 
quit betel chewing and were smokers was too small (<5) for logistic regression 
modelling.  Gender, alcohol consumption in the last 12 months and betel nut 
chewing independently influenced tobacco smoking (Table 5.7). Male participants 
were four times more likely to smoke tobacco, compared to their female 
counterparts.  Those who had consumed alcohol in the last 12 months and those 
who were current betel nut chewers were six times more likely to smoke, compared 
to those who did not consume alcohol or chew betel nuts.   
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Table 5.6 Factors associated with tobacco smoking   
Variable Current tobacco smoker p-value# 
No Yes 
Gender 
Female 
Male 
 
385 (75.9) 
181 (44.3) 
 
122 (24.1) 
228 (55.7) 
<0.001 
Age 
<50 
50 - 59 
≥60 
 
463 (59.8) 
77 (71.3) 
26 (76.5) 
 
311 (40.2) 
31 (28.7) 
8 (23.5) 
0.014 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
119 (63.6) 
208 (60.5) 
218 (61.8) 
18 (69.2) 
 
68 (36.4) 
136 (39.5) 
135 (38.2) 
8 (30.8) 
0.769 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
140 (56.5) 
350 (66.0) 
3 (30.0) 
67 (58.9) 
 
108 (43.5) 
180 (34.0) 
7 (70.0) 
47 (41.2) 
0.008 
Area of residence 
Urban 
Peri-urban 
 
391 (63.4) 
175 (58.5) 
 
226 (36.6) 
124 (41.5) 
0.157 
Region of origin 
Southern region 
New Guinea Islands 
Momase 
Highlands 
 
221 (60.7) 
55 (64.0) 
81 (69.8) 
208 (59.9) 
 
143 (39.3) 
31 (36.0) 
35 (30.2) 
139 (40.1) 
0.259 
Years of residence in Port Moresby 
≤10 
>10 
 
291 (62.0) 
230 (61.5) 
 
178 (38.0) 
144 (38.5) 
0.870 
Alcohol consumption in the previous 
12 months 
No 
Yes 
 
 
444 (82.8) 
122 (32.1) 
 
 
92 (17.2) 
258 (67.9) 
<0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
132 (94.3) 
26 (86.7) 
272 (67.5) 
130 (39.5) 
 
8 (5.7) 
4 (13.3) 
131 (32.5) 
199 (60.5) 
<0.001 
Betel nut chew components 
Betel nut + PBI + lime 
Betel nut ± PBI or lime 
Betel nut only 
 
196 (41.9) 
192 (75.6) 
19 (90.5) 
 
272 (58.1) 
62 (24.4) 
2 (9.5) 
<0.001 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations.  PBI = Piper betel inflorescence 
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Table 5.7 Multivariate logistic regression analysis of factors 
associated with tobacco smoking 
 
Variable 
 
n/N (%)* 
 
Adjusted OR 
 
95% CI 
 
p-value 
Gender 
Female 
Male 
 
122/507 (24.1) 
228/409 (55.7) 
 
0.44 
1 (reference) 
 
0.31 – 0.62 
<0.001 
Consumed alcohol in 
the previous 12 months 
No 
Yes 
 
 
92/536 (17.2) 
258/380 (67.9) 
 
 
1 (reference) 
6.72 
 
 
 
4.80 – 9.40 
<0.001 
Betel nut chewer 
No 
Yes 
 
12/171 (7.0) 
337/744 (45.3) 
 
1 (reference) 
6.89 
 
 
3.59 – 13.20 
<0.001 
The dependent variable was the answer “Yes” to tobacco smoker; *The column ‘n/N (%)’ 
shows the number (and percentage) of tobacco smokers within each variable.   
 
5.3.3.3 Betel nut chewing 
Of the 922 participants, 745 (80.8%) reported that they were current betel nut 
chewers.  One hundred and forty (15.2%) participants reported never chewing betel 
nut, while 30 (3.3%) had quit chewing betel nut.  Overall, of all the participants 
studied, 775 (84.1%) had chewed betel nut at some time in their lives. 
Of all the betel nut chewers, more than 60% of the participants chewed betel nut 
with lime and Piper betle inflorescence (PBI) and only 21 (2.8%) chewed the nut 
without lime or PBI (Table 5.8). 
The survey asked participants how many times they chewed betel nut daily.  For the 
purposes of analysis, the number of times a participant chewed betel nut daily was 
renamed quantity of betel nuts chewed daily, as it was assumed that participants 
chewed only one betel nut each time they chewed betel nut.   
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The mean number of betel nuts chewed by betel nut chewers per day was 6.6±5.7 
(range: 1 - 50).  For this category of participants, 403 (54.1%) chewed five or less 
and 29.4% chewed 10 or more betel nuts per day.   
Table 5.8 Frequency of betel nut chewing and characteristics of 
participants 
Variables Frequency* 
n/N(%) 
Betel nut chewer 
No 
Yes 
 
171/922 (18.5) 
745/922 (80.8) 
 
Mean number betel nut chewed/day ± SD 
 
6.6 ± 5.7 
Number of betel nuts/day† 
≤5 
6 - 9 
≥10 
 
403/745 (54.1) 
123/745 (16.5) 
219/745 (29.4) 
Betel nut chewing history 
Never  
Quit 
Current 
 
140/922 (15.2) 
30/922 (3.3) 
745/922 (80.8) 
Betel nut chewing status 
Never 
Ever 
 
140/922 (15.2) 
775/922 (84.1) 
Frequency of chewing betel nut with lime and PBI 
Always 
Sometimes 
Rarely 
Never  
 
469/745 (63.0) 
205/745 (27.5) 
49/745 (6.6) 
21/745 (2.8) 
Betel nut chewing components 
Betel nut + PBI + lime 
Betel nut ± PBI or lime 
Betel nut only 
 
469/745 (63.0) 
254/745 (34.1) 
21 (2.8) 
*May not add up to the total because of missing values; †Equivalent to average number of 
times betel nut used daily; PBI = Piper betle inflorescence 
 
Results indicated that gender, age, level of education, area of residence and region 
of origin were associated with betel nut chewing. (Table 5.9)  As age increased, the 
prevalence of betel nut chewing decreased.  Male participants, those who had 
completed basic and secondary education, those from urban areas and those from 
the Southern region were more likely to chew betel nut. Employment status and 
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number of years residing in Port Moresby were not associated with betel nut 
chewing.   
Table 5.9 Demographic factors associated with betel nut chewing 
Variable Betel nut chewer p-value# 
No Yes 
Gender 
Female 
Male 
 
113 (22.2) 
58 (14.2) 
 
395 (77.8) 
350 (85.8) 
0.002 
Age 
<50 
50 - 59 
≥60 
 
127 (16.4) 
32 (29.6) 
12 (35.3) 
 
647 (83.6) 
76 (70.4) 
22 (64.7) 
<0.001 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/vocational 
Tertiary education 
 
50 (26.7) 
58 (16.9) 
53 (15.0) 
8 (30.8) 
 
137 (73.3) 
286 (83.1) 
300 (85.0) 
18 (69.2) 
0.002 
Employment status 
Paid 
Unpaid/Unemployed 
Retired 
Self-employed 
 
47 (19.0) 
95 (17.9) 
0 (0.0) 
27 (23.7) 
 
201 (81.0) 
435 (82.1) 
10 (100.0) 
87 (76.3) 
0.224 
Area of residence 
Urban 
Peri-urban 
 
96 (15.6) 
75 (25.1) 
 
521 (84.4) 
224 (74.9) 
0.001 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
41 (11.2) 
21 (18.1) 
92 (26.6) 
16 (18.6) 
 
324 (88.8) 
95 (81.9) 
254 (73.4) 
70 (81.4) 
<0.001 
Years of residence in Port Moresby  
≤10 
>10 
 
89 (19.0) 
69 (18.4) 
 
380 (81.0) 
305 (81.6) 
0.845 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations. 
 
Analyses of the association of betel nut chewing with other lifestyle factors indicate 
that betel nut chewing is associated with alcohol consumption (p<0.001) , smoking 
(p<0.001) , vegetable  and fruit  servings per day and number of days that fruit (p = 
0.010) and vegetables (p < 0.001) are consumed in a typical week.  From these 
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analyses, it was found that those who had consumed alcohol and were current 
smokers were more likely to chew betel nut and that those who had quit smoking 
were less likely to chew betel nut, compared to their counterparts who had not.  
Those who were betel nut chewers were more likely to consume vegetables for only 
two days or less, in a typical week, compared to non-chewers.  Furthermore, betel 
nut chewers were more likely to consume less than three vegetable servings on any 
day when they had vegetables, compared to non-chewers. This finding was similar 
for fruit consumption.  Those who were betel nut chewers were more likely to 
consume fruit for two days or less in a typical week, compared to non-chewers.  
Furthermore, they were more likely to consume less than two serves of fruit on any 
day that they had fruit, but this was of borderline significance (p = 0.059).   The 
number of natural teeth also influenced the prevalence of betel nut use.  Those who 
still had all of their natural teeth were more likely to chew betel nut, compared to 
those who had lost some (p < 0.001). 
Multivariate analysis indicated that region of origin, alcohol consumption in the 
previous 12 months, smoking, number of days that vegetables were consumed in a 
typical week and number of natural teeth, were each independently associated with 
betel nut chewing. (Table 5.10)  Although those from the Momase and New Guinea 
Islands regions were less likely to chew betel nut, compared to their counterparts 
from the Southern region, the differences were not statistically significant.  
Highlanders were significantly less likely to chew betel nut, compared to those from 
the Southern region.  Those who were alcohol consumers were almost four times 
more likely to chew betel nut, compared to those who were not.  Those who were 
smokers were almost eight times more likely to chew betel nut, compared to those 
who were not smokers.  Having full sets of natural teeth positively influenced betel 
nut chewing;  that is, those who had all their natural teeth were two times more likely 
to chew betel nut compared to those who had lost some of their natural teeth.  Betel 
nut chewers were more physically active in terms of walking to get to and from 
places and participating in MISFRA. 
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Table 5.10 Multivariate analysis of factors associated with betel nut 
chewing 
 
Variable 
 
n/N (%) 
 
Adjusted OR 
 
95% CI 
 
p-value 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
324/365 (88.8) 
95/116 (81.9) 
254/346 (73.4) 
70/86 (81.4) 
 
1 (reference) 
0.72 
0.36 
0.64 
 
 
0.38 – 1.33 
0.26 – 0.56 
0.31 – 1.30 
<0.001 
 
0.291 
<0.001 
0.212 
Alcohol in the previous 
12 months 
No 
Yes 
 
 
385/535 (72.0) 
360/381 (94.5) 
 
 
1 (reference) 
3.60 
 
 
 
2.11 – 6.15 
<0.001 
Smoker status 
No 
Yes 
 
407/566 (71.9) 
337/349 (96.6) 
 
1 (reference) 
7.54 
 
 
3.84 – 14.82 
< 0.001 
Number of vegetable-
eating days/week 
0 - 2 
3 - 5 
6 - 7 
 
 
175/194 (90.2) 
233/278 (83.8) 
333/437 (76.2) 
 
 
2.06 
1.57 
1 (reference) 
 
 
1.16 – 3.67 
1.01 – 2.42 
0.018 
 
 
0.013 
0.044 
Number of natural teeth 
All of them 
Some missing 
 
527/621 (84.9) 
214/290 (73.8) 
 
2.10 
1 (reference) 
 
1.42 – 3.11 
<0.001 
Participates in MISFRA 
for at least 10 minutes 
No 
Yes 
 
 
484/625 (77.4) 
257/287 (89.5) 
 
 
1 (reference) 
1.90 
 
 
 
1.20 – 3.01 
0.006 
Walks to get to and from 
places 
No 
Yes 
 
 
67/102 (65.7) 
672/808 (83.2) 
 
 
1 (reference) 
2.02 
 
 
 
1.22 – 3.34 
0.006 
The dependent variable was the answer “Yes” to betel nut chewer; *The column ‘n/N (%)’ 
shows the number (and percentage) of betel nut chewers within each variable.   
 
5.3.3.4 Vegetable and fruit consumption 
Table 5.11 shows that vegetable and fruit consumption was poor amongst the study 
cohort.  Ninety two per cent of the participants reported consuming less than three 
servings of vegetables per day in a typical week.  Despite eating less serves of 
vegetables, 47.6% of the participants reported eating vegetables for 6 - 7 days in a 
typical week.  When compared with vegetable consumption, 70% of the participants 
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consumed fruit on two days or less in a typical week, and 66.6% had less than two 
serves of fruit on any day that they consumed fruit (Table 5.11). 
Table 5.11 Frequencies of fruit and vegetable consumption 
characteristics (N=922) 
Variables Frequency 
n (%)* 
Vegetable servings/day 
<3 
 ≥3 
 
848 (92.0) 
66 (7.2) 
Number of vegetable-eating days/week 
0 - 2 
3 - 5 
6 - 7 
 
196 (21.3) 
279 (30.3) 
439 (47.6) 
Fruit servings/day       
<2 
≥2 
 
614 (66.6) 
273 (29.6) 
Number of fruit-eating days/week 
0 - 2 
3 - 5 
6 - 7 
 
646 (70.1) 
207 (22.5) 
62 (6.7) 
*May not add up to total because of missing values 
Chi-square statistics indicate that the number of vegetable servings was influenced 
by area of residence and betel nut chewing (Table 5.12).  The number of vegetable 
servings also tended to be associated with level of education.  Those who did not 
complete basic education were more likely to consume ≥3 serves of vegetables in a 
day compared to those in other categories of level of education.  Participants 
residing in peri-urban areas were more likely to consume ≥3 serves of vegetables in 
a day, compared to their urban counterparts. Those who were betel nut chewers 
were less likely to consume ≥3 serves of vegetables, compared to those who were 
not.  The association of the number of vegetable serves consumed with employment 
status was of borderline significance.  
Chi-square statistics also indicate that the number of vegetable and fruit 
consumption days was influenced by betel nut chewing (not shown).   Those who 
were betel nut chewers were more likely to consume vegetables for only two days or 
less in a typical week, compared to non-chewers (p < 0.001).  This finding was 
similar for fruit consumption.  Those who were betel nut chewers were more likely to 
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consume fruit for only two days or less in a typical week, compared to non-chewers 
(p = 0.010).   
Table 5.12 Factors associated with vegetable servings consumed 
Variable Vegetable servings p-value
# 
<3 ≥3 
Gender 
Female 
Male 
 
466 (91.9) 
382 (93.9) 
 
41 (8.1) 
25 (6.1) 
0.259 
Age 
 <50 
50 - 59 
≥60 
 
718 (93.1) 
98 (90.7) 
32 (91.4) 
 
53 (6.9) 
10 (9.3) 
3 (8.6) 
0.637 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/vocational 
Tertiary education 
 
165 (88.2) 
324 (94.2) 
331 (94.3) 
24 (92.3) 
 
22 (11.8) 
20 (5.8) 
20 (5.7) 
2 (7.7) 
0.043 
Employment status 
Paid 
Unpaid/Unemployed 
Retired 
Self-employed 
 
223 (90.7) 
499 (94.3) 
11 (100.0) 
102 (89.5) 
 
23 (9.3) 
30 (5.7) 
0 (0.0) 
12 (10.5) 
0.099 
Area of residence 
Urban 
Peri-urban 
 
588 (95.3) 
260 (87.5) 
 
29 (4.7) 
37 (12.5) 
<0.001 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
344 (94.0) 
108 (93.1) 
311 (90.4) 
82 (96.5) 
 
22 (6.0) 
8 (6.9) 
33 (9.6) 
3 (3.5) 
0.144 
Years of residence in Port Moresby  
≤10 
>10 
 
434 (92.9) 
348 (92.8) 
 
33 (7.1) 
27 (7.2) 
0.940 
Alcohol consumed in the previous 12 months 
No  
Yes 
 
497 (92.9) 
351 (92.6) 
 
38 (7.1) 
28 (7.4) 
0.873 
Smoker status 
No 
Yes 
 
517 (91.8) 
325 (94.2) 
 
46 (8.2) 
20 (5.8) 
0.181 
Betel nut chewer 
No 
Yes 
 
149 (88.7) 
694 (93.7) 
 
19 (11.3) 
47 (6.3) 
0.025 
Number of natural teeth 
All of them 
Some missing 
 
579 (93.1) 
265 (92.0) 
 
43 (6.9) 
23 (8.0) 
0.562 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations. 
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The sample number for those who were retired was very small, so this group was 
amalgamated with the unpaid/unemployed category, leading to the three-category 
employment variable shown in Table 5.13.  Results of multivariate logistic 
regression analysis indicate that consuming ≥3 servings of vegetables per day was 
associated with employment status and area of residence. Those who were in the 
unpaid/unemployed group were statistically less likely to consume ≥3 servings per 
day, compared to those who were in paid employment.  Those who were self-
employed consumed vegetables similarly to those in paid employment.   
 
Table 5.13 Multivariate logistic regression of factors associated with 
vegetable servings 
Variable n/N (%)* Adjusted OR 95% CI p-value 
Employment status 
Paid 
Unpaid/unemployed 
Self-employed 
 
23/246 (9.3) 
30/540 (5.6) 
12/114 (10.5) 
 
1 (reference) 
0.50 
0.94 
 
 
0.28 – 0.90 
0.43 – 2.04 
0.042 
 
0.020 
0.875 
Area of residence 
Urban 
Peri-urban 
 
29/617 (4.7) 
37/297 (12.5) 
 
1 (reference) 
3.46 
 
 
2.04 – 5.89 
<0.001 
The dependent variable was ≥3 vegetable servings per day; *The column ‘n/N (%)’ shows 
the number (and percentage) of participants who consumed ≥3 serves of vegetables per day 
within each variable group.   
 
Factors associated with the number of fruit servings consumed were level of 
education, employment and smoking status.  The association of betel nut chewing 
and area of residence with the number of fruit servings per day were of borderline 
significance (Table 5.14). Those who completed tertiary and secondary/vocational 
education were more likely to consume ≥2 serves of fruit per day, compared to 
those who did not complete or only completed primary basic education.  No other 
demographic variables appear to influence fruit consumption.   
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Table 5.14 Factors associated with fruit servings consumed 
Variable Fruit servings p-value# 
<2 ≥2 
Gender 
Female 
Male 
 
342 (69.4) 
272 (69.0) 
 
151 (30.6) 
122 (31.0) 
0.914 
Age 
<50 
50 - 59 
≥60 
 
523 (69.5) 
69 (67.6) 
22 (66.7) 
 
229 (30.5) 
33 (32.4) 
11 (33.3) 
0.879 
Level of Education 
Did not complete basic education 
Basic primary basic education 
Secondary/vocational 
Tertiary education 
 
136 (73.1) 
248 (73.4) 
212 (63.1) 
14 (60.9) 
 
50 (26.9) 
90 (26.6) 
124 (36.9) 
9 (39.1) 
0.013 
Employment status 
Paid 
Unpaid/Unemployed 
Retired 
Self-employed 
 
142 (60.2) 
373 (72.4) 
11 (100.0) 
80 (71.4) 
 
94 (39.8) 
142 (27.6) 
0 (0.0) 
32 (28.6) 
0.001 
Area of residence 
Urban 
Peri-urban 
 
397 (67.2) 
217 (73.3) 
 
194 (32.8) 
79 (26.7) 
0.062 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
254 (72.2) 
70 (62.5) 
235 (69.5) 
53 (64.6) 
 
98 (27.8) 
42 (37.5) 
103 (30.5) 
29 (35.4) 
0.201 
Years of residence in Port Moresby 
≤10 
>10 
 
309 (67.5) 
255 (70.8) 
 
149 (32.5) 
105 (29.2) 
0.302 
Alcohol consumed in the previous 12 months 
No  
Yes 
 
353 (67.4) 
261 (71.9) 
 
171 (32.6) 
102 (28.1) 
0.150 
Smoking status 
No 
Yes 
 
358 (64.7) 
251 (76.5) 
 
195 (35.3) 
77 (23.5) 
<0.001 
Betel nut chewer 
No 
Yes 
 
104 (63.0) 
506 (70.6) 
 
61 (37.0) 
211 (29.4) 
0.059 
Number of natural teeth 
All of them 
Some missing 
 
410 (67.9) 
202 (74.2) 
 
194 (32.1) 
77 (27.6) 
0.176 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations. 
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For multivariate logistic regression analysis of demographic factors and fruit 
servings, level of education was re-categorised because of the small number of 
participants who were in the tertiary education category.  Tertiary education was 
combined with the secondary/vocational category because there was little difference 
between the two groups in the proportions who consumed two or more servings of 
fruit per day. 
 
As shown in Table 5.15, multivariate logistic regression analysis indicates that 
employment and smoking independently influence the number of servings of fruit 
consumed.  Those in paid employment were more likely to consume ≥2 servings of 
fruit per day, in a typical week, than those who were in the unpaid/unemployed 
category.  Those who were self-employed were less likely to consume ≥2 servings 
of fruit per day compared to those who were in paid employment.  Smokers were 
less likely to consume ≥2 servings of fruit per day compared to those who did not 
smoke. 
 
Table 5.15 Multivariate logistic regression of factors associated with 
consumption of ≥2 fruit servings/day 
Variable n/N (%)* Adjusted OR 95% CI p-value 
Employment status 
Paid 
Unpaid/unemployed 
Self-employed 
 
94/236 (39.8) 
142/526 (27.0) 
32/112 (28.6) 
 
1 (reference) 
0.53 
0.60 
 
 
0.38 – 0.74 
0.37 – 0.98 
0.001 
 
<0.001 
0.042 
Smoker status 
No 
Yes 
 
195/553 (35.3) 
77/328 (23.5) 
 
1 (reference) 
0.55 
 
 
0.38 – 0.74 
<0.001 
The dependent variable was ≥2 fruit servings per day; *The column ‘n/N (%)’ shows 
the number (and percentage) of participants who consumed ≥2 servings of fruit per 
day, within each variable.   
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5.3.3.5 Physical activity 
As shown in Table 5.16, results indicated that walking, to get to and from places, 
was the most common physical activity, with 88.0% (n = 811) of participants 
reporting that they walked for at least 10 minutes continuously to get to and from 
places. The number of participants involved in work-related physical activity was 
higher than those involved in physical activity through sports, fitness and 
recreational activities.  More than 60% (n = 634) of participants reported undertaking 
sufficient physical activity.   
For those who reported undertaking vigorous-intensity physical activity, more than 
60% performed work-related vigorous-intensity activity (VIA) and vigorous-intensity 
sports, fitness and recreational activity (VISFRA) for ≥75 minutes per week.   For 
participants involved in moderate-intensity activities (MIA), more than 50% 
performed them as work-related activities, while only 33.9% were involved in sports, 
fitness and recreational activities for ≥150 minutes per week. 
Using the Chi-square statistics, the amount of physical activity, which includes all 
the different types of physical activity, was further examined to determine whether 
there was any association and, if so, the strength of the association, with 
demographic factors.  Furthermore, the Chi-square statistics also were used to 
determine whether there was an association between either age or employment 
status with the different types of physical activity. 
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Table 5.16 Frequencies of self-reported physical activity  
Variables Frequency* 
n/N (%) 
Work-related VIA for at least 10 minutes 
No 
Yes 
 
428/922 (46.4) 
484/922 (52.5) 
Minutes of work-related VIA/week 
<75 
≥75 
 
89/484 (18.4) 
354/484 (73.1) 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
597/922 (64.8) 
316/922 (34.3) 
Minutes of VISFRA/week 
<75 
≥75 
 
102/316 (32.3) 
210/316 (66.5) 
Work-related MIA for at least 10 minutes 
No  
Yes 
 
359/922 (38.9) 
548/922 (59.4) 
Minutes of work-related MIA/week 
<150 
≥150 
 
191/548 (34.9) 
315/548 (57.5) 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
626/922 (67.9) 
289/922 (31.3) 
Minutes of MISFRA/week 
<150 
≥150 
 
183/289 (63.3) 
98/289 (33.9) 
Walks to get to and from places for at least 10 minutes 
No 
Yes 
 
102/922 (11.1) 
811/922 (88.0) 
Minutes walking/week 
<150 
≥150 
 
367/811 (45.3) 
368/811 (45.4) 
Amount of physical activity/week 
Sufficient  
None/Insufficient 
 
634/922 (68.8) 
239/922 (25.9) 
*May not add up to total because of missing values; VIA = vigorous-intensity activity; MIA = 
moderate-intensity activity; VISFRA = vigorous-intensity sports, fitness and recreational 
activity; MISFRA = moderate-intensity sports, fitness and recreational activity 
 
Results indicated that the factors which were associated with the amount of physical 
activity were age, gender, area of residence and region of origin (Table 5.17).  The 
association of level of education with amount of physical activity was of borderline 
significance. 
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Table 5.17 Demographic factors associated with amount of physical 
activity   
Variable Amount of physical activity p-value# 
Sufficient None/Insufficient 
Age 
<50 
50 - 59 
 ≥60 
 
545 (74.3) 
68 (64.8) 
21 (61.8) 
 
189 (25.7) 
37 (35.2) 
13 (38.2) 
0.044 
Gender 
Female 
Male 
 
 320 (66.4) 
314 (80.3) 
 
162 (33.6) 
77 (19.7) 
<0.001 
Level of Education 
Did not complete basic education    
Primary basic education 
Secondary/Vocational  
Tertiary education 
 
117 (66.5) 
251 (76.5) 
245 (72.7) 
16 (61.5) 
 
59 (33.5) 
77 (23.5) 
92 (27.3) 
10 (38.5) 
0.059 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
174 (75.3) 
360 (70.7) 
7 (70.0) 
80 (73.4) 
 
57 (24.7) 
149 (29.3) 
3 (30.0) 
29 (26.6) 
0.620 
Area of residence 
Urban 
Peri-urban 
 
444 (75.3) 
190 (67.1) 
 
146 (24.7) 
93 (32.9) 
0.012 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
268 (78.1) 
54 (66.7) 
87 (75.0) 
223 (67.6) 
 
75 (21.9) 
27 (33.3) 
29 (25.0) 
107 (32.4) 
0.010 
Years of residence in Port Moresby 
≤10 
>10 
 
342 (76.0) 
255 (71.6) 
 
108 (24.0) 
101 (28.4) 
0.160 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations.  *Fisher’s Exact Test 
 
Work-related VIA, MISFRA and VISFRA were associated with age. (Table 5.18) 
Those younger than 50 years were more likely to participate in both work-related 
VIA and sports, fitness and recreational activities, compared to those who were 50 
years and older.  Walking to get to and from places and work-related MIA were not 
associated with age.     
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Table 5.18 Association of age with physical activity 
Variable Age category (years) 
 
 
p-value# 
 
<50 
 
 
50 – 59 
 
≥60 
Walks to get to and from places for 
at least 10 minutes 
No 
Yes 
 
 
87 (11.3) 
683 (88.7) 
 
 
12 (11.1) 
96 (88.9) 
 
 
3 (8.6) 
32 (91.4) 
0.882 
Work-related VIA for at least 10 
minutes 
No 
Yes 
 
 
349 (45.4) 
420 (54.6) 
 
 
56 (51.9) 
52 (48.1) 
 
 
23 (65.7) 
12 (34.3) 
0.034 
Work-related MIA for at least 10 
minutes 
No 
Yes 
 
 
299 (39.1) 
465 (60.9) 
 
 
47 (43.5) 
61 (56.5) 
 
 
13 (37.1) 
22 (62.9) 
0.654 
Performs VISFRA for at least 10 
minutes 
No 
Yes 
 
 
466 (60.5 ) 
304 (39.5) 
 
 
96 (88.9) 
12 (11.1) 
 
 
35 (100.0) 
0 (0.0) 
<0.001 
Performs MISFRA for at least 10 
minutes 
No 
Yes 
 
 
497 (64.4) 
275 (35.6) 
 
 
97 (89.8) 
11 (10.2) 
 
 
32 (91.4 
3 (8.6) 
<0.001 
Amount of physical activity 
Sufficient 
None/Insufficient 
 
545 (74.3) 
189 (25.7) 
 
68 (64.8) 
37 (35.2) 
 
21 (61.8) 
13 (38.2) 
0.044 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations; VIA = vigorous-intensity activity; MIA = moderate-intensity activity; VISFRA = 
vigorous-intensity sports, fitness and recreational activities; MISFRA = moderate-intensity 
sports, fitness and recreational activities 
 
The number of participants who were retired was small, so a three-category 
employment variable was created.  Participants that had been classified as retired 
were included in the unpaid/unemployed category to increase category size.   
Results indicated that participants who were unpaid/unemployed were more likely to 
walk, to get to and from places, and to undertake work-related MIA and MISFRA 
(Table 5.19).  Those who were self-employed were more likely not to participate in 
MISFRA and VISFRA.  
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Table 5.19 Association of employment status with physical activity 
Variable Employment category 
 
 
p-value# 
 
Paid 
 
Unpaid/ 
unemployed 
 
Self-
employed 
Walk to get to and from places for 
at least 10 minutes 
No 
Yes 
 
 
35 (14.2) 
212 (85.8) 
 
 
48 (8.9) 
490 (91.1) 
 
 
19 (16.7) 
95 (83.3) 
0.016 
Work-related VIA for at least 10 
minutes 
No 
Yes 
 
 
109 (44.1) 
138 (55.9) 
 
 
262 (48.8) 
275 (51.2) 
 
 
50 (43.9) 
64 (56.1) 
0.376 
Work-related MIA for at least 10 
minutes 
No 
Yes 
 
 
119 (48.6) 
126 (51.4) 
 
 
192 (36.0) 
342 (64.0) 
 
 
45 (39.5) 
69 (60.5) 
0.004 
Performs VISFRA for at least 10 
minutes 
No 
Yes 
 
 
157 (63.6) 
90 (36.4) 
 
 
340 (63.2) 
198 (36.8) 
 
 
91 (79.8) 
23 (20.2) 
0.002 
Performs MISFRA for at least 10 
minutes 
No 
Yes 
 
 
170 (68.8) 
77 (31.2) 
 
 
354 (65.6) 
186 (34.4) 
 
 
93 (81.6) 
21 (18.4) 
0.004 
Amount of physical activity 
Sufficient 
None/Insufficient 
 
174 (75.3) 
57 (24.7) 
 
367 (70.7) 
152 (29.3) 
 
80 (73.4) 
29 (26.6) 
0.412 
# The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations.  VIA = vigorous-intensity activity; MIA = moderate-intensity activity; VISFRA = 
vigorous-intensity sports, fitness and recreational activity; MISFRA = moderate-intensity 
sports, fitness and recreational activity 
 
Level of education, area of residence and region of origin were associated with the 
likelihood of walking to get to and from places (Table 5.20). Employment status also 
tended to be a factor.  Those who had completed basic primary and 
secondary/vocational education, as well as those who had not completed basic 
education, were more likely to walk to get to and from places than those with a 
tertiary education.  However, the association was only significant when comparing 
those who had completed basic primary and secondary/vocational education with 
those who had completed tertiary education.  Although those who had not 
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completed basic education were twice as likely to walk to get to and from places, 
this did not reach statistical significance. Those who were in the unpaid/unemployed 
category of employment and those who had retired had twice the odds of walking to 
get to and from places but this did not reach statistical significance for those who 
were retired.  Participants who were in paid or self-employed work were less likely to 
walk to get to and from places.  Those from the New Guinea Islands and Highlands 
regions were less likely to walk, compared to their counterparts from the Southern 
region.  Although those from the Momase region were less likely to walk to get to 
and from places, this did not reach statistical significance.  Those from the peri-
urban areas were less likely to walk to get to and from places, compared to their 
urban counterparts.   
Although level of education, area of residence, region of origin and employment 
status all were associated with walking to get to and from places, these factors were 
not associated with the amount of time spent walking (Table 5.21). The number of 
minutes spent walking to get to and from places was associated with gender.  
Female participants were less likely to walk, compared to their male counterparts.   
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Table 5.20 Univariate analysis of demographic factors affecting 
whether or not a participant walked to get to and from places   
Variable Crude OR 95% CI p-value 
Age 
<50 
50 - 59 
≥60 
 
1 (reference) 
1.02 
1.36 
 
 
0.54 – 1.93 
0.41 – 4.53 
0.883 
 
0.954 
0.618 
Gender 
Female 
Male 
 
0.94 
1 (reference) 
 
0.62 – 1.42 
0.756 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
2.16 
3.99 
3.05 
1 (reference) 
 
0.83 – 5.62 
1.55 – 10.28 
1.21 – 7.74 
0.014 
0.116 
0.004 
0.019 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1.21 
2.04 
2.00 
1 (reference) 
 
0.66 – 2.23 
1.15 – 3.64 
0.24 – 16.56 
0.043 
0.537 
0.015 
0.520 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
0.52 
 
 
0.34 – 0.79 
0.002 
Region 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
1 (reference) 
0.36 
0.57 
0.35 
 
 
0.17 – 0.75 
0.27 – 1.18 
0.21 – 0.58 
0.001 
 
0.006 
0.128 
<0.001 
Years of residence in Port Moresby 
≤10 
>10 
 
1.25 
1 (reference) 
 
0.81 – 1.95 
0.313 
The dependent variable was the answer “Yes” to walks to get to and from places. 
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Table 5.21 Univariate analysis of demographic factors associated with 
number of minutes spent walking to get to and from places   
Variable Crude OR 95% CI p-value 
Age 
<50 
50 - 59 
≥60 
 
1 (reference) 
1.03 
1.07 
 
 
0.66 – 1.59 
0.52 – 2.20 
0.978 
 
0.911 
0.854 
Gender 
Female 
Male 
 
0.68 
1 (reference) 
 
0.51 – 0.91 
 
0.009 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational/Tertiary 
 
2.30 
2.10 
1.85 
1 (reference) 
 
0.82 – 6.48 
0.77 – 5.75 
0.68 – 5.07 
0.359 
0.114 
0.149 
0.231 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
0.92 
0.88 
1.86 
1 (reference) 
 
0.55 – 1.54 
0.55 – 1.40 
0.44 – 7.94 
0.722 
0.756 
0.597 
0.400 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
1.09 
 
 
0.80 – 1.49 
0.592 
Region 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
1 (reference) 
0.75 
1.20 
1.12 
 
 
0.44 – 1.27 
0.76 – 1.89 
0.80 – 1.55 
0.438 
 
0.284 
0.435 
0.520 
Years of residence in Port Moresby 
≤10 
>10 
 
1.1 
1 (reference) 
 
0.82 – 1.50 
0.509 
The dependent variable was ≥150 minutes per week spent walking. 
5.3.4 Physical measurements and medical characteristics 
Characteristics analysed included physical measurements (such as weight, waist 
and hip circumferences, and blood pressure), biochemical measurements (capillary 
blood glucose, 2-hour oral glucose tolerance) and bioelectrical impedance 
(percentage body fat). 
As shown in Table 5.22, the mean FCBG and 2-hour oral glucose tolerance levels 
were within the ideal values of <6.0 and <8.9 mmol/L, respectively.   The mean body 
mass index (BMI) was above normal (>25 kg/m2), while systolic and diastolic blood 
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pressures (SBP and DBP, respectively) were within the normal range (≤130 and ≤80 
mmHg, respectively).  However, as shown in Table 5.23, 258 (28.0%) and 259 
(28.1%) participants had abnormally high SBP and DBP, respectively.  Sixty five per 
cent of participants were either overweight or obese.  The mean waist circumference 
was within normal values (102 cm) for males but was higher than normal (88 cm) for 
females.  
Table 5.23 also shows that, of the 918 participants whose capillary blood glucose 
(CBG) was measured, 897 (97.7%) of the blood glucose levels were fasted while 21 
(2.3%) were random (not fasted). Participants with random blood glucose levels 
were excluded in any analysis requiring fasting blood glucose results.  Of the 897 
participants who fasted, 60.1% had normal FCBG, 22.1% had impaired fasting 
glucose (IFG) and 17.8% had CBG indicating a possibility of T2DM.  Of the 471 
participants who did the 2-hour oral glucose tolerance test, 82.2% had normal 
glucose tolerance while 14.4% had impaired glucose tolerance (IGT) and 1.7% had 
levels indicating a possibility of T2DM.  Based on the PNG Diabetes Clinical 
Guidelines 2012, the prevalence of postprandial hyperglycaemia and 
hyperglycaemia were 4.9% and 17.8%, respectively. 
Table 5.2  Medical characteristics of participants (N = 922) 
Variable n (%)* Mean SD 
Weight (kg) 913 (99.0) 70.0 13.2 
Waist circumference (cm) 
Female 
Male 
914 (99.1) 
507 (99.2) 
407 (99.0) 
89.1 
91.3 
86.3 
15.3 
16.2 
13.7 
Hip circumference (cm) 914 (99.1) 96.9 14.4 
BMI (kg/m2) 912 (98.9) 27.5 5.9 
SBP (mmHg) 915 (99.2) 123.7 14.8 
DBP (mmHg) 915 (99.2) 73.8 11.2 
CBG (mmol/L) 
Fasting 
Random 
918 (99.6) 
897/918 (97.7) 
21/918 (2.3) 
5.5 
5.5 
5.3 
1.5 
1.5 
0.8 
OGT†  (mmol/L) 471 (51.1) 7.7 2.9 
Bioelectric impedance (% body fat) 908 (98.5) 24.9 8.5 
*Percentages do not add up to 100 because of missing values; †Only a selected number of 
participants were required to undergo this test; BMI = body mass index; SBP = systolic blood 
pressure; DBP= diastolic blood pressure; CBG = capillary blood glucose level; OGT = oral 
glucose tolerance 
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Table 5.23 Physical and biochemical characteristics of participants 
Variable Frequency [n/N (%)*] 
Systolic Blood Pressure (mmHg) 
≤130 
>130 
 
657/922 (71.3) 
258/922 (28.0) 
Diastolic Blood Pressure (mmHg) 
≤80 
>80 
 
656/922 (71.1) 
259/922 (28.1) 
Body Mass Index category 1 
Underweight 
Normal weight 
Overweight 
Obese 
 
 18/922 (2.0) 
291/922 (31.6) 
356/922 (38.6) 
247/922 (26.8) 
Body Mass Index category 2 (kg/m2)# 
<25 
≥25 
 
291/904 (32.2) 
603/904 (66.7) 
Waist circumference 
Normal 
Above normal  
 
595/922 (64.5) 
319/922 (34.9) 
Fasting capillary blood glucose (mmol/L) 
 <5.6 (normal) 
5.6 – 6.0 (impaired fasting glucose) 
≥6.1 (T2DM)† 
 
539/897 (60.1) 
198/897 (22.1) 
160/897 (17.8) 
OGT for diagnosis of T2DM (mmol/L) 
<11.1  
≥11.1 (T2DM) 
 
448/471 (95.1) 
23/471 (4.9) 
OGT; impaired glucose tolerance (mmol/L) 
<8.9 
8.9 – 12.1 (impaired glucose tolerance) 
>12.1 (T2DM) 
 
387/471 (82.2) 
68/471 (14.4) 
16/471 (1.7) 
*May not add up to total because of missing values; #Excludes those who were underweight 
T2DM = type 2 diabetes mellitus; OGT= oral glucose tolerance; †Diagnosis arrived at if 
glucose level associated with signs and symptoms of T2DM occurred in repeated tests; 
Normal waist circumference is ≤102cm (male) and ≤88cm (female). 
 
5.3.4.1 Blood pressure 
Blood pressure was categorised according to the PNG Diabetes Clinical Guidelines 
2012, in which an SBP >130 mmHg and a DBP >80 mmHg are classified as being 
high (abnormal). 
Two hundred and fifty eight (28.0%) participants had high SBP, while 28.1% had a 
high DBP (Table 5.23).   
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As shown in Table 5.24, SBP was influenced by age, body mass index (BMI), waist 
circumference and number of years living in the suburb (Port Moresby).  Younger 
participants (<50 years of age) were less likely to have an abnormally high SBP, 
with those aged 50 – 59 years having twice the odds of having an abnormally high 
SBP.  Although those aged 60 years and older also had almost twice the odds of 
having a high SBP compared to those less than 50 years of age, this did not reach 
statistical significance.   
Those with BMI ≥25 kg/m2 and those with an abnormally large waist circumference 
had twice the odds of having an abnormally high SBP compared to their 
counterparts.  Those who had lived in Port Moresby for more than 10 years had 
almost twice the odds of having an SBP >130 mmHg compared to those who had 
lived there for 10 years or less.  
Using logistic regression (backwards elimination) to determine which demographics 
and physical measurements were independently associated with high SBP, results 
indicated that age, BMI, waist circumference and number of years living in Port 
Moresby were independently associated with an SBP >130 mmHg (Table 5.25).  
Participants aged 50 – 59 years, and 60 years and older, had twice the odds of 
having an SBP of >130 mmHg but this was only significant when comparing those 
younger than 50 years with those aged 50 – 59 years. 
Those with a BMI ≥25 kg/m2 were twice as likely to have an SBP >130 mmHg and, 
similarly, those with a waist circumference above normal were almost twice as likely 
to have an SBP >130 mmHg.  Those who had lived in Port Moresby for more than 
10 years also were almost twice as likely to have an SBP >130 mmHg.  
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Table 5.24 Univariate logistic regression of demographic factors and 
physical measurements associated with high SBP (>130 mmHg).   
Variable Crude OR 95% CI p-value 
Gender 
Female 
Male 
 
0.85 
1 (reference) 
 
0.64 – 1.14 
0.285 
Age 
<50 
50 - 59 
≥60 
 
1 (reference) 
2.56 
1.84 
 
 
1.69 – 3.86 
0.90 – 3.73 
<0.001 
 
<0.001 
0.094 
Level of Education 
Did not complete basic education 
Basic primary education 
Secondary/Vocational 
Tertiary 
 
0.72 
0.54 
0.67 
1 (reference) 
 
0.31 – 1.68 
0.24 – 1.23 
0.29 – 1.52 
0.279 
0.447 
0.141 
0.332 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1 (reference) 
0.99 
3.21 
1.28 
 
 
0.70 – 1.39 
0.95 – 10.85 
0.79 – 2.08 
0.178 
 
0.941 
0.061 
0.310 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
1.04 
 
 
0.77 – 1.42 
0.791 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
1 (reference) 
0.91 
1.39 
1.44 
 
 
0.56 – 1.48 
1.00 – 1.93 
0.87 – 2.40 
0.110 
 
0.696 
0.050 
0.158 
Years of residence in Port Moresby 
≤10  
>10 
 
1 (reference) 
1.67 
 
 
1.23 – 2.25 
0.001 
BMI category 
Underweight 
Normal weight 
Overweight 
Obese 
 
0.16 
0.29 
0.48 
1 (reference) 
 
0.04 – 0.73 
0.19 – 0.42 
0.34 – 0.68 
<0.001 
0.017 
<0.001 
<0.001 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
2.40 
 
 
1.71 – 3.36 
<0.001 
Waist circumference 
Normal 
Above normal 
 
1 (reference) 
2.09 
 
 
1.56 – 2.81 
<0.001 
The dependent variable was SBP >130 mmHg; SBP = systolic blood pressure; BMI = body 
mass index; Normal waist circumference is ≤102 cm (male) and ≤88cm (female) 
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Table 5.25 Multivariate analysis of demographics and physical 
measurements independently associated with abnormally high SBP 
(SBP >130 mmHg) 
Variable n/N (%)* Adjusted OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
195/773 (25.2) 
50/108 (46.3) 
13/34 (38.2) 
 
1 (reference) 
2.12 
2.05 
 
 
1.35 – 3.32 
0.95 – 4.44 
0.001 
 
0.001 
0.068 
BMI (kg/m2) 
<25 
≥25 
 
54/309 (17.5) 
203/603 (33.7) 
 
1 (reference) 
2.07 
 
 
1.41 – 3.04 
<0.001 
Waist circumference  
Normal 
Above normal 
 
136/595 (22.9) 
122/319 (38.2) 
 
1 (reference) 
1.76 
 
 
1.26 – 2.45 
0.001 
Years of residence in Port 
Moresby 
≤10 
>10 
 
 
109/467 (23.3) 
126/375 (33.6) 
 
 
1 (reference) 
1.55 
 
 
 
1.13 – 2.13 
0.007 
The dependent variable was SBP >130 mmHg; *The column ‘n/N (%)’ shows the number 
(and percentage) of participants with SBP >130 mmHg within each variable; SBP = systolic 
blood pressure; BMI = body mass index; Normal waist circumference is ≤102cm (male), 
≤88cm (female) 
 
When examining the associations of lifestyle factors (tobacco smoking, vegetable 
and fruit consumption) with SBP, results indicated that fruit servings and number of 
days in a week that fruits were consumed tended to have an influence (Table 5.26).  
Those who consumed less than two servings of fruit per day and those who 
consumed fruit for two days or more per week tended to have a higher SBP 
compared to their counterparts.  
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Table 5.26 Univariate logistic regression of lifestyle factors (alcohol, 
vegetable and fruit consumption, and tobacco smoking) associated 
with high SBP (>130 mmHg). 
Variable Crude OR 95% CI p-value 
Alcohol consumption in the previous 12 
months 
No  
Yes 
 
 
1.30 
1 (reference) 
 
 
0.97 – 1.75 
0.081 
Smoker status 
Current 
Never  
Quit 
 
1 (reference) 
1.33 
1.39 
 
 
0.97 – 1.82 
0.84 – 2.29 
0.162 
 
0.073 
0.203 
Vegetable servings/day 
<3 
≥3 
 
1.65 
1 (reference) 
 
0.88 – 3.08 
0.116 
Number of vegetable-eating days in a 
typical week 
0 - 5 
6 - 7 
 
 
0.91 
1 (reference) 
 
 
0.68 – 1.21 
0.520 
Fruit servings/day 
<2 
≥2 
 
1.55 
1 (reference) 
 
1.11 – 2.17 
0.010 
Number of fruit-eating days in a typical 
week 
0 - 1 
2 - 7 
 
 
0.72 
1 (reference) 
 
 
0.53 – 0.97 
0.030 
The dependent variable was SBP >130 mmHg. SBP = systolic blood pressure 
 
Betel nut chewing was associated with SBP (Table 5.27).  Results of univariate 
logistic regression analysis indicated that those who were not current betel nut 
chewers and those who had never chewed were more likely to have an SBP >130 
mmHg.  When comparing those who had quit the habit and those who chewed ≤5 
nuts per day with those who chewed >5 nuts per day, the association was not 
significant.  For those classified as betel nut chewers, the quantity chewed per day 
and the components of betel nut chewing were not associated with SBP. 
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Table 5.27 Univariate logistic regression of betel nut chewing and 
high SBP (>130 mmHg) 
Variable Crude OR 95% CI p-value 
Betel nut chewer 
No  
Yes      
 
1.70 
1 (reference) 
 
1.19 – 2.41 
0.003 
Betel nut chewing history 
Current  
Never  
Quit  
 
1 (reference) 
1.89 
1.03 
 
 
1.30 – 2.75 
0.45 – 2.35 
0.004 
 
0.001 
0.943 
Betel nut chewing status 
Never 
Ever 
 
1.89 
1 (reference) 
 
1.30 – 2.74 
0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
2.03 
1.11 
1.11 
1 (reference) 
 
1.33 – 3.10 
0.48 – 2.59 
0.80 – 1.56 
0.008 
0.001 
0.811 
0.529 
Quantity of betel nuts chewed/day† 
≤5 
6 - 9 
≥10 
 
1.06 
0.94 
1 (reference) 
 
0.73 – 1.54 
0.57 – 1.57 
0.882 
0.775 
0.823 
Betel nut chew composition 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
0.79 
1.06 
1 (reference) 
 
0.30 – 2.08 
0.40 – 2.84 
0.235 
0.632 
0.909 
The dependent variable was SBP >130 mmHg; †Only includes those who were betel nut 
chewers; SBP = systolic blood pressure; PBI = Piper betle inflorescence 
 
When examining any association of SBP with physical activity, results indicated that 
those who participated in MISFRA and VISFRA for at least 10 minutes per day 
appeared to be  less likely to have an SBP >130 mmHg (Table 5.28).  The amount 
of time (minutes) spent on these activities, however, did not influence SBP.  
Although participants who performed insufficient physical activities in a week had 
four times the odds of having an abnormally high SBP, this did not reach statistical 
significance.  All other physical activities were not associated with SBP.   
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Table 5.28 Univariate logistic regression analysis of physical activity 
characteristics associated with high SBP (>130 mmHg) 
Variable Crude OR 95% CI p-value 
Work-related MIA for at least 10 minutes 
No 
Yes 
 
0.87 
1 (reference) 
 
0.65 – 1.18 
0.379 
Minutes of work-related MIA/week 
<150 
≥150 
 
1.15 
1 (reference) 
 
0.77 – 1.70 
0.498 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
1.57 
1 (reference) 
 
1.13 – 2.17 
0.007 
Minutes of MISFRA/week 
<150 
≥150 
 
1.08 
1 (reference) 
 
0.59 – 1.97 
0.810 
Work-related VIA for at least 10 minutes 
No 
Yes 
 
0.94 
1 (reference) 
 
0.70 – 1.25 
0.660 
Minutes of work-related VIA/week 
<75 
≥75 
 
1.29 
1 (reference) 
 
0.78 – 2.14 
0.314 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
1.93 
1 (reference) 
 
1.40 – 2.68 
<0.001 
Minutes of VISFRA/week 
<75 
≥75 
 
1.35 
1 (reference) 
 
0.76 – 2.40 
0.307 
Walks to get to and from places for at least 
10 minutes 
No 
Yes 
 
 
0.81 
1 (reference) 
 
 
0.50 – 1.31 
0.389 
Minutes of walking/week 
<150 
≥150 
 
1.10 
1 (reference) 
 
0.80 – 1.51 
0.570 
Amount of physical activity/week 
Sufficient 
None/Insufficient  
 
1 (reference) 
1.30 
 
 
0.94 – 1.79 
0.118 
The dependent variable was SBP >130 mmHg; SBP = systolic blood pressure; MIA = 
moderate-intensity activity; MISFRA = moderate-intensity sports, fitness and recreational 
activity; VIA = vigorous-intensity activity; VISFRA = vigorous-intensity sports, fitness and 
recreational activity 
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Results of multivariate logistic regression analysis indicated that the lifestyle factors 
which were independently associated with an SBP >130 mmHg were fruit servings, 
number of days in a week that fruits were consumed, betel nut exposure and 
VISFRA (Table 5.29). Of all these factors, VISFRA was the most important 
influencing factor, with results indicating that those who did not perform any VISFRA 
were more likely to have a high systolic blood pressure (>130 mmHg). Participants 
who never chewed betel nut, those who consumed less than two serves of fruit and 
those who consumed fruit for more than one day per week were more likely to have 
a high SBP.   
Table 5.29 Multivariate analysis of lifestyle factors independently 
associated with elevated SBP (>130 mmHg) 
Variable n/N (%)* Adjusted OR 95% CI p-value 
Fruit servings/day 
<2 
≥2 
 
180/612 (29.4) 
60/270 (22.2) 
 
1.65 
1 (reference) 
 
1.16 – 2.34 
0.005 
Number of fruit-eating days 
in a typical week 
0 - 1 
2 - 7 
 
 
91/375 (24.3) 
165/535 (30.8) 
 
 
0.69 
1 (reference) 
 
 
0.50 – 0.95 
0.023 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
56/140 (40.0) 
8/30 (26.7) 
107/400 (26.8) 
81/328 (24.7) 
 
1 (reference) 
0.60 
0.62 
0.51 
 
 
0.25 – 1.47 
0.40 – 0.94 
0.33 – 0.79 
0.027 
 
0.265 
0.024 
0.003 
Performs VISFRA for at 
least 10 minutes 
No 
Yes 
 
 
193/594 (32.5) 
63/316 (19.9) 
 
 
1.85 
1 (reference) 
 
 
1.31 – 2.60 
<0.001 
The dependent variable was SBP >130 mmHg; *The column ‘n/N (%)’ shows the number 
(and percentage) of participants with SBP >130 mmHg within each variable; SBP = systolic 
blood pressure; VISFRA = vigorous-intensity sports, fitness and recreational activity 
 
When demographic, lifestyle and medical factors were adjusted for each other using 
multivariate logistic regression analysis (backward elimination), results indicated that 
the factors independently associated with SBP were age, number of years living in 
Port Moresby, betel nut exposure, fruit servings, body mass index and waist 
circumference (Table 5.30). 
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Table 5.30 Multivariate analysis of demographic, lifestyle and medical 
factors independently associated with abnormally high SBP (SBP >130 
mmHg) 
Variable n/N (%)* Adjusted OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
195/773 (25.2) 
50/108 (46.3) 
13/34 (38.2) 
 
1 (reference) 
1.96 
1.93 
 
 
1.22 – 3.17 
0.84 – 4.44 
0.010 
 
0.006 
0.124 
BMI (kg/m2) 
<25 
≥25 
 
54/309 (17.5) 
203/603 (33.7) 
 
1 (reference) 
1.85 
 
 
1.25 – 2.74 
0.002 
Waist circumference  
Normal 
Above normal 
 
136/595 (22.9) 
122/319 (38.2) 
 
1 (reference) 
1.75 
 
 
1.23 – 2.48 
0.002 
Years of residence in Port 
Moresby 
≤10 
>10 
 
 
109/467 (23.3) 
126/375 (33.6) 
 
 
0.68 
1 (reference) 
 
 
0.49 – 0.95 
0.023 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
56/140 (40.0) 
8/30 (26.7) 
107/400 (26.8) 
81/328 (24.7) 
 
1 (reference) 
0.43 
0.63 
0.48 
 
 
0.15 – 1.25 
0.40 – 0.98 
0.30 – 0.78 
0.021 
 
0.122 
0.042 
0.003 
Fruit servings/day 
<2 
≥2 
 
180/612 (29.4) 
60/270 (22.2) 
 
1.55 
1 (reference) 
 
1.07 – 2.24 
0.020 
The dependent variable was SBP >130 mmHg; *The column ‘n/N (%)’ shows the number 
(and percentage) of participants with SBP >130 mmHg within each variable; SBP = systolic 
blood pressure; BMI = body mass index; Normal waist circumference is ≤102 cm (male) and 
≤88cm (female) 
 
As shown in Table 5.31, age, BMI, waist circumference and number of years living 
in Port Moresby were the most important factors influencing a high DBP (>80 
mmHg).  Area of residence, level of education and region of origin also appear to 
affect DBP.  Gender and employment status were not associated with DBP. Those 
aged 50 years and older were more likely to have an abnormally high DBP (> 80 
mmHg) compared to their younger counterparts. The association, however, was 
only significant when comparing those aged <50 years with those aged 50 – 59 
years but not with those aged 60 years and older. Participants with a BMI ≥25 kg/m2 
had almost twice the odds of having an abnormally high DBP, compared to their 
counterparts.  Those with a waist circumference above normal were three times 
more likely to have an abnormally high DBP.   
256 
 
 
Table 5.31 Univariate logistic regression of demographic and physical 
factors associated with high DBP (>80 mmHg) 
Variable Crude OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
1 (reference) 
2.54 
1.82 
 
 
1.68 – 3.83 
0.90 – 3.71 
<0.001 
 
<0.001 
0.098 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary 
 
0.50 
0.29 
0.44 
1 (reference) 
 
0.22 – 1.13 
0.13 – 0.64 
0.20 – 0.98 
0.002 
0.096 
0.002 
0.044 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
1.59 
 
 
1 – 2.14 
0.003 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
1 (reference) 
1.25 
1.70 
1.74 
 
 
0.77 – 2.02 
1.22 – 2.37 
1.05 – 2.90 
0.011 
 
0.362 
0.002 
0.033 
Years of residence in Port Moresby 
≤10  
>10 
 
1 (reference) 
1.81 
 
 
1.33 – 2.45 
<0.001 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
1.82 
 
 
1.31 –  2.51 
<0.001 
Waist circumference 
Normal 
Above normal 
 
1 (reference) 
2.60 
 
 
1.93 – 3.50 
<0.001 
The dependent variable was DBP >80 mmHg; DBP = diastolic blood pressure; BMI = body 
mass index; Normal waist circumference is ≤102cm (male) and ≤88cm (female) 
 
The most important lifestyle factors (other than betel nut chewing) influencing DBP 
were numbers of days per week that any vegetables were consumed, work-related 
MIA and VIA, MISFRA and VISFRA, and walking to get to and from places (Table 
5.32).  Other factors which had an association with DBP were tobacco smoking and 
the amount of time spent doing work-related MIA.  Those who did not perform work-
related MIA and VIA, MISFRA and VISFRA, and did not walk to get to and from 
places, were more likely to have an abnormally higher DBP than those who did. 
Those who undertook work-related MIA for less than 150 minutes per week were 
less likely to have a DBP >80 mmHg. Participants who did a sufficient amount of 
physical activity per week were significantly less likely to have an abnormally high 
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DBP.  All other lifestyle factors (other than betel nut chewing) did not have an 
association with DBP.   
Table 5.32 Univariate logistic regression of lifestyle factors associated 
with high DBP (>80 mmHg) 
Variable Crude OR 95% CI p-value 
Smoker status 
Current 
Never  
Quit 
 
1 (reference) 
1.27 
2.05 
 
 
0.93 – 1.74 
1.27 – 3.32 
0.013 
 
0.135 
0.003 
Number of vegetable-eating days in a 
typical week 
0 - 5 
6 - 7 
 
 
0.55 
1 (reference) 
 
 
0.41 – 0.74 
<0.001 
Work-related MIA for at least 10 minutes 
No 
Yes 
 
2.01 
1 (reference) 
 
1.50 – 2.70 
<0.001 
Minutes of work-related MIA/week 
<150 
≥150 
 
0.573 
1 (reference) 
 
0.36 – 0.90 
0.017 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
2.24 
1 (reference) 
 
1.59 – 3.15 
<0.001 
Work-related VIA for at least 10 minutes 
No 
Yes 
 
1.81 
1 (reference) 
 
1.35 – 2.42 
<0.001 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
2.20 
1 (reference) 
 
1.58 – 3.05 
<0.001 
Walks to get to and from places for at least 
10 minutes 
No 
Yes 
 
 
2.21 
1 (reference) 
 
 
1.45 – 3.36 
<0.001 
Amount of physical activity/week 
Sufficient 
None/Insufficient 
 
1 (reference) 
1.70 
 
 
1.23 – 2.33 
0.001 
The dependent variable was DBP >80 mmHg; DBP = diastolic blood pressure; MIA = 
moderate-intensity activity; MISFRA = moderate-intensity sports, fitness and recreational 
activity; VIA = vigorous-intensity activity; VISFRA = vigorous-intensity sports, fitness and 
recreational 
Participants who were not betel nut chewers, or those who had never chewed, were 
more likely to have a DBP> 80 mmHg when compared to their counterparts who 
chewed betel nut (Table 5.33). Those who never chewed betel nut had twice the 
odds of having a DBP >80 mmHg.  When comparing daily betel nut use, those who 
chewed less than 10 nuts per day were less likely to have an abnormally high DBP, 
but the association only reached statistical significance when comparing those who 
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chewed 6-9 nuts with those who chewed ≥10 nuts per day.  Those who chewed ≤5 
nuts per day were significantly less likely to have a DBP> 80 mmHg compared to 
their counterparts who chewed ≥10 nuts per day.   
Table 5.33 Univariate logistic regression analysis of betel nut chewing 
variables associated with high DBP (>80 mmHg) 
Variable Crude OR 95% CI p-value 
Betel nut chewer 
No  
Yes   
 
2.38 
1 (reference) 
 
1.68 – 3.36 
<0.001 
Betel nut chewing history 
Current  
Never  
Quit  
 
1 (reference) 
2.35 
2.33 
 
 
1.62 – 3.41 
1.11 – 4.88 
<0.001 
 
<0.001 
0.025 
Betel nut chewing status 
Never 
Ever 
 
2.26 
1 (reference) 
 
1.56 – 3.28 
<0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
1.87 
1.85 
0.63 
1 (reference) 
 
1.24 – 2.81 
0.86 – 3.95 
0.45 – 0.89 
<0.001 
0.003 
0.113 
0.008 
Quantity of betel nuts chewed/day# 
≤5 
6 - 9 
≥10 
 
0.55 
0.69 
1 (reference) 
 
0.38 – 0.80 
0.42 – 1.14 
0.008 
0.002 
0.145 
Betel nut chew composition 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
0.92 
0.63 
1 (reference) 
 
0.35 – 2.43 
0.23 – 1.72 
0.126 
0.872 
0.370 
The dependent variable was DBP >80 mmHg; DBP = diastolic blood pressure; PBI = Piper 
betle inflorescence 
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As can be seen in Table 5.34, multivariate logistic regression analysis indicated that 
age, area of residence, years of living in Port Moresby, waist circumference, betel 
nut chewing status, walking to get to and from places and minutes of undertaking 
work-related MIA were independently associated with DBP.  However, the 
association between years of living in Port Moresby and high DBP did not reach 
statistical significance. Participants aged 50 years and older had twice the odds of 
having a DBP >80 mmHg compared to their younger counterparts.  However, this 
was only statistically significant when comparing those aged 50 years or less with 
those aged 50 – 59 years.  Those who had an abnormally large waist circumference 
were twice as likely to have a DBP >80 mmHg. Participants who never chewed betel 
nut were almost twice as likely to have a DBP >80 mmHg, compared with those who 
quit, having an adjusted odds ratio of 1.80.  Not walking to get to and from places 
predisposed participants to an abnormally high DBP.  Those who did not walk were 
three times more likely to have an abnormally high DBP, compared to those who 
did.  Undertaking work-related MIA for less than 150 minutes per week was less 
likely to predispose a participant to an abnormally high DBP.  Participants residing in 
peri-urban areas had twice the odds of having an abnormally high DBP.  
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Table 5.34 Multivariate analysis of factors independently associated 
with high DBP (>80 mmHg). 
Variable n/N (%) Adjusted OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
196/773 (25.4) 
50/108 (46.3) 
13/34 (38.2) 
 
1 (reference) 
2.67 
2.18 
 
 
1.39 – 5.11 
0.73 – 6.50 
0.008 
 
0.003 
0.163 
Area of residence 
Urban 
Peri-urban 
 
155/616 (25.2) 
104/299 (34.8) 
 
1 (reference) 
2.12 
 
 
1.28 – 3.50 
0.003 
Years of residence in Port 
Moresby 
≤10  
>10 
 
 
105/467 (22.5) 
129/375 (34.4) 
 
 
1 (reference) 
1.52 
 
 
 
0.95 – 2.45 
0.082 
Waist circumference 
Normal 
Above normal 
 
127/575 (21.3) 
132/319 (41.4) 
 
1 (reference) 
2.06 
 
 
1.26 – 3.38 
0.004 
Betel nut status 
Never 
Quit 
Current 
 
61/140 (43.6) 
13/30 (43.3) 
183/740 (24.7) 
 
2.19 
1.80 
1 (reference) 
 
1.20 – 3.98 
0.51 – 6.36 
0.030 
0.010 
0.360 
Walk to get to and from 
places for at least 10 
minutes 
No 
Yes 
 
 
 
45/102 (44.1) 
213/808 (26.4) 
 
 
 
3.48 
1 (reference) 
 
 
 
1.01 – 2.02 
0.049 
Minutes of MIA at 
work/week 
<150 
≥150 
 
32/190 (16.8) 
82/314 (26.1) 
 
0.57 
1 (reference) 
 
0.34 – 0.96 
0.035 
The dependent variable was DBP > 80 mmHg; *The column ‘n/N (%)’ shows the number 
(and percentage) of participants with SBP >130 mmHg within each variable; DBP = diastolic 
blood pressure; MIA = moderate-intensity activity; Normal waist circumference is ≤102cm 
(male) and ≤88cm (female) 
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5.3.4.2 Body mass index 
As was shown in Table 5.23 earlier, more than 60% of participants were either 
overweight (38.6%) or obese (26.8%) and 31.6% had normal weight. To determine 
any association between demographic and lifestyle variables and BMI those who 
were underweight were excluded from analysis.   
Univariate logistic regression analysis indicated that age, gender, region of origin 
and employment status influenced BMI (Table 5.35).  Those younger than 50 years 
were less likely to be overweight or obese, however, there was no statistically 
significant difference between this age category and those aged 60 years or older.  
Female participants were more likely to have a BMI ≥25 kg/m2 when compared to 
their male counterparts.  Participants who were in paid employment and those in the 
unpaid/unemployed category were significantly less likely to have a BMI ≥25 kg/m2.  
Although retirees were two times more likely to have a BMI ≥25 kg/m2, this did not 
reach statistical significance.  
Those from the Highlands and Momase regions were more likely to have a BMI ≥25 
kg/m2, compared to their counterparts from the Southern region.  Participants from 
the Highlands region were twice as likely to have a BMI ≥25 kg/m2 when compared 
with those from the Southern region.  There was no statistically significant difference 
in having a BMI≥ 25 kg/m2 between those from the Southern and New Guinea 
Islands regions.   
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Table 5.35 Univariate logistic regression analysis of demographic 
factors associated with abnormally high BMI (≥25 kg/m2).   
Variable Crude OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
1 (reference) 
2.66 
1.37 
 
 
1.57 – 4.51 
0.63 – 3.01 
0.001 
 
<0.001 
0.428 
Gender 
Female 
Male 
 
1.75 
1 (reference) 
 
1.32 – 2.32 
<0.001 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
0.49 
0.46 
0.43 
1 (reference) 
 
0.18 – 1.36 
0.17 – 1.26 
0.16 – 1.18 
0.410 
0.169 
0.132 
0.100 
Employment Status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
0.39 
0.44 
2.03 
1 (reference) 
 
0.22 – 0.66 
0.27 – 0.73 
0.24 – 16.92 
0.003 
0.001 
0.002 
0.512 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
1.16 
 
 
0.86 – 1.57 
0.333 
Region 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
1 (reference) 
1.36 
1.64 
2.41 
 
 
0.82 – 2.23 
1.05 – 2.58 
1.74 – 3.35 
<0.001 
 
0.232 
0.031 
<0.001 
Years of residence in Port Moresby 
≤10 
>10 
 
1.19 
1 (reference) 
 
0.89 – 1.60 
0.247 
The dependent variable was BMI ≥25kg/m2; BMI = body mass index 
 
Tobacco smoking, alcohol consumption and the number of days that participants 
consumed fruit in a typical week had associations with BMI (Table 5.36). 
Participants who never smoked tobacco and never consumed alcohol were more 
likely to have a BMI ≥25 kg/m2.   There was no statistically significant difference in 
having a BMI ≥25 kg/m2 between current tobacco smokers and those who had quit 
smoking.  Those who did not consume fruit and those who consumed fruit for one 
day in a typical week were less likely to have a BMI ≥25 kg/m2.   
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Table 5.36 Univariate logistic regression analysis of lifestyle factors 
associated with abnormally high BMI (≥25 kg/m2).   
Variable Crude OR 95% CI p-value 
 
Smoking history 
Current 
Never 
Quit 
 
1 (reference) 
2.09 
1.54 
 
 
1.55 – 2.80 
0.95 – 2.49 
<0.001 
 
<0.001 
0.078 
Alcohol consumed in the previous 12 
months 
No 
Yes 
 
 
1.90 
1 (reference) 
 
 
1.43 – 2.53 
<0.001 
Vegetable servings/day 
<3 
≥3 
 
1.14 
1 (reference) 
 
0.67 – 1.94 
0.626 
Vegetable-eating days/week 
0 - 5 
6 - 7 
 
1.14 
1 (reference) 
 
0.86 – 1.50 
0.373 
Fruit servings/day 
<2 
≥2 
 
1.21 
1 (reference) 
 
0.89 – 1.65 
0.219 
Fruit-eating days/week 
0 - 1 
2 - 7 
 
0.52 
1 (reference) 
 
0.39 – 0.69 
<0.001 
The dependent variable was BMI ≥25 kg/m2; BMI = body mass index 
 
Betel nut chewing had an association with BMI (Table 5.37). Participants who never 
chewed betel nut were more likely to have a BMI ≥25 kg/m2 when compared to their 
counterparts who were betel nut chewers.  When comparing the number of betel 
nuts chewed by those classified as per day betel nut chewers, results indicated that 
those chewing 6 - 9 betel nuts per day were more likely to have a BMI ≥25 kg/m2.  
Components chewed with betel nut also affected BMI.  Those who chewed betel nut 
with or without PBI or lime were more likely to have an abnormally high BMI 
compared to those who always chewed betel nut with both PBI and lime.  There was 
no difference in association between BMI and current betel nut chewers or those 
who had quit the habit.  
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Table 5.37 Univariate logistic regression analysis of betel nut chewing 
variables associated with abnormally high BMI (≥25 kg/m2).   
Variable Crude OR 95% CI p-value 
Betel nut chewer 
No  
Yes  
 
1.54 
1 (reference) 
 
1.06 – 2.23 
0.024 
Betel nut chewing history 
Current  
Never  
Quit  
 
1 (reference) 
1.95 
0.59 
 
 
1.27 – 2.98 
0.28 – 1.25 
0.003 
 
0.002 
0.169 
Betel nut chewing status 
Never 
Ever 
 
1.99 
1 (reference) 
 
1.30 – 3.04 
0.002 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
1.77 
0.54 
0.85 
1 (reference) 
 
1.11 – 2.80 
0.25 – 1.16 
0.62 – 1.15 
0.005 
0.015 
0.112 
0.286 
Quantity of betel nuts chewed/day# 
≤5 
6 - 9 
≥10 
 
1.09 
2.08 
1 (reference) 
 
0.78 – 1.54 
1.26 – 3.43 
0.011 
0.608 
0.004 
Betel nut chew composition 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
1 (reference) 
1.55 
0.84 
 
 
1.11 – 2.15 
0.35 – 2.04 
0.027 
 
0.009 
0.703 
The dependent variable was BMI ≥ 25 kg/m2; BMI = body mass index; PBI = Piper betle 
inflorescence 
 
Physical activities associated with BMI were work-related MIA and VIA, MISFRA 
and VISFRA, and the number of minutes undertaking work-related VIA (Table.38).  
Surprisingly, participants who undertook work-related MIA or VIA were more likely to 
have a BMI ≥25 kg/m2, compared to those who did not.  In comparison, those who 
were involved in MISFRA and VISFRA were less likely to have a BMI ≥25 kg/m2.  
Those who performed work-related VIA for <75 minutes per week were less likely to 
have a BMI ≥25 kg/m2.  
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Table 5.38 Univariate logistic regression analysis of physical activity 
performance associated with abnormally high BMI (≥25 kg/m2).   
Variable Crude OR 95% CI p-value 
Amount of physical activity 
Sufficient 
None/Insufficient 
 
1 (reference) 
0.83 
 
 
0.61 – 1.14 
0.246 
Work-related VIA for at least 10 
minutes 
No 
Yes 
 
 
1 (reference) 
1.52 
 
 
 
1.15 – 2.02 
0.003 
Minutes of work-related VIA/week 
<75 
≥75 
 
0.59 
1 (reference) 
 
0.36 – 0.98 
0.040 
Performs VISFRA for at least 10 
minutes 
No 
Yes 
 
 
2.06 
1 (reference) 
 
 
1.54 – 2.75 
<0.001 
Minutes of VISFRA/week 
<75 
≥75 
 
0.76 
1 (reference) 
 
0.46 – 1.23 
0.258 
Work-related MIA for at least 10 
minutes 
No  
Yes 
 
 
1 (reference) 
1.74 
 
 
 
1.31 – 2.32 
<0.001 
Minutes of work-related MIA/week 
<150 
≥150 
 
0.81 
1 (reference) 
 
0.54 – 1.21 
0.298 
Performs MISFRA for at least 10 
minutes 
No 
Yes 
 
 
1 (reference) 
0.54 
 
 
 
0.41 – 0.73 
<0.001 
Minutes of MISFRA/week 
<150 
≥150 
 
0.61 
1 (reference) 
 
0.37 – 1.02 
0.058 
Walks to get to and from places for at 
least 10 minutes 
No 
Yes 
 
 
1.26 
1 (reference) 
 
 
0.79 – 2.00 
0.330 
Minutes walking/week 
<150 
≥150 
 
0.77 
1 (reference) 
 
0.56 – 1.06 
0.095 
The dependent variable was BMI ≥25 kg/m2; BMI = body mass index; VIA = vigorous-
intensity activity; MIA = moderate-intensity activity; VISFRA = vigorous-intensity sports, 
fitness and recreational activity; MISFRA = moderate-intensity sports, fitness and 
recreational activity 
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As demonstrated in Table 5.39, results indicated that region of origin, tobacco 
smoking, number of days/week that fruit and vegetables were consumed, VISFRA 
and the number of minutes of work-related VIA in a week were independently 
associated with BMI.   
Those from the Highlands region had three times the odds of having a BMI ≥25 
kg/m2 when compared to those from other regions.  Although betel nut exposure 
was an independent factor, the association did not reach statistical significance.  
There was, however, a significant association when comparing those who had 
chewed >5 nuts per day with those who had chewed ≤5 nuts per day.  Those who 
chewed ≤5 nuts per day were less likely to have a BMI ≥25 kg/m2, compared to 
those who chewed >5 nuts. Those who never smoked and those who had quit were 
three and two times more likely to have a BMI ≥25 kg/m2, respectively.  Not 
participating in VISFRA and undertaking work-related VIA for ≥75 minutes per week 
were both associated with a BMI ≥25 kg/m2.  
 Participants who consumed vegetables for less than 6 - 7 days in a week were 
more likely to have a BMI ≥25 kg/m2.  In comparison, those who consumed fruit for 
less than two days in a week were less likely to have a BMI ≥25 kg/m2.   
Those who never smoked tobacco were almost four times more likely to have a BMI 
≥25 kg/m2 compared to their counterparts who were tobacco smokers.  Although 
those who had quit the habit had twice the odds of having a BMI ≥25 kg/m2, this did 
not reach statistical significance.    
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Table 5.39 Multivariate logistic regression analysis of demographic 
and lifestyle factors associated with abnormally high BMI (≥25 kg/m2).   
Variable n/N (%)* Adjusted OR 95% CI p-value 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
202/363 (55.6) 
79/116 (68.1) 
265/345 (76.8) 
54/85 (63.5) 
 
1 (reference) 
1.56 
3.12 
1.51 
 
 
0.76 – 3.22 
1.70 – 5.73 
0.66 – 3.27 
0.004 
 
0.225 
<0.001 
0.314 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
109/140 (77.9) 
15/29 (51.7) 
251/400 (62.8) 
217/326 (66.6) 
 
0.46 
0.46 
0.49 
1 (reference) 
 
0.19 – 1.13 
0.04 – 5.36 
0.29 – 0.84 
0.064 
0.090 
0.537 
0.010 
Smoker status 
Never 
Quit 
Current 
 
341/467 (73.0) 
62/93 (66.7) 
196/347 (56.5) 
 
3.73 
2.43 
1 (reference) 
 
2.21 – 6.63 
0.85 – 6.00 
<0.001 
<0.001 
0.067 
Number of vegetable-eating 
days/week 
0 - 5 
6 - 7 
 
 
316/470 (67.2) 
282/436 (64.7) 
 
 
1.79 
1 (reference) 
 
 
1.06 – 3.00 
0.029 
Number of fruit-eating 
days/week 
0 - 1 
2 - 7 
 
 
213/373 (57.1) 
386/534 (72.3) 
 
 
0.36 
1 (reference) 
 
 
0.22 – 0.57 
<0.001 
Performs VISFRA for at 
least 10 minutes 
No 
Yes 
 
 
426/594 (71.7) 
173/313 (55.3) 
 
 
1.71 
1 (reference) 
 
 
1.05 – 2.77 
0.030 
Minutes of work-related 
VIA/week 
<75 
≥75 
 
 
55/89 (61.8) 
258/353 (73.1) 
 
 
0.57 
1 (reference) 
 
 
0.29 – 0.90 
0.021 
The dependent variable was BMI ≥ 25 kg/m2; *The column ‘n/N (%)’ shows the number (and 
percentage) of participants with BMI ≥25 kg/m2 within each variable; BMI = body mass index; 
VISFRA = vigorous-intensity sports, fitness and recreational activity; VIA = vigorous-intensity 
activity 
 
5.3.4.3 Waist circumference 
Waist circumference was categorised into normal and above normal.  The normal 
waist circumference used for females was ≤88cm and, for males, was ≤102cm, 
based on the PNG Diabetes Clinical Guidelines 2012. 
268 
 
 
As Table 5.23 showed earlier, 319 (34.9%) participants had a larger than normal 
waist circumference. 
Univariate logistic regression analysis indicated that age, gender, level of education 
and area of residence were associated with waist circumference (Table 5.40).  
Participants aged 50 – 59 years were four times more likely to have an abnormally 
large waist circumference compared to those aged 60 years and older.  Although 
those younger than 50 years appeared to be more likely to have an abnormally large 
waist circumference when compared to those aged 60 years and older, this did not 
reach statistical significance.  Female participants had 10 times the odds of having a 
larger than normal waist circumference, compared to their male counterparts.   
Results indicated that betel nut exposure, tobacco smoking, consumption of alcohol 
in the preceding 12 months, vegetable servings per day and number of days per 
week that vegetables were consumed affected waist circumference (Table 5.41). 
Participants who never chewed betel nut had almost twice the odds of having an 
abnormally large waist circumference, compared to betel nut chewers and those 
who had quit the habit. Current tobacco smokers were less likely to have a waist 
circumference above normal compared to those who never smoked or those who 
had quit smoking.  Participants who had consumed alcohol in the preceding 12 
months were less likely to have a waist circumference above normal.  Those who 
did not consume vegetables or those who consumed vegetables for up to five days 
per week were less likely to have an abnormally large waist circumference 
compared to those who consumed vegetables for six to seven days per week.  
Furthermore, participants who consumed ≥3 serves of vegetables per day were 
twice as likely to have a waist circumference above normal.   
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Table 5.40 Univariate logistic regression analysis of demographic 
factors associated with abnormally large waist circumference  
Variable Crude OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
1.94 
3.86 
1 (reference) 
 
0.83 – 4.51 
1.55 – 9.61 
0.001 
0.125 
0.004 
Gender 
Female 
Male 
 
10.11 
1 (reference) 
 
7.05 – 14.51 
<0.001 
Level of Education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
1 (reference) 
0.61 
0.63 
0.96 
 
 
0.42 – 0.88 
0.44 – 0.91 
0.42 – 2.20 
0.035 
 
0.009 
0.014 
0.923 
Employment Status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
1 (reference) 
1.32 
0.22 
0.99 
 
 
0.96 – 1.82 
0.03 – 1.71 
0.62 – 1.60 
0.095 
 
0.090 
0.147 
0.981 
Region 
Southern 
Momase 
Highlands  
New Guinea Islands 
 
0.91 
0.96 
1.27 
1 (reference) 
 
0.55 – 1.50 
0.53 – 1.73 
0.78 – 2.09 
0.180 
0.716 
0.886 
0.341 
Years of residence in Port Moresby 
≤10 
>10 
 
0.76 
1 (reference) 
 
0.57 – 1.02 
0.064 
Area of residence 
Urban 
Peri-urban 
 
1 (reference) 
1.46 
 
 
1.10 – 1.95 
0.009 
The dependent variable was waist circumference above normal; Normal waist circumference 
is ≤102cm (male) and ≤88cm (female). 
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Table 5.41 Univariate logistic regression analysis of tobacco smoking, 
and fruit and vegetable consumption variables, associated with 
abnormally large waist circumference  
Variable Crude OR 95% CI p-value 
Smoking history 
Current 
Never 
Quit 
 
0.44 
1.13 
1 (reference) 
 
0.27 – 0.72 
0.72 – 1.78 
<0.001 
0.001 
0.599 
Alcohol consumed in the previous 12 
months 
No 
Yes 
 
 
1 (reference) 
0.45 
 
 
 
0.33 – 0.60 
<0.001 
Vegetable servings/day 
<3 
≥3 
 
1 (reference) 
2.25 
 
 
1.36 – 3.73 
0.002 
Number of vegetable-eating days/week 
0 - 5 
6 - 7 
 
0.50 
1 (reference) 
 
0.38 – 0.66 
<0.001 
Fruit servings/day 
<2 
≥2 
 
1 (reference) 
1.05 
 
 
0.78 – 1.41 
0.769 
Number of fruit-eating days/week 
0 - 1 
2 - 7 
 
0.763 
1 (reference) 
 
0.58 – 1.01 
0.058 
The dependent variable was waist circumference above normal; Normal waist circumference 
is ≤102cm (male) and ≤88cm (female). 
 
Table 5.42 demonstrates that betel nut chewing was associated with waist 
circumference.  Those who never chewed betel nut were more likely to have a waist 
circumference above normal.  For the subgroup classified as betel nut chewers, 
those who chewed ≤5 nuts per day were significantly less likely to have a waist 
circumference above normal, compared to those who chewed 10 or more.  For the 
same subgroup, the components chewed with betel nut did not have an association 
with waist circumference.  When comparing those who were current chewers with 
those who had quit the habit, the difference in association with waist circumference 
did not reach statistical significance.   
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Table 5.42 Univariate logistic regression analysis of betel nut chewing 
variables associated with abnormally large waist circumference  
Variable Crude OR 95% CI p-value 
Betel nut chewer 
No  
Yes  
 
2.04 
1 (reference) 
 
1.45 – 2.85 
<0.001 
Betel nut chewing history 
Current  
Never  
Quit  
 
1 (reference) 
2.29 
1.08 
 
 
1.59 – 3.30 
0.50 – 2.34 
<0.001 
 
<0.001 
0.847 
Betel nut chewing status 
Never 
Ever 
 
2.28 
1 (reference) 
 
1.58 – 3.28 
<0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
1.85 
0.87 
0.66 
1 (reference) 
 
1.24 – 2.76 
0.40 – 1.92 
0.48 – 0.90 
<0.001 
0.003 
0.739 
0.008 
Quantity of betel nuts chewed/day# 
≤5 
6-9 
≥10 
 
0.53 
0.57 
1 (reference) 
 
0.37 – 0.75 
0.35 – 0.91 
0.001 
<0.001 
0.020 
Betel nut chew composition# 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
0.97 
0.86 
1 (reference) 
 
0.38 – 2.45 
0.34 – 2.23 
0.787 
0.945 
0.761 
The dependent variable was waist circumference above normal; Normal waist circumference 
is ≤102cm (male) and ≤88cm (female); #Includes only those who were betel nut chewers; PBI 
= Piper betle inflorescence 
 
As highlighted in Table 5.43, the amount of physical activity, including work-related 
MIA and VIA, MISFRA and VISFRA, and walking to get to and from places, was 
associated with waist circumference.  Although these activities had an impact on 
waist circumference, the amount of time spent on these activities did not.  Those 
who undertook these activities were less likely to have a waist circumference above 
normal, compared to those who did not.   
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Table 5.43 Univariate logistic regression analysis of association 
between physical activity and abnormally large waist circumference  
Variable Crude OR 95% CI p-value 
Amount of physical activity 
Sufficient 
None/Insufficient 
 
1 (reference) 
1.91 
 
 
1.41 – 2.60 
<0.001 
Work-related VIA for at least 10 minutes 
No  
Yes 
 
1.40 
1 (reference) 
 
1.06 – 1.84 
0.016 
Minutes of work-related VIA/week 
<75 
≥75 
 
1.08 
1 (reference) 
 
0.66 – 1.79 
0.753 
Performs VISFRA for at least 10 
minutes 
No  
Yes 
 
 
2.01 
1 (reference) 
 
 
1.52 – 2.80 
<0.001 
Minutes of VISFRA/week 
<75 
≥75 
 
1.33 
1 (reference) 
 
0.78 – 2.28 
0.295 
Work-related MIA for at least 10 
minutes 
No  
Yes 
 
 
1.67 
1 (reference) 
 
 
1.26 – 2.21 
<0.001 
Minutes of work-related MIA/week 
<150 
≥150 
 
0.86 
1 (reference) 
 
0.58 – 1.28 
0.457 
Performs MISFRA for at least 10 
minutes 
No 
Yes 
 
 
2.14 
1 (reference) 
 
 
1.56 – 2.93 
<0.001 
Minutes of MISFRA/week 
<150 
≥150 
 
1.27 
1 (reference) 
 
0.70 – 2.30 
0.440 
Walks to get to and from places for at 
least 10 minutes 
No 
Yes 
 
 
1.57 
1 (reference) 
 
 
1.03 – 2.38 
0.034 
Minutes of walking/week 
<150 
≥150 
 
1.28 
1 (reference) 
 
0.94 – 1.74 
0.116 
The dependent variable was waist circumference “above normal”; Normal waist 
circumference is ≤102 cm (male) and ≤88 cm (female); VIA = vigorous-intensity activity; 
VISFRA = vigorous-intensity sports, fitness and recreational activity; MIA = moderate-
intensity activity; MISFRA = moderate-intensity sports, fitness and recreational activity 
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Results indicated that age, gender, area of residence, betel nut exposure, number of 
vegetable-eating days and VISFRA appeared to be independently associated with 
waist circumference (Table 5.44).   
Those aged 50 – 59 years old had twice the odds of having a waist circumference 
above normal, compared to those younger than 50 years.  The association, 
however, did not reach statistical significance when comparing those younger than 
50 years with those aged 60 years and older.   
Female participants were 14 times more likely to have a waist circumference above 
normal, compared to their male counterparts. Those who chewed ≤5 nuts/day were 
significantly less likely to have a waist circumference above normal, compared to 
those who never chewed.  The association, however, did not reach statistical 
significance when comparing those who chewed >5 nuts/day and those who had 
quit the habit with those who never chewed betel nut.   
Those who either didn’t consume vegetables or those who consumed vegetables for 
up to five days per week appeared to be less likely to have a waist circumference 
above normal, and those who did not do VISFRA had twice the odds of a higher 
than normal waist circumference.   
 
 
274 
 
 
Table 5.44 Multivariate logistic regression analysis of demographic 
and lifestyle risk factors independently associated with abnormally 
large waist circumference  
Variable n/N (%)* Adjusted OR 95% CI p-value 
Age (years) 
<50  
50 - 59 
≥60 
 
258/772 (33.4) 
54/108 (50.0) 
7/34 (54.4) 
 
1 (reference) 
2.14 
0.90 
 
 
1.16 – 3.96 
0.22 – 3.61 
0.049 
 
0.015 
0.877 
Gender 
Female 
Male 
 
276/507 (54.4) 
43/407 (10.6) 
 
14.29 
1 (reference) 
 
8.77 – 23.27 
<0.001 
Area of residence 
Urban 
Peri-urban 
 
197/615 (32.0) 
122/299 (40.8) 
 
1 (reference) 
1.88 
 
 
1.20 – 2.95 
0.006 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
72/140 (51.4) 
10/30 (33.3) 
109/400 (27.3) 
119/327 (36.4) 
 
1 (reference) 
1.05 
0.44 
0.70 
 
 
0.28 – 3.95 
0.25 – 0.77 
0.40 – 1.23 
0.019 
 
0.946 
0.004 
0.212 
Vegetable-eating 
days/week 
0 - 5 
6 - 7 
 
 
128/470 (27.2) 
188/438 (42.9) 
 
 
0.64 
1 (reference) 
 
 
0.42 – 0.98 
0.039 
Performs VISFRA for at 
least 10 minutes 
No  
Yes 
 
 
238/594 (40.1) 
77/315 (24.4) 
 
 
2.15 
1 (reference) 
 
 
1.40 – 3.31 
<0.001 
The dependent variable was waist circumference above normal.  Normal waist 
circumference is ≤102 cm (male) and ≤88 cm (female); *The column ‘n/N (%)’ shows the 
number (and percentage) of participants with abnormally large waist circumference within 
each variable; VISFRA = vigorous-intensity sports, fitness and recreational activity 
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5.3.4.4 Fasting blood glucose  
Analysis for FCBG excluded those participants who did not fast (random CBG).  
FCBG was grouped into different categories of hyperglycaemia according to the 
PNG Diabetes Clinical Guidelines 2012.  Using those guidelines for definition of 
T2DM, one of the FCBG variables was created with a cut-off of 6.1, where a FCBG 
of 6.1 mmol/L or higher would indicate that the participant could have T2DM.  FCBG 
levels were also categorised according to PNG Diabetes Clinical Guidelines 2012 as 
<5.6, 5.6 - 6.0 and >6.0 mmol/L, indicating normal, IFG and possible T2DM, 
respectively.   
As shown in Table 5.45, participants aged ≥60 years, and those who were retired, 
had the highest mean FCBG compared to the other age groups. The minimum and 
maximum FCBG for all participants were 3.5 and 27.7 mmol/L, respectively.  Those 
who had completed tertiary education, those who were self-employed and those 
who resided in peri-urban areas tended to have lower FCBG ranges.   
As can be seen in Table 5.46, age was the only demographic factor that was 
associated with a FCBG of >6.0 mmol/L.  Those aged 60 years and older were more 
likely to have T2DM, compared to their younger counterparts.  Those residing in 
urban areas and those who had lived in Port Moresby for 10 years or less appeared 
to have a FCBG of >6.0 mmol/L more often, but none of these associations reached 
statistical significance.   
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Table 5.45 Mean, standard deviation and range values of FCBG of 
participants (N = 897) 
Variable n (%)* Mean SD Range 
All participants 897 (100.0) 5.50 1.53  3.5 – 27.7 
Gender  
Female 
Male 
 
447 (49.8) 
360 (40.1) 
 
5.49 
5.51 
 
1.28 
1.73 
 
3.5 – 21.1 
3.5 – 27.7 
Age (years) 
<50 
50 - 59 
≥60 
 
 680 (75.8) 
93 (10.4) 
31 (3.5) 
 
5.42 
5.65 
6.83 
 
1.03 
1.91 
4.82 
 
3.5 – 14.4 
3.5 – 21.1 
3.5 – 27.7 
Level of education 
Did not complete basic 
education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
 
163 (18.2) 
313 (34.9) 
310 (34.6) 
21 (2.3 
 
 
5.53 
5.53 
5.46 
5.48 
 
 
1.99 
1.28 
1.45 
0.67 
 
 
3.5 – 27.7 
3.5 – 17.5 
3.6 – 21.1 
4.4 – 7.1 
Employment Status 
Paid employment 
Unpaid/unemployed 
Retired 
Self-employed 
 
219 (24.4) 
471 (52.6) 
11 (1.2) 
106 (11.8) 
 
5.49 
5.45 
7.20 
5.58 
 
1.35 
1.32 
6.83 
0.98 
 
3.5 – 17.5 
3.5 – 21.1 
4.1 – 27.7 
3.5 – 8.6 
Area of residence 
Urban 
Peri-urban 
 
542 (60.4) 
265 (29.5) 
 
5.58 
5.34 
 
1.72 
0.87 
 
3.5 – 27.7 
3.5 – 8.5 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
320 (35.7) 
72 (8.0) 
107 (11.9) 
308 (34.3) 
 
5.51 
5.52 
5.62 
5.44 
 
1.38 
2.05 
2.35 
1.03 
 
3.5 – 17.5 
3.6 – 21.1 
3.5 – 27.7 
3.5 – 11.3 
Years of residence in Port 
Moresby 
≤10 
>10 
 
 
452 (50.4) 
355 (39.6) 
 
 
5.52 
5.47 
 
 
1.33 
1.69 
 
 
3.5 – 21.1 
3.5 – 27.7 
*May not add up to total because of missing values; FCBG = fasting capillary blood glucose 
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Table 5.46 Demographic factors associated with T2DM  
Variable Fasting capillary blood glucose 
(mmol/L) 
 
Non-T2DM 
≤6.0 (N [%]) 
T2DM 
>6.0(N [ %]) 
p-value# 
Gender 
 Female 
 Male 
 
405 (81.8) 
332 (82.6) 
 
90 (18.2) 
70 (17.4) 
0.765 
Age (years) 
 <60 
 ≥60 
 
730 (82.7) 
24 (68.6) 
 
153 (17.3) 
11 (31.4) 
0.033 
Area of residence 
Urban 
Peri-urban  
 
482 (80.6) 
255 (85.3) 
 
116 (19.4) 
44 (14.7) 
0.084 
Years of residence in Port Moresby 
≤10 
>10 
 
367 (79.6) 
308 (84.8) 
 
94 (20.4) 
55 (15.2) 
0.052 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations; T2DM = type 2 diabetes mellitus 
 
Of all the demographic factors, only age tended to be associated with IFG.  Those 
aged 50 - 59 years appeared more likely to have IFG, while those aged 60 years 
and older appeared more likely to have FCBG of >6.0 mmol (χ2, p=0.032), indicating 
that the latter were more likely to have T2DM.  Lifestyle factors, such as tobacco 
smoking and alcohol, vegetable and fruit consumption, did not have an impact on 
FCBG. Neither tobacco smoking nor fruit consumption had an impact on FCBG.  
However, the number of days in a week that vegetables were consumed did appear 
to have an impact on FCBG, with those consuming vegetables for 6 - 7 days being 
more likely to have normal FCBG (χ2, p=0.011).  Participants who consumed more 
than two serves of fruit in a week appeared to be more likely to have IFG but this did 
not reach statistical significance (χ2, p=0.088).   
As shown in Tables 5.47 and 5.48, none of the betel nut chewing variables was 
associated with FCBG. 
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Table 5.47 Betel nut chewing variables associated with T2DM  
Variable Fasting capillary blood glucose 
Non-T2DM 
≤6.0 (N [%]) 
T2DM 
>6.0 (N [ %]) 
p-value# 
Betel nut chewer 
No  
Yes      
 
141 (84.9) 
592 (81.7) 
 
25 (15.1) 
133 (18.3) 
0.318 
Betel nut chewing history 
Current  
Never  
Quit  
 
592 (81.7) 
116 (85.3) 
24 (82.8) 
 
133 (18.3) 
20 (14.7) 
5 (17.2) 
0.593 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
116 (85.3) 
24 (82.8) 
324 (82.2) 
258 (81.1) 
 
20 (14.7) 
5 (17.2) 
70 (17.8) 
60 (18.9) 
0.767 
Betel nut chew composition† 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
366 (80.3) 
210 (84.3) 
17 (85.0) 
 
90 (19.7) 
39 (15.7) 
3 (15.0) 
0.380 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; T2DM = type 2 diabetes mellitus; FCBG = fasting capillary blood glucose; PBI 
= Piper betle inflorescence; †Includes only those who were classified as betel nut chewers 
 
Table 5.48 Betel nut chewing variables associated with IFG and T2DM  
Variable Fasting capillary blood glucose (mmol/L) p-value# 
Normal 
<5.6 
(N [%]) 
IFG 
5.6 - 6.0       
(N [%]) 
T2DM 
>6.0       
(N [ %]) 
Betel nut chewer 
No  
Yes      
 
103 (62.0) 
434 (59.9) 
 
38 (22.9) 
158 (21.8) 
 
25 (15.1) 
133 (18.3) 
0.606 
Betel nut chewing history 
Current  
Never  
Quit  
 
434 (59.9) 
88 (64.7) 
15 (51.7) 
 
158 (21.8) 
28 (20.6) 
9 (31.0) 
 
133 (18.3) 
20 (14.7) 
5 (17.2) 
0.577 
Betel nuts exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
88 (64.7) 
15 (51.7) 
232 (58.9) 
193 (60.7) 
 
28 (20.6) 
9 (31.0) 
92 (23.4) 
65 (20.4) 
 
20 (14.7) 
5 (17.2) 
70 (17.8) 
60 (18.9) 
0.713 
Betel nut chew composition† 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
280 (61.4) 
142 (57.0) 
12 (60.0) 
 
86 (18.9) 
68 (27.3) 
5 (25.0) 
 
90 (19.7) 
39 (15.7) 
3 (15.0) 
0.115 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; †Includes only those who were classified as betel nut chewers; IFG = impaired 
fasting glucose; T2DM = type 2 diabetes mellitus; FCBG = fasting capillary blood glucose; 
PBI = Piper betle inflorescence 
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As demonstrated in Table 5.49, of all the physical activities investigated in this 
study, work-related VIA was the only variable associated with FCBG. Those whose 
work involved VIA were more likely to have FCBG >6.0 mmol/L compared to those 
who did not. 
When FCBG was classified into three categories (<5.6, 5.6 - 6.0 and >6.0 mmol/L), 
the physical activities which were associated with FCBG were work-related MIA and 
VIA (Table 5.50). Those who were involved in work-related MIA were more likely to 
have IFG compared to those who did not.  Those involved in work-related VIA were 
more likely to have FCBG >6.0 mmol/L.   
Table 5.49 Association of physical activity with T2DM.   
Variable Fasting capillary blood 
glucose 
 
p-value# 
Non-T2DM 
≤6.0 (N [%]) 
T2DM 
>6.0 (N [ %]) 
Work-related MIA for at least 10 minutes 
No  
Yes        
 
295 (84.5) 
432 (81.1) 
 
54 (15.5) 
101 (18.9) 
0.185 
Performs  MISFRA for at least 10 
minutes 
No 
Yes 
 
 
236 (84.3) 
497 (81.5) 
 
 
44 (15.7) 
113 (18.5) 
0.307 
Work-related VIA for at least 10 minutes   
No  
Yes         
 
361 (86.2) 
369 (78.8) 
 
58 (13.8) 
99 (21.2) 
0.004 
Performs VISFRA for at least 10 minutes 
No  
Yes         
 
473 (81.6) 
258 (83.8) 
 
107 (18.4) 
50 (16.2) 
0.410 
Walks to get to and from places for at 
least 10 minutes         
No  
Yes         
 
 
80 (81.6) 
651 (82.4) 
 
 
18 (18.4) 
139 (17.6) 
0.850 
Amount of physical activity/week 
Sufficient 
None/Insufficient 
 
519 (82.3) 
197 (82.8) 
 
112 (17.7) 
41(17.2) 
0.857 
#The p-values were obtained from Chi-square statistics, and assess the strengths of 
associations; T2DM = type 2 diabetes mellitus; MIA = Moderate-intensity activities; MISFRA 
= Moderate-intensity sports, fitness and recreational activities; VIA = Vigorous-intensity 
activities; VISFRA = Vigorous-intensity sports, fitness and recreational activities 
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Table 5.50 Physical activities associated with IFG and T2DM 
Variable Fasting capillary blood glucose  (mmol/L) p-
value# Normal 
<5.6 (N[%]) 
IFG 
5.6 - 6.0 (N 
[%]) 
T2DM 
>6.0 (N [%]) 
Work-related MIA for at least 
10 minutes 
No  
Yes         
 
 
231 (66.2) 
302 (56.7) 
 
 
64 (18.3) 
130 (24.4) 
 
 
54 (15.5) 
101 (18.1) 
0.017 
Performs  MISFRA for at 
least 10 minutes 
No  
Yes         
 
 
357 (58.5) 
180 (64.3) 
 
 
140 (23.0) 
56 (20.0) 
 
 
113 (18.5) 
44 (15.7) 
0.263 
Work-related VIA for at least 
10 minutes   
No  
Yes         
 
 
273 (65.2) 
262 (56.0) 
 
 
88 (21.0) 
107 (22.9) 
 
 
58 (13.8) 
99 (21.2) 
0.006 
Performs VISFRA for at 
least 10 minutes 
No  
Yes          
 
 
339 (58.4) 
197 (64.0) 
 
 
134 (23.1) 
61 (19.8) 
 
 
107 (18.4) 
50 (16.2) 
0.277 
Walks to get to and from 
places for at least 10 
minutes 
No  
Yes         
 
 
 
61 (62.2) 
475 (60.1) 
 
 
 
19 (19.4) 
176 (22.3) 
 
 
 
18 (18.4) 
139 (17.6) 
0.808 
Amount of physical activity 
/week 
Sufficient 
None/Insufficient 
 
 
379 (60.1) 
148 (62.2) 
 
 
140 (22.2) 
49 (20.6) 
 
 
112 (17.7) 
41 (17.2) 
0.836 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; MIA = moderate-intensity activity; MISFRA = moderate-intensity sports, fitness 
and recreational activities; VIA = Vigorous-intensity activities; VISFRA = Vigorous-intensity 
sports, fitness and recreational activities; IFG = impaired fasting glucose; T2DM = type 2 
diabetes mellitus 
 
The only medical factors associated with FCBG were BMI and waist circumference 
(Table 5.51).  Participants with a BMI ≥25 kg/m2 and those with abnormally large 
waist circumferences were more likely to have a FCBG of >6.0 mmol/L that 
indicated a possibility of T2DM.  Blood pressure was not associated with FCBG.   
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Table 5.51 Medical factors associated with T2DM  
 
Variable Fasting capillary blood glucose 
Non-T2DM 
≤6.0 (N [%]) 
T2DM 
>6.0 (N [ %]) 
p-value# 
Body mass index (kg/m2) 
<25 
≥25 
 
264 (87.4) 
466 (79.7) 
 
38 (12.6) 
119 (20.3) 
0.004 
Waist circumference 
Normal 
Above normal 
 
489 (84.6) 
243 (78.1) 
 
89 (15.4) 
68 (21.9) 
0.016 
Systolic blood pressure (mmHg) 
≤130 
>130 
 
529 (82.4) 
204 (82.3) 
 
113 (17.6) 
44 (17.7) 
0.961 
Diastolic blood pressure (mmHg) 
≤80 
>80 
 
529 (82.4) 
204 (82.3) 
 
113 (17.6) 
44 (17.7) 
0.961 
# The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; T2DM = type 2 diabetes mellitus; Normal waist circumference is ≤102cm 
(male) and ≤88cm (female) 
 
When FCBG was grouped into three categories, BMI and waist circumference were 
associated with FCBG (Table 5.52). However, those with a BMI ≥25 kg/m2 and 
those who had a waist circumference above normal were more likely to be 
associated with FCBG >6.0 mmol/L rather than having an IFG of 5.6 – 6.0 mmol/L.   
When comparing those who were normal with the overweight and obese, results 
indicated that, as the BMI increased, the percentage of those with FCBG >6.0 
mmol/L increased.  Those who were underweight were less likely to have a normal 
or IFG but were more likely to have a FCBG >6.0 mmol/L when compared with the 
other categories of BMI.  The sample number (n=16; 2 missing) for the former was 
very small.   
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Table 5.52 Medical factors associated with IFG (5.6 - 6.0 mmol/L) and 
T2DM (>6.0 mmol/L) 
Variable Fasting capillary blood glucose 
 
p-
value# 
Normal 
<5.6 
(N [%]) 
IFG 
5.6 - 6.0       
(N [%]) 
T2DM 
>6.0       
(N [ %]) 
BMI category 
Underweight 
Normal 
Overweight 
Obese 
 
9 (56.3) 
183 (64.0) 
207 (60.2) 
136 (56.4) 
 
2 (12.5) 
70 (24.5) 
73 (21.2) 
50 (20.7) 
 
5 (31.3) 
33 (11.5) 
64 (18.6) 
55 (22.8) 
0.024 
BMI (kg/m2) 
<25 
≥25 
 
192 (63.6) 
343 (58.6) 
 
72 (23.8) 
123 (21.0) 
 
38 (12.6) 
119 (20.3) 
0.016 
Waist circumference 
Normal 
Above normal 
 
351 (60.7) 
185 (59.5) 
 
138 (23.9) 
58 (18.6) 
 
89 (15.4) 
68 (21.9) 
0.025 
SBP (mmHg) 
≤130 
>130 
 
387 (60.3) 
150 (60.5) 
 
142 (22.1) 
54 (21.8) 
 
113 (17.6) 
44 (17.7) 
0.994 
DBP (mmHg) 
≤80 
>80 
 
386 (60.1) 
151 (60.9) 
 
143 (22.3) 
53 (21.4) 
 
113 (17.6) 
44 (17.7) 
0.958 
# The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; IFG = impaired fasting glucose; T2DM = type 2 diabetes mellitus; BMI = body 
mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; Normal waist 
circumference is ≤102cm (male) and ≤88cm (female) 
 
Factors significantly associated with FCBG were entered into a univariate logistic 
regression model to determine the direction of association.  Results indicated that 
work-related via, BMI and waist circumference had a significant influence on FCBG 
(Table 5.53).  Participants who performed work-related VIA and those who had a 
BMI >25 kg/m2 and an abnormally high waist circumference were more likely to 
have a FCBG of >6.0 mmol/L.  Those aged 60 years and older had twice the odds 
of having a FCBG >6.0 mmol/L but the impact of age on FCBG was only significant 
when comparing those aged 60 years and older with those younger than 50 years.   
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Table 5.53 Univariate logistic regression analysis of factors 
associated with abnormally high FCBG (>6.0 mmol/L). 
Variable Crude OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
1 (reference) 
0.87 
2.16 
 
 
0.49 – 1.52 
1.03 – 4.51 
0.099 
 
0.617 
0.041 
Number of vegetable-eating days in a 
typical week 
0 - 2 
3 - 5 
6 - 7 
 
 
1.29 
1.44 
1 (reference) 
 
 
0.82 – 2.01 
0.97 – 2.14 
0.177 
 
0.271 
0.070 
Work-related MIA for at least 10 
minutes 
No  
Yes         
 
 
0.78 
1 (reference) 
 
 
0.55 – 1.13 
0.185 
Work-related VIA for at least 10 
minutes   
No  
Yes         
 
 
0.60 
1 (reference) 
 
 
0.42 – 0.85 
0.005 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
1.77 
 
 
1.20 – 2.63 
0.004 
Waist circumference 
Normal 
Above normal 
 
1 (reference) 
1.54 
 
 
1.08 – 2.18 
0.016 
The dependent variable was FCBG >6.0 mmol/L; FCBG = fasting capillary blood glucose; 
BMI = body mass index; MIA = moderate-intensity activity; VIA = vigorous-intensity activity; 
Normal waist circumference is ≤102cm (male) and ≤88cm (female) 
 
As can be seen in Table 5.54, multivariate logistic regression analysis indicated that 
age, work-related VIA, BMI and waist circumference independently had an impact 
on FCBG.   
Participants aged 60 years had two times the odds of having a FCBG >6.0 mmol/L.  
Those involved in work-related vigorous-intensity were almost twice as likely to have 
a FCBG >6.0 mmol/L.  Waist circumference had a more significant impact on FCBG 
than BMI.  The association between BMI and FCBG appeared to be statistically 
significant  
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Table 5.54 Multivariate logistic regression analysis factors 
independently associated with high FCBG (>6.0 mmol/L)  
Variable n/N (%)* Adjusted OR 95% CI p-value 
Age (years) 
 <50 
 50 - 59 
 ≥60 
 
136/777 (17.5) 
17/106 (16.0) 
11/35 (31.4) 
 
1 (reference) 
0.78 
2.69 
 
 
0.44 – 1.39 
1.25 – 5.77 
0.023 
 
0.394 
0.011 
Work-related VIA for at least 
10 minutes   
No  
Yes  
 
 
60/427 (14.1) 
101/481 (21.0) 
 
 
0.59 
1 (reference) 
 
 
0.41 – 0.86 
0.005 
BMI (kg/m2) 
<25 
≥25 
 
38/307 (12.4) 
123/601 (20.5) 
 
1 (reference) 
1.53 
 
 
1.00 – 2.34 
0.050 
Waist circumference 
Normal 
Above normal 
 
92/592 (15.5) 
69/318 (21.7) 
 
1 (reference) 
1.51 
 
 
1.03 – 2.21 
0.035 
The dependent variable was FCBG >6.0mmol/L; *The column ‘n/N (%)’ shows the number 
(and percentage) of participants who had FCBG >6.0 mmol/L within each variable; FCBG = 
fasting capillary blood glucose; BMI = body mass index; VIA= vigorous-intensity activity; 
Normal waist circumference is ≤102cm (male) and ≤88cm (female) 
 
5.3.4.5 Oral glucose tolerance  
As with FCBG, 2-hour oral glucose tolerance (OGT) was grouped into different 
categories of hyperglycaemia according to the PNG Diabetes Clinical Guidelines 
2012.  One of the variables was created with a cut-off of 11.0, where an OGT >11.0 
mmol/L indicated that the participant could have T2DM.  OGT was also categorised 
according to PNG Diabetes Clinical Guidelines 2012 as <8.9, 8.9 - 12.1 and >12.1 
mmol/L, indicating normal, IGT and possibleT2DM, respectively.   
OGT was not normally distributed and, therefore, are reported as median and range 
in Table 5.55.  As shown in this Table, median values for all age categories were 
within the normal OGT of <8.9 mmol/L but these levels ranged from 3.7 to 32.9 
mmol/L.   
The highest median OGT value was observed in those aged 60 years and older.  
This subgroup also had the highest minimum OGT value compared to those who 
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were younger.  Participants who had completed tertiary education and those who 
were self-employed had the narrowest and the second narrowest range of values, 
respectively.   
The only factor associated with abnormally high OGT was age (Table 5.56).  As age 
increased, the prevalence of having an abnormally high OGT also increased.  Those 
aged 60 years and older appeared to have an abnormally high OGT, however the 
sample number for this subgroup was small.   
Table 5.55 Median and range values of oral glucose tolerance test 
levels of participants (N = 471) 
Variable 
 
n (%)* Median Range 
All participants 
 
471 (100.0) 7.2 3.7 – 32.9 
Gender  
Female 
Male 
 
242 (51.4) 
186 (39.5) 
 
7.2 
7.2 
 
3.8 – 32.9 
3.7 – 30.0 
Age (years) 
< 50 
50 - 59 
≥ 60 
 
352 (74.7) 
58 (12.3) 
18 (3.8) 
 
7.1 
7.4 
8.3 
 
3.7 – 31.8 
4.8 – 32.9 
5.7 – 30.0 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary/Vocational 
Tertiary education 
 
83 (17.6) 
174 (36.9) 
158 (33.5) 
13 (2.8) 
 
7.6 
7.0 
7.8 
7.2 
 
3.8 – 30.0 
3.7 – 26.0 
4.6 – 32.9 
5.3 – 9.5 
Employment status 
Paid employment 
Unpaid/unemployed 
Retired 
Self-employed 
 
110 (23.4) 
246 (52.2) 
7 (1.5) 
65 (13.8) 
 
7.3 
7.2 
7.5 
6.9 
 
3.7 – 26.0 
3.8 – 32.9 
4.9 – 30.0 
4.8 – 12.7 
Area of residence 
Urban 
Peri-urban 
 
296 (62.8) 
132 (28.0) 
 
7.1 
7.6 
 
3.9 – 32.9 
3.7 – 18.8 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
177 (37.6) 
40 (8.5) 
57 (12.1) 
154 (32.7) 
 
7.4 
6.9 
7.4 
7.0 
 
3.7 – 31.8 
4.8 – 32.9 
5.1 – 30.0 
3.8 – 18.8 
Years of residence in Port Moresby 
≤10 
>10 
 
231 (49.0) 
197 (41.8) 
 
7.2 
7.2 
 
3.8 – 32.9 
3.7 – 31.8 
*May not add to total because of missing values 
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Table 5.56 Demographic factors associated with possible T2DM (OGT 
>11.0 mmol/L).   
Variable OGT levels (mmol/L) 
 
p-value# 
Non-T2DM 
≤11.0 (N [%]) 
T2DM 
>11.0(N [ %]) 
Gender 
 Female 
 Male 
 
252 (95.8) 
196 (94) 
 
11 (4.2) 
12 (5.8) 
0.428 
Age (years) 
 <50 
 50 - 59 
 ≥60 
 
376 (97.2) 
56 (87.5) 
16 (80.0) 
 
11 (2.8) 
8 (12.5) 
4 (20.0) 
<0.001 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary education/Vocational 
Tertiary education 
 
92 (94.8) 
178 (96.2) 
160 (93.6) 
16 (100.0) 
 
5 (5.2) 
7 (3.8) 
11 (6.4) 
0 (0.0) 
0.533 
Employment status 
Paid 
Unpaid/unemployed 
Retired 
Self-employed 
 
114 (95.0) 
255 (94.8) 
6 (85.5) 
68 (98.6) 
 
6 (5.0) 
14 (5.2) 
1 (14.3) 
1 (1.4) 
0.264* 
Area of residence 
Urban 
Peri-urban  
 
302 (94.1) 
146 (97.3) 
 
19 (5.9) 
4 (2.7) 
0.127 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
181 (92.8) 
42 (93.3) 
57 (96.6) 
166 (97.6) 
 
14 (7.2) 
3 (6.7) 
2 (3.4) 
4 (2.4) 
0.136* 
Years of residence in Port Moresby 
≤10 
>10 
 
227 (96.6) 
188 (93.1) 
 
8 (3.4) 
14 (6.9) 
0.093 
#The p-values were obtained from the Chi-square statistics, and assess the 
strengths of associations; *Fisher’s exact test; OGT = oral glucose tolerance; T2DM 
= type 2 diabetes mellitus 
 
When OGT was grouped into three categories, demographic factors such as age 
and area of residence tended to affect OGT (Table 5.60).   Participants aged 50 - 59 
years and those aged 60 years and older were more likely to have IGT and T2DM, 
respectively.   
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Sample numbers for those aged 60 years and older, and those with OGT >12.1 
were small.  Those in peri-urban areas tended to have a higher prevalence of IGT, 
while their counterparts in urban areas tended to have OGT levels indicating T2DM.   
The demographic factors associated with IGT were age and area of residence with 
age being the most important.  Those aged 50-59 years (χ2, p<0.001) and those 
residing in the peri-urban areas (χ2, p=0.022) were more likely to have IGT  
Tobacco smoking was associated with OGT but this association was only significant 
when participants were classified as smokers or non-smokers (Table 5.57).  When 
participants were categorised as current, never or quit smokers, the association of 
smoking with OGT was not significant.  Those who reported being smokers were 
less likely to have OGT >11.1 mmol/L.   
Of the participants who consumed alcohol, vegetables or fruits, only the number of 
days/week that fruit was consumed appeared to have an association with an 
abnormally high OGT.  Those who did not consume fruit or consumed fruits for up to 
two days per week were more likely to have an abnormally high OGT compared to 
those who consumed fruits for more than two days per week.  However, the 
association was of non-significance.  
Using the three-category OGT, results indicated that tobacco smoking and the 
consumption of alcohol, vegetables and fruit were not associated with OGTT 
abnormalities (Table 5.58). 
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Table 5.57 Tobacco smoking and alcohol, vegetable and fruit 
consumption variables associated with possible T2DM (OGT >11.0 
mmol/L) 
Variable Capillary OGT (mmol/L) 
 
p-value# 
Non-T2DM 
≤11.0 (N [%]) 
T2DM 
>11.0(N [ %]) 
Alcohol in the previous 12 
months 
No  
Yes     
 
 
274 (94.2) 
174 (96.7) 
 
 
17 (5.8) 
6 (3.3) 
0.220 
Vegetable servings/day 
<3  
≥3  
 
408 (94.9) 
36 (97.3) 
 
22 (5.1) 
1 (2.7) 
1.000* 
Number of vegetable-eating 
days in a typical week 
0 - 2 
3 - 5 
6 - 7 
 
 
97 (96.0) 
134 (94.4) 
213 (95.1) 
 
 
4 (4.0) 
8 (5.6) 
11 (4.9) 
0.838 
Fruit servings/day 
<2  
≥2  
 
302 (94.4) 
129 (97.0) 
 
18 (5.6) 
4 (3.0) 
0.238 
Number of fruit-eating days in 
a typical week 
0 - 2 
3 - 5 
6 - 7 
 
 
299 (93.4) 
111 (98.2) 
34 (100.0) 
 
 
21 (6.6) 
2 (1.8) 
0 (0.0) 
0.050 
Current smoker 
No  
Yes 
 
285 (93.8) 
161 (98.2) 
 
19 (6.2) 
3 (1.8) 
0.031 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; *Fisher’s exact test; T2DM = type 2 diabetes mellitus; OGT = oral glucose 
tolerance 
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Table 5.58 Lifestyle (alcohol, vegetable and fruit consumption, and 
tobacco smoking) risk factors associated with IGT and T2DM 
Variable Capillary OGT (mmol/L) 
 
 
Normal 
<8.9 
(N [%]) 
IGT 
8.9 - 12.1  
(N [%]) 
T2DM 
>12.1      
(N [ %]) 
p-
value# 
Alcohol in the previous 12 
months 
No  
Yes 
 
  
236 (81.1) 
151 (83.9) 
 
 
43 (14.8) 
25 (13.9) 
 
 
12 (4.1) 
4 (2.2) 
0.509 
Vegetable servings/day 
<3  
≥3  
 
352 (81.9) 
31 (83.8) 
 
62 (14.4) 
6 (16.2) 
 
16 (3.7) 
0 (0.0) 
0.480 
Number of vegetable-eating 
days in a typical week 
0 - 2 
3 - 5 
6 - 7 
 
 
81 (80.2) 
118 (83.1) 
184 (82.1) 
 
 
18 (17.8) 
18 (12.7) 
32 (14.3) 
 
 
2 (2.0) 
6 (4.2) 
8 (3.6) 
0.738* 
Fruit servings/day 
<2  
≥2  
 
258 (80.6) 
115 (86.5) 
 
49 (15.3) 
16 (12.0) 
 
13 (4.1) 
2 (1.5) 
0.229 
Number of fruit-eating days in a 
typical week 
0 - 2 
3 - 5 
6 - 7 
 
 
257 (80.3) 
99 (87.6) 
27 (79.4) 
 
 
49 (15.3) 
12 (10.6) 
7 (20.6) 
 
 
14 (4.4) 
2 (1.8) 
0 (0.0) 
0.278* 
Current smoker 
No  
Yes      
 
248 (81.6) 
138 (84.1) 
 
43 (14.1) 
24 (14.6) 
 
13 (4.3) 
2 (1.2) 
0.201 
Smoker history 
Current 
Never  
Quit  
 
138 (84.1) 
215 (81.7) 
33 (80.5) 
 
24 (14.6) 
38 (14.4) 
5 (12.2) 
 
2 (1.2) 
10 (3.8) 
3 (7.3) 
0.319 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; OGT = oral glucose tolerance; IGT = impaired glucose tolerance; T2DM = type 
2 diabetes mellitus 
 
Betel nut chewing was associated with abnormally high OGT (Table 5.9).  Those 
who did not chew betel nut were more likely to have an abnormally high OGT (>11.0 
mmol/L) when compared with chewers.  Current betel nut chewers, ever chewers 
(‘current’ and ‘quit’) and those who chewed betel nut with lime and PBI were less 
likely to have an abnormally higher OGT.  When investigating the impact of daily 
quantities of betel nut chewed, among those who were classified as betel nut 
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chewers, results indicated that the quantity of betel nut chewed per day did not 
influence OGT.  
Table 5.59 Betel nut chewing variables associated with possible T2DM 
(OGT >11.0 mmol/L)    
Variable Capillary OGT (mmol/L) 
 
p-value# 
≤11.0 (N [%]) >11.0(N [ %]) 
Betel nut chewer 
No  
Yes      
 
84 (90.3) 
363 (96.5) 
 
9 (9.7) 
13 (3.5) 
0.023* 
Betel nut chewing history 
Current  
Never  
Quit  
 
363 (96.5) 
74 (90.2) 
9 (90.0) 
 
13 (3.5) 
8 (9.8) 
1 (10.0) 
0.029* 
Betel nut chewing status 
Never 
Ever 
 
74 (90.2) 
372 (96.4) 
 
8 (9.8) 
14 (3.6) 
0.038* 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
74 (90.2) 
9 (90.0) 
190 (96.4) 
167 (96.5) 
 
8 (9.8) 
1 (10.0) 
7 (3.6) 
6 (3.5) 
0.082* 
Betel nut chew composition†§ 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
223 (97.4) 
129 (95.6) 
10 (83.3) 
 
6 (2.6) 
6 (4.4) 
2 (16.7) 
0.037 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; *Fisher’s Exact Test; †Includes only those classified as betel nut chewers; 
§data for 1 participant missing; OGT = oral glucose tolerance; PBI = Piper betle inflorescence 
 
Using the three-category OGT, results indicated that betel nut chewing was not 
associated with OGT (Table 5.60).   Sample numbers were small, especially for the 
category of OGT >12.1 mmol/L and therefore, a two-category variable (<8.9 and 
≥8.9 mmol/L) with a cut-off of 8.9 mmol/L was created to investigate the association 
of betel nut chewing with OGT around this cut-off.  Using this cut-off, results 
indicated that none of the betel nut chewing variables were associated with an OGT 
>8.9 mmol/L (Table 5.61).   
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Table 5.60 Association of betel nut variables with IGT (OGT = 8.9 - 12.1 
mmol/L) and T2DM (OGT >12.1mmol/L) 
Variable Capillary OGT (mmol/L)  
Normal 
<8.9 
(N [%]) 
IGT 
8.9 - 12.1  
(N [%]) 
T2DM 
>12.1  
(N [ %]) 
p-value# 
Betel nut chewer 
No  
Yes   
 
73 (78.5) 
314 (83.5) 
 
15 (16.1) 
52 (13.8) 
 
5 (5.4) 
10 (2.7) 
0.329 
Betel nut chewing history 
Current  
Never  
Quit  
 
314 (83.5) 
64 (78.0) 
8 (80.0) 
 
52 (13.8) 
13 (15.9) 
2 (20.0) 
 
10 (2.7) 
5 (6.1) 
0 (0.0) 
0.409* 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
64 (78.0) 
8 (80.0) 
162 (82.3) 
146 (84.4) 
 
13 (15.9) 
2 (20.0) 
30 (15.2) 
22 (12.7) 
 
5 (6.1) 
0 (0.0) 
5 (2.5) 
5 (2.5) 
0.679* 
Betel nut chew composition† 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
194 (84.7) 
110 (81.5) 
9 (75.0) 
 
31 (13.5) 
20 (14.8) 
2 (16.7) 
 
4 (1.7) 
5 (3.7) 
1 (8.3) 
0.353 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; *Fisher’s Exact Test; †Includes only those classified as betel nut chewers; OGT 
= oral glucose tolerance; IGT = impaired glucose tolerance; T2DM = type 2 diabetes mellitus
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Table 5.61 Association of betel nut chewing with IGT  
Variable Capillary OGT (mmol/L) p-value# 
<8.9 (N [%]) ≥8.9 (N [ %]) 
Betel nut chewer 
No  
Yes   
 
73 (78.5) 
314 (83.5) 
 
20 (21.5) 
62 (16.5) 
0.254 
Betel nut chewing history 
Current  
Never  
Quit  
 
314 (83.5) 
64 (78.0) 
8 (80.0) 
 
18 (22.0) 
2 (20.0) 
62 (16.5) 
0.488 
Betel nut chewing status 
Never 
Ever 
 
64 (78.0) 
322 (83.4) 
 
18 (22.0) 
64 (16.6) 
0.245 
Quantity of betel nuts chewed/day† 
 ≤ 5 
6 - 9 
≥ 10 
 
162 (82.2) 
54 (81.8) 
98 (86.7) 
 
35 (17.8) 
12 (18.2) 
15 (13.3) 
0.544 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
64 (78.0) 
8 (80.0) 
162 (82.2) 
146 (84.4) 
 
18 (22.0) 
2 (20.0) 
35 (17.8) 
27 (15.6) 
0.666 
Betel nut chew composition† 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
194 (84.7) 
110 (81.5) 
9 (75.0) 
 
35 (15.3) 
25 (18.5) 
3 (25.0) 
0.538 
#The p-values were obtained from the Chi-square statistics, and assess the strengths of 
associations; †Includes only those classified as betel nut chewers; PBI = Piper betle 
inflorescence; IGT = impaired glucose tolerance; OGT = oral glucose tolerance 
 
As Table 5.62 demonstrates, none of the different types of physical activities 
included in this study had an association with abnormally high OGT (>11.0 mmol/L) 
but the number of minutes spent on MISFRA tended to influence OGT.   Those who 
did this type of activity for <150 minutes per week were less likely to have an OGT 
>11.0 mmol/L.  When OGT was divided into three categories none of the physical 
activities included in this study influenced OGT. 
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Table 5.62 Physical activity variables associated with possible T2DM   
Variable 
Non-T2DM 
≤11.0  
(N [%]) 
T2DM 
>11.0 
(N [ %]) 
p-value# 
Work-related MIA for at least 10 minutes 
No  
Yes 
 
177 (94.1) 
268 (95.7) 
 
11 (5.9) 
12 (4.3) 
0.443 
Minutes of work-related MIA/week 
<150 
≥150 
 
94 (96.9) 
153 (95.6) 
 
3 (3.1) 
7 (4.4) 
0.747* 
Performs  MISFRA for at least 10 minutes            
No  
Yes 
 
308 (94.2) 
138 (97.2) 
 
19 (5.8) 
4 (2.8) 
0.168 
Minutes of MISFRA/week 
<150 
≥150 
 
81 (100.0) 
53 (93.0) 
 
0 (0.0) 
4 (7.0) 
0.027* 
Work-related VIA for at least 10 minutes   
No  
Yes 
 
211 (95.0) 
234 (95.1) 
 
11 (5.0) 
12 (4.9) 
0.969 
Minutes of work-related VIA/week 
<75 
≥75 
 
44 (100.0) 
169 (93.9) 
 
0 (0.0) 
11 (6.1) 
0.128* 
Performs VISFRA for at least 10 minutes 
No  
Yes  
 
300 (94.0) 
145 (97.3) 
 
19 (6.0) 
4 (2.7) 
0.127 
Minutes of VISFRA/week 
<75 
≥75 
 
45 (100.0) 
99 (96.1) 
 
0 (0.0) 
4 (3.9) 
0.314* 
Walks to get to and from places for at least 
10 minutes  
No  
Yes  
 
 
53 (96.4) 
392 (94.9) 
 
 
2 (3.6) 
21 (5.1) 
1.000 
Minutes of walking/week 
<150 
≥150 
 
174 (95.6) 
181 (93.8) 
 
8 (4.4) 
12 (6.2) 
0.433 
Amount of physical activity/week 
Sufficient 
Insufficient/None 
 
306 (95.3) 
120 (93.8) 
 
15 (4.7) 
2 (6.2) 
0.494 
#The p-values were obtained from Chi-square statistics, and assess the strengths of 
associations; *Fisher’s Exact Test; OGT = oral glucose tolerance; MIA = moderate-intensity 
activities; MISFRA = moderate-intensity sports, fitness and recreational activities; VIA = 
vigorous-intensity activities; VISFRA = vigorous-intensity sports, fitness and recreational 
activities 
 
As shown in Table 5.63, SBP, BMI and waist circumference tended to be associated 
with abnormally high OGT (>11.0 mmol/L).  Those with a BMI ≥25 kg/m2 and a waist 
circumference above normal were more likely to have an abnormally high OGT.  
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Participants with SBP >130 mmHg were more likely to have an OGT >11.0 mmol/L.  
DBP did not affect OGT.   
 
Table 5.63 Medical factors associated with possible T2DM (OGT >11.1 
mmol/L) 
Variable Capillary OGT (mmol/L) p-value# 
Non-T2DM 
≤11.0  
(N [%]) 
T2DM 
>11.0 
(N [ %]) 
BMI category 
Underweight 
Normal 
Overweight 
Obese 
 
5 (83.3) 
140 (98.6) 
173 (95.6) 
125 (91.2) 
 
1 (16.7) 
2 (1.4) 
8 (4.4) 
12 (8.8) 
0.019 
BMI (kg/m2) 
<25 
 ≥25 
 
145 (98.0) 
298 (93.7) 
 
3 (2.0) 
20 (6.3) 
0.048 
Waist circumference 
Normal 
Above normal 
 
285 (96.6) 
159 (92.4) 
 
10 (3.4) 
13 (7.6) 
0.045 
SBP (mmHg) 
≤130 
>130 
 
311 (96.9) 
133 (91.1) 
 
10 (3.1) 
13 (8.9) 
0.007 
DBP (mmHg) 
≤80 
>80 
 
308 (95.7) 
136 (93.8) 
 
14 (4.3) 
9 (6.2) 
0.390 
#The p-values were obtained from Chi-square statistics, and assess the strengths of 
associations; OGT = oral glucose tolerance; BMI = body mass index; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; Normal waist circumference is ≤102cm (male) and 
≤88cm (female). 
 
Using the  three-category OGT to investigate which medical factors were associated 
with IGT (8.9 – 12.1 mmol/L), if any, results indicated that BMI was associated with 
IGT, with participants having a BMI ≥25 kg/m2 being more likely to have IGT (Table 
5.64).  Those with an SBP ≤130 mmHg appeared to be more likely to have IGT, 
while those with an SBP >130 mmHg were more likely to have an abnormally high 
OGT (>12.1 mmol/L).   
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Table 5.64 Medical factors associated with IGT and T2DM 
Variable Capillary OGT (mmol/L)  
p-
value# Normal 
<8.9 
(N [%]) 
IGT 
8.9 - 12.1  
(N [%]) 
T2DM 
>12.1      
(N [ %]) 
BMI category 
Underweight 
Normal 
Overweight 
Obese 
 
4 (66.7) 
129 (90.8) 
147 (81.2) 
103 (75.2) 
 
1 (16.7) 
13 (9.2) 
26 (14.4) 
27 (19.7) 
 
1 (16.7) 
0 (0.0) 
8 (4.4) 
7 (5.1) 
0.002* 
BMI (kg/m2) 
<25 
≥25 
 
133 (89.9) 
250 (78.6) 
 
14 (9.5) 
53 (16.7) 
 
1 (0.7) 
15 (4.7) 
0.007 
Waist circumference 
Normal 
Above normal 
 
251 (85.1) 
133 (77.3) 
 
36 (12.2) 
31 (18.0) 
 
8 (2.7) 
8 (4.7) 
0.103 
SBP (mmHg) 
≤130 
>130 
 
263 (81.9) 
121 (82.9) 
 
52 (16.2) 
15 (10.3) 
 
6 (1.9) 
10 (6.8) 
0.008 
DBP (mmHg) 
≤80 
>80 
 
264 (82.0) 
120 (82.8) 
 
48 (14.9) 
19 (13.1) 
 
10 (3.1) 
6 (4.1) 
0.762 
#The p-values were obtained from Chi-square statistics, and assess the strengths of 
associations; *Fisher’s exact test; OGT = oral glucose tolerance; IGT = impaired glucose 
tolerance; T2DM = type 2 diabetes mellitus; BMI = body mass index; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; Normal waist circumference is ≤102cm (male) and 
≤88cm (female). 
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Variables associated with OGT using the two- and the three-category OGT were 
entered into a univariate logistic regression model to determine the direction of 
association.  The variable MISFRA was dropped because the sample number of 
participants with OGT >11.0 mmol/L was too small to enter into the model. 
The results, outlined in Table 5.65, indicated that age was the important factor which 
influenced OGT.  Other factors were betel nut chewing, smoking and SBP.  As 
participant age increased, the likelihood of having an abnormally high OGT 
increased.  Participants aged 50 – 59 years and 60 years and older were four and  
eight times, respectively, more likely to have an OGT >11.0 mmol/L, compared to 
their younger counterparts.  
 Participants who never chewed betel nut had almost three times the odds of having 
an OGT >11.0 mmol/L.  Although the association between betel nut chew 
composition and OGT did not reach statistical significance, a significant association 
was observed when comparing chewing betel nut only with chewing the nut with 
both PBI and lime. Those who chewed betel nut only were seven times more likely 
to have an abnormally high OGT when compared with those who chewed the nut 
with PBI and lime.   
Those who had a high SBP had three times the odds of an abnormally high OGT.  
Having a BMI ≥25 kg/m2 and waist circumference above normal appeared to have 
an association with OGT >11.0 mmol/L but this did not reach significance.   
 
 
 
 
 
 
 
297 
 
 
Table 5.65 Univariate logistic regression analysis of factors 
associated with abnormally OGT (>11.0mmol/L) 
Variable Crude OR 95% CI p-value 
Age (years) 
<50 
50 - 59 
≥60 
 
1 (reference) 
4.88 
8.55 
 
 
1.88 – 12.66 
2.45 – 29.80 
<0.001 
 
0.001 
0.001 
Area of residence 
Urban 
Peri-urban  
 
1 (reference) 
0.44 
 
 
0.15 – 1.30 
0.137 
Number of fruit-eating days in a typical 
week 
0 - 1 
2 - 7 
 
 
1.98 
1 (reference) 
 
 
0.85 – 4.61 
0.114 
Betel nut chewer 
No  
Yes      
 
2.99 
1 (reference) 
 
1.24 – 7.23 
0.015 
Betel nut chewing status 
Never 
Ever 
 
2.87 
1 (reference) 
 
1.16 – 7.09 
0.022 
Betel nut chew composition† 
Betel nut, lime and PBI 
Betel nut ± PBI or lime 
Betel nut only 
 
1 (reference) 
1.73 
7.43 
 
 
0.55 – 5.47 
1.33 – 41.56 
0.072 
 
0.352 
0.022 
Current smoker 
No  
Yes 
 
3.58 
1 (reference) 
 
1.04 – 12.28 
0.043 
SBP (mmHg) 
≤130 
>130 
 
1 (reference) 
3.04 
 
 
1.30 – 7.11 
0.010 
BMI (kg/m2) 
<25 
≥25 
 
1 (reference) 
3.24 
 
 
0.95 – 11.09 
0.061 
Waist circumference 
Normal 
Above normal 
 
1 (reference) 
2.33 
 
 
1.00 – 5.44 
0.050 
The dependent variable was >11.0 mmol/L; OGT = oral glucose tolerance; PBI = Piper betle 
inflorescence; SBP = systolic blood pressure; BMI = body mass index; Normal waist 
circumference is ≤102cm (male) and ≤88cm (female) 
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Age was the most important factor which was independently associated with OGT 
(Table 5.66).   Participants aged 50 years and older were more likely to have an 
abnormally high OGT.   
Although tobacco smoking and SBP were independently associated with OGT, the 
associations did not reach statistical significance.  The sample numbers for the 
prevalence of OGT >11.0 mmol/L were small so valid conclusions could not be 
made.   
 
Table 5.66 Multivariate logistic regression analysis of factors 
independently associated with high OGT (>11.0 mmol/L). 
Variable 
 
n/N (%)* Adjusted OR 95% CI p-value 
Age category (years) 
<50 
50 - 59 
≥60 
 
11/387 (2.8) 
8/64 (12.5) 
4/20 (20.0) 
 
1 (reference) 
4.27 
5.39 
 
 
1.62 – 11.25 
1.32 – 21.91 
0.004 
 
0.003 
0.019 
Current smoker 
No  
Yes 
 
19/304 (6.3) 
3/164 (1.8) 
 
3.16 
1 (reference) 
 
0.91 – 11.04 
0.071 
SBP (mmHg) 
≤130 
>130 
 
10/321 (3.1) 
13/146 (8.9) 
 
1 (reference) 
2.31 
 
 
0.95 – 5.61 
0.065 
The dependent variable was >11.0 mmol/L; OGT = oral glucose tolerance; SBP = 
systolic blood pressure; *The column ‘n/N (%)’ shows the number (and percentage) 
of participants who had OGT >11.0 mmol/L within each variable. 
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5.3.4.6 Bioelectric impedance body composition measurement (% 
body fat) 
Statistical analysis of this variable and factors associated with it used >25.0% as a 
cut-off for males and >35.0% for females.  These cut offs were previously used in a 
recent  Vanuatu study.2  Other factors affecting percentage body fat were not 
considered in the analysis because the focus of the current research was on 
glycaemic control and betel nut chewing. 
Considering gender as a factor which affects percentage body fat, Chi-square 
analysis indicated that no demographic, lifestyle, physical and biochemical factors 
were associated with percentage body fat in males.  The only factor which was 
associated with percentage body fat in females was age.  As age increased in 
females, the proportion of those with percentage body fat >35% increased from 
those aged <30 to those 49 years of age.  A reduction in the proportion of those with 
percentage body fat > 35% was observed in those aged 50-59 years compared to 
those younger than 50 years.  For those in the age group 60-69 years, an equal 
proportion was observed in those with ≤35% and >35% body fat.  However the 
sample number of females in the latter age category was small (n=10, Table 5.67).   
None of the betel nut variables was associated with percentage body fat in both 
genders 
Table 5.67 Association of age with % body fat in females (p=0.003) 
Age category Percentage body fat [n (%)] 
≤35.0% >35.0% 
< 30 
30-39 
40-49 
50-59 
60-69 
220 (90.5) 
112 (88.2) 
56 (86.2) 
53 (88.3) 
5 (50.0) 
23 (9.5) 
15 (11.8) 
9 (13.8) 
7 (11.5) 
5 (50.0) 
The p-value was obtained from Chi-square statistics, and assesses the strength of 
association 
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5.4 Discussion 
5.4.1 Demographic characteristics 
The highest numbers of participants were in the age group ≤ 39 years.    The 
majority of participants were from the Highlands (37.7%) and the Southern (39.9%) 
regions.  The region from which the highest numbers of participants were originally 
from may be reflective of the sites used for the survey.  Some of the peri-urban sites 
used for this survey were squatter settlements belonging to those from the highlands 
region (Tari and Chimbu blocks) and Kerema in the Southern region. However, as 
discussed in Chapter IV, a cross-sectional study by Benjamin3 also reported that the 
highest numbers of participants were from the highlands (34.0%) and southern 
(37.7%) regions.  That study used a different recruitment process to the current 
study.  These results may be a reflection of which regions of PNG make up the 
majority of the Port Moresby population.  The finding of the present study, that the 
highest number of participants were 39 years or younger, is consistent with the 
finding from the study by Benjamin.3   The study reported that the highest number of 
participants were aged 40 years or younger.  This is also a reflection of the age-
specific population in PNG where >80% of the population is in the age group <50 
years.4 
Twenty five percent of participants reported being unemployed, although almost half 
of these were fit to work.  When homemakers, students and those who were in 
unpaid employment were included as one category (unemployed/non-paid), the 
largest proportion (56.4%) of participants was in this category.  This may be a 
reflection of the sites selected for the survey, urban drift, age groups included in this 
study, or extended family culture in PNG.  One third of the participants included in 
this study were from squatter settlements which are the main dwellings for those 
who migrate to the city, the majority of whom are either unemployed or low income 
earners.  However, due to other socioeconomic issues such as lack of appropriate 
housing for employees and high costs of housing rentals, a number of middle 
income earners may reside in these squatter settlements as well.  One of the 
challenges in the City of Port Moresby is urban drift especially by young people.  
Young people are migrating to the city with the hope of a better life.  Furthermore, 
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those who are unemployed may be immediate or extended family members of those 
who are employed and living in urban areas.   
Almost a quarter of participants did not complete primary basic education.  Getting 
at least basic primary education in PNG is not compulsory and PNG has had one of 
the lowest literacy rates in the Asia-Pacific region.5  However, the literacy rate for 
those aged 15 years and older has increased from 56% reported in the 2000 
census5 to 62.4% in 20116. There are many factors which influence whether or not a 
child attends school, one of which is cultural.   
5.4.2 Lifestyle factors 
5.4.2.1 Alcohol consumption 
The prevalence rate of alcohol consumption in the preceding 12 months observed in 
the present study was 41.4%.  This finding is similar to that reported by similar 
studies (STEPS survey) in PICs like Fiji7 and Nauru8 but is higher than that reported 
in the Solomon Islands9, the Marshall Islands10, Kiribati11 and Vanuatu12, with 
Vanuatu having the lowest prevalence.  The STEPS survey in the Cook Islands13 
however reported a higher (62.9%) prevalence of alcohol consumption. 
The finding that males are more likely to consume alcohol is consistent with many 
other findings in the PICs 7-16 and elsewhere.17-19 This study also observed that 
prevalence of alcohol consumption decreased with increasing age with those 
younger than 50 years having the highest prevalence.  Younger people tend to 
consume alcohol in social gatherings more than their older counterparts. Padrao et 
al18 however reported an increasing prevalence of alcohol consumption with 
increasing age in a Mozambique study in adults aged 25-64 years.  Also consistent 
with the Mozambique study is the finding of this present study that alcohol 
consumption is influenced by income among men.  The positive influence of 
completing tertiary education on alcohol consumption in the present study is also an 
indication that those who attain this level of education are more likely to have an 
income and therefore more likely to consume alcohol.  The Mozambique study also 
reported an increasing prevalence of alcohol consumption with increasing level of 
education but only in women. 
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5.4.2.2 Tobacco smoking 
The prevalence of tobacco smoking among participants of this study was 38.0%.  
The prevalence of tobacco smoking seen amongst this PNG cohort is similar to that 
reported in Melanesian countries like Fiji7 and the Solomon Islands9.  Another 
Melanesian country, Vanuatu12, however has reported a lower prevalence compared 
to PNG, Fiji7 and the Solomon Islands9.  Other PICs such as Nauru8 and Kiribati11 
have reported higher prevalence rates of smoking compared to PNG, Fiji, Vanuatu 
and the Solomon Islands. 
Smoking was influenced by gender, age and employment status.  The findings of 
the present study that males are more likely to smoke compared to females, is 
consistent with many other findings in the PICs 7-16 and elsewhere 17, 20, 21.  The 
influence of age on tobacco smoking in this study was similar to that seen in alcohol 
consumption.  As with alcohol, the prevalence of tobacco smoking decreased with 
increasing age which is consistent with another study.21  The finding that those who 
retired were more likely to smoke tobacco compared to the other employment status 
may have been due to the small sample number (n=10) of those who retired. Apart 
from this, those in paid employment were more likely to smoke which is consistent 
with another study.21  The present study was conducted in urban/peri-urban areas 
where tobacco products cost money compared to rural villages where smokers 
usually supplement manufactured tobacco products with home-grown tobacco.   The 
cost of manufactured tobacco products may have contributed to the statistically 
significant influence of paid employment on smoking.   
5.4.2.3 Vegetable and fruit consumption 
Dietary intake of vegetable and fruit reported by participants was poor.  More than 
90% of participants consumed <3 vegetable servings and 66.6% consumed <2 fruit 
servings per day in a typical week.  An average of 79.3% of participants consumed 
<5 combined fruit and vegetable serves.  This finding is similar to the Cook 
Islands13, a country with a much smaller land mass than PNG.  Amongst the 
Melanesian countries, vegetable and fruit consumption was much worse in the 
Solomon Islands9 with 93.6% consuming <5 combined fruit and vegetable serves.  
Vanuatu12, however has reported a better dietary intake compared to PNG and the 
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Solomon Islands9 with 61.8% consuming < 5 combined fruit and vegetable serves.  
Other PICs that have reported more than 90% consuming < 5 combined fruit and 
vegetable serves include Nauru8, The Marshall Islands10 and Kiribati11, with Kiribati 
reporting the worst (99.3%) vegetable and fruit consumption.   
Despite the majority of participants in this study consuming <3 vegetable serves of 
vegetables per day, almost half (47.6%) of those who consumed vegetables did so 
for 6-7 days in a typical week.  The reverse was seen in the number of days per 
week fruit was consumed.  As the number of days increased, the number of those 
consuming fruit decreased. 
The present study however requested the participants to think of a typical week on 
which they consumed fruit which may have under or overestimated fruit and 
vegetable consumption among the participants. 
 The most important factor which influenced the number of vegetable servings per 
day was area of residence and betel nut chewing.  Those in the peri-urban areas 
were more likely to consume ≥ 3 vegetable servings compared to their counterparts 
in urban areas.  This may be because those who live in peri-urban areas may have 
vegetable garden plots on vacant land in surrounding areas while those in urban 
areas rely mostly on vegetables bought from local vegetable markets or 
supermarkets.   
Those who did not complete basic education tended to be more likely to consume ≥ 
3 serves of vegetables compared to the other subgroups.  The influence of 
employment on vegetable servings was of borderline significance.  Both those in 
paid and self-employment were more likely to consume ≥3 vegetable servings 
compared to the other employment statuses. This may be a reflection of the cost of 
living in Port Moresby.   Those who did not complete basic education may have 
been living in peri-urban areas and had vegetable garden plots or they may have 
lived with immediate or extended family members who were employed.  Vegetables 
are generally cheaper than protein especially for those living in urban areas so for 
many who cannot afford protein in their meals, carbohydrates are usually consumed 
with vegetables only.  In general, the results observed in terms of vegetable and fruit 
consumption reflects a change in the diet of Papua New Guineans.  PNG people 
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used to have a vegetable-rich diet but as westernisation and urbanisation increases, 
there is an increasing trend to consume processed food.  Processed foods such as 
rice cost less to feed a large family compared to fresh sweet potatoes and green 
leafy vegetables from the markets.  These findings however may not reflect 
vegetable consumption in rural areas where those living in these areas thrive on 
subsistence farming. 
The number of fruit servings consumed per day in a typical week when fruit was 
consumed was influenced by level of education and employment status.  The 
influence of area of residence on fruit serving was of borderline significance.  Fruits 
sold in PNG are either imported from overseas or are grown in rural villages and 
sold in the supermarkets and local fresh food markets.  Imported fruits such as 
apples, pears and oranges are usually expensive and are therefore usually afforded 
by those who have some form of income.  This is reflected in the observations of the 
present study that those in paid employment were more likely to have ≥2 fruit 
servings per day.  There was a small difference in those who consumed ≥ 2 fruit 
servings between those in unpaid/unemployed and those who were self-employed.  
It is possible that unpaid/unemployed participants may have been living with those 
who were in paid employment or were involved in the informal economic sector to 
generate income.  The informal economic sector in Port Moresby encourages those 
who are unemployed to set up minimarkets to sell their goods or produce to make 
an income.  If the unpaid/unemployed were involved in the informal economic 
sector, vegetables or fruits may have been commodities they were selling for 
income.  Those involved in this sector often buy fresh produce from rural villagers 
and resell them in the urban markets or their residential minimarkets.  Umezaki et 
al22 in a study conducted in three PNG settlements found that certain informal sector 
activities of those in settlements were generating more money per day in 
comparison to other settlers who were employed in the formal sector.  Residents in 
settlements employed in the formal sector may mostly have been low income 
earners as observed by Umezaki et al.  That study also reported that energy intake 
but not nutrient intake was closely associated with per adult net earnings in a week.   
When comparing lifestyle characteristics such as alcohol consumption, tobacco 
smoking and vegetable and fruit intake amongst PICs with that of this study cohort, 
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the findings of this study cohort may not reflect lifestyle characteristics of PNG as a 
whole as the PNG cohort in this study was made up of those from urban and peri-
urban dwellings in Port Moresby, the largest city in PNG.  The STEPS surveys in 
other PICs included those from the rural villages in those countries.  
5.4.2.4 Physical activity  
The most common physical activity was walking for travel which is consistent with a 
study among urban black Soweto women.23  The finding that the most common type 
of physical activity reported by participants of this study was walking to get to and 
from places may be a reflection of the inefficient public transport system in Port 
Moresby.  Public buses usually run on the main roads but not through streets of the 
suburbs.  Many of those using public transport therefore have to walk fairly long 
distances to nearest bus stops.  Furthermore, public buses are often overloaded and 
lack maintenance which discourages use of public transport services.   
Walking for travel was more common among the unpaid/unemployed and levels of 
education lower than tertiary which may be a reflection of income, affordability of 
public transport or owning a motor vehicle.  As the level of education affects the 
likelihood of employment and the type of employment, the subgroup who completed 
tertiary education are more likely to have high paying jobs and therefore are more 
likely to own vehicles or be provided transport by their employers.  The employed 
(paid and self-employed) are therefore less likely to walk to get to and from places.   
Sixty eight percent of participants reported doing sufficient physical activity (≥ 75 or 
150 minutes of VIA or MIA respectively per week).  The high prevalence of sufficient 
physical activity was contributed to largely by ‘walking” as a physical activity.  The 
amount of physical activity was influenced by area of residence and region of origin.  
Those living in urban areas were more likely to do more sufficient physical activity 
compared to those in peri-urban areas.  This may be due to more availability of 
sports, fitness and recreational facilities in urban areas but not peri-urban areas.   
Age significantly influenced sports, fitness and recreational activity.  The prevalence 
of participating in sports, fitness and recreational physical activity decreased with 
increasing age.  Age also inversely influenced work-related VIA; that is as age 
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increased, the prevalence of undertaking work-related VIA decreased.  These 
findings are expected because as age increases, the intensity of physical activity a 
person can comfortably perform also decreases.   
Employment had a significant influence on work-related MIA with the 
unpaid/unemployed and those who were self-employed being more likely to do 
work-related MIA.  This may be a reflection of the type of work done by those in 
regularly paid employment compared to those are unpaid/unemployed and those 
self-employed.  Those in unpaid/unemployed may have been involved in doing 
household chores such as cleaning houses or gardening.  This also reflects the 
prevalence of homemakers in this study.  Those who were self-employed were less 
likely to participate in sports fitness and recreational activities compared to those 
who were unpaid/unemployed and in regularly paid employment.  The most obvious 
reason for those self-employed not participating in sports, fitness and recreational 
activities may have been due to time or financial constraints to undertake such 
activities.  Although this study did not specify the types of jobs done by those who 
were employed, it is likely that those who were self-employed were working on a 
need basis for non-specific duration of time.  Those who were self-employed were 
also less likely to do sufficient physical activity and this may be an indirect indication 
of the type of jobs done by those who are self-employed. 
5.4.3 Physical measurements 
5.4.3.1 Blood pressure 
Twenty eight per cent of participants of this study had hypertension.  This is similar 
to that found in Fiji7, lower than that in Vanuatu12 and the Cook Islands13 and higher 
than in the Solomon Islands9, the Marshall Islands10, Kiribati11 and Nauru8.  
However, in these PICs, high blood pressure (BP) cut-offs were higher (SBP > 140, 
DBP >90 mmHg) than that used for this study (SBP >130, DBP>80 mmHg) and 
therefore the prevalence may have been lower if higher BP cut-offs were used for 
the PNG cohort.  
The likelihood of a high SBP and DBP increased with age but was slightly lower in 
those aged 60 years or more possibly because of the small sample of participants in 
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this age group. The finding that the likelihood of high SBP and DBP are associated 
with increasing age is consistent with other studies.23-26  It is known that as age 
increases, the risk of high BP increases as a consequence of the ageing process in 
organ systems.27-29.  Other studies have reported that as age increases, SBP 
increases while DBP either decreases or is maintained.30-32  
The odds of having a high SBP and DBP significantly increased with increasing BMI 
and waist circumference which is consistent with other studies 24, 26, 33-35 reporting an 
association of obesity or weight gain with hypertension. 
  The finding that consuming ≥2 serves of fruit has a beneficial effect on systolic 
blood pressure is consistent with other studies demonstrating an association of fruit 
consumption with blood pressure.36, 37.  The study by Gibbons36 however used six to 
eight servings of potassium rich fruits in a follow up study of 6 weeks of African 
Americans.  Berry et al 38 however reported that increased potassium intake from 
fruits and vegetables did not lower BP in 57 UK men and women.   
The present study found that occupational physical activity did not influence SBP but 
moderate and vigorous-intensity leisure-time physical activities did with an increase 
in likelihood of a high SBP in those who did not perform these activities. Further, not 
taking part in all of the different physical activities included in this study increased 
the likelihood of having a high DBP.  The finding that leisure-time physical activity 
reduces blood pressure is consistent with other findings.39-41  However, undertaking 
work-related MIA for >150 minutes per week was associated with an increased risk 
of high DBP; for reasons which are unclear.  Diastolic blood pressure is affected by 
peripheral resistance and increases with increased resistance.  It is not known why 
this result was observed.  It may have arisen by chance. 
Living in urban Port Moresby for 10 years or more was associated with a high DBP.  
This is in agreement with another study 42 that longer duration of residing in urban 
areas increases the likelihood of high BP.  This may be related to modernisation of 
way of life in urban areas increasing risk factors for high BP such as sedentary 
lifestyles, obesity and dietary changes.43   Physical activity, obesity and diet are 
major influences of high blood pressure.44-47  
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5.4.3.2 Measures of obesity and adiposity 
In the present study, obesity was determined by BMI, waist circumference and 
percentage body fat.   Using BMI, more than 60% of participants were either 
overweight or obese (38.6% overweight, 26.8% obese).  The prevalence of 
abnormally high waist circumference was 34.9%. 
The pattern of obesity indicated by BMI is consistent with findings of two studies3, 48 
conducted in PNG by Benjamin.  The prevalence of overweight observed in this 
study is similar to that reported in the Marshall Islands10 but higher than that 
reported in Vanuatu12.  The prevalence of obesity (BMI ≥ 30 kg/m2) is much higher 
than that reported in Fiji7.  Other PICs have reported higher prevalence rates of 
obesity than PNG. 8, 11, 13, 15, 16 
BMI is a measure of general obesity.  In the present study, it was influenced by 
demographic factors such as age, gender, employment status and region of origin, 
and lifestyle factors such as smoking, alcohol consumption, betel nut consumption, 
physical activity and diet.  After adjusting for each other, the important independent 
and significant factors which influenced BMI were region of origin, smoking, dietary 
factors, physical activity and betel nut chewing.   The loss of significance of the 
influence of gender on BMI after adjusting for other confounding factors suggests 
that there are other important interacting factors affecting BMI in this study 
population. 
Waist circumference is a measure of central obesity.  After adjusting for each other, 
the significant independent factors affecting waist circumference were age, gender, 
area of residence, betel nut chewing, physical activity, and frequency of vegetable 
intake.  Although level of education was associated with waist circumference, it was 
not an independent factor.  The same was observed for smoking, alcohol, vegetable 
servings, and frequency of fruit consumption.   
Percentage body fat is a measure of adiposity.  There are many factors which are 
known to affect percentage body fat and therefore acceptable values in different 
populations have been reported to vary.  A literature search for current 
recommended acceptable percentage body fat values for Papua New Guineans did 
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not find any.  Therefore, the acceptable cut-off values for percentage body fat used 
study2 of a Melanesian population of Vanuatu were used for analysis.  In the present 
study, none of the demographic, lifestyle, physical and biochemical factors affected 
percentage body fat in male participants.  The only factor which appeared to 
influence percentage body fat in female participants was age. Age has been 
reported to be one of the most important factors influencing percentage body fat.49, 50 
The common significant factor which affected BMI and waist circumference was 
physical activity.  Performing VISFRA was independently associated with a normal 
waist circumference suggesting that MIA and occupational physical activity are not 
sufficient to have a beneficial impact on waist circumference in this population, 
especially in the presence of usual dietary patterns.  Surprisingly, performing 
leisure-time physical activity had a beneficial effect on BMI while occupational 
physical activity had an adverse effect.  The duration of work-related VIA also had 
an independent adverse effect on BMI.  This may be due to increased food intake 
influenced by culture. As already discussed in Chapter IV, in PNG, it is usual or 
cultural for the person who does vigorous-intensity work to be served large 
quantities of food as a token of appreciation for bringing food or money home for 
family, for example.  This is also observed during feasting where those who work 
hard are appreciated with large quantities of food.  Similar appreciation is not usually 
given to those involved in leisure-time activity.  Therefore cultural reasons may be 
the reason for such a finding. (personal knowledge) 
The finding that females were more likely to have a waist circumference in this 
cohort is the same as that in the T2DM cohort of this study.  Possible reasons for 
the association of gender with waist circumference above normal have already been 
discussed in Chapter IV (Section 4.4.4.2).  
Age had an independent influence on waist circumference in this cohort compared 
to the T2DM cohort where gender appeared to be the most important adverse 
factor.  The highest association of age with waist circumference was in the age 
group 50-59 years with no difference between those aged <50 and ≥60 years.  As 
age increased, the likelihood of an elevated percentage body fat increased with age 
with a peak at 50-59 years and decreased from 60 years.    Smoking only had an 
independent beneficial effect on BMI and not waist circumference.   This suggests 
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that smoking may confer a protective effect on BMI.  The likelihood of having a BMI 
≥25 kg/m2 was doubled in those who quit and tripled in those who never smoked.  It 
is well known that smoking is associated with a reduction in food intake and 
subsequent lower body weight. The finding that those who quit smoking have a high 
BMI is consistent with a follow up study by Munafo et al51 and other studies52 which 
found that BMI in those who quit smoking increases over time.  For those who quit 
and return to smoking, research has also shown weight loss after returning to 
smoking.52 The beneficial influence of smoking on BMI is most likely a result of 
appetite suppression by nicotine in cigarettes53 which is probably mediated by the 
central nervous system54 and levels of leptin 55.   In the study by Moffat et al52, an 
increase in percentage body fat was observed in those who quit smoking but after 
30 days of quitting, the percentage remained the same up to the 60th day.   
A surprise finding from this study is that eating fruit for less than 2 days a week had 
a beneficial effect on BMI even after adjusting for other confounding factors 
suggesting an increase in frequency of fruit consumption may have an adverse 
effect on BMI.   Although consumption of vegetable did not have a significant 
influence on BMI in the univariate analysis, it became a significant independent 
factor when it was entered into the multivariate logistic regression model with other 
confounding factors.  Consuming vegetables for 6 to 7 days in a week had a 
beneficial influence on BMI. Although this finding is based on the number of days 
which may not accurately quantify vegetable consumption, this suggests that an 
increased frequency of vegetable consumption has a beneficial effect on BMI.  
Studies have reported conflicting results on the association of vegetable and fruit 
intake with weight gain.56-58  The conflicting findings on the association of vegetable 
and fruit consumption with measures of obesity may partly be due to the fact that 
weight gain or obesity is multifactorial. 
PNG has different indigenous groups.  Although classified as Melanesians, those 
from the Central Province are more Polynesian than Melanesian and therefore may 
be of different ethnicity.  The finding that those from the Southern region (mainly 
from Central Province), were more likely to be leaner (BMI) than those from other 
regions is surprising as it has been reported that Polynesians have a stronger 
association with increased body weight.  Perhaps the frequent visits to rural villages 
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by those from the Southern region (Gulf and Central Provinces) living in urban Port 
Moresby confers a beneficial effect on BMI as a consequence of interchange 
between refined foods and a traditional diet while in the village.  Physical activity 
may also increase while in the village.  The study by Benjamin showed that 52% of 
rural villagers from the Central Province had a BMI <20kg/m2.48   
5.4.3.3 Potential mechanisms linking obesity to high blood pressure 
BMI and waist circumference are measures of adiposity which were significantly 
associated with high BP (both SBP and DBP) and this relationship remained after 
adjusting for other confounders such as age.  More than 50% of those included in 
this study were overweight or had increased adiposity.  This suggests a high risk of 
cardiovascular and metabolic disorders in this population 
There are many potential mechanisms linking obesity to high BP.  These include 
dietary factors, metabolic, endothelial and vascular dysfunction, neuroendocrine 
imbalances, sodium retention, glomerular hyperfiltration, proteinuria and 
maladaptive immune and inflammatory responses.59, 60.  Adipose tissue is the site of 
production of important molecules and hormones such as adiponectin, leptin, 
resistin, TNF and IL-6, all of which have been linked to cardiovascular and metabolic 
disorders.  Visceral adipose tissue not only is the site of altered secretion for these 
molecules and hormones but also becomes resistant to insulin and leptin.59.  Recent 
studies have also reported a role of gut microbiota on metabolism which may affect 
BP.61, 62  
5.4.4 Betel nut chewing 
5.4.4.1 Prevalence of betel nut chewing 
The present study reports an 80% crude prevalence of betel nut chewing amongst 
Papua New Guineans in NCD, Port Moresby.  The prevalence of betel nut chewing 
in this study is much higher than what was reported by an earlier study3 conducted 
in the same district.  The low prevalence of betel nut chewing (13.0%) reported by 
Benjamin3 may be low because the majority (78%) of participants were Seventh Day 
Adventist church followers who usually do not chew betel nut.  The prevalence of 
betel nut chewing varies in different regions or within countries where the habit is 
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practised. The prevalence rates of betel nut chewing from STEPS surveys 9, 10, 12, 63 
in the Pacific Islands have been reported to range from 0.1% to 62.6% making PNG 
the highest consumers of betel nut in the region.  Another smaller study consisting 
315 participants in the Solomon Islands reported a prevalence rate of 76.8%.64   In 
Taiwanese population-based studies17, 65, 66 including men only, the prevalence of 
betel nut chewing reported ranges from 14.4% to 20.4% .  These studies indicated 
that women had very low prevalence rates of betel nut chewing; findings which are 
different to what have been observed in PNG.  In Bangladesh67, the prevalence 
reported in both men and women in selected rural areas was 33.2% and a Sri 
Lankan study68 reported an average of 9.6% in males living in both rural and urban 
residences (rural 17.6%, urban 1.7%).    These figures show a large variation in 
prevalence rates of betel nut chewing not only between different countries but also 
within countries. 
5.4.4.2 Demographic factors associated with betel nut chewing 
The present study indicated that the factors associated with betel nut chewing were 
age, gender, level of education, area of residence and region of origin.  Other 
factors reported by other studies to be associated with the prevalence of betel nut 
chewing include types of employment65, 67, income level69, level of education65, 67, 69, 
physical activity65, smoking17, 65, 67, 69, 70, alcohol consumption17, 65, 68-70 and, fruit and 
vegetable consumption17, 65.   
Results of this study support the finding by Yen et al 65 that the prevalence of betel 
nut chewing is higher in lower levels of education.  The study by Yen et al reported 
that those with less years of education, those who are unemployed and those who 
are manual labourers or have service trade jobs are more likely to chew betel nut 
compared to teachers, officer holders, military personnel and business or 
professional workers.  This study did not report details of types of employment but 
employment status did not influence prevalence of betel nut chewing. As previously 
discussed in Chapter IV, betel nut chewing is a social habit and betel nut is usually 
shared.   A possible reason for the higher prevalence of betel nut chewing amongst 
those with lower levels of education than tertiary education is that those with lower 
level of education may be more likely to sell betel nuts to make an income.   
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The finding that males were more likely to chew betel nut in this study is consistent 
with findings elsewhere 17, 65, 66.  The prevalence of betel nut chewing among males 
was only slightly higher than that of the females.  The small difference in prevalence 
of betel nut chewing between males and females is similar to that found in 
Bangladesh.67  Other studies conducted in different population groups have reported 
large differences in prevalence of betel nut chewing among males and females.17, 65, 
66, 69, 71, 72  
Urban dwellers were more likely to chew betel nut compared to peri-urban dwellers.  
There is now a ban on the sale of betel nuts in places other than designated 
markets out of the urban areas of Port Moresby.  Furthermore, the ban of betel nut 
chewing in public places has been reinforced.  This study was conducted before the 
ban which came into effect in 2013.  Before the current ban on betel nut chewing in 
public places and sale of betel nut at residential premises, many residences in urban 
areas had mini-markets within their premises.  Most of these mini markets were 
selling betel nuts and therefore increased the availability.  The unemployed or 
homemakers living in those residences often manned the mini markets.  The cost of 
a betel nut can be expensive during seasons when the supplies are low and 
therefore it is mostly those who can afford betel nut who chew or buy and share with 
those who cannot afford it.   
Region of origin may have influenced betel nut chewing because of increased 
availability and affordability.  In terms of the influence of region of origin on betel nut 
chewing, those from the Southern region were more likely to chew betel nut.  The 
most important reasons for this are firstly because betel nut trees are grown in rural 
villages and those from the region are more likely to have access through relatives 
or family living in the rural villages.  Secondly, betel chewing has been practised in 
the Southern region for a long time.    Betel nut is grown locally in the rural villages 
of Central Province and the nearby Gulf province which is the only other Southern 
region province connected to Port Moresby by road.  One of the sites for this study 
was the Kerema block of which its inhabitants are from Gulf province, the only betel 
nut growing province connected to Port Moresby by road.  Those from the Highlands 
region were statistically significantly less likely to chew betel nut.  This is because 
betel nut trees do not grow in higher altitudes such as that of the highlands of PNG.  
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This habit is a recent introduction to those from the highlands region by those from 
the coastal regions.   
As age increased, the prevalence of betel nut chewing decreased therefore the habit 
is more common in those aged <50 years.  This may be due to dental reasons.  
Chewing betel nut requires fairly good sets of strong teeth as some of the nuts 
chewed may be hard in texture.  This study found that betel nut chewing was 
significantly associated with the number of intact teeth a chewer has with those 
missing some teeth having a less likelihood of chewing betel nut.  The finding of this 
study that the prevalence of betel nut chewing decreased with increasing age or  
that younger people are more likely to chew betel nut is consistent with findings in 
other PICs9, 12, 63 and elsewhere 65, 66, 69, 70, 72 where the habit is practised.   In 
countries other than those in the Pacific islands, the current finding that betel nut 
chewing is more common among younger people are different to what has been 
reported in Sri Lanka68 and rural Bangladesh67 . These studies reported that the 
prevalence of betel nut increased with increasing age and the highest was among 
those aged >65 and > 50 years, respectively.  The Sri Lankan study however 
included only male participants.   
5.4.4.3 Lifestyle factors associated with betel nut chewing 
Alcohol consumption, smoking, and vegetable and fruit consumption were 
associated with betel nut chewing.  Of these, alcohol consumption and smoking 
were independently associated with betel nut chewing after adjusting for other 
factors.  Alcohol consumption and smoking are also social habits like betel nut 
chewing.  In PNG, betel nut chewing is usually followed by smoking or vice versa. 
The finding that smoking is associated with betel nut chewing has been reported 
elsewhere 65, 67, 69, 70.  Many alcohol consumers in PNG usually consume their 
alcohol with friends or relatives in a group at any one time when alcohol is 
consumed.  During these times of consuming alcohol, betel nut and tobacco 
products are also shared and used. It is therefore not surprising that the three habits 
were associated with each other.  Other studies have also reported the association 
of betel nut chewing with alcohol. 17, 65, 68-70 
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The finding that betel nut chewers are not eating the recommended amounts of fruit 
and vegetable is of concern.  Instead of eating fruit for example, betel nut chewers 
are probably chewing betel nut.   The habit of chewing betel nut requires money for 
most and money is probably spent on betel nut instead of a healthy meal consisting 
of vegetables and instead of snacking on fruits, betel nut is chewed.  The 
observation that betel nut chewers are eating less vegetable has been reported 
elsewhere.65  
5.4.4.4 Physical factors associated with betel nut chewing 
This study indicated that betel nut was negatively associated with BMI and waist 
circumference.  Non-betel nut chewers were more likely to be overweight or obese 
and have an abnormally high waist circumference compared to those who did.  
Those who quit the habit were least likely to be obese but the sample number for 
this subgroup was small.  The finding that betel nut chewers were less overweight or 
less obese is different to that reported by other studies among Taiwanese. 17, 65, 69-73  
Heck et al67 however did not find any association of betel nut chewing with BMI or 
overweight.   
The finding that betel nut chewing has a beneficial effect on BMI and waist 
circumference is contradictory to a study by Iqbal et al74 investigating the effects of 
betel nut on cardiovascular risk factors in a rat model.  That study reported that betel 
nut ingestion did not affect mean body weights.  The finding that betel nut chewing 
may have a beneficial effect on BMI and waist circumference may be partly 
supported by two animal studies which demonstrated cholesterol-lowering effects of 
betel nut extracts. 75, 76  The mechanism by which betel nut is thought to lower 
cholesterol is by decreasing cholesterol absorption through inhibition of pancreatic 
cholesterol esterase 75, 76 and intestinal acyl-CoA cholesterol acyltransferase 76. 
Chewing betel nut was associated with lower SBP and DBP.  Those who never 
chewed betel nut were more likely to have an abnormally high SBP and DBP.  This 
finding is different to that reported by Heck et al67 who found that betel nut chewing 
increased both SBP and DBP or high BP.17  In the study by Yen et al65 betel nut 
chewing was associated with high BP and in another study it was not.73  Tseng73 
reports that the prevalence of hypertension was significantly lower in the chewers 
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compared to non-chewers who were males but in women the prevalence of 
hypertension remained significantly higher in chewers than in non-chewers.  
However the differences were small for both SBP and DBP in the chewing groups in 
both genders.   The results of these studies indicate inconsistencies on the 
association of betel nut chewing with blood pressure.  Inokuchi et al77 reported an 
antihypertensive effect of a tannin fraction from betel nut in rats.  Oral administration 
of the betel nut fraction produced a dose-related antihypertensive effect in 
spontaneous hypertensive rats; an effect which was comparable to captopril at 
doses of 30 and 100 mg/kg.  In the same study77, intravenous treatment produced a 
dose-related inhibition of the pressor responses to angiotensin I and II.  Differences 
in effects of betel nut chewing on BP with regards to angiotensin effects may be 
partly explained by polymorphisms in the angiotensin converting enzyme gene.  
Chung et al78 reported that betel nut chewers with the DD genotype had significantly 
lower BP, pulse pressure and prevalence of hypertension compared to those with II 
or ID genotypes.  It is well known that genes interact with the environment and 
therefore environmental factors may be contributing to differences in the association 
of betel nut with BP.  Another study 79 which supports the antihypertensive effect of 
betel nut shown in this study is one conducted by Gilani et al.  That study reported 
beneficial activities of betel nut on the cardiovascular system.  The benefits reported 
by the study were hypotensive, cardiosuppressant, endothelium-dependent 
vasodilator and antiplatelet activities.  Gilani et al 79 demonstrated a dose-dependent 
atropine-sensitive fall in the arterial blood pressure of normotensive rats under 
anaesthesia.  That study further reported that only arecoline showed atropine-
sensitive cardio-suppressant and vasodilator effects while catechin exhibited 
atropine-insensitive vasodilator and antiplatelet effects.  This indicates that different 
chemical constituents of betel nut have different effects on the cardiovascular 
system.  A study investigating the effects of PBL on blood pressure further supports 
the antihypertensive effect of betel nut chewing. 80  Gilani et al80 from that study 
suggest that PBL reduces blood pressure by blocking calcium channels.  Lin et al, in 
a study investigating the haemodynamic effects of betel nut showed that betel nut 
reduced DBP; a finding that is consistent with the present study.81 
Physical activity was strongly associated with betel nut chewing.  Betel nut chewers 
were more likely to do physical activity compared to their counterparts.  This finding 
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is different to that from a Taiwanese study65 which reported that less physical activity 
was reported among betel nut chewers. 
5.4.5 Glycaemic control 
The study reports a 17.8% prevalence of fasting hyperglycaemia and a 4.9% 
prevalence of post prandial hyperglycaemia.  The prevalence rates for IFG and IGT 
were 22.1% and 14.4% respectively indicating a high prevalence of pre-diabetes in 
this study cohort. The study by Benjamin3 reported a slightly lower prevalence rate 
(13.0%) of fasting hyperglycaemia.  That study used a higher FCBG cut off of 
7.0mmol/L compared to the 6.1mmol/L used by the present study.  The slightly 
lower prevalence therefore may have been due to the higher FCBG used by 
Benjamin. 
5.4.6 Factors associated with fasting and post prandial 
hyperglycaemia 
5.4.6.1 Influence of demographic factors on glycaemic control 
According to FCBG and OGT, the only statistically significant demographic factor 
associated with both fasting and postprandial hyperglycaemia, respectively, was 
age; those aged 60 years and older were more likely to have hyperglycaemia or 
T2DM compared to those who were younger.    After adjusting for other 
confounders, age continued to be associated with fasting hyperglycaemia. This is 
consistent with findings from studies in Fiji.82, 83.  It is well known that the risk of 
T2DM increases with increasing age.  This may be due to declining beta cell 
function either as a result of ageing or longer exposure to risk factors of T2DM.84  
Those aged 50-59 years of age were more likely to have IFG and IGT.  The finding 
that this age group (50-59 years) is more likely to have IFG and IGT may partly 
explain why those aged 60 years or older in this study were more likely to have 
T2DM.  IFG and IGT eventually progress to T2DM.  DeFronzo et al84 reported that 
the mean age of participants with IGT was 53.3±0.5 years which is consistent with 
the present study.  That study84 investigated the determinants of glucose tolerance 
in a study cohort with IGT and demonstrated that the main determinant of 
progression of normal glucose tolerance to IGT was progressive beta cell failure.   
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5.4.6.2 Influence of lifestyle factors on glycaemic control 
Those consuming vegetables for 5 days or less in a typical week were more likely to 
have IFG and T2DM.  As the number of days during which vegetables were 
consumed was reduced, the prevalence of IFG and T2DM increased.  Consuming 
≥2 fruit servings appeared to be associated with IFG but this did not reach statistical 
significance.  Studies investigating the beneficial effects of fruit and vegetable intake 
on blood glucose control have reported conflicting results which may be largely due 
to the methodologies used and may also suggest that vegetable and fruit 
consumption is not a stronger predictor of diabetes risk.  Cooper et al85 in their 
adjusted analyses reported that quantity of vegetable intake was inversely 
associated with T2DM; an association which was not observed for fruit intake.  This 
is consistent with findings by Villegas et al 86 in a cohort of Chinese women.  Other 
studies 86-89 have also reported the beneficial influence of vegetable consumption on 
glycaemic control.  The present study found that the number of days vegetables 
were consumed in a week was inversely associated with T2DM which is consistent 
with studies reporting a beneficial association of vegetable intake on glycaemic 
control.  A meta-analysis90 reported that the amount of green leafy vegetables in an 
individual’s diet could help reduce the risk of T2DM but did not find any significant 
association of fruits, vegetables or a combination of both with the incidence of 
T2DM.  Other studies 87, 88, 91 have found a beneficial association of fruit consumption 
either on its own or in combination with vegetables on glycaemic control.  Cooper et 
al85 found that a greater variety of fruit rather than the quantity was inversely 
associated with incident T2DM after adjusting for other factors. 
The only type of physical activity that was significantly associated with fasting 
hyperglycaemia was work-related VIA.  Unexpectedly, those who were involved in 
work-related VIA were likely to have fasting hyperglycaemia.  This may be due to 
compensatory increases in food intake which may be partly due to cultural reasons 
(personal knowledge) as previously discussed in Chapter IV (Section 4.4.6.2).  
Performing VISFRA was not associated with glycaemic control but the amount of 
VISFRA per week was associated with glycaemic control.  Those who did VISFRA 
for ≥75 minutes per week were appeared to be more likely to have hyperglycaemia. 
The association however was of borderline significance.   
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In a genome-wide association study, Li et al92 demonstrated that genetic 
polymorphism in rs12104705 of a glucagon gene (GCG) may interact with physical 
activity to modify the risk of T2DM.  The study suggests that moderate and high 
physical activity with the C-C genotype may be associated with decreased risk of 
T2DM compared with low physical activity with the genotype.  The GCG gene 
encodes glucagon proteins GLP-1, GLP-2 and oxyntomodulin which are essential 
for energy metabolism. 92  Genetics may therefore play a role in differences 
observed in association of lifestyle factors such as physical activity with 
development of T2DM. 
5.4.6.3 Influence of physical measurements on glycaemic control 
Those with a BMI ≥25 kg/m2 and those with a waist circumference above normal 
were more likely to have FCBG and post prandial hyperglycaemia.  This finding is 
consistent with studies elsewhere.82, 93   An earlier study82 in the same ethnic group 
of Fijian Melanesians showed BMI to be one of the most important predictors of 
T2DM.  A 16-year follow-up of female nurses in England found that the most 
important risk factor for T2DM was BMI. 94  The study showed that as the BMI 
increased from 30.0-34.9 kg/m2 to ≥35 kg/m2, the relative risk of diabetes increased 
from 20.1% to 38.8% respectively.  T2DM in those who are not obese may be 
contributed to by predominantly β-cell dysfunction rather than insulin resistance.95  
High BP was not associated with fasting hyperglycaemia but those who had a higher 
than normal SBP were significantly more likely to have post prandial 
hyperglycaemia.  High SBP appeared to have an independent association with OGT 
which was of borderline significance.  Studies have shown that OGT is a strong 
predictor of cardiovascular risk.96-98  Tomiyami et al99 demonstrated that abnormal 
glucose tolerance determined by using OGT may have a direct pathological 
association with endothelial dysfunction.  That study included participants with 
borderline hypertension.  Endothelial dysfunction is associated with cardiovascular 
risk. 100  The present study also observed that obesity was associated with high SBP 
and postprandial hyperglycaemia which therefore increases the risk of high SBP in 
the present study cohort. 
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5.4.6.4 The influence of betel nut chewing on glycaemic control 
The present study did not find any association between betel nut chewing and 
fasting hyperglycaemia but found a beneficial influence on post prandial 
hyperglycaemia.  Further, betel nut chewing was not associated with IFG.  This 
finding is different to an earlier PNG study3 where fasting hyperglycaemia was more 
prevalent in betel nut chewers.  That study however included a small sample of betel 
nut chewers. 
Using fasting blood glucose of ≥ 6.1 mmol/L to indicate hyperglycaemia, studies in 
Taiwan among male betel nut chewers have reported an association between betel 
nut chewing and hyperglycaemia.65, 66  These studies reported betel nut chewers 
were more likely to have hyperglycaemia.   Tung et al66 further reported a dose-
dependent association of betel nut chewing with T2DM.   
Tseng73 classified chewers as ever or never chewers and reported that the 
incidence rate for newly diagnosed T2DM was higher in ever chewers than never 
chewers and the incidence rates increased with increasing age peaking at age 60-
69 years.  Further the incidence rate in never chewers continued to increase in 
those aged ≥70 years compared to ever chewers which peaked at age 60-69 years. 
It is most likely that increasing prevalence of incident T2DM may have been due to 
increasing age.  The present study found that age was the most important 
demographic factor influencing both fasting and post prandial glycaemic control with 
risk increasing with increasing age.  The study by Tseng did not adjust for other risk 
factors for T2DM such as age; the only confounding factor which was examined 
using Chi-square statistic was obesity. 
Those who quit and those who never chewed were more likely to have 
hyperglycaemia or T2DM suggesting that betel nut chewing appears to have a 
beneficial effect on blood glucose levels.  Participants who chewed betel nut only 
were more likely to have hyperglycaemia or T2DM compared to those who chewed 
betel nut with PBI and lime or with PBI.   
The finding that betel nut chewing has a beneficial influence on blood glucose is in 
contrast to other studies which have found that betel nut or arecoline causes 
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hyperglycaemia. 101-103.  Iqbal et al74 reported no effect on glucose in a 
normoglycaemic rat model. 
Dasgupta et al104 demonstrated an acute hyperglycaemic effect of arecoline but a 
hypoglycaemic effect after chronic administration intraperitoneally in mice.  This 
effect has been attributed to the effect of betel nut on adrenal function.  
Chempakan105 in a small sample of humans also reported a hypoglycaemic effect of 
arecoline after subcutaneous administration.  Other studies have also reported 
hypoglycaemic effects of not only arecoline but also some unidentified chemical 
constituents in PBL. 106, 107 
 5.5 Conclusions 
The prevalence of betel nut chewing amongst the population in this study is higher 
than reported elsewhere.  The present study found that betel nut chewing is not 
associated with hyperglycaemia.  By contrast to other Asian studies, betel nut 
chewers had better glycaemic control compared to those who were not current 
chewers.  This finding was related to postprandial glucose but not fasting glucose.  
This beneficial association however was not independent.    Further, betel nut 
chewing had an independent beneficial influence on important risk factors for T2DM; 
these risk factors were BMI, waist circumference, SBP and DBP.  In terms of 
lifestyle risk factors for T2DM, betel nut had an independent positive influence on 
physical activity.  The beneficial and non-beneficial association of betel nut chewing 
with smoking, and vegetable and fruit intake, respectively is however a concern.  
Although smoking had a beneficial influence on BMI, it is a known health risk.   
In conclusion, the positive influence of betel nut chewing on post prandial 
hyperglycaemia is therefore most probably through its beneficial influence on these 
other known risk factors.  Betel nut chewing in a population with very high 
prevalence of the habit therefore does not directly influence glycaemic control but 
exerts its influence through a beneficial effect on adiposity. 
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Chapter VI: Comparisons between the T2DM and 
the non-T2DM cohort 
6.1 Objectives 
The main objective of this part of the research was to compare and identify any 
significant differences between the type 2 diabetes mellitus (T2DM) and non-T2DM 
cohorts in terms of demographics, lifestyle, betel nut chewing, physical 
measurements and medical characteristics. 
6.2 Methodology 
Records of the diabetes survey data (N = 385) were compared against the records 
of those STEPS survey respondents who identified themselves as not having T2DM 
(N = 922).  Univariate comparisons of the key features outlined above were 
performed using the Chi-square test or t-test, as appropriate.  In addition, a 
multivariate logistic regression model was used to identify variables independently 
associated with T2DM.  Following convention, a p-value of <0.05 was taken to 
indicate a statistically significant association in all tests. 
 
6.3  Results 
6.3.1 Participant characteristics 
Participant characteristics that were compared included demographic, lifestyle, 
physical and medical factors.   
6.3.2 Demographic characteristics 
There were statistically significant differences in demographic characteristics 
between the two study cohorts (Table 6.1).  The non-T2DM cohort had more 
participants younger than 50 years while, in the T2DM cohort, the greatest 
proportion of participants was in the age group 50-59 years.  Those with T2DM were 
more likely to have completed tertiary education compared to those without T2DM.  
In addition, those who had T2DM were more likely to be retired, compared to those 
without T2DM.  Both cohorts had very similar unpaid/unemployment rates.  The 
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study involving non-T2DM participants included only those in selected urban 
suburbs and peri-urban areas, while the other study involved T2DM patients from 
any area of residence.  However, in both studies, the highest number of participants 
resided in urban areas.  When comparing the numbers of participants from the two 
studies who resided in peri-urban areas, the figure was higher for the non-T2DM 
cohort.  There were more highlanders in the non-T2DM cohort. 
Table 6.1 Comparison of demographic characteristics between the 
non-diabetes and diabetes study cohorts 
Variable Study cohort p-value# 
Non-T2DM 
(N=922) 
n (%) 
T2DM 
(N=385) 
n (%) 
Gender 
Female 
Male 
 
511 (55.4) 
411 (44.6) 
 
241 (62.6) 
144 (37.4) 
0.017 
Age category (years) 
<50 
50 – 59 
≥60 
 
779 (84.5) 
108 (11.7) 
35 (3.8) 
 
113 (31.0) 
145 (39.7) 
107 (29.3) 
<0.001 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary/vocational 
Tertiary 
 
188 (20.5) 
347 (37.9) 
355 (38.8) 
26 (2.8) 
 
88 (22.9) 
111 (28.9) 
115 (29.9) 
70 (18.2) 
<0.001 
Employment status 
Paid 
Unpaid/Unemployed 
Retired 
Self-employed 
 
250 (27.5) 
533 (58.7) 
11 (1.2) 
114 (12.6) 
 
81 (21.0) 
195 (50.6) 
70 (18.2) 
39 (10.1) 
<0.001 
Area of residence 
Urban 
Peri-urban 
Rural 
Outside Province 
 
622 (67.5) 
300 (32.5) 
0 (0.0) 
0 (0.0) 
 
212 (55.2) 
77 (20.1) 
80 (20.8) 
15 (3.9) 
<0.001 
Region of origin 
Southern 
New Guinea Islands 
Momase 
Highlands 
 
368 (40.0) 
86 (9.4) 
117 (12.7) 
348 (37.9) 
 
294 (76.4) 
36 (9.4) 
26 (6.8) 
29 (7.5) 
<0.001 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations 
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6.3.3 Lifestyle characteristics 
Lifestyle factors included were alcohol consumption, tobacco smoking, fruit and 
vegetable consumption, and physical activity.   
There were statistically significant differences observed between the cohorts with 
T2DM and without T2DM cohorts (Table 6.2).  These differences were seen in 
alcohol consumption, smoking and the number of days that participants had 
consumed fruits in a typical week.  However, there were no differences observed in 
the frequency and number of servings of vegetables consumed. 
For the study cohort without T2DM, questions on alcohol consumption requested 
information in relation to the preceding 12 months but, for the cohort with T2DM, 
information was requested only for the preceding three months.  However, the two 
studies requested information on whether or not participants had consumed alcohol 
in the preceding 30 days, so this variable was the one used for comparisons.  The 
prevalence of alcohol consumption within the preceding 30 days was higher in those 
without T2DM compared to those with T2DM.   
Those without T2DM were more likely to smoke compared to those who had T2DM.  
However, those with T2DM were more likely to have quit smoking compared to 
those without T2DM.   
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Table 6.2 Comparison of differences in lifestyle characteristics 
between the non-T2DM and T2DM study cohorts 
Variable Study cohort p-value# 
Non-T2DM 
(N=922) 
n (%) 
T2DM 
(N=385) 
n (%) 
Alcohol consumption within the past 
30 days 
No 
Yes 
 
 
688 (74.6) 
234 (25.4) 
 
 
354 (91.9) 
31 (8.1) 
<0.001 
Smoking status 
Current 
Never 
Quit 
 
350 (38.2) 
472 (51.5) 
94 (10.3) 
 
24 (6.2) 
272 (70.6) 
89 (23.1) 
0.001 
Smoking history 
Ever  
Never 
 
444 (48.6) 
472 (51.5) 
 
113 (29.4) 
272 (70.6) 
0.001 
Vegetable consumption (servings/day) 
<3 
≥3 
 
848 (92.8) 
66 (7.2) 
 
355 (92.7) 
28 (7.3) 
0.955 
Vegetable consumption (days/week) 
0 - 5 
6 - 7 
 
475 (52.0) 
439 (48.0) 
 
220 (57.4) 
163 (42.6) 
0.071 
Fruit consumption (servings/day) 
<2 
≥2 
 
614 (69.2) 
273 (30.8) 
 
271 (70.8) 
112 (29.2) 
0.585 
Fruit consumption (days/week) 
0 - 1 
2 - 7 
 
375 (41.0) 
540 (59.0) 
 
186 (48.6) 
197 (51.4) 
0.012 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations 
The cohort without T2DM was more physically active than those with T2DM in 
relation to work and recreational activities with the exception of walking to get to and 
from places (Table 6.3).  In terms of the total amount of physical activity per week, 
those with T2DM were less likely to undertake sufficient physical activity per week. 
When comparing the differences in the number of minutes spent on physical 
activities between the two cohorts, there was no statistically significant difference in 
all but work-related VIA.  The non-T2DM cohort was more likely to undertake work-
related VIA for ≥75 minutes per week (Table 6.3). 
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Table 6.3 Comparison of physical activity characteristics between 
the non-T2DM and T2DM study cohorts 
Variable Study cohort p-value# 
Non-T2DM 
(N=922) 
n (%) 
T2DM 
(N=385) 
n (%) 
Amount of physical activity 
Sufficient 
Insufficient 
 
634 (72.6) 
239 (27.4) 
 
234 (60.8) 
151 (39.2) 
<0.001 
Work-related VIA for at least 10 minutes 
No 
Yes 
 
428 (46.9) 
484 (53.1) 
 
332 (86.2) 
53 (13.8) 
<0.001 
Minutes of work-related VIA/week 
<75 
≥75 
 
89 (20.1) 
354 (79.9) 
 
17 (32.7) 
35 (67.3) 
0.036 
Performs VISFRA for at least 10 
minutes 
No 
Yes 
 
 
597 (65.4) 
316 (34.6) 
 
 
351 (91.2) 
34 (8.8) 
<0.001 
Minutes of VISFRA/week 
<75 
≥75 
 
102 (32.7) 
210 (67.3) 
 
14 (41.2) 
20 (58.8) 
0.320 
Work-related MIA for at least 10 
minutes 
No 
Yes 
 
 
359 (39.6) 
548 (60.4) 
 
 
225 (58.4) 
160 (41.6) 
<0.001 
Minutes of work-related MIA/week 
<150 
≥150 
 
191 (37.7) 
315 (62.3) 
 
56 (35.4) 
102 (64.6) 
0.601 
Performs MISFRA for at least 10 
minutes 
No 
Yes 
 
 
626 (68.4) 
289 (31.6) 
 
 
317 (82.3) 
68 (17.7) 
<0.001 
Minutes of MISFRA/week 
<150 
≥150 
 
183 (65.1) 
98 (34.9) 
 
51 (75.0) 
17 (25.0) 
0.120 
Walks to get to and from places 
No 
Yes 
 
367 (49.9) 
368 (50.1) 
 
133 (46.7) 
152 (53.3) 
0.349 
Minutes of walking/week 
<150 
≥150 
 
367 (49.9) 
368 (50.1) 
 
133 (46.7) 
152 (53.3) 
0.349 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations; VIA = vigorous-intensity activity; VISFRA = vigorous-intensity sports, fitness 
and recreational activity; MIA = moderate-intensity activity; MISFRA = moderate-intensity 
sports, fitness and recreational activity. 
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6.3.4 Medical and physical characteristics 
 
The medical characteristics compared included physical measurements, such as 
body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure 
(DBP), waist circumference and fasting capillary blood glucose (FCBG).  Regarding 
biochemical measurements, the study involving those with T2DM did not include 
measurements such as the two-hour oral glucose tolerance test and percentage 
body fat, while the study involving those without T2DM did not include glycated 
haemoglobin (HbA1c) measurements.  Comparisons between the two study cohorts, 
therefore, only included physical measurements and FCBG.  The only physical 
measurement which was not included in the comparisons was hip circumference.  
Hip circumference measurements were included in both studies but, because of 
discrepancies in measurement of this variable in those with T2DM, this variable was 
not used in comparisons between the two different cohorts.   
 
As shown in Table 6.4, the only statistically significant differences in medical 
characteristics between the two cohorts were FCBG, SBP and DBP.  Those with 
T2DM were more likely to have high BP, compared to those without T2DM.  The 
cohort with T2DM was also more likely to have FCBG ≥6.1 mmol compared to those 
without the disease.   
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Table 6.4 Comparison of medical characteristics between the non-
T2DM and T2DM study cohorts. 
Variable Study cohort p-value# 
Non-T2DM 
(N=922) 
n (%) 
T2DM 
(N=385) 
n (%) 
BMI category  
Underweight 
Normal weight 
Overweight 
Obese 
 
18 (2.0) 
291 (31.9) 
356 (39.0) 
247 (27.1) 
 
12 (3.3) 
117 (31.8) 
143 (38.9) 
96 (26.1) 
0.582 
BMI (kg/m2) 
<25 
≥25 
 
309 (33.9) 
603 (66.1) 
 
104 (30.3) 
239 (69.7) 
0.232 
Waist circumference 
Normal 
Above normal 
 
595 (65.1) 
319 (34.9) 
 
270 (70.3) 
114 (29.7) 
0.069 
SBP (mmHg) 
≤130 
>130 
 
657 (71.8) 
258 (28.2) 
 
93 (24.5) 
287 (75.5) 
<0.001 
DBP (mmHg) 
≤80 
>80 
 
656 (71.7) 
259 (28.3) 
 
174 (45.8) 
206 (54.2) 
<0.001 
FCBG (mmol/L) 
<6.1 
≥6.1 
 
754 (82.1) 
164 (17.9) 
 
36 (9.5) 
344 (90.5) 
<0.001 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; FCBG = fasting capillary blood glucose; T2DM = type 2 diabetes mellitus; Normal 
waist circumference is ≤102cm (male) and ≤88cm (female). 
 
6.3.5 Betel nut chewing 
Results indicated that there were statistically significant differences in betel nut 
chewing habits among those with T2DM and those without T2DM.  The non-T2DM 
cohort was more likely to chew betel nut compared to those with T2DM.  For the 
subgroup of betel nut chewers, this cohort was more likely to chew >5 betel nuts per 
day and they chewed betel nut with or without Piper betle inflorescence (PBI) or 
lime.  Those with T2DM were more likely to have quit betel nut chewing but those 
that were still chewing were more likely to chew betel nut with PBI and lime (all 3 
components) compared to betel nut chewers without T2DM. 
339 
 
 
Table 6.5 Comparison of betel nut chewing characteristics between 
the two different study cohorts  
Variable Study cohort p-value# 
Non-T2DM 
N=922 
n (%) 
T2DM 
N=922 
n (%) 
Betel nut chewer 
No 
Yes 
 
171 (18.7) 
745 (81.3) 
 
173 (44.9) 
212 (55.1) 
<0.001 
Betel nut chewer status 
Current 
Quit 
Never 
 
745 (81.4) 
30 (3.3) 
140 (15.3) 
 
212 (55.1) 
77 (20.0) 
96 (24.9) 
<0.001 
Betel nut exposure 
Never 
Quit 
≤5 nuts/day 
>5 nuts/day 
 
140 (15.5) 
30 (3.3) 
403 (44.7) 
329 (36.5) 
 
96 (26.6) 
77 (21.3) 
118 (32.7) 
70 (19.4) 
<0.001 
Betel nut chew components* 
Betel nut, PBI and lime 
Betel nut ±PBI or lime 
Betel nut only 
 
469 (63.0) 
254 (34.1) 
21 (2.8) 
 
177 (83.9) 
12 (5.7) 
22 (10.2) 
<0.001 
#The p-values were obtained from the Chi-square statistics and assess the strengths of 
associations; *Includes betel nut chewers only; PBI = Piper betel inflorescence; T2DM = type 
2 diabetes mellitus. 
 
6.3.6 Factors independently associated with T2DM 
Multivariate analysis, with the T2DM cohort being the dependent variable, indicated 
that the factors independently associated with this cohort were age, smoking, betel 
nut chew components, work-related VIA, SBP and FCBG (Table 6.6)   
The non-T2DM cohort was more likely to be younger, while those with T2DM were 
more likely to be older than 50 years of age.  Those who had never smoked or who 
had quit the habit were more likely to be those with T2DM compared to those who 
were current smokers.  
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Those with T2DM were more likely to chew all three components of the betel nut 
chew. In terms of work-related VIA, those who did not undertake such activities were 
more likely to be those with T2DM, compared to those who did.  Those who had 
SBP >130 mmHg or FCBG ≥6.1 mmol/L were more likely to be those with T2DM.   
Table 6.6 Multivariate analysis of factors independently associated 
with T2DM 
Variable Adjusted OR 95% CI p-value 
Age category (years) 
<50 
50 - 59 
≥60 
 
1 (reference) 
11.97 
11.06 
 
 
5.34 – 26.84 
3.91 – 31.26 
<0.001 
 
<0.001 
<0.001 
Smoke history 
Current 
Never 
Quit 
 
1 (reference) 
2.65 
5.95 
 
 
1.24 – 5.66 
2.24 – 15.80 
0.001 
 
0.012 
<0.001 
Betel nut chew components* 
Betel nut, PBI and lime 
Betel nut ±PBI or lime 
Betel nut only 
 
1 (reference) 
0.060 
0.88 
 
 
0.02 – 0.16 
0.28 – 2.76 
<0.001 
 
<0.001 
0.829 
Work-related VIA 
No 
Yes 
 
12.56 
1 (reference) 
 
5.96 – 26.50 
<0.001 
SBP (mmHg) 
≤130 
>130 
 
0.12 
1 (reference) 
 
0.06 – 0.23 
<0.001 
FCBG (mmol/L) 
<6.1 
≥6.1 
 
1 (reference) 
107.72 
 
 
45.67 – 254.04 
<0.001 
The dependent variable was the T2DM cohort; PBI = Piper betle inflorescence; VIA = 
vigorous-intensity activity; SBP = systolic blood pressure; FCBG = fasting capillary blood 
glucose; T2DM = type 2 diabetes mellitus. 
 
 
6.4 Discussion 
6.4.1 Demographic differences 
There were significant demographic differences between the two cohorts.  The 
T2DM cohort was older, had higher level of education and had the highest 
proportion in the retired category.  The highest proportion of those with T2DM was 
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from the Southern region while in the non-T2DM cohort, there was an equal 
proportion from both the Highlands and Southern regions.   There were no 
participants from the rural areas in the non-T2DM cohort and a higher proportion 
than the T2DM cohort resided in peri-urban areas. 
The cohort with T2DM was older because of the fact that T2DM tends to affect those 
who are 40 years old and older.1  The risk of T2DM increases with age as has been 
observed in population based studies.2, 3   This was also observed among the non-
T2DM cohort in the current study which showed that those 60 years and older were 
more likely to have a FCBG>6.0 mmol/L compared to their younger counterparts. In 
the same cohort, glucose intolerance (oral glucose tolerance test >11.0mmol/L) 
increased with age. These results provide evidence of increasing blood glucose 
levels with age from a PNG population.  Furthermore, the results provide evidence 
that T2DM tends to affect those who are older than 40 years of age. The finding that 
the T2DM cohort had higher level of education than their counterparts is different to 
what has been reported in other population groups.4-6  It has been suggested that 
those with high educational levels may be receptive to messages of disease 
prevention, have a greater ability to change their health behaviour and have better 
use of health care systems.7-9  It is not certain why the T2DM cohort had a higher 
level of education than their counterparts in the present study, however one could 
postulate better education leads to better employment and income which may have 
adverse effects on lifestyle. 
The possible reasons for the highest proportion of the T2DM being from the 
Southern region have previously been discussed in Chapters IV and V.  As 
previously reported in Chapter V, 70% of the non-T2DM cohort was younger than 40 
years old.   This may have led to the observation that the T2DM cohort had the 
highest proportion of participants in the retired category compared to the non-T2DM 
cohort.  
6.4.2 Lifestyle characteristics 
The prevalence rates of smoking and alcohol consumption were higher in the non-
T2DM cohort than in the T2DM.  As discussed in Chapter IV this may be because 
those with T2DM are quitting these habits as part of their diabetes management. 
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However, from the study, it is not known whether or not T2DM participants quit 
smoking after being diagnosed with the disease as further analysis was not done to 
relate the time the participant quit smoking to the date of diagnosis with T2DM. To a 
certain extent, the finding that those with T2DM are quitting smoking as part of their 
disease management may be supported by the observation that the proportion of 
T2DM participants who quit smoking is higher than in the non-T2DM cohort.  The 
finding that prevalence of current smokers is lower in those with T2DM compared to 
those without the disease has been reported elsewhere.10    
The only dietary variable with a significant difference between the two cohorts was 
the number of fruit-eating days per week.  The T2DM cohort had a lower frequency 
of fruit consumption than their counterparts.  The most obvious reason for this may 
be the fear of fruits increasing blood glucose.  It has been found in other countries 
that the associations with the risk of T2DM differs significantly among individual 
fruits and that the risk is greater with consumption of fruit juice rather than whole 
fruits.11, 12   To date, there are no locally written guidelines on fruit consumption for 
those with T2DM in PNG but international guidelines form the basis of dietary 
education for those who are affected (Personal communication). 
 A significant difference in performance of physical activity was observed between 
the two cohorts. The non-T2DM cohort was more physically active than those with 
T2DM in relation to the different physical activities included in this study, with the 
exception of walking to get to and from places.    The observation that there was no 
difference between the two cohorts in terms of walking for travel, has been 
discussed in Chapters IV and V.   T2DM patients are usually more inactive 
compared to those without the disease and this has been discussed in Chapter IV.  
The observation that the T2DM cohort had a greater number of retirees and those 
40 years and older compared to the non-T2DM cohort may have contributed to the 
significant differences in physical activity.  It has been reported that overall physical 
activity appears to decline with retirement.12, 13  
6.4.3 Physical and biochemical measurements 
High BP often co-exists with T2DM, and persistent hyperglycaemia is the underlying 
issue in this cohort so as expected, the T2DM cohort had a high prevalence of high 
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BP and high FCBG.  Less than 10% of the T2DM cohort achieved optimal fasting 
glycaemic control. 
 
The prevalence of obesity (both central and general) was similar among the T2DM 
and non-T2DM cohort.  The increase in T2DM may therefore be related to the 
increasing prevalence of obesity in PNG.  In PNG and many PICs where “being fat 
is good”, education is important to shift this culturally accepted mindset.14  Papua 
New Guineans without T2DM have a high risk of developing the disease not only 
because of genetics but because of factors such as obesity, increasing 
westernisation and urbanisation, and lifestyle behaviours.  Obesity also has been 
linked to genetics. 15   Studies have reported the association between the Pro12Ala 
substitution and T2DM and/or obesity. 16-18  The polymorphism is said to have a 
protective effect against obesity and T2DM.  In a PNG study, Sakaue et al. 19 
investigated the Pro12Ala substitution in PPARγ2 gene among 252 Balopa islanders 
and their analyses revealed that the substitution was not found in any of the groups 
(non-obese, overweight and obese).  . Sakaue et al.19 in that PNG study further 
examined Trp64Arg polymorphism in β3-AR gene and found that the polymorphism 
was significantly higher in overweight and obese than in non-obese participants.  
These findings indicate a high risk of obesity among Papua New Guineans as 
Pro12Ala polymorphism in PPARγ2 is said to have a protective effect against 
obesity and T2DM while the Trp64Arg polymorphism increases the risk.  Genetics is 
therefore possibly contributing to the increasing prevalence of obesity and T2DM in 
PNG.  The sample population however may not be reflective of PNG as a whole as 
nutritional factors have been reported to influence expression of PPARγ2 in human 
adipocytes 20, 21 and also because the sample of participants in the study by Sakaue 
et al was recruited from one particular island.   
6.4.4 Betel nut chewing 
Like other behavioural factors such as smoking and alcohol consumption, the 
prevalence of betel nut chewing was lower in the T2DM cohort compared to the non-
T2DM cohort.  Again, like smoking, those with T2DM were more likely to quit betel 
nut chewing compared to their counterparts.  As previously discussed in Chapter IV, 
those with T2DM may be quitting betel nut chewing and smoking as part of their 
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diabetes management.  The study did not investigate reasons for quitting betel nut 
and did not perform further analysis to correlate the age participants quit betel nut 
chewing with age at diabetes diagnosis.  The diabetes clinic does not advise those 
with T2DM to quit betel nut chewing.  Although the data collection involving the 
T2DM cohort did not collect data on oral health and dentures, results related to oral 
health including the non-T2DM cohort indicated that those with some teeth missing 
were less likely to chew betel nut compared to those with all of their teeth intact.  To 
some extent, this may have contributed to the lower numbers of the T2DM cohort 
chewing betel nut compared to the non-T2DM cohort because those in the former 
cohort were older than the latter.   
6.5 Conclusions 
In conclusion, there were significant differences between the two cohorts, in terms of 
demographic characteristics, lifestyle behaviour and biochemical and physical 
measurements. However, there were some similarities between the two study 
cohorts in terms of prevalence of obesity, vegetable consumption and walking for 
travel.  Some of these differences such as reduced physical activity and physical 
measurements such as increased prevalence of high BP in the T2DM cohort are a 
reflection of the impact of T2DM on an individual.  Quitting habits such as smoking 
and betel nut chewing and a lower prevalence of alcohol consumption in the T2DM 
cohort is an indication that these habits are less common in those with the disease.  
Although low dose betel nut chewing has been observed to be associated with 
better glycaemic control in both study cohorts, chronic use can be expensive 
especially in urban areas and therefore patients may spend much needed funds on 
the habit rather than on costs associated with diabetes management.   
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Chapter VII: Acute glycaemic effect of betel nut 
chewing in T2DM 
7.1 Objectives 
 
The main objectives of this part of the research, involving a cohort of participants 
with type 2 diabetes mellitus (T2DM), were to: 
1 Document their betel nut chewing characteristics 
2 Determine the immediate effect of betel nut chewing on blood glucose by 
measuring capillary blood glucose (CBG) just prior to, and approximately 5-
10 minutes after, each chewing occasion. 
3 Determine any differences in hourly CBG between the betel nut chewing 
and non-chewing days 
7.2 Methodology 
7.2.1 Study setting 
 
This study (Phase 2) was conducted in the pharmacy practice laboratory at the 
School of Medicine and Health Sciences, University of PNG. 
 
7.2.2 Study design 
 
This study was a single-subject design where each participant served as their own 
control. 
 
7.2.3 Study participants  
 
Participants included in this study were betel nut chewers recruited from the T2DM 
cohort.  The study protocol was explained verbally for those who requested further 
information.   Participants who understood the study protocol and gave their consent 
to participate were included.  The consent form was signed by both the participant 
and the investigator.  The recruitment process is shown in Figure 7.1 below. 
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Figure 7.1  Recruitment process 
Phase 1 participants who were Betel nut chewers (212): 
        
Participant Information Sheet given and study explained (n=148) 
 
Total number of people who gave 
consent (n=70): 
      
Person refused (n=57) 
Included Excluded 
Potential betel nut chewers were those from urban and peri-urban and 
interested rural village dwellers (n=15). Total (n=159)   
Initial and follow-up phone calls 
to obtain consent and make 
appointments 
Excluded:  insulin (n=11)  
Excluded:  Other province (7), 
rural (n=45) 
Consent given in person and appointments made during baseline (Phase 1) 
study (n=21); total number of people contacted by phone (n=127); not 
contactable (n=17), hospitalised (n=3), deceased (n=1); number of people 
requested consent from by phone (n=106) 
 
Excluded (n=21):  not 
contactable (n=17), 
hospitalised (n=3), deceased 
 
 
Eligibility 
check 1:  
Area of 
residence; 
 
Not on 
insulin 
 
Eligibility 
check 2: 
Participant 
consent 
Data 
collection 
Done 
during 
baseline 
study 
T2DM 
study 
(Phase 1) 
Betel nut/ 
Clinical 
study 
 
(Phase 2) 
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7.2.4 Data collection 
Data for this study were collected over 2 days.  During Day 1, participants chewed 
betel nut according to their individual chewing habits and during Day 2, participants 
abstained from betel nut chewing. 
 
During the study days, different activities such as knitting, watching movies and peer 
education sessions were organised in the study room.   Each day started with a 
fasting blood glucose measurement followed by a reminder of what was happening 
during the study period.  Participants were under observation by the investigator 
throughout the study period from 8.00am to 3.30pm.   
 
7.2.4.1 Study tools 
An instrument was developed to collect data for this study (Appendix 11).  The 
design of the questionnaire was initially constructed based on the objectives of the 
study and review of relevant literature.  Data collected included fasting CBG and 
time of measurement, names of medications and time taken, hourly CBG and full 
details of betel nut chewing activity.  This included the time of starting to chew and 
duration of chewing, as well as details of the chewing habit including: number of 
nuts chewed, whether they were chewed with other constituents [lime, Piper betle 
leaf (PBL) or inflorescence (PBI)], whether the betel juice was swallowed or spat 
out, and whether the betel nut was ultimately swallowed or spat out and the time at 
which the chewing was finished.  This information was recorded for each occasion 
of chewing during the 2 days of the study.  CBG was measured just prior to, and 
approximately 5-10 minutes after, each chewing occasion.  The time of the most 
recent chewing occasion prior to the start of data collection was also recorded.   
 
CBG was measured using a hand-held Omnitest® Plus (B.Braun, Melsungen, 
Germany) capillary blood glucose meter. 
 
Betel nut was supplied by the researcher to ensure consistency in size and maturity.  
A standard diet (Appendix 12) was given to participants for breakfast and lunch and 
this was consistent over the 2 days of the study. 
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7.2.4.2 Pilot questionnaire and testing of study protocol 
The study questionnaire and protocol were pretested on four participants with T2DM 
at the study venue in October 2011. 
 
7.2.4.3 Final questionnaire and study protocol 
The pretesting of the questionnaire and study protocol resulted in minor changes to 
the final questionnaire and protocol.  The times for the CBG and meals were 
included on the final questionnaire.  In terms of the study protocol, participants were 
initially required to have breakfast at 8.00am and were required to cease the study 
at 3.00pm.   These participants were required to have their fasting CBG measured 
before 8.00am.  After pre-testing the study protocol, the breakfast time was changed 
to 8.30am and CBG measurements were therefore done by 8.30am.  The cessation 
time for the final study protocol was consequently changed to 3.30pm. The change 
of time was due to logistical reasons.  Most participants were travelling by public 
transport making it difficult to get to the study setting before 8.00am.  As a result of 
the change in study commencement time, the times for the hourly sugar were 
changed on the final questionnaire. 
7.2.5 Study days 
The protocol for the study is shown in Figure 7.2 below 
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CBG = capillary blood glucose 
Figure 7.2 Day 1 and day 2 Study protocol 
 
7.2.5.1 Day 1:  Betel nut chewing 
Data was collected on the participants’ chewing habits and recorded on the 
questionnaire developed for the study.  Participants had to return to their own 
accommodation after completion of Day 1. 
 
After completion of Day 1, appointments were confirmed for Day 2.  Participants 
were expected to return the next day but for various reasons, many patients were 
not able to do so and therefore, appointments were made for the next available 
date. 
7.2.5.2 Day 2:  Abstinence from betel nut 
During this day, the same protocol as in Day 1 was followed except that participants 
abstained from betel nut chewing for the whole day.  In this case hourly CBG levels 
were measured. 
 
Fasting CBG measurements followed by 
     
Standard breakfast 
Standard lunch 
End of study 
8.00am -8.25am 
8.30am 
Hourly CBG 
9.30am, 10.30am, 11.30am, 12.30am 
12.30pm 
Hourly CBG 
1.30pm, 2.30pm, 3.30pm 
3.30pm 
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7.2.6 Sample size and sampling 
Estimation of an adequate sample size for this study was difficult.  There were many 
measurements of CBG on each participant, and each one of these was an 
observation as far as the analysis was concerned.  However, the correlation 
between measurements made on the same individuals influenced the estimated 
sample size.  If all measurements were un–correlated, then a sample of 
approximately N=120 would have been adequate to identify variables exhibiting a 
moderate effect size, with 80% power and α=0.05. 1    With many observations per 
person, it was anticipated that a sample of approximately N=70 people may be 
adequate for this study. 
 
7.2.7 Statistical analysis 
Standard descriptive statistics (frequencies and percentages for categorical 
variables, and means and standard deviations for continuous variables) were used 
to summarise the profile of the study participants.  Similar descriptive statistics were 
used to describe their betel nut chewing habits. 
 
For the hourly CBG data for Days 1 and 2, the area under the curve (AUC) was 
calculated using the simple trapezoidal rule (dividing the curve up into blocks and 
assuming a straight line between the hourly measurements).  The difference in AUC 
from Day 1 to Day 2 was calculated and a paired t-test was used to determine the 
significance of any difference between Days 1 and 2. 
 
The individual CBG measurements were also compared separately at each hour of 
the two days.  This was performed using a paired t-test to identify any consistent 
difference between the two days (at each measurement hour). 
 
The Kappa statistic was used to assess agreement between fasting and the average 
CBG over the day for each person.  For this analysis, the CBG was divided into its 
recommended brackets of <6.0 mmol/L for fasting, and <8.0 mmol/L for appropriate 
glycaemic control. 
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A repeated measures analysis was used to identify any relationship between CBG 
and timing of the betel nut chewing episodes, meals and medications.  This analysis 
was carried out as random effects regression model using SAS version 9.2 
statistical software.  This analysis took into account the correlations between 
observations made on the same individuals.  A p-value < 0.05 was taken to indicate 
a statistically significant association in all tests.  This analysis was performed in 3 
stages – firstly, a gross comparison between the measurements taken on Day 1 and 
Day 2 was performed not taking into account details of meals or medications.  This 
analysis included all the hourly measurements made on individuals, and aimed to 
find if there was any detectable difference between the two days.  Secondly, the 
analysis was repeated taking into account time delays between meals, medications 
and CBG measurements.  Thirdly, the data from Day 1 only (BN chewing day) were 
analysed in the same manner, to identify any relationship between CBG and delays 
between BN chewing and CBG (as well as delays from meals and medications). 
 
7.2.8 Ethics 
Participants were provided with a Participant Information Sheet [(PIS) Appendix 10] 
which was written in English.  Participants had to read the PIS before they were 
asked if they wanted to participate.  The PIS was orally translated or explained in 
Pidgin for those who were interested in the study but requested more information in 
the language they were more fluent in.   
 
Approval for the study was granted by the Curtin University Human Research Ethics 
Committee (approval number HR38/2011), The University of PNG School of 
Medicine and Health Sciences Research and Ethics Committee, and the Medical 
Research Advisory Committee of the National Department of Health of PNG. 
Permission to undertake the study in a pharmacy practice laboratory, University of 
PNG School of Medicine and Health Sciences was approved by the school. 
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7.3 Results 
7.3.1 Study setting 
The Pharmacy Practice Laboratory at the School of Medicine and Health Sciences, 
University of Papua New Guinea (UPNG), where the study was conducted is located 
at the Taurama campus of UPNG and is within the grounds of the Port Moresby 
General Hospital. 
 
7.3.2 Participant recruitment 
Of the 385 participants, there were 212 (55%) potential participants (betel nut 
chewers) for this study.  Of these 212, 7(3.3%) were from outside provinces, 60 
(28.3%) from rural villages, and 144 (67.9%) from urban and peri-urban areas.  Data 
for the area of residence for one participant was missing.  For logistical purposes, 
that is, ease of travel arrangements to the study vicinity, only participants who 
resided in the urban and periurban areas were eligible for the study.  However, 
fifteen betel nut chewers from rural villages who expressed interest in the study and 
were able to organise their own logistics were allowed to participate.  After excluding 
the rest of the rural participants, a total of 159 betel nut chewers (144 urban/peri-
urban,15 rural) were therefore potential participants for the study.  Eleven of the 
159(6.9%) participants on insulin were further excluded on the basis of potential risk 
of adverse effects on glycaemic control and to avoid it being a confounding factor 
because of its pharmacology and pharmacokinetics. The PIS was therefore handed 
to 148 participants. 
 
Of the 148 who were given the PIS, 21(14.2%) gave consent and immediately made 
appointments to participate before leaving the hospital after the baseline study.  
Phone calls were made to obtain consent and make appointments for the rest of the 
participants.  Of those who were contacted by phone, 3 (2.4%) were hospitalised, 
one was deceased and 17 (13.4%) were not contactable and were therefore 
excluded.  Those who were not contactable by phone were excluded after four daily 
attempts.  Consent was therefore sought from 106 (83.5%) of the 127 participants 
contacted by phone. Of these, 57(53.8%) refused to participate while 49 (46.2%) 
agreed to participate.  
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Seventy participants gave consent to participate and of these, 59 (84.3%) 
appointments were confirmed while the rest were still undecided on convenient days 
to do the study.  Of the fifty nine, 44 (74.6%) participated in the study, but five 
(11.4%) of them did not complete the study leaving a total of 39 participants 
completing the study.  However, one further participant was subsequently excluded 
because he ceased medications before and during the second day of the study.  
The final analysis for this study therefore included only the 38 participants who 
completed the study.   
 
Common reasons cited for refusal included feeling unwell, babysitting grandchildren, 
death in the family and fear of travelling to the study location during the civil/political 
unrest which was occurring in Port Moresby during the time of the study.   
7.3.3 Participant characteristics at baseline 
Participant characteristics at baseline were those measured and recorded at the 
Port Moresby General Hospital Diabetes Clinic during a face to face interview.  
These included demographic, lifestyle and medical and physical characteristics. 
7.3.3.1 Demographic characteristics 
Of the participants, 76.3% were females and 50% of them were in the age range 50-
59 years (Table 7.1).  Only four (10.5%) were in paid employment while the rest 
were unemployed, unpaid or retired.  More than 80% of the participants were urban 
or peri-urban dwellers. The majority of participants (42.1%) were born and had lived 
in Port Moresby for their lifetime.  Thirty-three (86.8%) participants were from the 
Southern region.  Eighteen (47.3%) of the participants either did not complete basic 
or completed only basic primary education.   
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Table 7.1 Frequencies of demographic characteristics (N=38) 
Characteristics n* Percentage* 
Gender 
Male 
Female 
 
9 
29 
 
23.7 
76.3 
Age 
<50 
50-59 
≥60 
 
9 
19 
10 
 
23.7 
50.0 
26.3 
Region of origin 
Southern 
Momase 
Highlands 
New Guinea Islands 
 
33 
1 
2 
2 
 
86.8 
2.6 
5.3 
5.3 
Level of education 
Did not complete basic education 
Primary basic education 
Secondary education 
Vocational training 
Tertiary education 
 
4 
14 
8 
2 
10 
 
10.5 
36.8 
21.1 
5.3 
26.3 
Area of residence 
Urban 
Peri-urban 
Rural village 
 
18 
15 
5 
 
47.4 
39.5 
13.2 
Employment status 
Paid employment 
Unpaid/unemployed 
Retired 
 
4 
26 
8 
 
10.5 
68.4 
21.1 
Years of residence in Port Moresby 
0 
1-10 
>10 
Lifetime 
 
5 
4 
10 
16 
 
13.2 
10.5 
26.3 
42.1 
*May not add up to total because of missing values 
 
7.3.3.2 Lifestyle characteristics 
Only four (10.5%) of the participants consumed alcohol in the preceding 3 months 
while only one (2.6%) was a current smoker (Table 7.2).  In terms of diet, more than 
50% of the participants were consuming vegetables for 6-7 days per week but only 
four (10.5%) were consuming 3 or more servings on days when vegetables were 
consumed.  When comparing fruit and vegetable days, most of the participants 
(60.5%) were either not consuming fruit at all, or were consuming fruit for no more 
than 2 days per week.  Like servings of vegetables, more participants were 
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consuming fewer servings of fruit.  About half of the participants consumed less than 
5 betel nuts per day and about three quarters had consumed betel nut for more than 
25 years.  Nearly all (94.7%) consumed betel nut with Piper betle inflorescence 
(PBI) and lime.   
 
Table 7.2 Frequencies of lifestyle characteristics at baseline (N=38) 
Characteristics n* Percentage* 
Alcohol consumed in the last 3 months 
No 
Yes 
 
34 
4 
 
89.5 
10.5 
Smoker status 
Current 
Never 
Quit 
 
1 
24 
13 
 
2.6 
63.2 
34.2 
Vegetable servings /day 
<3 
≥3 
 
34 
4 
 
89.5 
10.5 
Number of vegetable days/week 
0-2 
3-5 
6-7 
 
8 
9 
21 
 
21.1 
23.7 
55.3 
Fruit servings /day 
<2 
≥2 
 
22 
16 
 
57.9 
42.1 
Number of fruit days / week 
0-2 
3-5 
6-7 
 
23 
10 
5 
 
60.5 
26.3 
13.2 
Number of betel nuts chewed/day 
≤5 
>5 
 
21 
16 
 
55.3 
42.1 
Number of years of chewing betel nut 
≤25 
>25 
 
5 
28 
 
13.2 
73.7 
Betel nut chewing components 
Betel nut + PBI + Lime 
Betel nut only or with PBI but no lime 
 
36 
2 
 
94.7 
5.3 
PBI = Piper betel inflorescence; *May not add to total because of missing values 
 
The most common type of physical activity was walking to and from places with 
more than 70% reporting undertaking such physical activity (Table 7.3).  For those 
who walked to and from places, about 50% walked for less than 150 minutes in a 
week.   Only a very small number of participants reported participating in vigorous-
intensity activity either at work or in sports, fitness and recreation.  The same was 
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seen in the number of participants participating in moderate-intensity sports, fitness 
and recreational activity (MISFRA).  Overall, 57.9% of participants reported sufficient 
physical activity while the rest either did insufficient or no physical activity in a week.   
 
Table 7.3 Physical activity characteristics of participants at baseline 
Characteristics 
 
n Percentage 
Work-related VIA for at least 10 minutes 
No  
Yes 
 
35/38 
3/38 
 
92.1 
7.9 
Minutes of work-related VIA/week 
<75 
≥75 
 
2/3 
1/3 
 
66.7 
33.3 
Work-related MIA for at least 10 minutes 
No 
Yes  
 
20/38 
18/38 
 
52.6 
47.4 
Minutes of work-related MIA/week 
<150 
≥150 
 
8/18 
10/18 
 
44.4 
55.6 
Walk to get to and from places for at least 10 
minutes 
No 
Yes  
 
 
8/38 
30/38 
 
 
21.1 
78.9 
Minutes of walking/week 
<150 
≥150 
 
17/30 
13/30 
 
56.7 
43.3 
Performs VISFRA for at least 10 minutes 
No 
Yes 
 
36/38 
2/38 
 
94.7 
5.3 
Minutes of VISFRA/week 
<75 
≥75 
 
0/2 
2/2 
 
0.0 
100.0 
Performs MISFRA for at least 10 minutes 
No 
Yes 
 
34/38 
4/38 
 
89.5 
10.5 
Minutes of MISFRA/week 
<150 
≥150 
 
3/4 
1/4 
 
75.0 
25.0 
Amount of physical activity/week 
Sufficient 
Insufficient 
None 
 
22/38 
12/38 
4/38 
 
57.9 
31.6 
10.5 
VIA=vigorous-intensity activity; MIA = moderate-intensity activity; VISFRA = vigorous-
intensity sports, fitness and recreational activity; MISFRA = moderate-intensity sports, fitness 
and recreational activity. 
 
359 
 
 
7.3.3.3 Physical and biochemical characteristics 
Physical measurements included body mass index (BMI), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), weight, and hip and waist circumferences.  
The number of years a participant had lived with T2DM was also included in this 
section.  As shown in Table 7.4, the median values for continuous physical and 
biochemical characteristics fell outside the ‘healthy’ values except for waist 
circumference.  The waist circumference was within the normal values only for male 
participants (the median for females was high).  According to the Diabetes Clinical 
Practice Guidelines for PNG, the normal waist circumference for males is ≤102 cm 
while that for females is ≤88 cm.  The median DBP was just above target value, 
however the median SBP significantly above the target value.  The median number 
of years participants were diagnosed with T2DM was 3.0 years with a minimum of 
0.5 and a maximum of 30 years.   
 
Table 7.4 Median and range values of continuous physical and 
biochemical characteristics (N=38) 
Characteristics n (%) Median Range 
Weight (kg) 37 (97.4) 71.0 52 - 22 
Waist circumference (cm) 
Female 
Male 
38 (100.0) 
29 (76.3) 
9 (23.7) 
99.5 
104.0 
96.0 
80 – 141.5 
87.0-141.5 
80.0-101.0 
Hip circumference (cm) 38 (100.0) 101.0 80 - 144.5 
BMI (kg/m2) 37 (97.4) 27.1 19.4 -  47.7 
SBP (mmHg) 38 (100.0) 146.5 108 - 200 
DBP (mmHg) 38 (100.0) 80.5 51 - 118 
HbA1c (%) 37 (97.4) 8.1 5.4 - 12.7 
CBG (mmol/L) 
Fasting 
Random 
Unknown 
38 (100.0) 
13 (34.2) 
20 (52.6) 
5 (13.2) 
 
10.0 
12.2 
8.4 
 
6.1 - 17.9 
5.0 - 27.2 
8.2 - 15.3 
Number of years diagnosed with diabetes 38 (100.0) 3.0 0.5 - 30 
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
CBG = capillary blood glucose 
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When measurements were classified into categories (widely accepted to indicate 
‘healthy’ or ‘unhealthy’ behaviour), it appeared that results for the majority of 
participants fell outside the ‘healthy’ range.  In particular, this was the case for waist 
circumference, BMI, SBP, DBP and HbA1c.  Participants were equally divided with 
regard to healthy or unhealthy DBP.  Twenty six (68.4%) of the participants had 
been living with T2DM for five years or less.  See Table 7.5 
 
Table 7.5 Categorical variables for physical measurements at 
baseline (N=38) 
Characteristics n  Percentage 
Waist circumference (cm) 
Normal 
Above normal 
 
10 
28 
 
26.3 
73.7 
BMI (kg/m2) 
<25 
≥25 
 
7 
28 
 
18.4 
73.7 
SBP (mmHg) 
≤130 
>130 
 
8  
30  
 
21.1  
78.9 
DBP (mmHg) 
≤80 
>80 
 
19 
19 
 
50.0 
50.0 
HbA1c (%) 
≤7.0 
>7.0 
 
9 
28 
 
23.7 
73.7 
Number of years diagnosed with diabetes 
≤5 
>5 
 
26 
12 
 
68.4 
31.6 
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; 
HbA1c = glycated haemoglobin; Normal waist circumference is ≤88cm (females) and 
≤102cm (males) 
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7.3.4 Medications during study 
 
Participants on insulin were excluded from this study and therefore all participants 
had either diet-controlled diabetes or were on oral hypoglycaemic medications.  
Nearly 50% (n=18) of participants were on combination oral therapy including 
glibenclamide and metformin.  More than 50% of participants were not on any co-
medications (e.g. antihypertensive medication, lipid-lowering agents). Table 7.6 
 
Table 7.6 Hypoglycaemic medications used during study (N=38) 
Variable n  Percentage 
Diabetes management 
Diet 
Metformin 
Glibenclamide 
Combination 
 
5 
5 
10 
18 
 
13.2 
13.2 
26.3 
47.4 
Co-medications used 
No 
Yes 
 
17 
21 
 
55.3 
44.7 
 
7.3.5 Betel nut chewing characteristics during the study 
During the betel nut chewing day, there were 109 occasions on which betel nut was 
chewed amongst the 38 participants.  This corresponded to an average of 2.8 
chewing episodes per participant.  More than 90% of betel nut chewing episodes 
included lime and PBI, and swallowing betel nut rather than spitting it out.  In more 
than 60% of episodes of chewing, betel nut juice was swallowed.  Usually, one betel 
nut was chewed at a time (68.8%), with half a nut chewed on most other occasions.  
Fifty six (51.4%) episodes of betel nut chewing lasted for up to 10 minutes. Table 
7.7 
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Table 7.7 Betel nut chewing characteristics (N=109) 
Variable n(%) 
Lime used 
No 
Yes      
 
7 (6.4) 
102 (93.6) 
Piper betle inflorescence 
No 
Yes       
 
4 (3.7) 
105 (96.3) 
Betel nut juice swallowed or spat out 
Spat out 
Swallowed 
 
37 (33.9) 
72 (66.1) 
Betel nut swallowed or spat out 
Spat out 
Swallowed 
 
8 (7.3) 
101 (92.7) 
Number of nuts chewed per episode 
0.5 
1 
2 
 
31 (28.4) 
75 (68.8) 
3 (2.8) 
Duration of chewing betel nut (minutes) 
≤ 10  
>10  
 
56 (51.4) 
53 (48.6) 
 
7.3.6 Differences in hourly CBGL during the betel nut chewing and 
betel nut abstinence days 
 
The mean fasting CBG for the betel nut chewing day was slightly less than that for 
the betel nut abstinence day but there were no statistically significant differences in 
CBG between days, when based on the fasting, average or hourly glucose 
measurements.  The data in Table 7.8 below were obtained from a random effects 
regression model (to adjust for the correlations between observations on the same 
participant).  This is equivalent to a paired t-test on these measurements. 
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Table 7.8 Differences in the CBG taken at various times during the 
day, and overall (average CBG measurement), between betel nut 
chewing and non-chewing days 
Variable  Betel nut chewing day 
Mean (SE) 
No betel nut day 
Mean (SE) 
p-value* 
Fasting CBG (mmol/L) 7.9 (0.4) 8.4 (0.4) 0.1796 
Average CBG (mmol/L) 9.2 (0.4) 9.3 (0.4) 0.4182 
Hourly BGL (mmol/L) 
 9:30am 
 10:30am 
 11:30am 
 12:30pm 
 1:30pm 
 2:30pm 
 3:30pm 
 
10.3 (0.5) 
11.1 (0.5) 
9.2 (0.5) 
7.7 (0.4) 
9.0 (0.4) 
9.4 (0.5) 
8.6 (0.5) 
 
10.9 (0.5) 
11.5 (0.5) 
9.4 (0.5) 
7.5 (0.4) 
9.2 (0.4) 
9.1 (0.5) 
8.4 (0.5) 
 
0.1395 
0.3349 
0.6092 
0.4870 
0.5554 
0.4874 
0.6369 
*P-values were obtained from a ‘paired’ analysis which took into account the correlations 
between measurements on the same individual; CBG = capillary blood glucose; SE = 
standard error. 
 
 
The CBG was put into categories, and the fasting values tabulated against the 
average for each day (Table 7.9).  The cut-off value for the fasting level was 6.0 
mmol/L, while the cut-off for the average was 8 mmol/L.  Not surprisingly, there 
appeared to be some agreement between low values for both fasting and average 
values, and similarly for the high values.  The Kappa statistic was used to assess 
the agreement between these measures, and the results were: 0.37 and 0.34 for 
Day 1 and Day 2 respectively.  Kappa is a statistic whose value lies between about -
0.2 and 1.  The values greater than 0.7 are considered to indicate excellent 
agreement, those from 0.5 to 0.7 show good agreement, while values less than 0.5 
indicate fair to poor agreement.  In this case, the kappa statistics indicate fair to poor 
agreement.  On examining the data, it appears that over 25% of the participants who 
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had ‘fasting’ readings which were over 6 mmol/L, had average CBG readings which 
were under 8 mmol/L, and this discrepancy accounts for most of the disagreement.  
In summary, it may be that the fasting measurement of CBG is not a very specific 
predictor of the average CBG throughout the day. 
 
Table 7.9 Fasting and average daily hourly CBG 
Variable Average capillary blood glucose * kappa 
≤ 8.0 >8.0 
Day 1 fasting CBG 
≤6.0 mmol/L 
>6.0 mmol/L 
 
6 (75.0) 
8 (28.6) 
 
2 (25.0) 
20 (71.4) 
0.37 
Day 2 fasting CBG 
≤6.0 mmol/L 
>6.0 mmol/L 
 
5 (71.4) 
8 (26.7) 
 
2 (28.6) 
22 (73.3) 
0.34 
*The average capillary blood glucose for each day was different; CBG = capillary blood 
glucose 
 
7.3.7 Area under the Curve (AUC) analysis 
7.3.7.1 Hourly CBG 
The difference in AUC from Day 1 to Day 2 was small (+1.37 mmol/L) and a paired 
Student’s t-test showed that the difference was not significant (p=0.56) indicating 
that there was no significant change in AUC between a betel nut chewing day and 
non-chewing day.  See Table 7.10. 
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Table 7.10  Differences in AUC between the betel nut chewing and non-
chewing day 
Variable 
 
N Minimum Median Maximum Mean SD 
AUC – 1 
 
38 45.20 67.45 124.40 74.28 20.73 
AUC – 2 
 
38 42.55 72.25 122.05 75.65 20.61 
Difference 
 
38 -32.50 0.30 55.15 1.38 14.50 
AUC = area under the curve. 
 
The differences were calculated for each participant separately, and the t-test was 
used to identify whether the difference was significantly different from zero (which 
would indicate a systematic difference).  The p-value of 0.56 shows that there was 
no real difference in CBG between the betel nut-chewing and the non-chewing days.    
 
The difference between CBG before and after chewing betel nut (on Day 1 only) 
was calculated for each participant by subtracting the CBG after from the CBG 
before betel nut chewing.  The duration of betel nut chewing, from onset of each 
chewing episode to spitting out or swallowing the chew ranged from 1-33 minutes.  
Table 7.11 shows the distribution of these differences for each episode of betel nut 
chewing.  
 
Table 7.11 CBG difference after betel nut chewing 
CBG = capillary blood glucose 
CBG difference 
(mmol/L) 
Frequency Percentage Range 
< -0.1 
-0.1 – 0.1 
> 0.1 
51 
14 
44 
46.8 
12.8 
40.4 
-0.4.5 - -0.2 
-0.1 – 0.1 
0.2 – 5.7 
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7.3.8 Random effects regression models 
 
Different random effects regression models using each episode of betel nut chewing 
were used to determine any glycaemic effect of betel nut.   
7.3.8.1 Hourly CBG for betel nut and no betel nut days 
The hourly CBG measurements were also analysed using a random effects 
regression model.  This model takes into account the correlations between 
measurements made on the same individual.  The model was applied in different 
stages.  Firstly, a direct comparison of Day 1 (betel nut chewing) to Day 2 (no betel 
nut) was performed, using the hourly CBG measurements.  This model showed that 
the mean CBG on Day 1 was 9.16 (SE: 0.40), and on Day 2 it was 9.30 (SE: 0.40), 
and that this difference was not significantly different from zero (p=0.43).  This is 
consistent with the findings from the AUC analysis, but it takes into account the 
individual measurements rather than the summarising of each individual’s 
observations as the AUC for each day. 
7.3.8.2 Association between CBG, medication and meals 
A second analysis was performed to identify any association between CBG and the 
timing of medication and meals.  For the purpose of this analysis, the delay between 
the most recent meal and CBG measurement was calculated, and categorised into: 
up to 1 hr, 1-2 hrs, 2-4 hrs, more than 4 hrs.  Similarly, the delay between 
medication time and CBG time was calculated and categorised (same categories).   
There appeared to be a strong association between the timing of the meal and the 
CBG; the more recent the meal, the higher the CBG.  There is also a strong 
association between timing of medications and CBG, with the CBG appearing to be 
lower 2 hours after medication than within the first 2 hours (suggesting that the 
medication takes at least 2 hours to have effect).  The findings from this analysis are 
shown in Table 7.12 
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Table 7.12 Comparison of CBG between betel nut chewing and non-
chewing days, after adjustment for timings of meals, medications, and 
blood sampling. 
Variable Mean CBG 
(adjusted) 
95% CI p-value 
Delay from medication 
 < 1 hour 
 (1,2]  hrs# 
 (2,4]  hrs 
 4 or more hours 
 No medication (diet only) 
 
10.10 
10.51 
8.74 
8.25 
9.54 
 
9.18 – 11.02 
9.59 – 11.42 
7.87 – 9.61 
7.41 – 9.09 
8.61 – 10.47 
<0.0001* 
(reference) 
0.2162 
<0.0001 
<0.0001 
0.2008 
Delay from most recent meal 
 < 1 hour 
 (1,2] hrs 
 (2,4 hrs 
 4 or more hours 
 
10.00 
10.50 
9.27 
7.95 
 
9.18 – 11.02 
9.68 – 11.31 
8.46 – 10.08 
6.94 – 8.97 
<0.0001* 
(reference) 
0.0161 
0.0004 
<0.0001 
Betel nut chewing day 
 No (Day 2) 
 Yes (Day 1) 
 
9.36 
9.50 
 
8.56 – 10.15 
8.71 – 10.29 
0.2917 
*Overall p-value.  The p-values shown in the table above are all ‘after adjustment’ for each 
other.  This means that any influence of the meal (for example) is taken into account in 
calculation of the influence of medication and betel nut chewing (and vice versa); # The 
notation: (1,2] means a delay ‘strictly greater than 1 hour, and less than or equal to 2 hours’.  
Round brackets exclude the endpoint, while square brackets include it; CBG = capillary 
blood glucose 
 
7.3.8.3 Association between CBG and betel nut chewing, meals and 
medications 
The final analysis was undertaken to focus only on the first day of the study, when 
betel nut was chewed.  In addition to the delay between CBG measurement and 
timing of medication and meals, the time between the most recent betel nut chew 
was also calculated.  These varied from a few minutes (when CBG was assessed 
very shortly after an episode of chewing), to an hour or more.  The pattern of 
adjusted CBG was similar for delay from medication and meals, except that the 
CBG within an hour of meal time was not as high as it was for the whole group (over 
2 days).  Consequently, the significance of differences from that baseline (meal 
shortly before CBG assessment) was not as significant as they were previously.  
The main finding was that there appeared to be no significant association between 
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timing of betel nut chewing and CBG.  The results of this analysis are shown in the 
Table 7.13 
 
Table 7.13 Analysis of the influence of timing of betel nut chewing on 
CBG, after adjustment for timings of meals, medications, and blood 
sampling. 
Variable Mean CBG 
(adjusted) 
95% CI p-value 
Delay from medication 
 < 1 hour 
 (1,2] hrs# 
 (2,4] hrs 
 4 or more hours 
 No medication (diet only) 
 
10.40 
10.70 
8.68 
8.84 
9.28 
 
9.20 – 11.61 
9.62 – 11.78 
7.58 – 9.78 
7.89 – 9.79 
7.95 – 10.60 
<0.0001* 
(reference) 
0.4740 
0.0004 
0.0001 
0.1051 
Delay from most recent meal 
 < 1 hour 
 (1,2] hrs 
 (2,4] hrs 
 4 or more hours 
 
9.39 
10.61 
9.59 
8.72 
 
8.39 – 10.40 
9.63 – 11.60 
8.58 – 10.61 
7.50 – 9.94 
<0.0001* 
(reference) 
<0.0001 
0.5763 
0.1110 
Delay from most recent BN 
 < 1 hour 
 (1,2] hrs 
 (2,4] hrs 
 4 or more hours 
 
9.74 
9.54 
9.51 
9.53 
 
8.76 – 10.72 
8.40 – 10.68 
8.33 – 10.70 
8.55 – 10.52 
0.8356* 
(reference) 
0.5487 
0.5642 
0.5140 
*Overall p-value.  The p-values shown in the table above are all ‘after adjustment’ for each 
other.  This means that any influence of the meal (for example) is taken into account in 
calculation of the influence of medication and betel nut chewing (and vice versa); # The 
notation: (1,2] means a delay ‘strictly greater than 1 hour, and less than or equal to 2 hours’.  
Round brackets exclude the endpoint, while square brackets include it; CBG = capillary 
blood glucose   BN = betel nut 
7.4 Discussion 
This part of the research was designed to investigate the immediate glycaemic 
effects of betel nut chewing.  Evidence from animal and cell studies, and 
epidemiological evaluation indicates there is a link between betel nut, PBL/PBI and 
arecoline (major constituent of betel nut) and metabolic disorders.  Based on 
evidence from the literature, it was hypothesised that betel nut chewing increases 
blood glucose.  Based on that hypothesis, the overall study was designed to 
investigate both the long term and acute glycaemic effects of betel nut chewing.  It 
was envisaged that any acute effect would confirm or deny findings from the cross-
sectional studies. 
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Thirty eight participants were included and among them they chewed a total of 109 
times which corresponded to an average of 2.8 (range: 1 – 6 episodes) per 
participant.   Participants were not given a set dose of betel nut and were required to 
chew according to their normal habits. The study was designed this way to 
investigate if any blood glucose changes were dependent on the dose and the 
chewing habit.  Other studies have reported a dose-dependent effect of betel nut or 
arecoline on blood glucose. 2-4  Diet and physical activity were controlled, and 
participants were observed closely during the two study days.  Participants moved 
around the room where the study was conducted but did not leave the room for the 
duration of the study. 
The hypothesis that betel nut chewing increases blood glucose was tested in two 
different ways; i.e. using AUC and random effects regression models. 
7.4.1 AUC and random effects regression models  
Using hourly AUC analysis to determine any difference in CBG between Day 1 (the 
betel nut chewing day) and Day 2 (the non-chewing day), a small non-significant 
difference was observed.  The AUC reflected the overall glycaemic control during 
the period of the study from 8.30am to 3.30pm.   From this analysis, the present 
study demonstrated that betel nut chewing does not alter blood glucose levels in 
people with T2DM, and rejects the hypothesis that betel nut chewing increases 
blood glucose.  Random effects regression analysis took into consideration the 
effect of meals and medication on blood glucose to determine if betel nut chewing 
was associated with changes in blood glucose.  The analysis resulted in no 
significant association between timing of betel nut chewing and CBG, also rejecting 
the hypothesis that betel nut chewing increases blood glucose in T2DM.  
7.4.2 Difference in CBG immediately before and after each chewing 
episode 
 A simple calculation to determine the difference between CBG before and after 
chewing betel nut indicated that there were three types of responses which were all 
non-significant; a reduction, no effect and an increase in CBG after betel nut 
chewing.  CBG after chewing was measured 5-10 minutes after swallowing or 
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spitting out the betel nut chew.  The duration of betel nut chewing from onset of 
each chewing episode to spitting out or swallowing the chew ranged from 1 to 33 
minutes.  No CBG was measured while the participant was still chewing.  The 
observation that blood glucose increased, stayed the same or decreased indicates 
individual responses of blood glucose to betel nut chewing.  However, this confirms 
the variable responses and that any acute glycaemic effect of betel nut appears to 
be short-lived.  The finding that the glycaemic effect of betel nut is short-lived is 
consistent with reports of studies investigating the pharmacokinetics of arecoline in 
Alzheimer patients.  Asthana et al 2 who intravenously infused 5mg arecoline to 
Alzheimer patients over 30 minutes reported that plasma arecoline concentrations 
were detectable by 5 minutes and increased to peak by the end of the infusion (30 
minutes).  That study determined the mean plasma half-lives of arecoline to be 0.95 
± 0.54 (t1/2) and 9.3 ± 4.5 (SD) (t1/2β) minutes.   
7.4.3 Possible reasons for results observed 
Those on insulin were excluded from the study as previously mentioned (in the 
results) due to potential risk of adverse glycaemic events.  The two medications 
used by participants during the study were glibenclamide and metformin.  
Glibenclamide 5 is a sulphonylurea which increases insulin secretion from the Islets 
of Langerhan’s.  It requires a functioning β-cell to exert its effect and it is long acting 
with a duration of action of 6-24 hours.  Its long-acting effect may have had an effect 
on blood glucose levels, although this was not evident from the random effects 
regression model.   
Metformin 5 is a biguanide with a different mode of action and has a shorter duration 
of action compared to glibenclamide.  It does not stimulate pancreatic insulin 
secretion but increases insulin action and reduces hepatic glucose production and is 
therefore useful in reduced β-cell function.  Other modes of action include 
stimulation of tissue uptake of glucose and reduction of gastrointestinal absorption 
of carbohydrate.  There is a possibility that the increased insulin action by metformin 
may counteract the acute glucose increase caused by adrenaline release stimulated 
by arecoline in betel nut.  Animal/cell studies have shown that arecoline 
administration increases adrenaline which in turn increases blood glucose. 3, 6, 7  
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Although no effect on glucose was observed by the end of the study days, transient 
effects of betel nut may have been missed.  The onset of action has been reported 
to be within two 8 to 10 minutes 9 Blood glucose in this study was measured at the 
end of a chewing episode.  A chewing episode was from the onset of chewing to the 
swallowing or spitting out of betel nut.  The minimum and maximum duration for 
chewing was 1 minute and 33 minutes, respectively.  Any small non-significant 
change that was observed would probably have been from systemic absorption 
rather than buccal absorption while the chew was in the mouth.  Buccal absorption 
avoids first-pass effect.  What is usual at the end of chewing is volume of material in 
the mouth is smaller than when chewing began because during mastication bits of 
the chew are continuously swallowed.  Chronic administration of arecoline has been 
reported to be hypoglycaemic in animal studies.3, 10 
 
7.4.4 Other observations from the study 
Although it was not part of the study to observe behaviour of study participants, it 
was observed during the two study days that when participants were not chewing 
betel nut, they were feeling sleepy.  Some actually fell asleep. On the day of betel 
nut chewing, none of the participants was sleepy of fell asleep. Several were 
sweating profusely while they were chewing betel nut.  However, participants did not 
sweat consistently with every betel nut they chewed, which may indicate that not 
every betel nut was the same chemically.  These manifestations are thought to be 
due to stimulation of the autonomic nervous system. 8, 11  
7.4.5 Acute glycaemic effect of betel nut 
A review of the literature did not find any reports on the acute glycaemic effects of 
betel nut chewing in humans.  However, a study 3 using arecoline to investigate both 
the acute and chronic effects on blood glucose was conducted by Dasgupta using 
mice.  That study administered arecoline intraperitoneally at a dose of 10mg/kg.  
Serum corticosterone, adrenal adrenaline and noradrenaline, and blood glucose and 
liver glycogen were measured at 20, 40 and 60 minutes.  It was found from this 
study that serum corticosterone increased at 20 and 40 minutes with no change at 
60 minutes.  In terms of the increase, this was most significant at 20 minutes as 
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compared to 40 minutes after administration.  The same trend was observed on 
blood glucose levels with the most significant increase at 20 minutes.  Liver 
glycogen decreased at all times (i.e. 20, 40 and 60 minutes) but the most significant 
decrease was observed at 20 minutes compared to the other measurement times.  
There was a difference in levels of adrenal adrenaline and noradrenaline with 
adrenaline levels relatively higher than noradrenaline.  However, levels of both 
catecholamines increased at 20 minutes without any significant change at 40 or 60 
minutes after administration.  Although blood glucose was measured only once after 
chewing, the same pattern of a short-lived effect was observed in the present study.  
The hourly glucose did not show any difference in glucose levels on the betel nut 
chewing and non-chewing days.  Dasgupta et al 3 provide some understanding of 
the acute effect of arecoline on adrenal function and blood glucose.   Other in vitro 
studies 7 have reported that arecoline or betel nut influences release of 
catecholamines and Dasgupta et al 3 confirm these findings in their in vivo study.   
As observed by Dasgupta et al 3, the most significant increase in blood glucose was 
in the first 20 minutes.  The present study measured blood glucose 5-10 minutes 
after the betel nut chew was spat out or swallowed.  The minimum duration of 
chewing was 1 minute and the maximum was 33 minutes. Perhaps the delay in 
measuring blood glucose may have contributed to the small observed increases, 
decreases or no change in blood glucose.  Had the measurements been done 5-10 
minutes after onset of chewing, a difference in readings would probably have been 
observed.  However, like other studies, this would have been short lived.  The 
finding that blood glucose was similar on the betel nut chewing and non-chewing 
days indicates that betel nut did not have an overall acute effect on blood glucose. 
It appears from other studies that the acute increase in blood glucose is due to 
catecholamine release or corticosterone in response to the arecoline.3  It is possible 
that the increase in blood glucose from catecholamine or corticosterone release 
triggers insulin release which reduces blood glucose quickly.  Jensen et al 12 
reported that adrenaline increased blood glucose concentration but the 
concentration decreased to physiological level within 30 minutes when insulin 
infusion was initiated.  That study included 10 healthy volunteers (5 women and 5 
men) who were infused with adrenaline. 
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The finding that betel nut chewing did not affect blood glucose is inconsistent with 
what was observed in the two cross-sectional studies performed as part of the 
present study.  The two cross-sectional studies observed that betel nut chewing has 
beneficial effects on blood glucose levels of those with T2DM as well as those 
without the disease.  Those who never chewed betel nut were more likely to have 
hyperglycaemia while those who chewed betel nut had better glycaemic control.  
Better glycaemic control may be partly due to inhibition of catecholamine release as 
a result of chronic use of betel nut.  A study 6 using continuous perfusion of 
arecoline into an adrenal vein for 60 minutes demonstrated that arecoline inhibits 
catecholamine release from a rat adrenal gland.  That study found that arecoline 
dose-dependently inhibited catecholamine release.  Lower doses did not inhibit 
catecholamine release but a larger dose did.6  Dasgupta et al 3, apart from giving 
one dose of arecoline also administered the drug daily for 15 days to investigate the 
chronic effects of arecoline.  That study found that chronic administration of 
arecoline was hypoglycaemic.  The hypoglycaemic effect of arecoline was 
demonstrated to be a result of its inhibition of adrenocortical activity at ultrastructural 
and hormonal levels.  Ultrastructural studies showed depletions of noradrenaline 
and adrenaline containing granules.  The study by Dasgupta et al 3 also reported 
that although corticosterone levels were reduced in the adrenal gland, it was 
increased in the blood serum.    
The mechanism of action of arecoline on adrenaline is suggested to be through the 
effect of arecoline on the calcium channels.6, 13 It is suggested that the inhibitory 
effect of arecoline may be mediated by blocking calcium (Ca2+) influx and not 
through inhibition of Ca2+ release from the cytoplasmic store. 6   Inhibition of 
catecholamines through inhibition of Ca2+ influx may partly be responsible for 
hypoglycaemia resulting from chronic arecoline administration.  There may be other 
mechanisms by which arecoline causes hypoglycaemia.  It has also been 
demonstrated that arecoline inhibits hepatic gluconeogenesis.14  The opposite effect 
is exhibited by adrenaline where it stimulates hepatic glucose release. 15, 16   Yao et 
al 14 reported that a low dose of arecoline decreased the mRNA expression of 
hepatic G6Pase, PEPCK, Fox01 and PGC-α in a T2DM rat model thereby inhibiting 
hepatic glucose release. Fasting blood glucose and total cholesterol were reduced.  
A high dose of arecoline in that study caused hepatic damage. 14  Arecoline has also 
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been reported to prevent the dysfunction of β cells of the pancreas induced by high 
fructose via up-regulation of PDX-1. 4  
7.5 Conclusions 
Regardless of how the underlying influence of betel nut chewing on glucose levels 
occurs and how it was assessed (either using AUC or a random effects regression 
model) results from the present study indicate that betel nut chewing does not 
acutely influence the blood glucose of patients with T2DM.     
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Chapter VIII: General discussion 
8.1 Prevalence of betel nut chewing  
The present study has investigated the prevalence of betel nut chewing in Papua 
New Guinea (PNG) in those with and without type 2 diabetes mellitus (T2DM).  
Findings of this study report a very high prevalence of betel nut chewing not only in 
those without the disease but also those with the disease.  This finding appears to 
be the highest reported thus far.  However the study included a sample of urban and 
peri-urban location and the rate may have been less if PNG populations where the 
habit is not common were included in the study.  Those from regions where the habit 
was not common appear after relocation to have picked up the habit from coastal 
people where the habit is more prevalent. 
8.2 The glycaemic effect of betel nut chewing 
Epidemiological studies in Asia have shown an association of betel nut chewing with 
metabolic syndrome or individual components of this syndrome such as 
hyperglycaemia and diabetes or obesity.1-3 The same findings have been reported 
from two cross-sectional studies in PNG. 4, 5 
It was hypothesised that betel nut chewing increased blood glucose in those with 
T2DM.  This hypothesis was tested in both acute and long term chronic betel nut 
exposure.  In terms of long term chronic betel nut exposure, this hypothesis was not 
accepted since univariate analysis indicated a positive difference in glycaemic 
control between betel nut chewers and non-chewers (p=0.027).   That is to say, 
betel nut chewers had better glycaemic control than their counterparts.  However the 
association of non-exposure (never chewed) and high betel nut dose with glycaemic 
control was similar.  A lower dose had a beneficial effect while a higher dose did not.   
To determine the immediate glycaemic effects of acute exposure, the hypothesis 
was tested in two different ways; firstly through an area under the curve (AUC) 
analysis and secondly through a random effects regression analysis.   Here again 
the hypothesis was rejected since AUC analysis (a measure of glycaemic control) 
did not show any significant difference between the AUC during a day when the 
participants chewed betel nut compared to a day when they did not chew betel nut.  
377 
 
 
Furthermore, the hypothesis was also rejected after considering the influence of 
meals and medication using random effects regression analysis which again failed 
to show any significant differences in glycaemic control secondary to betel nut 
chewing.  Calculation of the difference in capillary blood glucose (CBG) before and 
after each chewing episode showed small insignificant changes.  The null 
hypothesis that betel nut has no effect on blood glucose is therefore accepted for 
the effect of acute betel nut exposure on blood glucose.    
T2DM patients already have problems with poor glycaemic control as a 
consequence of β-cell dysfunction and/or insulin action so to investigate whether 
betel nut chewing had the same effect in those without the disease, a cohort of non-
T2DM was included in the present study.  Univariate analysis testing the association 
of betel nut chewing and glycaemic control in the non-T2DM cohort also resulted in 
a significant difference in glycaemic control between betel nut chewers and non-
chewers.   Betel nut chewers had better glucose tolerance than those who were not 
chewers.  Fasting blood glucose however was not associated with betel nut 
chewing.  Further, betel nut chewing did not independently influence glycaemic 
control in the non-T2DM cohort. 
These findings suggest that the beneficial effect of low dose betel nut chewing on 
glycaemic control may be independent of defects in insulin release and/or action.  A 
higher dose however may adversely affect blood glucose.  The finding that betel nut 
chewing did not independently influence postprandial hyperglycaemia suggests that 
there are other factors contributing to the problem.  Further, the finding that betel nut 
chewing did not affect fasting hyperglycaemia suggests that betel nut chewing 
probably does not have any effect on hepatic glucose control.   
The findings from this study of the beneficial effects of betel nut chewing, arecoline 
and Piper betle leaf (PBL) or Piper betle inflorescence (PBI) on glycaemic control of 
those with T2DM is in agreement with animal and human studies.6-10  Yao et al.10 
found that a low dose was beneficial while a high dose caused hepatic damage.  
However, there are also other studies which are in conflict with the findings of the 
present study.3, 11-13  
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The finding of this study is in disagreement with the previous study by Benjamin and 
Margis in T2DM.4  That study did not perform any further statistical analysis apart 
from calculating frequencies.  The conclusion was based on the observation that 
73.0% of the 167 patients with poor glycaemic control were betel nut chewers.  
Benjamin and Margis used a higher fasting CBG cut-off (CBG>10.0 mmol/L) to 
define poor glycaemic control compared to the present study.  Further, the present 
study used a different blood glucose parameter [glycosylated haemoglobin (HbA1c)] 
than used by Benjamin and Margis.  The majority of participants in that study were 
betel nut chewers; only 55 (26.0%) were non-chewers.  Although the sample 
number was smaller than the present study, the strength of that study was random 
recruitment of participants.  However, demographic characteristics of participants of 
the present study and that of Benjamin and Margis were similar in terms of gender, 
dispersion of age, region of origin and percentage of participants from rural villages.  
The study reported a higher prevalence (74.0%) of betel nut chewing compared to 
the present study (55.0%).  Further the prevalence rates of those with tertiary 
education, alcohol consumption and smoking were higher than the present study.  
Alcohol consumption, smoking and level of education did not affect glycaemic 
control in the present T2DM cohort.  Given the high prevalence of betel nut chewing 
reported by Benjamin and Margis, and that the majority of participants were betel 
nut chewers, it is possible that the report is biased and therefore the finding that 
betel nut chewing contributes to poor glycaemic control is possibly inconclusive. 
The finding of the present study that betel nut chewing had a beneficial influence on 
glycaemic control in the non-T2DM cohort is also in disagreement with another 
study by Benjamin.5  The blood glucose parameter used in that study was fasting 
CBG while the present study used both fasting CBG and oral glucose tolerance 
(OGT).  As previously reported the present study did not find any association of 
betel nut chewing with fasting CBG but did with OGT.  Benjamin reports a low 
prevalence (13.0%) of betel nut chewing among 769 participants.  The conclusion 
drawn from the study that betel nut is a risk factor for T2DM was based on a sample 
that lacks sufficient power to detect any differences.  Only 92 betel nut chewers 
were included in the statistical analysis.  The recruitment of participants for that 
study was conducted at church halls and therefore the lower prevalence of betel nut 
chewing.  Some churches discourage their followers from habits such as betel nut 
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chewing, smoking and alcohol consumption.  The majority (78.0%) of participants 
were from the Seventh Day Adventist church which discourages such social habits.  
 The finding of the beneficial effect of betel nut chewing is also in disagreement with 
three Taiwanese studies.  Tung et al.11 and Yen et al. recruited participants from the 
same database to investigate the effect of betel nut on T2DM and the metabolic 
syndrome, respectively.  The strength of these studies were their sample sizes 
(>10,000).  Another Taiwanese study by Guh et al14 was smaller in sample size 
compared to that by Tung et al.11 and Yen et al.15   The finding by Guh et al.14 was 
not consistent with that of Tung et al. and Yen et al. but did report hyperglycaemia in 
women.  The prevalence of betel nut chewing in women in that study was 2.3%.  In 
another population-based study in Taiwan, Tseng3 reported that the incidence of 
T2DM increased with age but peaked at 60-69 years for “ever” chewers but not 
“never” chewers.  That is, the incidence of T2DM kept increasing beyond 69 years 
for “never” chewers.  A common observation from these studies is that betel nut 
chewers are younger but diabetes is increasing with increasing age suggesting that 
age is a factor.  Tung et al.11 also reported that there was no significant difference in 
blood glucose between non-chewers and chewers who were 40 years or younger.  
This is an age group that has a high prevalence of betel nut chewing in those 
studies.  This probably agrees with the present study that any effect of betel nut is 
detected after years of chronic chewing.     
8.3 Factors associated with betel nut chewing and their 
association with hyperglycaemia and T2DM 
As reported in Chapter IV for the T2DM cohort, the known modifiable risk factors for 
poor glycaemic control such as systolic blood pressure (SBP) and waist 
circumference were not associated with betel nut chewing.  The modifiable risk 
factors for poor glycaemic that had a positive (benefit) effect were physical activity 
and body mass index (BMI).  As reported in Chapter V, for the non-T2DM cohort, 
risk factors such as SBP, diastolic blood pressure (DBP), physical activity, BMI, 
waist circumference, percentage body fat, smoking and alcohol were significantly 
associated with betel nut chewing.  These findings further support the potential 
benefit of betel nut chewing in preventing T2DM. 
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It has been reported that there are disparities in the prevalence of diabetes and pre-
diabetes between fasting glucose and HbA1c data.16-21  Reductions in HbA1c have 
been reported to indicate improved β-cell function rather than increased insulin 
sensitivity.22  It is also worth mentioning that although T2DM patients at the Port 
Moresby General Hospital (PMGH) Diabetes Clinic are expected to fast before their 
blood glucose is measured, the present study found that a proportion of them did not 
fast.  It is important that these patients inform their doctors whether or not their 
glucose measurement is a fasting level or not, as this affects decisions on diabetes 
management.   
8.4 Possible reasons for differences in glycaemic effects of betel 
nut chewing 
There are several possible mechanisms of action for glycaemic effects of betel nut 
chewing as discussed in Chapter II.  The chemical constituents of betel nut and 
PBL/PBI as discussed in Chapter II are numerous of which many are yet to be 
discovered.  There are also metabolites which have been discovered but whose 
mechanisms of action are yet to be determined.  Genetics also plays a role in drug 
metabolism.  Differences in genetics, ethnicity, cultures and socioeconomic 
development affect an individual, the environment that individual lives in and the 
lifestyle that the individual maintains.  The interactions between an individual, the 
environment and their lifestyle perhaps results in the differences in consequences of 
betel nut chewing.  A possible explanation for any difference between what has 
been reported in animal studies and humans is interspecies differences.  Further, 
any difference between different ethnic groups in metabolism of chemicals in betel 
nut and PBI/PBL may be dietary or genetic-related.  As discussed in Chapter II, the 
gut microbiota is probably responsible for some of the differences observed between 
populations.  As such, perhaps one of the reasons for the differences in glycaemic 
effects of betel nut between Asians and Papua New Guineans may be their diet.  
The diet of Papua New Guineans is mostly composed of tubers while that of Asians 
mostly includes rice and noodles.  It is also possible that the differences may be due 
to betel nut chewing methods and the content of arecoline or chemical composition 
of betel nuts found in Asia compared to PNG.  However, an earlier study 
investigating the arecoline content of Port Moresby betel nuts compared to that of 
381 
 
 
Indian betel nuts did not show much difference.23  Arecoline content is also known to 
differ with betel nut maturity.  Betel nut chewers in this study generally had the same 
method of chewing betel nut with a small proportion chewing the nut only or with PBI 
but not lime.  Further, most Papua New Guineans choose to chew fresh nut rather 
than dried or cured nut. 
There may also be a need to improve research methodologies to confirm the 
metabolic effects of betel nut chewing and if there are differences among human 
population groups, the reasons for these differences are important. 
8.5 Study limitations 
There were limitations of the present study.  The cross-sectional surveys requested 
participants to recall lifestyle behaviours and recall for example the number of days 
per week a particular physical activity was performed and the frequency of 
participating in such an activity.  The need to recall these events may have led 
inaccurate recall.  The questionnaire used to interview the cohort with T2DM was 
based on the STEPS survey from which data for the cohort with non-T2DM was 
obtained but the period of recall was longer for the STEPS survey.  When answering 
lifestyle behaviour questions, participants were requested to think back over the 
previous 12 months.  Recall in the T2DM cohort would probably have been better 
because they were requested to think back over the previous 3 months.  In terms of 
physical activity and vegetable or fruit consumption, participants were requested to 
think of a week when such an event occurred and report the amount and frequency 
of consumption.  Participants may have therefore reported the best week in terms of 
amount and frequency of an event, leading to overestimation. 
The timing of glucose measurements to determine the glycaemic effect of acute 
betel nut exposure may have missed the transient effect of betel nut chewing.  
Arecoline and arecaidine are rapidly absorbed from the buccal membrane so waiting 
till the end of the chewing episode could miss the transient effect and arecoline has 
a very short half-life.  However, the finding that a proportion of participants had small 
increases, decreases or no effect shows that there is individual variability in 
glycaemic responses to betel nut among those with T2DM.   
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Most continuous variables were categorised and dichotomised, particularly the main 
dependent variables of this study; variables of glycaemic control.  HbA1c in 
particular was only assessed as a dichotomised variable because the 
Siemens/Bayer DCA Vantage point-of-care (POC) HbA1c analyser did not give a 
continuous reading beyond 14.0%.  Any reading more than 14.0% was indicated as 
>14.0% on the analyser so it was not possible to calculate mean values and perform 
t-tests for HbA1c. HbA1c was also dichotomised to determine prevalent rates of 
poor/optimal control according to clinical guidelines.  There are several 
disadvantages of dichotomising continuous variables.  The extent of variation in 
outcome between groups such as the odds of having poor glycaemic control may 
have been underestimated.  Variability may have also been absorbed within each 
group.   
Independent tests to correlate POC and laboratory results for glucose concentration 
showed that laboratory results for glucose concentration were reasonably well 
correlated.24  The values obtained by the DCA Vantage analyser and laboratory 
testing were identical statistically, analytically and clinically, demonstrating an 
acceptable accuracy for its use in monitoring glycaemic control in those with 
T2DM.24  An internal validation study reported the precision coefficient of variation 
ranged between 2.6-2.8%.25 These values are less than 3% indicating that clinically 
significant changes in serial HbA1c can be detected.26   
The generalizability of some of the results of this study to other diabetes care 
facilities with limited care such as those in other provinces of PNG may be limited as 
this study was in a highly specialised setting.  Further, the two study cohorts for the 
cross-sectional studies were in an urbanised and westernised setting and may not 
be comparable to settings that are different.  
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Chapter IX: Conclusions and recommendations 
9.1 Conclusions 
This research has investigated the glycaemic effect of betel nut chewing in T2DM.  
The first part of the research investigated any long term effect of betel nut chewing 
in T2DM through a cross-sectional study as described in Chapter IV.  This research 
has also investigated the acute glycaemic effect of betel nut chewing in T2DM as 
described in Chapter VII.  The importance of investigating the immediate effects was 
to establish any acute glycaemic effects and link that with any long term effects to 
confirm the glycaemic effect of betel nut chewing in T2DM. Further, T2DM patients 
already have defective glucose homeostasis so it was also important to investigate 
the issue in those with “normal” (no known T2DM) glucose homeostasis. The 
importance of any findings of glycaemic effects in non-T2DM (Chapter V) could form 
part of public health education on the issue of chewing betel nut.  
In terms of a long term glycaemic effect of betel nut chewing in T2DM, a strong 
positive association was observed.  That is T2DM betel nut chewers had better 
glycaemic control than those who were non-chewers.  However, this finding should 
be interpreted with caution.  It is possible that there may have been residual 
confounders which were not included in this study mostly because glycaemic control 
is multifactorial. Categorical variables were used rather than continuous variables. 
The study has found that the acute glycaemic effect of betel nut chewing was non-
significant and variable, and overall, no acute glycaemic effect of betel nut chewing 
was observed in T2DM.  However, this finding is important knowledge to those with 
T2DM that betel nut chewing does not affect glycaemic control, provided they 
continue to take their medications as required and that they are careful with what 
they are eating.  Diet was controlled during the study.  An interesting observation 
during the research was that all participants of the study investigating acute 
glycaemic effects of betel nut chewing (Phase 2) were either sleepy or actually fell 
asleep during the betel nut abstinence study day but were all alert during the betel 
nut chewing day, reflecting that betel nut is a stimulant. 
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In terms of glycaemic effect of betel nut chewing in non-T2DM participants, low dose 
betel nut chewing was associated with better glycaemic control but it was not an 
independent factor.  There were other important factors affecting blood glucose.     
In the non-T2DM cohort, betel nut chewing had a strong beneficial independent 
association with important risk factors for T2DM such as physical activity, BMI, waist 
circumference and percentage body fat.  That is, betel nut chewers were leaner and 
were more physically active.  In T2DM participants, betel nut chewing also had a 
beneficial influence on physical activity, waist circumference and body mass index. 
It is therefore concluded from this study that low dose betel nut chewing improves 
glycaemic control in terms of glycated haemoglobin and glucose tolerance but it has 
no effect on fasting blood glucose.   
9.2 Recommendations 
Although betel nut had a beneficial influence on long term glycaemic control in 
T2DM and also non-T2DM participants, this data must be interpreted with care.  The 
finding that no acute glycaemic effect of betel nut chewing was observed in T2DM 
patients must also be interpreted with care.   
There is a need to improve methodology to further investigate the issue not only in 
those with T2DM but also non-T2DM.  In terms of methodology, case controlled 
studies should be employed to further investigate both acute and long term effects 
of betel nut chewing.    
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Appendix 1:  Ethical clearance with conditions, HREC, Curtin University 
 
 
 
Memorandum   
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for your application submitted to the Human Research Ethics Committee (HREC) 
for the project titled “Glycaemic Effects of Betel Nut chewing in type 2 Diabetes Mellitus”.   
Your application has been reviewed by the HREC and will be approved subject to the 
conditions detailed below: 
1. Please clarify who will be collecting the blood sample; 
2. Please provide further information on why only one day cessation from betel 
nut chewing would show causation as this has not been identified; 
3. Please provide justification for not having a control group; 
4. Participant Information Sheets (Phase 1 and Phase 2) requires 
   amendment: 
a. Please consider revising the language to an equivalent Grade 8 in 
the Flesch-Kincaid Grade Level.    i.e.; alternative wording “stop” 
instead of abstain’, “timetable” rather than ‘protocol’.   Refer to the 
Ethics Webpage for example 
http://research.curtin.edu.au/guides/Consent.cfm; 
b. Please ensure that the Consent Form is a separate document for the 
participant to sign their consent as the Participant Information Sheet 
should be kept by the participants; 
c. Contact details of the researchers must be included; 
d. The following standard statement must be included; 
To Professor Jeffery Hughes, School of Pharmacy 
From  Miss Linda Teasdale, Manager, Research Ethics 
Subject Protocol Approval HR 38/2011 
Date 16 May 2011 
Copy Mrs Stella Tilu Tulo, School of Pharmacy 
Dr Lloyd Ipai, Diabetes Consultant (Port Moresby General 
Hospital), 
Graduate Studies Officer, Faculty of Health Sciences 
Office of Research and Development 
Human Research Ethics Committee 
TELEPHONE 9266 2784 
FACSIMILE 9266 3793 
EMAILhrec@curtin.edu.au 
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This study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR38/2011). The committee is comprised of members of the public, 
academics, lawyers, doctors, and pastoral carers.  Its main role is to protect participants.   If 
needed, verification of approval can be obtained either by writing to the Curtin University 
Human Research Ethics Committee, c/- Office of Research and Development, Curtin 
University, GPO Box U1987, Perth, 6845 or by telephoning 9266 2784 or by emailing 
hrec@curtin.edu.au. 
Please ensure that all documentation to be provided to the participants has the correct Curtin 
University logo. Refer to the Curtin Brand website http://brand-staff.curtin.edu.au/index.cfm. 
Please proof read all documents to be provided to participants for typographical and 
grammatical errors; 
5. Question (xi), Page 7 – please amend to read as Papua New Guinea 
National Department of Health. 
Please do not commence your research until your response to the above conditions has 
been approved and final clearance has been granted by the Human Research Ethics 
Committee. 
------------------------------------------------------------------------------------------------------
 Please note the following: 
• Reference Number: HR 38/2011.  Please quote this number in any future 
correspondence. 
• The following standard statement must be included in the information sheet 
to participants: 
This study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR38/2011). The Committee is comprised of members of the public, 
academics, lawyers, doctors, and pastoral carers. Its main role is to protect the participants. 
If needed, verification of approval cab be obtained either by writing to the Curtin University 
Human Research Ethics Committee, c/-  Office of Research and Development, Curtin 
University,  GPO Box U1987, Perth, 6845 or by telephoning 9266 2784 or by emailing 
hrec@curtin.edu.au. 
• It is the policy of the HREC to conduct random audits on a percentage of 
approved projects. 
These audits may be conducted at any time after the project starts.   In cases where the 
HREC considers that there may be a risk of adverse events, or where participants may be 
especially vulnerable, the HREC may request the chief investigator to provide an outcomes 
report, including information on the follow-up of participants. 
Regards, 
 
Miss Linda Teasdale 
Manager, Research Ethics 
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Appendix 2:  Response to conditions set by HREC, Curtin University 
Memorandum 
To: The HREC, Office of Research and Development 
From: Stella Tulo, PhD candidate, School of Pharmacy 
Subject: Response to conditions set by HREC on application number HR 38/2011 
Date: 23 May 2011  
I write in response to the conditions set by the HREC on the application submitted to the 
committee for the research project titled “Glycaemic Effects of Betel Nut chewing in Type 2 
Diabetes Mellitus”.  My response is according to the conditions set by the committee. 
1.  Clarification on who will be collecting blood sample. 
Blood sample collection will be done by finger prick for capillary blood test.  For 
Phase 1, finger pricking and HbA1c testing will be done by the registered nurses as 
part of routine patient checks at the Diabetes clinic.  For Phase 2, I will do the finger 
pricking for capillary blood tests and I will do the blood sugar measurements using a 
glucose meter.  I will receive training for finger pricks and blood sugar 
measurements from the registered nurses during phase 1 of the study. 
2. Explanation on why there is only one day cessation of betel nut chewing  for 
the study 
One day cessation should be sufficient to show any immediate effects of “no betel 
nut” whilst diet is standardised for participants.  Betel nut effect is short lived.  A 
study in humans has shown that the half-life of arecoline, the major constituent in 
betel nut, is 0.95+-0.54 minutes and the clearance is 13.6+-4.5 L/min.  Based on this 
data it is predicted that arecoline would clear the system in minutes. 
3. Justification for not having a control group 
The participants will serve as their own controls because the primary interest is the 
change in BSL within an individual rather than between individuals.  Diet will be 
standardised, names of medications and dosage times will be recorded during the 
study days to assess compliance.   The doses of betel nut will not be standardised 
on day 1, rather will represent the individual’s normal usage pattern.  Data will be 
pooled to see if there is a population effect.   
4.  Participant information sheets (Phase 1 and Phase 2) amendments 
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a. Language has been simplified (participant information sheets for Phase 1 and 2 
are attached) 
b. Consent form (attached) has been separated.  The same consent form will be 
used for both Phase 1 and Phase 2 
c. Contact details of all investigators have been added on the participant 
information sheets 
d. The HREC approval statement has been added to the participant information 
sheets 
e. Curtin logo has been inserted on the participant information sheets and the 
consent form 
f. All documents to be provided to participants have been proof read. 
 
5. Question (xi), page 7 which reads PNG Department of Health to read as Papua 
New Guinea National Department of Health 
The amendment has been done.  See the HREC application form. 
 
Regards, 
 
 
 
Stella Tulo 
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Appendix 3:  Final ethical clearance, HREC, Curtin University 
 
 
 
Memorandum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for providing the additional information for the project titled “Glycaemic Effects of 
Betel Nut chewing in type 2 Diabetes Mellitus”.   The information you have provided has 
satisfactorily addressed the queries raised by the Committee. Your application is now 
approved. 
• You have ethics clearance to undertake the research as stated in your 
proposal. 
• The approval number for your project is HR 38/2011. Please quote this 
number in any future correspondence. 
• Approval for this project is for a period of twelve months 30-05-2011 to 29-
05-2012. To renew this approval a completed Form B (attached) must be 
submitted before the expiry date 29-05-2012. 
• If you are a Higher Degree by Research student, data collection must not 
begin before your Application for Candidacy is approved by your Faculty 
Graduate Studies Committee. 
• The following standard statement must be included in the information sheet 
to participants: 
This study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR38/2011). The committee is comprised of members of the public, 
academics, lawyers, doctors, and pastoral carers.  Its main role is to protect participants.   If 
needed, verification of approval can be obtained either by writing to the Curtin University 
To Professor Jeffery Hughes, School of Pharmacy 
From  A/Professor Stephen Millett, Chair, Human Research 
Ethics 
Subject Protocol Approval HR 38/2011 
Date 30 May 2011 
Copy Mrs Stella Tilu Tulo, School of Pharmacy 
Dr Lloyd Ipai, Diabetes Consultant (Port Moresby General 
Hospital), School of Pharmacy 
Office of Research and Development 
Human Research Ethics Committee 
 
TELEPHONE 9266 2784 
FACSIMILE 9266 3793 
EMAILhrec@curtin.edu.au 
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Human Research Ethics Committee, c/- Office of Research and Development, Curtin 
University, GPO Box U1987, Perth, 6845 or by telephoning 9266 2784 or by emailing 
hrec@curtin.edu.au. 
 Applicants should note the following: 
It is the policy of the HREC to conduct random audits on a percentage of approved projects.  
These audits may be conducted at any time after the project starts.   In cases where the 
HREC considers that there may be a risk of adverse events, or where participants may be 
especially vulnerable, the HREC may request the chief investigator to provide an outcomes 
report, including information on the follow-up of participants. 
The attached FORM B should be completed and returned to the Secretary, HREC, C/- Office 
of Research & Development: 
When the project has finished, or 
• If at any time during the twelve months changes/amendments occur, or 
• If a serious or unexpected adverse event occurs, or 
• 14 days prior to the expiry date if renewal is required. 
• An application for renewal may be made with a Form B three years running, 
after which a new application form (Form A), providing comprehensive 
details, must be submitted. 
  
Regards, 
 
 
A/Professor Stephen Millett 
Chairman Human Research Ethics Committee 
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Appendix 4:  Ethical clearance, University of PNG   
   UNIVERSITY OF PAPUA NEW GUINEA 
   SCHOOL OF MEDICINE AND HEALTH SCIENCES 
   DIVISION OF CLINICAL SCIENCES 
   UPNG TAURAMA  FAX NO.    325 0809 
   P.O.BOX 5623    TEL. NO.  311 2626 / 325 3340 
   BOROKO, NCD, PAPUA NEW GUINEA 
____________________________________________________________ 
 
5TH October 2010 
 
Ms. Stella Pihau-Tulo 
School of Pharmacy 
Curtin University of Technology 
Western Australia 
 
Dear Stella 
 
SUBJECT: ETHICAL CLEARNACE FOR YOUR RESEARCH PROPOSAL ON 
“GLYCAEMIC EFFECTS OF BETEL NUT CHEWING IN TYPE 2 DIABETES 
MELLITUS” 
Thank you for submitting this Research proposal for Ethical Clearance, which is 
important because this project will ultimately involve patients at Port Moresby 
General Hospital, Papua New Guinea. Therefore, the details of this project need to 
be reviewed by the SM&HS Research and Ethics Committee. 
Having read through the Research Proposal, I found it was well thought out and well 
written. Due to the delays you are facing on approval at Curtin University, I am in my 
capacity as Chairman of the SM&HS Research and Ethics Committee, and on 
behalf of the Committee ethically clear and approve this study so that you can do 
your data collection here in PNG. 
I will inform our next SMHS Research and Ethics Committee about my 
administrative clearance for formal record keeping only. 
 
Yours sincerely 
 
Professor Nakapi Tefuarani 
Chairman 
SM&HS Research and Ethics Committee 
Cc: Dr. J.A.K Lauwo, Head, Pharmacy Discipline 
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Appendix 5:  Ethical clearance, the Medical Research Advisory 
 Committee, NDOH, PNG 
 
Government of Papua New Guinea 
Medical Research Advisory Committee 
National Department of Health 
Po Box 807    Phone:  + (675)  3013650 
WAIGANI 131, NCD   Fax:   + (675)  325 1825 
Papua New Guinea   Email:  urarang_kitur@ health/gov.pg 
File: 54-6-2 
Date:  22/02/2012 
 
Mrs Stella Tulo 
School Of Pharmacy 
GPO Box U1987 
Curtin University 
Western Australia 
Dear Ms Tulo 
This is to certify that the proposal: 
Glycaemic effects of betel nut chewing in Type 2 Diabetes Mellitus 
Submitted by you and your colleagues has been examined by the Medical Research 
Advisory Committee of Papua New Guinea and assigned MRAC No.11.29 
Your proposal was initially not approved because your research proposal was incomplete in 
that a proper comprehensive literature review and referencing was not done.  The MRAC is 
satisfied with your literature recview and  and give you clearance to conduct your research. 
The MRAC of PNG acts as the National Ethical Clearance Committee and as the Institutional 
ethical committee for the PNG Institute of Medical Research. 
Investigators are reminded of the importance of keeping provincial health and research 
authorities informed on their study and its progress, and of submitting annual progress and 
outcome reports to the MRAC. 
With best wishes 
Dr Urarang Kitur 
 
Chairperson 
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Appendix 6:  Participant information sheet – Phase 1 
 
 
 
School of Pharmacy 
 
Participant Information Sheet (Phase 1) 
 
Title of Study:   Glycaemic Effects of Betel Nut chewing in Type 2 
   Diabetes Mellitus 
__________________________________________________ 
My name is Stella Tulo.  I am currently completing a piece of research for my Degree of 
Doctor of Philosophy in Pharmacy at Curtin University in Perth, Western Australia. 
___________________________________________________ 
Purpose of I am investigating the effect of betel nut chewing on blood sugar 
Research  levels of people with type 2 diabetes. 
___________________________________________________ 
 
Your role I am interested in finding out if betel nut affects blood sugar 
levels.  I will ask you questions about your: 
• Age 
• Education 
• Employment 
• Tobacco, alcohol and betel nut use 
• Fruit and vegetable intake 
• Physical activity 
• History of diabetes and medicines management. 
 
The interview process will take about 10-15 minutes 
___________________________________________________ 
Other information I will also collect information about you from your clinic notes.   
I will collect  The information I will collect will be your: 
• Height 
• Weight 
• Waist and hip circumference 
• Blood pressure 
• Sugar and fat levels in your blood 
___________________________________________________ 
Consent to  Your involvement in the research is entirely voluntary.  You 
Participate  have the right to withdraw at any stage without it affecting your  
rights or your care.  When you have signed the consent form I 
will assume that you have agreed to participate and allow me to 
use your data in this research. 
___________________________________________________ 
Your rights It is your right to: 
• Decline to take part in the study 
• Withdraw your consent at any time 
• Decline to answer any questions in the interview that you do 
not wish to answer 
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If you decide not to participate in this study, this will not affect 
your continued management at the diabetes clinic. 
___________________________________________________ 
Confidentiality I will write down your name and contact information so that I can 
contact you if there is any need to follow up with you after the 
face to face interview is conducted. 
 
Your participation and the information you provide will be kept 
separate from your personal details, and only myself and my 
supervisors will have access to this.  The interview transcript will 
not have your name or any other identifying information on it and 
in adherence to university policy, the interview information will be 
kept in a locked cabinet for at least 5 years, before a decision is 
made as to whether it should be destroyed. 
________________________________________________ 
Community  The results of this study will help find out if betel nut affects blood 
Benefits sugar levels in patients with type 2 diabetes.  If betel nut is found 
to affect blood sugar levels, then those with type 2 diabetes will 
be given appropriate advice.  The PNG Department of Health 
may also use the results of the study in public health programs 
aimed at reducing development of diabetes and improving blood 
sugar levels in patients with type 2 diabetes. 
___________________________________________________ 
Ethical   This study has been approved by the Curtin University Human  
approval Research Ethics Committee (Approval Number HR38/2011).  
The committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral carers.  Its main role is 
to protect participants.  If needed, verification of approval can be 
obtained either by writing to the Curtin University Human 
research Ethics Committee, C/- Office of Research and 
Development, Curtin University, GPO Box U1987, Perth, 6845 or 
by telephoning 9266 2784 or by emailing hrec@curtin.edu.au 
___________________________________________________ 
Further   If you would like further information about the study, please feel 
information free to contact me on 7685 8965 (mobile), 311 2626 (office) or  
By email sptulo@gmail.com.  You can also contact my two 
supervisors: 
1.  Professor Jeffery Hughes on +61 8 9266 7369 or 
J.D.Hughes@curtin.edu.au 
2. Dr Lloyd Ipai on 324 8200 
 
Thank you very much for your involvement in this research. 
Your participation is greatly appreciated 
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Appendix 7:  Consent form – Phase 1 and Phase 2 
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Appendix 8:  Questionnaire for T2DM cross-sectional study (Phase 1) 
 
GLYCAEMIC EFFECTS OF BETEL NUT IN TYPE 2 DIABETES MELLITUS 
Participant ID…………….. 
Time of interview………… 
Date……………………… 
1.  Family Name…………………….  First Name………………. 
2.  Contact phone number:   Home…………………. 
Work………………….   Mobile……………… 
PART 1:  DEMOGRAPHIC INFORMATION 
3.  Gender:  Male  □ Female  □2 
4. Date of birth: ......................  Age in Years: ............................ 
5.  Place of origin: District………………….. Province……………………….. 
6.  Suburb of residence………………………………. 
7. If you were not born in Port Moresby, how many years ago did you move here?  
  
No of years 
8.  Highest level of education completed 
a. No formal schooling………………………. □1  
b. Less than Grade 6………………………… □2 
c. Completed Grade 6……………………….. □3 
d. Completed Grade 8………………………... □4 
e. Completed Grade 10………………………. □5 
f. Vocational training…………………………. □6 
g. Completed Grade 12………………………. □7 
h. Completed tertiary education……………… □8 
9. Employment 
a. Government employee…………………… □1 
b. Non-government employee……………… □2 
c. Self-employed……………………………… □3 
d. Non-paid…………………………………… □4 
e. Student……………………………………… □5 
f. Homemaker………………………………… □6 
g. Retired……………………………………… □7 
h. Unemployed (able to work)……………… □8 
i. Unemployed (unable to work)............... □9 
 
PART II:  BEHAVIOURAL MEASUREMENTS 
Now I am going to ask you some questions about various health behaviours.  This includes things like smoking, 
chewing betel nut, drinking alcohol, eating fruits and vegetables, and physical activity.  Let’s start with tobacco. 
10. Do you currently smoke any tobacco products, such as cigarettes, cigars or pipes?  [If 
‘no’ go to q15] 
Yes □1  No  □2  
11.  If yes, do you currently smoke tobacco products daily? 
Yes   □1 No  □2  
12.  How old were you when you first started smoking daily? 
  
   Age (years) 
13.  Do you remember how long ago it was? 
  
   Number (years) 
  
   Number (months) 
14.  On average, how many of the following do you smoke each day? 
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   Manufactured cigarettes 
  
   Hand-rolled cigarettes 
  
   Pipes full of tobacco 
15.  In the past, did you ever smoke daily? [If ‘no’ go to q17] 
Yes  □1 No  □2 
16.  If yes, how old were you when you stopped smoking?  
  
   Age (years) 
17.  Do you chew betel nut? [If no, go to question 19]  
Yes  □1 No  □2 
18.  If yes, 
a. How many nuts do you chew per day? 
  
Number of nuts/day 
b. How many nuts do you chew each time you chew betel nut? 
  
Number  
c. When did you start chewing betel nut? 
  
Age (years) 
d. Do you chew betel nut with lime and mustard? 
Yes  □1 No □2 
19. If no,  
a. In the past did you ever chew betel nut?  [If ‘no’ go to q20] 
Yes  □1 No  □2 
b. When did you start chewing betel nut? 
  
Age (years) 
c. When did you stop chewing betel nut? 
  
In years 
  
In months 
  
In weeks 
d. Did you chew betel nut with lime and mustard? 
Yes  □1 No  □2 
ALCOHOL CONSUMPTION:  The next questions ask about consumption of alcohol  
20. Have you consumed alcohol (beer, wine, spirits, homebrew) within the past 3 months? .  
 [If ‘no’ go to q29] 
Yes  □1 No  □2 
21. In the past 3 months, how frequently do you drink at least one drink? 
a. Daily  □1 
b. 5-6 per week  □2 
c. 1-4 days per week □3 
d. 1-3 days per month □4 
e. Less than once a month □5 
22. When you drink alcohol, on average, how many drinks do you drink at any one time/during one day?  
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    Number  
23. During each of the past 7 days, how many standard drinks of any alcoholic drink did you have each day? 
 
a. Monday   
  
b. Tuesday   
  
c. Wednesday   
  
d. Thursday   
  
e. Friday    
  
f. Saturday   
  
g. Sunday   
  
      
24.  Have you consumed alcohol (such as beer, wine, spirits, homebrew) within the past 30 days? 
Yes   □1 No   □2 
25. In the past 3 months, what was the largest number of drinks you had on a single occasion, counting all types 
of standard drinks together? 
  
Largest Number 
26. For men only:  In the past 3 months, on how many days did you have five or more standard drinks in a single 
day? 
  
Number of days 
27. For women only:  In the past 3 months, on how many days did you have four or more standard drinks in a 
single day? 
  
Number of days 
28. Where do you get most of your alcoholic drinks from? Choose one only. 
a. I buy from the store   □1 
b. Friends and relatives give me  □2 
c. Homebrew   □3 
DIET.  The next questions ask about the fruits and vegetables that you usually eat.  I have a nutrition card here 
that shows you some examples of local fruits and vegetables.  Each picture represents the size of a serving.  As 
you answer these questions please think of a typical week in the last 3 months 
 
29. In a typical week, on how many days do you eat fruit? 
 
Number of days 
30.  How many servings of fruit do you eat on one of those days? 
  
Number of servings 
31. In a typical week, on how many days do you eat vegetables? 
  
Number of days per week 
32. How many servings of vegetables do you eat on one of those days? 
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Number of servings 
PHYSICAL ACTIVITY.  Next I am going to ask you about the time you spend doing different types of physical 
activity in a typical week.  Please answer these questions even if you do not consider yourself to be a physically 
active person.  Think first about the time you spend doing work.  Think of work as the things that you have to do 
such as paid or unpaid work, study/training, household chores, planting, tending and harvesting food/crops, 
fishing or hunting for food, marketing, seeking employment.  In answering the following questions ‘vigorous-
intensity activities’ are activities that require hard physical effort and cause large increases in breathing or heart 
rate; ‘moderate-intensity activities’ are activities that require moderate physical effort and cause small increases 
in breathing or heart rate. 
 
33. Does your work involve vigorous intensity activity that causes large increases in breathing or heart rate like 
carrying or lifting heavy loads, digging or construction work for at least 10 minutes continuously? 
Yes  □1  No  □2 
34. In a typical week, on how many days do you do vigorous-intensity activities as part of your work? 
   
Number of days per week 
35. How much time do you spend doing vigorous-intensity activities at work on a typical day? 
  
Hours 
  
Minutes 
36. Does your work involve moderate-intensity activity that increases in breathing or heart rate such as brisk 
walking (or carrying light loads) for at least 10 minutes continuously? 
Yes  □1  No  □2 
37. In a typical week, on how many days do you do moderate-intensity activities as part of your work? 
 
Number of days 
38. How much time do you spend doing moderate-intensity activities at work on a typical day? 
  
Hours 
  
Minutes 
39. Do you walk or use a bicycle for at least 10 minutes continuously to get to and from places? 
Yes  □1  No  □2 
40. In a typical week, on how many days do you walk or bicycle for at least 10 minutes continuously to get to and 
from places? 
 
Number of days per week 
41. How much time do you spend walking or bicycling for travel on a typical day? 
  
 Hours 
  
Minutes 
42.  Do you do any vigorous-intensity sports, fitness or recreational activities that cause large increases in 
breathing or heart rate, like running or football or basketball for at least 10 minutes continuously? 
Yes  □1  No  □2 
43. In a typical week, on how many days do you do vigorous-intensity sports, fitness or recreational activities? 
 
Number of days 
44. How much time do you spend doing vigorous-intensity sports, fitness or recreational activities on a typical 
day? 
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Hours 
  
Minutes 
45. Do you do any moderate intensity sports, fitness or recreational activities that causes a small increase in 
breathing or heart rate (such as brisk walking, cycling, swimming, volleyball) for at least 10 minutes continuously? 
Yes  □1  No  □2  
46. In a typical week, on how many days do you do moderate-intensity sports, fitness or recreational activities? 
 
Number of days 
47. How much time do you spend doing moderate-intensity sports, fitness or recreational activities on a typical 
day? 
  
   Hours 
  
   Minutes 
DIABETES AND MEDICATION MANAGEMENT.  Now I am going to ask you questions about diabetes and how 
you have been using your medicines.   
48.  In what year were you diagnosed with diabetes? 
    
   Year 
49. When you were diagnosed with diabetes for the first time, how was your diabetes initially managed? 
a. Insulin (Injections)   □1 
b. Oral medicines    □2 
c. Special prescribed diet   □3 
d. Advice or treatment to lose weight  □4 
e. Advice or treatment to stop smoking  □5 
f. Advice to start or do more exercise  □6 
g. Other forms of management   List 
___________________________________________ 
___________________________________________ 
___________________________________________ 
___________________________________________ 
50. For the last 3 months, what management have you been using for your diabetes? 
i. insulin (Injections)   □1 
ii. Oral medicines   □2 
iii. Special prescribed diet  □3 
iv. Treatment to lose weight  □4 
v. Treatment to stop smoking  □5 
vi. Exercise   □6 
vii. Other. List 
__________________________________ 
__________________________________ 
__________________________________ 
51. Name of medicines and doses 
a. Insulin 
i. Insulin type…………………… 
ii. Doses per day 
  
  Number of units; dose 1 
  
  Number of units; dose 2 
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  Number of units; dose 3 
  
  Number of units; dose 4 
b. Glibenclamide  
 Strength of tablets 
  
   mg 
Number of tablets per dose 
  
Number 
Doses per day 
 
Number of times 
c. Metformin 
Strength of tablets 
   
   mg 
 Number of tablets per dose 
 
   Number 
Doses per day 
 
 Number of times 
d. Other medicines you are taking including doses [including herbal medicines, if names known] 
i._________________________________________ 
ii._________________________________________ 
iii._________________________________________ 
iv._________________________________________ 
v._________________________________________ 
52. Have you ever missed a dose of any of your diabetes medicines in the last 3 months? [If no, go to 54] 
Yes  □1  No  □2 
53. If yes, try and think back for the last 3 months. 
 a. How many times have you missed a dose in the last 3 months? 
  
 Number of times 
b. Think back of a typical month in the last 3 months.  In that month, how often did you miss a dose? 
i. Daily    □1  
ii.  Weekly   □2  
iii.  Monthly    □3  
54.  What were the reasons for missing your dose? 
i.  Forgot  □1  
ii.  Ran out of medicine  □2  
iii. Did not want to take medicine  □3 
iv. Other reasons.  List  
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
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PART III:  PHYSICAL MEASUREMENTS 
 
55.   Height 
   
centimetres 
56.    Weight 
   
kilograms 
57.   Waist circumference 
   
Centimetres 
58. Hip circumference 
   
Centimetres 
59 Blood pressure 
   
Systolic (mmHg) 
   
Diastolic (mmHg) 
 
PART IV:  BIOCHEMICAL MEASUREMENTS 
No. Date Parameter Measurement 
60  Fasting Blood glucose  
61  Glycosylated Hb  
62  Total cholesterol  
63  Triglycerides  
64  LDL  
65  HDL  
66  Urea  
67  Creatinine  
68  Protein (urine)  
69  Glucose (urine)  
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Appendix 9:  Examples of show cards used during interview 
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Appendix 10:  Participant information sheet – Phase 2 
 
 
School of Pharmacy 
 
Participant Information Sheet (Phase 2) 
 
Study title:   Glycaemic Effects of Betel Nut chewing in Type 2 Diabetes 
 Mellitus 
    
My name is Stella Tulo.  I am currently completing a piece of research for my Degree of 
Doctor of Philosophy in Pharmacy at Curtin University in Perth, Western Australia. 
 
   
Purpose of I am investigating the effect of betel nut chewing on blood sugar  
Research levels in people with type 2 diabetes. 
 
What is I would like to collect information from a minimum of 120 
Involved patients who participated in phase 1 of the study.  The place where the 
study will take place is The School Of Medicine & Health Sciences 
(Medfac) 
 
If you are willing to stop chewing betel nut for about 15 hours I would like 
you to participate in this study. I will collect information for this part of the 
study over 2 days. 
 
Day 1  
• On this day all participants will continue chewing betel nut. 
• I  will ask you to stop chewing betel nut and stop eating by 12 
midnight before the study day 
 
•   I will ask you to arrive at the study place before 7.30 in the morning. 
 
• When you arrive at the study place, I will take a very small amount of 
blood by finger prick to measure your blood sugar level. 
 
• After I measure your blood sugar , I will give you a packed  
breakfast at 8.00am 
 
• I will measure your  blood sugar at regular time intervals at 
9am, 10am, 11am 
 
• At 12 noon I will give you a packed lunch and I will measure  
your blood glucose again at 1pm, 2pm and 3pm.   
 
• On this day, whenever you want to chew betel nut, I will record the 
time you put the betel nut in your mouth.  When you want to chew 
betel nut, I would like you to let me know so that I can record the way 
you chew betel nut. 
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• I will measure your blood sugar before you chew betel nut and again 
after you swallow the betel nut. 
 
Day 2  
• I will aske all participants to stop chewing betel nut 
 
• I will ask you to come in for Day 2 on a day that suits 
you.  
 
• The timetable will be the same as in Day 1  
 
• I will measure your blood sugar every hour as in day 1 
___________________________________________________________________ 
Important  During this study you will still take your medicines as directed 
Information I will discuss with you when you want to come in for the study and 
whether or not you will need transport. 
 
I will organise activities for you at the school during the period of study.   
________________________________________________________________ 
Timeframe The study will require you to be at the School Of Medicine & Health 
Sciences from about 7.30am till 3.00pm. 
________________________________________________________ 
Consent to Your involvement in the research is entirely voluntary.  You have 
Participate  the right to withdraw at any stage without it affecting your rights or  your  
care.  When you have signed the consent form I will assume that you 
have agreed to participate and allow me to use your data in this research. 
__________________________________________________ 
Your rights It is your right to: 
• Decline to take part in the study 
• Withdraw your consent at any time 
• Decline to answer any questions in the interview that you do not wish 
to answer 
If you decide not to participate in this study, this will not affect your 
continued management at the diabetes clinic. 
____________________________________________________________ 
Confidentiality I will write down your name and contact information so that I can contact 
you if there is any need to follow up with you after the face to face 
interview is conducted 
 
Your participation and the information you provide will be kept separate 
from your personal details, and only myself and my supervisors will have 
access to this.  The interview transcript will not have your name or any 
other identifying information on it and in adherence to university policy, 
the interview information will be kept in a locked cabinet for at least 5 
years, before a decision is made as to whether it should be destroyed 
___________________________________________________ 
Community  The results of this study will help find out if betel nut affects blood 
Benefits sugar level in patients with type 2 diabetes.  If betel nut is found to affect 
blood sugar levels, then those with type 2 diabetes will be given 
appropriate advice.  The PNG Department of Health may also use the 
results of the study in public health programs aimed at reducing 
development of diabetes and improving blood sugar levels in patients 
with type 2 diabetes. 
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___________________________________________________ 
 
Ethical  This study has been approved by the Curtin University Human 
Approval research Ethics Committee (Approval Number HR38/2011).  The 
committee is comprised of members of the public, academics, lawyers, 
doctors and pastoral carers.  Its main role is to protect participants.  If 
needed, verification of approval can be obtained either by writing to the 
Curtin University Human research Ethics Committee, C/- Office of 
Research and Development, Curtin University, GPO Box U1987, Perth, 
6845 or by telephoning 9266 2784 or by emailing hrec@curtin.edu.au 
___________________________________________________ 
Further  If you would like further information about the study, please feel 
information free to contact me on 7685 8965 (mobile), 311 2626 (office) or by 
 email sptulo@gmail.com.  You can also contact my two supervisors: 
1.  Professor Jeffery Hughes on +61 8 9266 7369 or 
J.D.Hughes@curtin.edu.au 
2. Dr Lloyd Ipai on 324 8200 
 
 
Thank you very much for your involvement in this research. 
Your participation is greatly appreciated 
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Appendix 11:  Data collection sheet, clinical study (Phase 2) 
 
GLYCAEMIC EFFECTS OF BETEL NUT IN TYPE 2 DIABETES MELLITUS - Phase 2: Clinical Study 
DAY 1- Betel nut chewing day 
Participant ID………………  
 Date………………………… 
Time chewed betel nut  Fasting BSL  
before midnight …………….  before breakfast………… 
Time of measurement……… 
BSL measurements:  
Morning    Afternoon 
9.30am…………….  12.30pm………….. 
10.30am…………….  1.30pm…………… 
11.30am…………….  2.30pm…………… 
3.30pm…………… 
Observations: (E.g. symptoms of hypoglycaemia, symptoms of betel nut withdrawal) 
Description of symptom(s) 
 ………………………………………………………………………………………….. 
 ………………………………………………………………………………………….. 
Time of event……………  BSL at time of event………..  
Action(s) taken 
 ………………………………………………………………………………. 
 ………………………………………………………………………………. 
Medication times 
 Diabetes Medication  Time(s) taken 
 Glibenclamide………………………………………………………………………….. 
Metformin………………………………………………………………………………. 
Other medications 
 1…………………………………………………………………………………………  
 2…………………………………………………………………………………………  
 3………………………………………………………………………………………… 
 4………………………………………………………………………………………….. 
Meal times 
Breakfast………………………………………………………………………………… 
Lunch……………………………………………………………………………………   
DAY 2- No betel nut chewing  
Participant ID………………   Date……………………………. 
Time chewed betel nut  Fasting BSL  
before midnight…………….  before breakfast…………… 
BSL (hourly) measurements:  
 Morning     Afternoon 
9.30am…………….   12.30pm………….... 
10.30am…………….   1.30pm……………. 
11.30am…………….   2.30pm……………. 
3.30pm……………. 
Observations: (E.g. symptoms of hypoglycaemia, symptoms of betel nut withdrawal) 
 Description of symptom(s) 
 ……………………………………………………………………………………………… 
 ……………………………………………………………………………………………… 
Time of event……………  BSL at time of event……………… 
 Action(s) taken: 
 …………………………………………………………………………………….. 
 …………………………………………………………………………………….. 
 …………………………………………………………………………………….. 
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Medication times 
 Diabetes medicines  Time(s) taken 
 Glibenclamide………………………………………………………………………………… 
Metformin……………………………………………………………………………………... 
Other medicines 
 1……………………………………………………………………………………………….. 
 2……………………………………………………………………………………………….. 
 3……………………………………………………………………………………………….. 
 4……………………………………………………………………………………………….. 
Meal times 
Breakfast……………………………………………………………. 
Lunch……………………………………………………………….. 
BETEL NUT CHEWING ACTIVITY RECORD SHEET 
Participant ID…………………   Date…………………………….  
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Appendix 12:  Standard meals for clinical study (Phase 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BREAKFAST 
3 slices of wholegrain bread 
1 boiled egg 
¼ teaspoon margarine 
1 cup lady grey tea (medium black) 
LUNCH 
1/3 cup boiled brown rice 
2 small unripe plantain bananas (approx. 100g each) 
100g chicken breast (no skin, no fat) 
1 cup steamed carrots and broccoli 
Water (available throughout the study) 
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Appendix 13:  STEPS survey instrument for Papua New Guinea 
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